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A B S T R A C T
Background
Smoking cessation therapies are not effective for all smokers, and researchers are interested in identifying those subgroups of individuals
(e.g. based on genotype) who respond best to specific treatments.
Objectives
To assess whether quit rates vary by genetically informed biomarkers within pharmacotherapy treatment arms and as compared with
placebo. To assess the effects of pharmacotherapies for smoking cessation in subgroups of smokers defined by genotype for identified
genome-wide significant polymorphisms.
Search methods
We searched the Cochrane Tobacco Addiction Group specialised register, clinical trial registries, and genetics databases for trials of
pharmacotherapies for smoking cessation from inception until 16 August 2016.
Selection criteria
We included randomised controlled trials (RCTs) that recruited adult smokers and reported pharmacogenomic analyses from trials
of smoking cessation pharmacotherapies versus controls. Eligible trials included those with data on a priori genome-wide significant
(P < 5 × 10-8) single-nucleotide polymorphisms (SNPs), replicated non-SNPs, and/or the nicotine metabolite ratio (NMR), hereafter
collectively described as biomarkers.
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Data collection and analysis
We used standard methodological procedures expected by Cochrane. The primary outcome was smoking abstinence at six months
after treatment. The secondary outcome was abstinence at end of treatment (EOT). We conducted two types of meta-analyses- one in
which we assessed smoking cessation of active treatment versus placebo within genotype groups, and another in which we compared
smoking cessation across genotype groups within treatment arms. We carried out analyses separately in non-Hispanic whites (NHWs)
and non-Hispanic blacks (NHBs). We assessed heterogeneity between genotype groups using T², I², and Cochrane Q statistics.
Main results
Analyses included 18 trials including 9017 participants, of whom 6924 were NHW and 2093 NHB participants. Data were available
for the following biomarkers: nine SNPs (rs1051730 (CHRNA3); rs16969968, rs588765, and rs2036527 (CHRNA5); rs3733829 and
rs7937 (in EGLN2, near CYP2A6); rs1329650 and rs1028936 (LOC100188947); and rs215605 (PDE1C)), two variable number
tandem repeats (VNTRs; DRD4 and SLC6A4), and the NMR. Included data produced a total of 40 active versus placebo comparisons,
16 active versus active comparisons, and 64 between-genotype comparisons within treatment arms.
For those meta-analyses showing statistically significant heterogeneity between genotype groups, we found the quality of evidence
(GRADE) to be generally moderate. We downgraded quality most often because of imprecision or risk of bias due to potential selection
bias in genotyping trial participants.
Comparisons of relative treatment effects by genotype
For six-month abstinence, we found statistically significant heterogeneity between genotypes (rs16969968) for nicotine replacement
therapy (NRT) versus placebo at six months for NHB participants (P = 0.03; n = 2 trials), but not for other biomarkers or treatment
comparisons. Six-month abstinence was increased in the active NRT group as compared to placebo among participants with a GG
genotype (risk ratio (RR) 1.47, 95% confidence interval (CI) 1.07 to 2.03), but not in the combined group of participants with a GA
or AA genotype (RR 0.43, 95% CI 0.15 to 1.26; ratio of risk ratios (RRR) GG vs GA or AA of 3.51, 95% CI 1.19 to 10.3).
Comparisons of treatment effects between genotype groups within pharmacotherapy randomisation arms
For those receiving active NRT, treatment was more effective in achieving six-month abstinence among individuals with a slow NMR
than among those with a normal NMR among NHW and NHB combined participants (normal NMR vs slow NMR: RR 0.54, 95%
CI 0.37 to 0.78; n = 2 trials). We found no such differences in treatment effects between genotypes at six months for any of the other
biomarkers among individuals who received pharmacotherapy or placebo.
Authors’ conclusions
We did not identify widespread differential treatment effects of pharmacotherapy based on genotype. Some genotype groups within
certain ethnic groups may benefit more from NRT or may benefit less from the combination of bupropion with NRT. The reader
should interpret these results with caution because none of the statistically significant meta-analyses included more than two trials
per genotype comparison, many confidence intervals were wide, and the quality of this evidence (GRADE) was generally moderate.
Although we found evidence of superior NRT efficacy for NMR slow versus normal metabolisers, because of the lack of heterogeneity
between NMR groups, we cannot conclude that NRT is more effective for slow metabolisers. Access to additional data from multiple
trials is needed, particularly for comparisons of different pharmacotherapies.
P L A I N L A N G U A G E S U M M A R Y
Do people’s genes affect how effective medicines can be in helping people to quit smoking?
Background
Quitting smoking dramatically reduces risk of premature death, but rates of smoking cessation remain low, even with the help of
smoking cessation treatments. Recent research has suggested that differences in parts of our genes, called ’genotypes’, may help us to
tell which smokers could be helped most by different treatments. However, more research is needed to confirm whether or not our
genes affect how effective different treatments are at helping people to quit.
Study characteristics
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We searched for studies of smokers treated with medicine to help them quit. We looked at people’s genes and at how well their bodies
could process nicotine, as this might help us to identify people more likely to quit successfully. We found 33 studies relevant to our
review, and we were able to get enough information for 18 clinical trials, including over 9000 smokers, that looked at differentmedicines
used to help people to stop smoking.
Key results
The results suggest that smokers with specific genotypes may be more likely to be successful quitting smoking with the use of nicotine
replacement therapies compared with smokers who do not have those specific genotypes. Smokers whose bodies process nicotine more
slowly may also benefit more from nicotine replacement therapy. We did not see effects of genes on the effectiveness of medicines other
than nicotine replacement therapy.
Quality of evidence
These results should be interpreted with caution because the included studies did not assign treatments to smokers on the basis of
genotype or the rate at which they process nicotine, and because a small number of clinical trials were included in some comparisons.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Active NRT compared with placebo - rs1051730 - non-Hispanic white for smoking cessationa
Patient or population: people who smoke
Setting: community and healthcare sett ings
Intervention: act ive NRT
Comparison: placebo




Quality of the evidence
(GRADE)
Comments




Abst inence at end of
treatment







result across studies, in-
cluding all genotypes.
Stat ist ically signif icant
between-genotype group
heterogeneity: P value =
0.004 (see results for in-





Abst inence at end of
treatment - homozy-
gous major






For part icipants with ho-
mozygous major geno-
type, low-quality evi-





Abst inence at end of
treatment - heterozy-
gous






For part icipants with
heterozygous genotype,
moderate-quality

































































































































Abst inence at end of
treatment - homozy-
gous minor






For part icipants with ho-
mozygous minor geno-
type, low-quality evi-





*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NRT: nicot ine replacement therapy; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
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aThis is the f irst of seven ’Summary of f indings’ tables for the main comparison. For a complete list , see the ’Addit ional
summary of f indings’ sect ion.
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genotypes.
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part icipants.
dDowngraded one level owing to imprecision: opt imal information size criterion is met, but 95%CIs include the null ef fect and
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eDowngraded one level owing to imprecision: opt imal information size criterion is not met in this stratum. Counts in this





























































































































B A C K G R O U N D
Table 1 presents a glossary of genetic terms.
Description of the condition
Tobacco smoking continues to be the leading cause of preventable
death in the world, and yet the most efficacious behavioural and
pharmacological treatments are ineffective for most treatment-
seeking smokers (Cahill 2012; Giovino 2012;Hughes 2014; Stead
2012a; Stead 2012b). Although social and other environmental
determinants are major contributors to tobacco use, twin and fam-
ily studies over decades have confirmed that genetic factors con-
tribute substantially to smoking behavior and to disease that can
be attributed to smoking (Bidwell 2016; Broms 2006; Carmelli
1992; Fisher 1958; Heath 2002; Li 2003; McCaffery 2008; True
1997; Xian 2008).
Given the low cessation success rate of the most efficacious smok-
ing cessation treatments and the observation of substantial heri-
tability for tobacco dependence, investigators have explored the
association between polymorphisms among genes involved in to-
bacco dependence and genes for smoking cessation drug targets
(many of which overlap), to better identify individuals who are
more or less likely to successfully quit and abstain from smok-
ing in response to specific medications (Mamoun 2015). It has
been postulated that hundreds of genes contribute and may inter-
act with each other and with the environment (e.g. via epigenetic
processes) to affect the many dimensions of tobacco dependence
through altered neuro-adaptations, metabolism, and conditioned
behaviour (Agrawal 2012; Sullivan 2004). Genomic analyses have
the potential to improve the efficacy of smoking cessation treat-
ment if meta-analyses can identify polymorphisms associated with
response to a given pharmacotherapy, and if this is followed by
validation of the finding in independent clinical trials and treat-
ment cohorts.
In this review, we used the term ’genomic’ to describe both sin-
gle-gene (traditionally described as ’genetic’) and whole-genome
(’genomic’) analyses. We did this because translational research
will continue to test more genetic loci of interest; genome-wide
analyses of clinical trials will be performed eventually; and fu-
ture reviews of more and more complex genetic data are better
described as genomic or pharmacogenomic analyses. Our review
assesses heterogeneity in treatment effects across genotype groups
or nicotine metabolite ratio (NMR) status, and heterogeneity in
treatment effects by genotype group or NMR status within treat-
ment arms. These analyses are motivated by specific hypotheses
that are pharmacogenomic (i.e. based on which genetic loci in the
genome have the greatest effect on nicotine dependence) or phar-
macometabolomic (i.e. based on the metabolite ratio of two stable
nicotinemetabolites that represent the nicotinemetabolism rate of
the enzyme with the greatest contribution to nicotine metabolism
among all protein-coding genes) in nature.
Description of the intervention
The US Food and Drug Administration (FDA) has approved
pharmacotherapies as aids to smoking cessation including five
forms of nicotine replacement therapy (NRT), bupropion SR
(Zyban), and varenicline (Chantix). NRT forms include gum,
lozenge, transdermal patch, nasal spray, and oral inhaler (numer-
ous brands, over-the-counter) (Pharmacologic Product Guide).
Different NRT therapies offer distinct benefits and limitations
with regard tomode of administration and ease of titration; bupro-
pion and varenicline offer alternative mechanisms of action to
those offered by NRT, and varenicline offers greater efficacy than
NRT monotherapy (Cahill 2013). Pharmacotherapies not ap-
proved by the FDA for use in smoking cessation as monotherapy
or combination therapy include adrenergics, monoamine oxidase
(MAO) inhibitors, selective serotonin reuptake inhibitors (SSRIs),
and serotonin-norepinephrine reuptake inhibitors (SNRIs), aswell
as other drugs and preparations.
Meta-analyses of the primary literature have identified signifi-
cant effects of monotherapy and combination therapy versus con-
trol therapy on abstinence at six-month follow-up (Cochrane
Tobacco Addiction Group). In a sample of 117 clinical trials of
NRT versus placebo or non-NRT control, data show a risk ratio
(RR) of 1.60-fold (95% confidence interval (CI) 1.53 to 1.68)
(Stead 2012a); in a sample of trials of the antidepressant bupro-
pion (44 trials) or nortriptyline (six trials) versus placebo, or of
bupropion versus nortriptyline (three trials), results include signif-
icant RRs of 1.62 (95% CI 1.49 to 1.76) and 2.03 (95% CI 1.48
to 2.78) (Hughes 2014); and in a sample of trials comparing the
cholinergic partial agonists varenicline (at standard dosage; 27 tri-
als) and cytisine (two trials) versus placebo, investigators reported
significant RRs of 2.24 (95% CI 2.06 to 2.43) and 3.98 (95% CI
2.01 to 7.87) (Cahill 2016). Multiple additional meta-analytical
comparisons provide evidence suggesting that varenicline is more
effective than bupropion or NRT monotherapy (Mills 2012).
How the intervention might work
Research on the molecular genetics of smoking has pointed to
at least two biologically plausible genetic loci contributing to
nicotine dependence, cigarette consumption, and smoking cessa-
tion. The α5-α3-β4 nicotinic acetylcholine receptor gene clus-
ter on chromosome15q25.1 (CHRNA5-CHRNA3-CHRNB4) has
been associated with cigarettes smoked per day in genome-wide
association studies; with lung cancer and chronic obstructive
pulmonary disease; and with smoking cessation in retrospective
pharmacogenetic analyses of clinical trials (Bergen 2013; Chen
2012; Chen 2014; David 2012; King 2012; Liu 2010; Munafò
2011; Saccone 2010; Thorgeirsson 2008; Thorgeirsson 2010;
Tobacco and Genetics Consortium 2010; Zhu 2014). The cy-
tochrome p450 2A6 enzyme inactivates approximately 80% of
nicotine to cotinine and other metabolites through oxidative hep-
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atic metabolism; extensive functional variation influencing the
speed of nicotinemetabolism is found atCYP2A6 (Benowitz 2006;
Benowitz 2009; McDonagh 2012; Murphy 2014). The NMR
3-hydroxycotinine/cotinine has been associated with cigarettes
smoked per day, lung and other aerodigestive cancers, and smok-
ing cessation (Bloom 2012; Canova 2009; Chen 2014; Dempsey
2004; Fujieda 2004; Gemignani 2007; Ho 2009; Lerman 2006;
Lerman 2010; Liu 2011; Patterson 2008; Rotunno 2009; Schnoll
2009; Schnoll 2010; Schoedel 2004; Tamaki 2011; Thorgeirsson
2010; Tobacco and Genetics Consortium 2010; Topcu 2002).
Variation in the CHRNA3-A5-B4 genetic locus is associated
with functional changes in key nicotinic acetylcholine receptors
in the brain, which in turn are related to behaviour (i.e. nico-
tine self-administration and smoking quantity) (Fowler 2011;
Scherf 2012; Ware 2012). Variation in the CYP2A6 genetic lo-
cus affects the rate of nicotine metabolism and is associated with
smoking quantity (McDonagh 2012). Therefore, biologic plau-
sibility underlies the relationship between these genetic loci and
smoking-related behaviour. Consistent with preclinical studies of
nicotine reinforcement and conditioned place preference, genes
in the dopamine pathway have been linked to smoking cessa-
tion (Balfour 2009; Herman 2014; Leventhal 2014; Tobacco and
Genetics Consortium 2010). Many other candidate genes and
pathways have been explored for association with smoking ces-
sation in relation to the pharmacology of nicotine and tobacco
dependence treatment. Bupropion and to a lesser degree nicotine
are metabolised by cytochrome 2B6, which converts bupropion
to the more pharmacologically active hydroxybupropion, which
in turn has been associated with smoking cessation (Benowitz
2013; Zhu 2012). A low-affinity organic cation transporter gene
(SLC22A2) has been associated with varenicline adverse effects
and with abstinence outcomes in individuals randomised to NRT
or varenicline (Bergen 2014; King 2012). Both the endogenous
opioid system and serotonin neuronal pathways are implicated
in some dimensions of nicotine dependence, and polymorphisms
in mu-opioid receptor 1 (OPRM1) and serotonin 5-HT3 recep-
tor (HTR3B) genes, respectively, have been linked to response to
smoking cessation drugs; however, results have been inconclusive
and mixed or without consistent replication for a variety of poly-
morphisms across both neurotransmitter systems (Balfour 2009;
David 2008;Hadjiconstantinou 2011; King 2012;Marteau 2012;
Munafò 2007; Munafò 2013a; Quaak 2012; Ray 2007; Verhagen
2012; Wang 2010).
Current clinical practice guidelines recommend clinician assess-
ment of every patient’s smoking behaviour, which is followed by
advice to quit, assessment of willingness to quit, assistance in quit-
ting, and arranging follow-up support (5 As) (European Smoking
CessationGuidelines 2012; Fiore 2008;West 2000).Clinical prac-
tice guidelines describe in detail aspects of patients, clinicians,
clinician engagement, behavioural therapy, and pharmacotherapy
that contribute towards abstinence (European Smoking Cessation
Guidelines 2012; Fiore 2008; West 2000). Both behavioural ther-
apies and pharmacotherapies are effective aids for patient smok-
ing cessation - therapies combining behavioural therapy and phar-
macotherapy are recommended for greatest therapeutic efficacy
(Patnode 2015). An intervention that addresses pharmacother-
apeutic efficacy by genotype or by metabolic activity offers the
prospect of improving therapeutic effectiveness beyond the mi-
nority of individuals who remain abstinent at 24 weeks with com-
bination therapies delivered by a clinician (European Smoking
Cessation Guidelines 2012; Fiore 2008; Kotz 2014; West 2000).
A genotype-based, or metabolism-based, pharmacogenomic assay
and associated intervention for smoking cessation might be de-
veloped if robust evidence for improved efficacy were to be de-
veloped through the established pathway of discovery and trans-
lation to clinical practice via retrospective and prospective tests
of clinical data, analytical validity, clinical validity, and clinical
utility. This review uses data from retrospective analyses of absti-
nence differences by genotype or metabolism subgroup in nearly
all cases (one trial contributed data from a prospective stratifica-
tion by metabolism); thus analyses of these data do not provide
clinical guidance for pharmacogenomic testing and treatment se-
lection. However, they do describe the scope of available data in
terms of sample sizes, clinical treatments, and selected available
genomic data. An intervention would be expected to be available
as a pharmacogenomic test that the physician can order; results of
the pharmacogenomic assay with clinical treatment recommenda-
tions based on prior clinical validity and utility analyses would be
available to assist the physician in treating individuals for tobacco
dependence.
Why it is important to do this review
Smoking cessation clinical trials have provided a growing body
of genotype-based subgroup analyses, but replication is rare, and
there have been no comprehensive systematic reviews with meta-
analyses. This review evaluated the effectiveness of pharmacother-
apy for smoking cessation in subgroups of treatment-seeking
smokers defined by genotype for genome-wide significant single-
nucleotide polymorphisms (SNPs), replicated non-SNP polymor-
phisms, and/or the NMR. Pharmacotherapies discussed in this
review include medications approved to treat symptoms of with-
drawal, craving, or other behavioural symptoms that affect the
ability of the individual to stop smoking and to remain abstinent;
these include all forms of NRT (e.g. patch, gum, lozenge, in-
haler, spray) andnon-nicotine pharmacotherapies (e.g. bupropion,
varenicline, cytisine, nortriptyline). Identifying whether clinically
important differences in treatment response between genomically
defined groups are likely is an essential first step in moving the
field closer to personalised treatments guided by genomic testing.
O B J E C T I V E S
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To assess whether quit rates vary by genetically informed biomark-
ers within pharmacotherapy treatment arms and as compared with
placebo. To assess the effects of pharmacotherapies for smoking
cessation in subgroups of smokers defined by genotype for iden-
tified genome-wide significant polymorphisms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished primary and secondary analyses
of randomised and quasi-randomised controlled trials (RCTs) in
which smoking cessation pharmacotherapies were initiated to en-
hance abstinence from smoking, and in which trial participants
were genotyped for polymorphisms that are genome-wide signifi-
cant (alpha threshold < 5 × 10-8) SNPs for cigarettes per day, nico-
tine dependence, or smoking cessation, as well as non-SNP poly-
morphisms that were not included in genome-wide association
studies but have been associated with smoking cessation treatment
response in at least two trials; or the NMR, which is highly influ-
enced by the cytochrome p450 2A6 (CYP2A6) gene, hereafter col-
lectively described as biomarkers (Chenoweth 2017; David 2012;
Saccone 2010; Thorgeirsson 2008; Thorgeirsson 2010; Tobacco
and Genetics Consortium 2010). Table 2 presents the polymor-
phisms of interest and NMR, which two review authors (AWB
and SPD) identified via literature review. The comparator could
be placebo, or usual/standard care, or a different pharmacother-
apy, or a non-pharmacotherapy intervention, or a no-intervention
control.We also considered trials comparing different doses or du-
rations or regimens of pharmacotherapy, or comparing different
formats of NRT, or comparing combinations of pharmacotherapy
versus a single type, or comparing different types or intensities of
behavioural support as adjuncts to pharmacotherapy. We applied
no language or date restrictions. For inclusion of a study in the
review, at least one other trial had to provide genetic or NMR
data for the same type of smoking cessation medication (e.g. if
we found only one genotyped venlafaxine or one genotyped nor-
triptyline trial, we did not perform meta-analysis).
Types of participants
Adult men and women who smoke, regardless of the setting from
which they were recruited and/or their initial level of nicotine
dependence. Participants could be of any ethnicity, butwe analysed
outcomes within different ethnic subgroups separately. We did
not anticipate a sufficient number of genomic pharmacotherapy
studies of minors (aged under 18 years) for inclusion in meta-
analyses.
Types of interventions
Smoking cessation pharmacotherapy, which included all forms
of NRT (e.g. patch, gum, lozenge, inhaler, spray) and non-nico-
tine pharmacotherapies (e.g. bupropion, varenicline, cytisine, nor-
triptyline).
Types of outcome measures
Primary outcomes
• Smoking abstinence at six months from the start of
treatment.
Secondary outcomes
• Smoking abstinence at end of treatment defined as
abstinence between 7 and 12 weeks after the start of treatment.
We did not collect information about adverse events reported in
included trials, because we expected the occurrence of such events
to be low, making power for analysis according to genotype insuf-
ficient.
Search methods for identification of studies
Electronic searches
On 16 August 2016, we searched the Cochrane Tobacco Addic-
tion Group specialised register for trials of pharmacotherapies for
smoking cessation, using the term ’genetic’, ’genomic’, ’pharmaco-
genetic’, or ’pharmacogenomic’ in the title, abstract, or keywords





• Reference lists of previous trials and overviews.
See details of search strategies applied for these databases in the
Tobacco Addiction Group module.
Additionally, we searched international online clinical trial reg-
isters for ongoing and recently completed trials, including the
WHO portal; the UK clinical trials gateway; the US clinical
trials register; and the Australian and New Zealand clinical trials
register.
In addition to the databasesmentioned above, we searched genetics
databases, including Pharmacogenomics Knowledgebase (Phar-
mGKB) and Pharmacogenomics ofNicotine AddictionTreatment
(PNAT). We considered additional searches of National Institutes
of Health (NIH) databases, but at the time of this review, smoking
cessation clinical trial data were not yet available on Genotypes
and Phenotypes (dbGaP), a database developed to archive and
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distribute data and results from studies that have investigated the
interaction of genotype and phenotype in humans.
Searching other resources
We checked the reference lists of published papers and consulted
with experts in the field to identify any relevant forthcoming or
unpublished research, or both. We contacted the authors of on-
going studies when necessary.
Data collection and analysis
Selection of studies
Two review authors (AWB and SPD) and Ms. Lindsey
Stead (Cochrane Tobacco Addiction Group, Oxford) conducted
database searches and performed initial screening of abstracts and
manuscripts. Two review authors (ES and SPD) independently
checked the abstracts and, if relevant, retrieved and reviewed the
full texts of records for data. We observed that most of the studies
eligible for inclusion were secondary analyses of pharmacotherapy
trials. For each eligible study, we identified the primary trial report
for long-term cessation outcomes.
If a given genome-wide significant SNP or non-SNP polymor-
phism was not reported in an RCT that reported other genotyp-
ing data, we contacted study authors to request these data from
unpublished genotyping data.
Data extraction and management
Four review authors (ES, OAP, AWB, and SPD) curated records
for extraction of study characteristics of primary trials.We assessed
each trial in duplicate. Review authors resolved disagreements by
consensus, or by recourse to a third review author, who was not
assigned to that particular trial. We recorded the following infor-
mation in the Characteristics of included studies tables.
• Methods: study design, study name (if applicable), study
recruitment period.
• Participants: number of participants in original trial, study
recruitment procedure, country, number of study centres, study
setting, inclusion and exclusion criteria.
• Interventions: description of intervention(s) (treatment,
dosage, regimen, behavioural support), description of control
(treatment, dosage, regimen, behavioural support), number of
participants in each treatment arm.
• Outcomes: primary outcome and secondary outcomes of
trials.
• Funding source.
• Declaration of interest.
• Notes: information on genomic analyses: whether they were
performed within the RCT or as secondary analysis, and the
number of participants successfully genotyped.
Outcome data
We contacted trial authors and asked them to supply genotype
counts by outcome, by pharmacotherapy arm, and by self-identi-
fied race/ethnicity for participants in their study for (a) a group (N
= 13) of single-nucleotide polymorphisms (SNPs) with reported
genome-wide significance with smoking cessation, cigarettes per
day, or nicotine dependence in genome-wide association study
(GWAS) investigations; (b) three variable numbers of tandem re-
peat polymorphisms (VNTRs); or (c) NMR data (David 2012;
Thorgeirsson 2010; Tobacco and Genetics Consortium 2010).
Table 2 provides an overview of all genetic polymorphisms and
major and minor alleles stratified by race group. We asked trial
authors to complete at least two predesigned data extraction forms
- one on the numbers of participants of different race/ethnicity
groups included in the trial, and another on abstinence rates for
each polymorphism, stratified by outcome, treatment arm, race/
ethnicity, and genotype. Some identified papers presented data
from multiple studies (e.g. from a meta-analysis) (Bergen 2013).
From the author of these combined analyses, we requested study
level data sowe could assess and account for differences across stud-
ies in the statistical analysis. We collected genotype information
for a given polymorphism in a trichotomised fashion (homozy-
gous major (M/M); heterozygous (M/m); homozygous minor (m/
m) alleles), and we gathered NMR information in a dichotomised
fashion (normal (NMR≥ 0.31) vs slow (NMR < 0.31) metabolis-
ers). For calculation of abstinence rates, we collected the number
of participants who were abstinent at the time point of interest
(i.e. at 6 months or at end of treatment) and the total number
randomised in that subgroup.
We contacted trial authors twice. When they did not respond to
our request, we tried to extract requested data from published
reports. If trial authors supplied or if the paper reported genotype
data in a dichotomised fashion (i.e. M/M vs M/m + m/m), we
used this information to perform analysis in a similar fashion.
Assessment of risk of bias in included studies
Four review authors (ES, OAP, AWB, and SPD) independently
assessed included studies for risks of selection bias (randomised se-
quence generation, allocation concealment), performance and de-
tection bias (presence or absence of blinding), attrition bias (levels
and reporting of loss to follow-up), and any other threats to study
quality, as recommended in Chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We assessed
each trial in duplicate. We also assessed trials for other sources of
bias specific to genotype studies: genotype frequencies for each
study and polymorphism; potential deviation from Hardy-Wein-
berg equilibrium; source of DNA (e.g. buccal swab, blood, saliva);
genotyping protocol; and any quality control (QC) methods de-
scribed. Review authors resolved disagreements by consensus, or
by recourse to a third review author, who was not assigned to that
particular trial.
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Measures of treatment effect
We calculated the cessation rate as the number of people absti-
nent at six monthsand at end of treatment, based on point preva-
lence abstinence (preferably biochemically verified but otherwise
self-reported), divided by the total number of participants in that
subgroup, separately in each genotype/treatment subgroup. We
assessed treatment effects by meta-analysing active versus placebo
effects on abstinence separately in M/M, M/m. and m/m geno-
type strata; we then generated separate RRs and 95% CIs for ac-
tive versus placebo for each genotype stratum for each biomarker.
Afterwards, we assessed heterogeneity in treatment effect across
genotype strata.
For analyses in which we found statistically significant heterogene-
ity in treatment effects across genotype subgroups, we estimated
the difference in treatment effects in M/M versus m/m and in
M/m versus m/m to capture the interaction effects of genotype x
treatment. Because estimates of treatment effects were expressed in
the log-scale (i.e. logRR), we expressed the genotype x treatment
interaction as the ratio of risk ratios (RRR) for treatment effect in
one genotype group over treatment effect in the other genotype
group. An RRR > 1 means that the treatment effect is greater in
individuals with the M/M versus non-M/M genotype.
Initially, we planned to address the potential effect of method-
ological heterogeneity in behavioural interventions across studies
for those analyses in which we found statistically significant het-
erogeneity in treatment effects across genotype subgroups. How-
ever, because the number of included studies in these analyses was
small, we deemed that such analysis was not reliable.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was reported as abstract only). In
cases for which we received individual participant data, we treated
participants lost to follow-up as continuing smokers, which yields
conservative absolute quit rates and makes little difference to the
risk ratio unless dropout rates differ substantially between groups.
For aggregate data, we relied on the decision of investigators of
the primary trial, which conventionally reports smokers who are
lost to follow-up as smoking, in keeping with intention-to-treat
analyses.
We noted in the ’Risk of bias’ tables whether results showed high
or differential loss to follow-up between treatment groups.
Assessment of heterogeneity
We evaluated levels of clinical heterogeneity between included
studies to decide whether it would be appropriate to pool data
in planned subgroups. We analysed different pharmacotherapies
separately but pooled studies using different types of NRT.
We assessed statistical heterogeneity in each meta-analysis using
T², I², and Chi² statistics (Higgins 2003). We regarded statistical
heterogeneity as substantial if I² was greater than 50% and either
T² was greater than zero, or the P value was low (< 0.10) in the
Chi² test for heterogeneity.
Assessment of reporting biases
We decided that if 10 or more studies contributed data to the
meta-analysis for either outcome, we would investigate reporting
biases (such as publication bias) using funnel plots, so as to as-
sess possible asymmetry visually. If asymmetry was suggested by
visual assessment, we planned to perform exploratory analyses to
investigate this using more formal tests, such as Egger’s and Begg’s
tests (Begg 1994; Egger 1997). This version of the review included
too few studies in each of the meta-analyses performed to allow
assessment of reporting bias.
Data synthesis
For each polymorphism, we undertook two types of analysis.
• Comparisons of relative treatment effect by genotype. We
grouped studies based on the characteristics of intervention and
control arms.
◦ Each individual pharmacotherapy or combination
compared with placebo/no pharmacotherapy control.
◦ Comparisons between different pharmacotherapies.
◦ Combinations of pharmacotherapy compared with a
single pharmacotherapy.
We tested for heterogeneity in relative effects between genotype
subgroups.
• Comparisons of treatment effects between genotype groups,
within pharmacotherapy randomisation arms. Some clinical
trials included only one pharmacotherapy arm but more than
one behavioural support arm, but we did not stratify analyses by
behavioural support arm. Analyses of genotype effects within
drug groups separately compared abstinence outcomes between 1
to 0 risk alleles and 2 to 0 risk alleles. If possible, we compared
risk allele heterozygotes and homozygotes versus reference alleles
in separate analyses (e.g. rs1051730 CT vs CC, or TT vs CC
rather than CT/TT vs CC).
Differences in genetic architecture (allele frequencies and/or link-
age disequilibrium) between ancestral groups may result in pop-
ulation structure, which may lead to confounding if smoking be-
haviour-related outcomes are associatedwith both ancestry and ge-
netic architecture. Conditions for population stratification aremet
for comparisons between African Americans and European Amer-
icans owing to differences in smoking behaviours (e.g. African
Americans smoke fewer cigarettes per day than European Amer-
icans and in genetic architecture at relevant loci; we conducted
separate analyses for white and black or African American study
populations at genotype-based biomarkers (Beirut 2008; Cardon
2003; Trinidad 2015; Wang 2013). We also considered other an-
cestries (e.g. Asian), but data were not sufficient to allow sepa-
rate meta-analyses in these populations. We did analyse the NMR
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across ancestry groups rather than separately by ancestry group be-
cause theNMR is a metabolic marker (not a genotype). TheNMR
is genetically informed by prior knowledge about the CYP2A6
genotype, but other genes and environmental factors affect NMR;
because it is not a genotype, the same concerns about population
stratification do not apply to the NMR.
We pooled risk ratios (RRs) using a Mantel-Haenszel random-
effects model with a 95% confidence interval (CI) for our meta-
analysis, so as to account for statistical heterogeneity across in-
cluded studies. When the event is defined as smoking cessation, an
RR greater than one indicates that more people in the treatment
group than in the control group successfully quit. We carried out
statistical analysis using RevMan (Review Manager 5.3).
Subgroup analysis and investigation of heterogeneity
In the event of evidence of heterogeneity within planned sub-
groups based on genotype and type of pharmacotherapy, we
planned to explore the impact of the following possible factors.
• Different comparators.
• Levels of behavioural support.
• Dose or duration of treatment.
• Gender differences.
• Motivation to quit.
• Level of nicotine dependence.
However, because heterogeneity within genotype groups was gen-
erally low and available data within genotype groups were gener-
ally sparse, we refrained from performing any such subgroup anal-
yses.
Sensitivity analysis
We planned to conduct sensitivity analyses to determine whether
inclusion of quasi-RCTs and risk of bias made a difference in our
findings. However, we did not identify any quasi-RCTs, and we
did not find enough studies at this time to undertake sensitivity
analyses.
’Summary of findings’ table
In keeping with standard Cochrane methods, we created a ’Sum-
mary of findings’ table for comparisons between active NRT and
placebo (because it is the most commonly administered interven-
tion of those included in the review) for the genotypes most fre-
quently studied. As part of this process, we used the five GRADE
considerations (study limitations, consistency of effect, impreci-
sion, indirectness, and publication bias) to assess the quality of the
body of evidence for each outcome. This assessment of the quality
of evidence within the review informs the confidence with which
we view our conclusions.
R E S U L T S
Description of studies
Results of the search
Through our search strategy, we identified a total of 479 unique
papers, ofwhich 94were eligible for inclusion in our review (Figure
1). These corresponded to 35 primary randomised clinical trials of
pharmacotherapies that compared two or more smoking cessation
intervention arms that met the inclusion criteria stated (Ahluwalia
2006; Aveyard 2007; Bloch 2010; Brown 2007; Cinciripini 2005;
Cox 2012; Gilbert 2009;Gonzales 2006;GPRG 1993;Hall 2008;
Hall 2009; Jorenby 2006;Kalman2011;Killen2006;Killen2008;
Killen 2010; King 2012; Lerman 2002; Lerman 2004; Lerman
2015; Marteau 2012; McCarthy 2008; McClure 2013; Oncken
2006; Piper 2007; Piper 2009; Rose 2010; Schnoll 2010; Sun
2012; Swan 2003; Swan 2010; Verde 2014;Wagena 2005;Wilcox
2011; Winst 2006). We excluded three of these studies (Bloch
2010; King 2012; McClure 2013; see Excluded studies). Of the
remaining 33 studies, we were able to obtain data from 14 studies
by contacting the principal investigator and for four studies by
extracting data from published reports (Ahluwalia 2006; Aveyard
2007; Brown 2007; Cox 2012; Gilbert 2009; GPRG 1993; Hall
2008; Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015;
Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009; Swan
2010; Wagena 2005; Winst 2006). In total, we included 18 ran-
domised clinical trials in the quantitative analysis (Ahluwalia 2006;
Aveyard 2007; Brown 2007; Cox 2012; Gilbert 2009; GPRG
1993;Hall 2008;Hall 2009; Lerman2002; Lerman 2004; Lerman
2015; Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009;
Swan 2010; Wagena 2005; Winst 2006). We did not consider
14 trials in the quantitative analysis because we obtained no rel-
evant data via contact with the principal investigator or through
review of published reports (Cinciripini 2005; Gonzales 2006;
Jorenby 2006; Kalman 2011; Killen 2006; Killen 2008; Killen
2010; Oncken 2006; Rose 2010; Schnoll 2010; Sun 2012; Swan
2003; Verde 2014; Wilcox 2011). For the remainder of this re-
port, we will focus only on those studies that contributed to the
quantitative analysis.
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Figure 1. Flow diagram of the search and study selection.
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Included studies
Refer to the Characteristics of included studies table for details.
We retrieved data (genotype counts by abstinence status, treat-
ment arm, and race/ethnicity) from 18 randomised clinical trials
including 9017 participants, of whom 6924 were non-Hispanic
whites (NHWs) and 2093 were non-Hispanic black or African
American (NHB) participants.
Data were available for 13 biomarkers: nine SNPs (rs1051730
(CHRNA3) (n = 13: Aveyard 2007; Becker 2008; Brown 2007;
GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman 2004;
Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009; Swan
2010; Winst 2006), rs16969968 (n = 7: Ahluwalia 2006; Cox
2012; Lerman 2015; McCarthy 2008; Piper 2007; Piper 2009),
rs588765 (n = 10: Ahluwalia 2006; Brown 2007; Cox 2012;
Hall 2008; Hall 2009; Lerman 2002; Lerman 2004; Lerman
2015; Piper 2009; Swan 2010), rs2036527 (CHRNA5) (n =
7: Ahluwalia 2006; Cox 2012; Lerman 2002; Lerman 2004;
McCarthy 2008; Piper 2007; Piper 2009), rs3733829 (n = 4:
Brown 2007; McCarthy 2008; Piper 2007; Piper 2009), rs7937
(EGLN2) (n = 3: McCarthy 2008; Piper 2007; Piper 2009),
rs1329650 (n = 3: McCarthy 2008; Piper 2007; Piper 2009),
rs1028936 (LOC100188947) (n = 3: McCarthy 2008; Piper
2007; Piper 2009), and rs215605 (PDE1C) (n = 3: McCarthy
2008; Piper 2007; Piper 2009)); two VNTRs (DRD4 (n = 4:
Aveyard 2007; Brown 2007; Gilbert 2009; GPRG 1993) and
SLC6A4 (n = 3: Aveyard 2007; Gilbert 2009;Wagena 2005)); and
the NMR (n = 3: Ahluwalia 2006; GPRG 1993; Lerman 2015).
Datawere insufficient to allow analysis for five additional biomark-
ers: four SNPs: rs13280604 (no trials), rs4105144 (no trials),
rs6474412 (n = 1: Brown 2007), and rs3025343 (n = 1: Brown
2007); and one VNTR: SLC6A3 (3’ 40 bp) (n = 1: Brown 2007),
which were identified initially as relevant to investigate.
We identified placebo-controlled trials of NRT (n = 4: Ahluwalia
2006; Gilbert 2009; GPRG 1993; Winst 2006); bupropion (n =
6: Brown 2007; Cox 2012; Hall 2008; Lerman 2002; McCarthy
2008; Wagena 2005); NRT, bupropion, and NRT + bupropion
(n = 1: Piper 2009); NRT and varenicline (n = 1: Lerman 2015);
and bupropion and NRT + bupropion (n = 1: Piper 2007). In
the other trials, all participants received NRT (n = 4: Aveyard
2007; Hall 2009; Lerman 2004; Marteau 2012) or varenicline (n
= 1: Swan 2010). NRT trials included gum (Ahluwalia 2006; Hall
2009; Piper 2007), lozenge (Piper 2009), patch (Aveyard 2007;
Cinciripini 2005; Gilbert 2009; GPRG 1993; Hall 2008; Kalman
2011; Killen 2006; Killen 2008; Killen 2010; Lerman 2004;
Lerman 2015; Marteau 2012; Piper 2009; Rose 2010; Schnoll
2010; Verde 2014; Winst 2006), and spray (Lerman 2004) NRT
interventions. Piper et al included NRT lozenge and transdermal
patch intervention arms in this five-arm trial (Piper 2009).
Trials contained at least one arm of NRT (n = 10: Ahluwalia 2006;
Aveyard 2007; Gilbert 2009; GPRG 1993; Hall 2009; Lerman
2004; Lerman 2015; Marteau 2012; Piper 2009; Winst 2006),
bupropion (n = 7: Brown 2007; Cox 2012; Hall 2008; Lerman
2002; McCarthy 2008; Piper 2007; Piper 2009; Wagena 2005),
varenicline (n = 2: Lerman 2015; Swan 2010), NRT + bupropion
(n = 2: Piper 2007; Piper 2009), or placebo (n = 13: Ahluwalia
2006; Brown 2007; Cox 2012; Gilbert 2009; GPRG 1993; Hall
2008; Lerman 2002; Lerman 2015; McCarthy 2008; Piper 2007;
Piper 2009; Wagena 2005; Winst 2006), resulting in a total of
40 active versus placebo, 16 active versus active, and 64 between-
genotype comparisons.
Data on the primary outcome - abstinence at six months -
were available from 16 trials (Ahluwalia 2006; Aveyard 2007;
Brown 2007; Cox 2012; Gilbert 2009; GPRG 1993; Hall 2008;
Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015; Marteau
2012; Piper 2009; Swan 2010; Wagena 2005; Winst 2006). Data
on abstinence at end of treatment were available from 17 tri-
als (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox 2012;
Gilbert 2009; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002;
Lerman 2004; Lerman 2015; McCarthy 2008; Piper 2007; Piper
2009; Swan 2010; Wagena 2005; Winst 2006). Eleven trials in-
cluded mostly NHW participants (Aveyard 2007; Brown 2007;
Gilbert 2009; GPRG 1993;Hall 2008; Hall 2009;Marteau 2012;
McCarthy 2008; Swan 2010;Wagena 2005;Winst 2006). Five tri-
als includedNHWandNHBparticipants (Lerman 2002; Lerman
2004; Lerman 2015; Piper 2007; Piper 2009). Two trials included
NHB participants only (Ahluwalia 2006; Cox 2012). Available
datawere insufficient to allowmeta-analyses forHispanic or Latino
race or for non-Hispanic or non-Latino ethnic groups other than
NHW or NHB.
Excluded studies
In total, we excluded three of the 36 identified randomised clini-
cal trials - one because researchers performed no individual geno-
typing, and two because investigators reported no genotypes of
interest and/or made none available (Becker 2008; King 2012;
McClure 2013). Additional information on these studies can be
found in the Characteristics of excluded studies tables.
Risk of bias in included studies
Overall risk of bias of randomised clinical trials included in
the quantitative analysis varied from low to high. Refer to the
Characteristics of included studies table for details, and to Figure
2 and Figure 3 for a summary of ‘Risk of bias’ assessments. For one
trial, we had only a protocol available, and this made it difficult
to assess risk of bias of this study as actually performed (Winst
2006).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We assessed random sequence generation as having low risk of bias
for 16 studies (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox
2012; Gilbert 2009; GPRG 1993; Hall 2008; Hall 2009; Lerman
2002; Lerman 2004; Lerman 2015; Marteau 2012; McCarthy
2008; Swan 2010; Wagena 2005; Winst 2006). We assessed two
studies as having unclear risk (Piper 2007; Piper 2009). We con-
sidered allocation concealment as having low risk of bias for 10
studies (Ahluwalia 2006; Aveyard 2007; GPRG 1993; Hall 2008;
Hall 2009; Lerman 2002; Lerman 2015; Marteau 2012; Piper
2009; Wagena 2005). We found unclear risk for seven studies
(Brown 2007; Cox 2012; Gilbert 2009; McCarthy 2008; Piper
2007; Swan 2010; Winst 2006). We determined that one study
was at high risk (Lerman 2004).
Blinding
We considered blinding of participants and personnel as having
low risk of bias for 11 studies (Ahluwalia 2006; Brown 2007;
Cox 2012; Gilbert 2009; GPRG 1993; Lerman 2002; Lerman
2015; Piper 2007; Piper 2009; Swan 2010; Wagena 2005). We
judged four studies as having unclear risk (Hall 2008; Hall 2009;
McCarthy 2008; Winst 2006). We found that three studies were
at high risk (Aveyard 2007; Lerman 2004; Marteau 2012). We
considered blinding of outcome assessment as having low risk
of bias for 13 studies (Aveyard 2007; GPRG 1993; Hall 2008;
Hall 2009; Lerman 2002; Lerman 2004; Lerman 2015; Marteau
2012; McCarthy 2008; Piper 2007; Piper 2009; Swan 2010;
Wagena 2005).Wedetermined that five studieswere at unclear risk
(Ahluwalia 2006; Brown 2007; Cox 2012; Gilbert 2009; Winst
2006).
Incomplete outcome data
We considered incomplete outcome data as having low risk of
bias for 12 studies (Ahluwalia 2006; Aveyard 2007; Brown 2007;
Cox 2012; Hall 2008; Hall 2009; Lerman 2015; Marteau 2012;
McCarthy 2008; Piper 2007; Piper 2009; Wagena 2005). We
deemed that four studies had unclear risk (Gilbert 2009; GPRG
1993; Swan 2010; Winst 2006). We found high risk for two stud-
ies (Lerman 2002; Lerman 2004).
Selective reporting
We considered selective reporting as having low risk of bias for
15 studies (Ahluwalia 2006; Aveyard 2007; Brown 2007; Cox
2012; GPRG 1993; Hall 2008; Hall 2009; Lerman 2002; Lerman
2015; Marteau 2012; McCarthy 2008; Piper 2007; Piper 2009;
Swan 2010; Wagena 2005).We determined that two studies were
at unclear risk (Lerman 2004; Winst 2006). We found that one
study was at high risk (Gilbert 2009).
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Other potential sources of bias
We assessed 11 studies as having low risk of bias for other poten-
tial sources of bias based on genotype frequencies (in study and
polymorphism), potential deviation from Hardy-Weinberg equi-
librium, source of DNA (e.g. buccal swab, blood, saliva), genotyp-
ing protocol, and QC methods (Ahluwalia 2006; Aveyard 2007;
Cox 2012; Hall 2008; Hall 2009; Lerman 2002; Lerman 2004;
Lerman 2015; Marteau 2012; Piper 2009; Wagena 2005). For
three studies, wewere unable to assess the risk of other biases (Piper
2007; Swan 2010; Winst 2006). For four studies, we considered
the risk of other bias to be high because a large proportion of origi-
nal trial participants were not genotyped, thereby opening the pos-
sibility of selection bias, or because relapsers were excluded from
analyses, which may have created study population imbalance for
genetic predisposition to successfully quit smoking (Brown 2007;
Gilbert 2009; GPRG 1993; McCarthy 2008).
Effects of interventions
See: Summary of findings for the main comparison Active
NRT compared with placebo - rs1051730 - non-Hispanic white
for smoking cessation; Summary of findings 2 Active NRT
compared with placebo - rs16969968 - non-Hispanic white for
smoking cessation;Summaryof findings 3ActiveNRTcompared
with placebo - rs16969968 - non-Hispanic black or African
American for smoking cessation; Summary of findings 4 Active
NRT compared with placebo - rs 588765 - non-Hispanic white
for smoking cessation; Summary of findings 5 Active NRT
compared with placebo - rs2036527 - non-Hispanic black or
African American for smoking cessation; Summary of findings
6 Active NRT compared with placebo - DRD4 (exon 3 48 bp) -
non-Hispanic white for smoking cessation; Summary of findings
7 Active NRT compared with placebo - NMR - non-Hispanic
black and white for smoking cessation
Results are presented according to type of analysis (comparisons
of relative treatment effect by genotype, or comparisons of treat-
ment effect between genotype groups, within pharmacotherapy
randomisation arms) and type of treatment (comparison). Table
3, Table 4, Table 5, and Table 6 show the summary results for each
type of analysis with separate tables for six-month abstinence and
abstinence at the end of treatment.
Comparisons of relative treatment effects by
genotype
Active NRT versus placebo
Six-month abstinence
Data were available for the following SNPs: rs1051730 (n = 3,
1597 participants, NHW; Analysis 1.1), rs16969968 (n = 2, 709
participants, NHB; Analysis 3.1), rs2036527 (n = 2, 709 partic-
ipants, NHB; Analysis 5.1), DRD4 (exon 3 48 bp) (n = 2, 900
participants, NHW; Analysis 6.1), and NMR (n = 2, 1418 partic-
ipants, NHW or NHB; Analysis 7.1).
Results showed statistically significant heterogeneity between
genotype groups in the analysis of NHB for rs16969968 (P = 0.03;
Analysis 3.1; Summary of findings 3). Six-month abstinence was
increased in the active NRT group as compared with the placebo
group among participants with a GG genotype (RR 1.47, 95%
CI 1.07 to 2.03), but not in the combined group of those with
a GA or AA genotype (RR 0.43, 95% CI 0.15 to 1.26; Analysis
3.1; Summary of findings 3; RRR GG vs GA or AA 3.51, 95%
CI 1.19 to 10.3). We found no such heterogeneity for any of the
other biomarkers.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n = 2,
1391 participants, NHW; Analysis 1.2), rs16969968 (n = 2, 1127
participants, NHW; Analysis 2.1; n = 2, 709 participants, NHB;
Analysis 3.2), rs588765 (n = 2, 923 participants, NHW; Analysis
4.1), rs2036527 (n = 2, 708 participants, NHB; Analysis 5.2),
DRD4 (exon 3 48 bp) (n = 2, 900 participants, NHW; Analysis
6.2), andNMR(n=2, 1417participants,NHWorNHB;Analysis
7.2).
We found statistically significant heterogeneity between geno-
type groups in the analysis of NHW for rs1051730 (heterogene-
ity P = 0.004; Analysis 1.2; Summary of findings for the main
comparison) and rs16969968 (heterogeneity P = 0.02; Analysis
2.1; Summary of findings for the main comparison), and of NHB
for rs16969968 (heterogeneity P = 0.003; Analysis 3.2; Summary
of findings 3). For the rs1051730 analysis in NHW, abstinence at
end of treatment was comparable between the active NRT group
and the placebo group among participants with a GG genotype
(RR 1.09, 95% CI 0.85 to 1.41), but was increased in those with
GA or AA genotype (RR 2.13, 95% CI 1.52 to 2.97; and RR
2.18, 95%CI 1.04 to 4.58, respectively; Analysis 1.2; Summary of
findings for the main comparison; RRR GG vs AA and GA vs AA
genotype of 0.54, 95%CI 0.26 to 1.14; and 0.96, 95%CI 0.44 to
2.11, respectively). For the rs16969968 analysis in NHW, end-of-
treatment abstinence increased with active NRT as compared with
placebo among individuals with GA genotype (RR 1.85, 95% CI
1.33 to 2.59), but was comparable among those with GG or AA
(RR 1.01, 95% CI 0.77 to 1.33; and RR 1.80, 95% CI 0.45 to
7.23, respectively; Analysis 2.1; Summary of findings for the main
comparison; RRR GG vs AA and GA vs AA genotype of 0.78,
95% CI 0.33 to 1.47; and 1.04, 95% CI 0.45 to 2.41, respec-
tively). For rs16969968 in NHB, active NRT increased end-of-
treatment abstinence compared with placebo among those with
GG genotype (RR 1.57, 95% CI 1.15 to 2.15), and it decreased
end-of-treatment abstinence among those with GA or AA pheno-
type (RR 0.29, 95% CI 0.10 to 0.86; Analysis 3.2; Summary of
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findings 3; RRR GG vs GA or AA genotype of 5.84, 95% CI 1.89




Data were available for the following SNPs: rs1051730 (n =
4, 1329 participants, NHW; Analysis 8.1; n = 3, 126 partic-
ipants, NHB; Analysis 9.1), rs16969968 (n = 2, 578 partici-
pants, NHB; Analysis 11.1), rs588765 (n = 4, 1108 participants,
NHW;Analysis 12.1), rs2036527 (n = 2, 738 participants, NHW;
Analysis 13.1; n = 3, 660 participants, NHB; Analysis 14.1), and
rs3733829 (n = 2, 571 participants, NHW; Analysis 15.1).
We found no heterogeneity between genotype groups when com-
paring bupropion versus placebo for any of the biomarkers.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n =
6, 1379 participants, NHW; Analysis 8.2; n = 3, 159 partici-
pants, NHB; Analysis 9.2), rs16969968 (n = 3, 557 participants,
NHW; Analysis 10.1; n = 3, 611 participants, NHB; Analysis
11.2), rs588765 (n = 4, 1107 participants, NHW; Analysis 12.2),
rs2036527 (n = 4, 975 participants, NHW; Analysis 13.2; n = 4,
693 participants, NHB; Analysis 14.2), rs3733829 (n = 4, 807
participants, NHW; Analysis 15.2; n = 2, 75 participants, NHB;
Analysis 16.1), rs7937 (n = 3, 557 participants, NHW; Analysis
17.1; n = 2, 76 participants, NHB; Analysis 18.1), rs1329650 (n =
3, 559 participants, NHW; Analysis 19.1; n = 2, 76 participants,
NHB; Analysis 20.1), rs1028936 (n = 3, 559 participants, NHW;
Analysis 21.1; n = 2, 76 participants, NHB; Analysis 22.1), and
rs215605 (n = 3, 558 participants, NHW; Analysis 23.1; n = 2,
76 participants, NHB; Analysis 24.1).
We found no heterogeneity between genotype groups when com-
paring bupropion versus placebo for any of the biomarkers.
Bupropion + any NRT versus placebo
Six-month abstinence
No data were available for this outcome.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n =
2, 444 participants, NHW; Analysis 25.1; n = 2, 69 partici-
pants, NHB; Analysis 26.1), rs16969968 (n = 2, 441 participants,
NHW;Analysis 27.1; n = 2, 69 participants, NHB; Analysis 28.1),
rs2036527 (n = 2, 443 participants, NHW; Analysis 29.1; n =
2, 69 participants, NHB; Analysis 30.1), rs3733829 (n = 2, 441
participants, NHW; Analysis 31.1; n = 2, 69 participants, NHB;
Analysis 32.1), rs7937 (n = 2, 442 participants, NHW; Analysis
33.1; n = 2, 69 participants, NHB; Analysis 34.1), rs1329650 (n =
2, 442 participants, NHW; Analysis 35.1; n = 2, 69 participants,
NHB; Analysis 36.1), rs1028936 (n = 2, 444 participants, NHW;
Analysis 37.1; n = 2, 69 participants, NHB; Analysis 38.1), and
rs215605 (n = 2, 442 participants, NHW; Analysis 39.1; n = 2,
68 participants, NHB; Analysis 40.1).
We found no heterogeneity between genotype groups when com-
paring bupropion + any NRT versus placebo for any of the
biomarkers.
Bupropion + any NRT versus bupropion alone
Six-month abstinence
No data were available for this outcome.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n =
2, 533 participants, NHW; Analysis 41.1; n = 2, 87 partici-
pants, NHB; Analysis 42.1), rs16969968 (n = 2, 531 participants,
NHW;Analysis 43.1; n = 2, 87 participants, NHB; Analysis 44.1),
rs2036527 (n = 2, 532 participants, NHW; Analysis 45.1; n =
2, 87 participants, NHB; Analysis 46.1), rs3733829 (n = 2, 531
participants, NHW; Analysis 47.1; n = 2, 94 participants, NHB;
Analysis 48.1), rs7937 (n = 2, 533 participants, NHW; Analysis
49.1; n = 2, 87 participants, NHB; Analysis 50.1), rs1329650 (n =
2, 531 participants, NHW; Analysis 51.1; n = 2, 87 participants,
NHB; Analysis 52.1), rs1028936 (n = 2, 533 participants, NHW;
Analysis 53.1; n = 2, 87 participants, NHB; Analysis 54.1), and
rs215605 (n = 2, 532 participants, NHW; Analysis 55.1; n = 2,
87 participants, NHB; Analysis 56.1).
We found no heterogeneity between genotype groups when com-
paring bupropion + any NRT versus bupropion for any of the
biomarkers.
Comparisons of treatment effects between genotype
groups within pharmacotherapy randomisation arms
Active NRT
Six-month abstinence
Data were available for the following SNPs: rs1051730 (n = 7,
2687 participants, NHW; Analysis 57.1; n = 2, 237 participants,
NHB; Analysis 58.1), rs16969968 (n = 2, 392 participants, NHB;
Analysis 59.1), rs588765 (n = 3, 832 participants, NHW;Analysis
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60.1), rs2036527 (n = 2, 948 participants, NHW; Analysis 61.1;
n = 2, 391 participants, NHB; Analysis 62.1), DRD4 (exon 3 48
bp) (n = 3, 1119 participants, NHW; Analysis 63.1), SLC6A4
(Promoter) (n = 2, 926 participants, NHW; Analysis 64.1), and
NMR (n = 2, 718 participants, NHW and NHB; Analysis 65.1).
Among those receiving active NRT, individuals with a slow NMR
were more successful in achieving six-month abstinence as com-
pared with those with a normal NMR among NHW and NHB
participants (normal NMR vs slow NMR: RR 0.54, 95% CI 0.37
to 0.78; Analysis 65.1).
We found no heterogeneity between genotype group comparisons
(homozygous major vs homozygous minor compared with het-
erozygous vs homozygous minor, or slow vs normal) among indi-
viduals randomised to active NRT for any of the other biomarkers.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n = 5,
2208 participants, NHW; Analysis 57.2), rs16969968 (n = 2,
392 participants, NHB; Analysis 59.2), rs588765 (n = 3, 832
participants, NHW; Analysis 60.2), rs2036527 (n = 2, 948 par-
ticipants, NHW; Analysis 61.2; n = 2, 391 participants, NHB;
Analysis 62.2), DRD4 (exon 3 48 bp) (n = 3, 1119 participants,
NHW; Analysis 63.2), SLC6A4 (Promoter) (n = 2, 926 partici-
pants, NHW; Analysis 64.2), and NMR (n = 2, 718 participants,
NHW and NHB; Analysis 65.2).
Among those receiving active NRT, GG genotype individuals
more often achieved end-of-treatment abstinence as compared
with individuals with a combination of GA and AA genotypes for
rs16969968 and rs2036527 in NHB (RR 2.75, 95% CI 1.08 to
7.02; Analysis 59.2; RR 1.73, 95%CI 1.20 to 2.49; Analysis 62.2;
respectively).
We found no heterogeneity between genotype group comparisons
(homozygous major vs homozygous minor compared with het-
erozygous vs homozygous minor, or slow vs normal) among indi-
viduals randomised to active NRT for any of the other biomarkers.
Bupropion
Six-month abstinence
Data were available for the following SNPs: rs1051730 (n = 4,
610 participants, NHW; Analysis 66.1; n = 2, 63 participants,
NHB; Analysis 67.1), rs16969968 (n = 2, 294 participants, NHB;
Analysis 69.1), rs588765 (n = 4, 596 participants, NHW;Analysis
70.1), rs2036527 (n = 2, 412 participants, NHW; Analysis 71.1;
n = 3, 331 participants, NHB; Analysis 72.1), and rs3733829 (n
= 2, 307 participants, NHW; Analysis 73.1).
Among those receiving bupropion, we identified no specific geno-
type groups that were more successful in achieving six-month ab-
stinence than other groups. Additionally, we found no hetero-
geneity between genotype group comparisons (homozygous major
vs homozygous minor compared with heterozygous vs homozy-
gous minor, or slow vs normal) among individuals randomised to
bupropion for any of the biomarkers.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n =
6, 743 participants, NHW; Analysis 66.2; n = 3, 84 partici-
pants, NHB; Analysis 67.2), rs16969968 (n = 3, 324 participants,
NHW; Analysis 68.1; n = 3, 315 participants, NHB; Analysis
69.2), rs588765 (n = 4, 596 participants, NHW; Analysis 70.2),
rs2036527 (n = 4, 546 participants, NHW; Analysis 71.2; n = 4,
352 participants, NHB; Analysis 72.2), rs3733829 (n = 4, 440
participants, NHW; Analysis 73.2; n = 2, 46 participants, NHB;
Analysis 74.1), rs7937 (n = 3, 324 participants, NHW; Analysis
75.1; n = 2, 47 participants, NHB; Analysis 76.1), rs1329650 (n =
3, 324 participants, NHW; Analysis 77.1; n = 2, 47 participants,
NHB; Analysis 78.1), rs1028936 (n = 3, 324 participants, NHW;
Analysis 79.1; n = 2, 47 participants, NHB; Analysis 80.1), and
rs215605 (n = 3, 324 participants, NHW; Analysis 81.1; n = 2,
47 participants, NHB; Analysis 82.1).
Among those receiving bupropion, we identified no specific geno-
type groups that were more successful in achieving end-of-therapy
abstinence than other groups. Additionally, we found no hetero-
geneity between genotype group comparisons (homozygous major
vs homozygous minor compared with heterozygous vs homozy-
gous minor, or slow vs normal) among individuals randomised to
bupropion for any of the biomarkers.
Varenicline
Six-month abstinence
Data were available for the following SNPs: rs16969968 (n = 2,
707 participants, NHW; Analysis 83.1) and rs588765 (n = 2, 699
participants; Analysis 84.1).
Among those receiving varenicline, we identified no specific geno-
type groups that were more successful than other groups in achiev-
ing six-month abstinence. Additionally, we foundnoheterogeneity
between genotype group comparisons (homozygous major vs ho-
mozygous minor compared with heterozygous vs homozygous mi-
nor, or slow vs normal) among individuals randomised to vareni-
cline for any of the biomarkers.
End-of-treatment abstinence
Data were available for the following SNPs: rs16969968 (n = 2,
707 participants, NHW; Analysis 83.2) and rs588765 (n = 2, 699
participants, NHW; Analysis 84.2).
Among those receiving varenicline, we identified no specific geno-
type groups that were more successful than other groups in achiev-
ing end-of-therapy abstinence. Additionally, we found no hetero-
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geneity between genotype group comparisons (homozygous major
vs homozygous minor compared with heterozygous vs homozy-
gous minor, or slow vs normal) among individuals randomised to
varenicline for any of the biomarkers.
Bupropion + any NRT
Six-month abstinence
No data were available for this outcome.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n =
2, 268 participants, NHW; Analysis 85.1; n = 2, 40 partici-
pants, NHB; Analysis 86.1), rs16969968 (n = 2, 266 participants,
NHW;Analysis 87.1; n = 2, 40 participants, NHB; Analysis 88.1),
rs2036527 (n = 2, 267 participants, NHW; Analysis 89.1; n =
2, 40 participants, NHB; Analysis 90.1), rs3733829 (n = 2, 267
participants, NHW; Analysis 91.1; n = 2, 40 participants, NHB;
Analysis 92.1), rs7937 (n = 2, 268 participants, NHW; Analysis
93.1; n = 2, 40 participants, NHB; Analysis 94.1), rs1329650 (n =
2, 266 participants, NHW; Analysis 95.1; n = 2, 40 participants,
NHB; Analysis 96.1), rs1028936 (n = 2, 268 participants, NHW;
Analysis 97.1; n = 2, 40 participants, NHB; Analysis 98.1), and
rs215605 (n = 2, 267 participants, NHW; Analysis 99.1; n = 2,
40 participants, NHB; Analysis 100.1).
Among those receiving bupropion + any NRT, GG genotype in-
dividuals more often achieved six-month abstinence as compared
with AA genotype individuals for rs1329650 inNHW(AA vsGG,
RR 0.64, 95% CI 0.43 to 0.94; Analysis 95.1), as did individuals
with GG or AG genotype compared with AA genotype individuals
for rs3733829 in NHB (AA vs AG or GG RR 0.36, 95% CI 0.13
to 0.99; Analysis 92.1).
We found no heterogeneity between genotype group comparisons
(homozygous major vs homozygous minor compared with het-
erozygous vs homozygous minor, or slow vs normal) among indi-




Data were available for the following SNPs: rs1051730 (n = 6, 974
participants, NHW; Analysis 101.1; n = 2, 63 participants, NHB;
Analysis 102.1), rs16969968 (n = 2, 343 participants, NHW;
Analysis 103.1; n = 3, 584 participants, NHB; Analysis 104.1),
rs588765 (n = 5, 723 participants, NHW; Analysis 105.1; n =
2, 566 participants, NHB; Analysis 106.1), rs2036527 (n = 2,
326 participants, NHW; Analysis 107.1; n = 4, 629 participants,
NHB; Analysis 108.1), DRD4 (exon 3 48 bp) (n = 3, 573 par-
ticipants, NHW; Analysis 109.1), rs3733829 (n = 2, 264 partic-
ipants, NHW; Analysis 110.1), SLC6A4 (Promoter) (n = 2, 151
participants, NHW; Analysis 119.1), and NMR (n = 2, 699 par-
ticipants, NHW and NHB; Analysis 120.1).
Among those receiving placebo, abstinence rates were not statisti-
cally significantly different between specific genotype groups. Ad-
ditionally, we found no heterogeneity between genotype group
comparisons (homozygous major vs homozygous minor com-
pared with heterozygous vs homozygous minor, or slow vs normal)
among individuals randomised to placebo for any of the biomark-
ers.
End-of-treatment abstinence
Data were available for the following SNPs: rs1051730 (n = 7, 983
participants, NHW; Analysis 101.2; n = 3, 83 participants, NHB;
Analysis 102.2), rs16969968 (n = 4, 445 participants, NHW;
Analysis 103.2; n = 4, 596 participants, NHB; Analysis 104.2),
rs588765 (n = 5, 658 participants, NHW; Analysis 105.2; n =
2, 566 participants, NHB; Analysis 106.2), rs2036527 (n = 4,
429 participants, NHW; Analysis 107.2; n = 5, 641 participants,
NHB; Analysis 108.2), DRD4 (exon 3 48 bp) (n = 3, 573 partici-
pants, NHW;Analysis 109.2), rs3733829 (n = 4, 367 participants,
NHW; Analysis 110.2), rs7937 (n = 3, 233 participants, NHW;
Analysis 111.1; n = 2, 29 participants, NHB; Analysis 112.1),
rs1329650 (n = 3, 235 participants, NHW; Analysis 113.1; n
= 2, 29 participants, NHB; Analysis 114.1), rs1028936 (n = 3,
235 participants, NHW; Analysis 115.1; n = 2, 29 participants,
NHB; Analysis 116.1), rs215605 (n = 3, 234 participants, NHW;
Analysis 117.1; n = 2, 29 participants, NHB; Analysis 118.1),
SLC6A4 (Promoter) (n = 2, 151 participants, NHW; Analysis
119.2), and NMR (n = 2, 718 participants, NHW and NHB;
Analysis 120.2).
Abstinence at the end of treatment among those receiving placebo
was greater among individuals with AA or GA genotype than
among those with GG genotype for rs16969968 in NHB (GG vs
GA or AA, RR 0.55, 95% CI 0.35 to 0.86; Analysis 104.2).
We found no heterogeneity between genotype group comparisons
(homozygous major vs homozygous minor compared with het-
erozygous vs homozygous minor, or slow vs normal) among indi-
viduals randomised to placebo for any of the other biomarkers.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Active NRT compared with placebo - rs16969968 - non-Hispanic white for smoking cessation
Patient or population: people who smoke
Setting: community and healthcare sett ings
Intervention: act ive NRT
Comparison: placebo




Quality of the evidence
(GRADE)
Comments
Risk with placebo -
rs16969968 - non-His-
panic white
Risk with active NRT








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.03
(see results for individ-
ual subgroups in below
rows)
251 per 1000 346 per 1000
(243 to 496)
End of treatment - ho-
mozygous major











333 per 1000 337 per 1000
(257 to 443)
End of treatment - het-
erozygous







t icipants with heterozy-
gous genotype, high-
quality evidence shows






























































































































193 per 1000 358 per 1000
(257 to 501)
End of treatment - ho-
mozygous minor









ity evidence shows that
point est imate favours
intervent ion, but 95%CI
crosses null ef fect
233 per 1000 420 per 1000
(105 to 1000)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NRT: nicot ine replacement therapy; RCT, randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level owing to imprecision: Optimal information size criterion is met, but 95%CIs include the null ef fect and
fail to exclude important benef it or important harm.
bNot downgraded owing to inconsistency, as large stat ist ical heterogeneity can be explained by dif ferences in genotypes.
cDowngraded one level owing to inconsistency: unexplained heterogeneity.
dDowngraded two levels owing to serious imprecision: opt imal information size criterion not met, and 95% CIs include the






























































































































Active NRT compared with placebo - rs16969968 - non-Hispanic black or African American for smoking cessation
Patient or population: people who smoke
Setting: community and healthcare sett ings
Intervention: act ive NRT
Comparison: placebo




Quality of the evidence
(GRADE)
Comments
Risk with active NRT -
rs16969968 - non-His-
panic black or African
American
Risk with placebo







result across studies, in-
cluding all genotypes.
Stat ist ically signif icant
between-genotype group
heterogeneity: P value =
0.03 (see results for indi-





Abst inence at 6 months
- homozygous major






For part icipants with ho-
mozygous major geno-
type, high-quality evi-
dence shows ef fect in




Abst inence at 6 months
- heterozygous or ho-
mozygous minor






For part icipants with het-
erozygous or homozy-
gous minor genotype,
point est imate favours
control, but 95% CI
































































































































Abst inence at end of
treatment







result across studies, in-
cluding all genotypes.
Stat ist ically signif icant
between-genotype group
heterogeneity: P value =
0.003 (see results for in-





Abst inence at end of
treatment - homozy-
gous major






For part icipants with ho-
mozygous major geno-
type, high-quality evi-
dence shows ef fect in























*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NRT: nicot ine replacement therapy; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.






























































































































aNot downgraded owing to inconsistency, as large stat ist ical heterogeneity can be explained by dif ferences in genotypes.
bDowngraded one level owing to imprecision: Optimal information size criterion is met, but 95%CIs include the null ef fect and
fail to exclude important benef it or important harm.
cDowngraded two levels owing to serious imprecision: opt imal information size criterion not met, but 95%CIs include the null
ef fect and fail to exclude important benef it or important harm.































































































































Active NRT compared with placebo - rs 588765 - non-Hispanic white for smoking cessation
Patient or population: people who smoke
Setting: community and healthcare sett ings
Intervention: act ive NRT
Comparison: placebo




Quality of the evidence
(GRADE)
Comments
Risk with placebo - rs
588765 - non-Hispanic
white
Risk with active NRT








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.92
(see results for individ-
ual subgroups in below
rows)
211 per 1000 281 per 1000
(220 to 361)
End of treatment - ho-
mozygous major










gests that point est i-
mate favours interven-
t ion, but 95%CI crosses
null ef fect
208 per 1000 288 per 1000
(185 to 448)
End of treatment - het-
erozygous







t icipants with heterozy-
gous genotype, point





























































































































vent ion, but 95% CI
crosses null ef fect
208 per 1000 265 per 1000
(185 to 373)
End of treatment - ho-
mozygous minor










gests that point est i-
mate favours interven-
t ion, but 95%CI crosses
null ef fect
226 per 1000 339 per 1000
(167 to 691)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NRT: nicot ine replacement therapy; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level owing to imprecision: low number of events; opt imal information size criterion not met.
bDowngraded two levels owing to serious imprecision: opt imal information size criterion not met, but 95%CIs include the null






























































































































Active NRT compared with placebo - rs2036527 - non-Hispanic black or African American for smoking cessation
Patient or population: people who smoke
Setting: community and healthcare sett ings
Intervention: act ive NRT
Comparison: placebo




Quality of the evidence
(GRADE)
Comments
Risk with placebo -
rs2036527 - non-His-
panic black or African
American
Risk with active NRT








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.19
(see results for individ-
ual subgroups in below
rows)
177 per 1000 208 per 1000
(132 to 330)
6-Month abst inence -
homozygous major








jor genotype, very low-
quality evidence sug-
gests that point est i-
mate favours interven-
t ion, but 95%CI crosses
null ef fect































































































































6-Month abst inence -
heterozygous or ho-
mozygous minor










evidence shows no ef -
fect
185 per 1000 167 per 1000
(74 to 377)








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.19
(see results for individ-
ual subgroups in below
rows)
199 per 1000 242 per 1000
(153 to 384)
End of treatment - ho-
mozygous major










gests that point est i-
mate favours interven-
t ion, but 95%CI crosses
null ef fect
197 per 1000 471 per 1000
(85 to 1000)
End of treatment - het-
erozygous or homozy-
gous minor










evidence shows no ef -
fect
202 per 1000 179 per 1000
(111 to 294)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).






























































































































GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect































































































































Active NRT compared with placebo - DRD4 (exon 3 48 bp) - non-Hispanic white for smoking cessation
Patient or population: people who smoke
Setting: community and healthcare sett ings
Intervention: act ive NRT
Comparison: placebo




Quality of the evidence
(GRADE)
Comments
Risk with placebo -
DRD4 (exon 3 48 bp) -
non-Hispanic white
Risk with active NRT








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.85
(see results for individ-
ual subgroups in below
rows)
141 per 1000 203 per 1000
(152 to 271)
6-month abst inence -
homozygous major








jor genotype, very low-
quality evidence sug-
gests that point est i-
mate favours interven-
t ion, but 95%CI crosses
null ef fect































































































































6-Month abst inence -
heterozygous






For part icipants with
heterozygous geno-
type, low-quality evi-
dence suggests ef fect
in favour of intervent ion
113 per 1000 198 per 1000
(113 to 349)
6-Month abst inence -
homozygous minor








nor genotype, very low-
quality evidence sug-
gests that point est i-
mate favours interven-
t ion, but 95%CI crosses
null ef fect
167 per 1000 213 per 1000
(67 to 685)








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.78
(see results for individ-
ual subgroups in below
rows)
271 per 1000 325 per 1000
(238 to 441)
End of treatment - ho-
mozygous major








jor genotype, very low-
quality evidence sug-
gests that point est i-
mate favours interven-
t ion, but 95%CI crosses
null ef fect































































































































End of treatment - het-
erozygous










point est imate favours
intervent ion, but 95%CI
crosses null ef fect
258 per 1000 362 per 1000
(147 to 876)
End of treatment - ho-
mozygous minor











333 per 1000 340 per 1000
(217 to 527)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NRT: nicot ine replacement therapy; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level owing to high risk of bias: high risk of select ion bias in GRPG 1993 due to low f ract ion of genotyped
part icipants.
bDowngraded one level owing to imprecision: low number of events; opt imal information size criterion not met.































































































































Active NRT compared with placebo - NMR - non-Hispanic black and white for smoking cessation
Patient or population: people who smoke
Setting: community and healthcare sett ings
Intervention: act ive NRT
Comparison: placebo




Quality of the evidence
(GRADE)
Comments
Risk with placebo -
NMR - non-Hispanic
black and white
Risk with active NRT








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.29
(see results for individ-
ual subgroups in below
rows)
99 per 1000 149 per 1000
(107 to 207)
6-Month abst inence -
slow NMR











116 per 1000 211 per 1000
(130 to 341)
6-Month abst inence -
normal NMR






For part icipants with
normal NMR genotype,
point est imate favours
intervent ion, but 95%CI






























































































































85 per 1000 103 per 1000
(66 to 159)








genotypes. Stat ist ically
signif icant between-
genotype group hetero-
geneity: P value = 0.52
(see results for individ-
ual subgroups in below
rows)
136 per 1000 205 per 1000
(162 to 258)
End of treatment - slow
NMR











127 per 1000 204 per 1000
(149 to 278)
End of treatment - nor-
mal NMR






For part icipants with
normal NMR genotype,
point est imate favours
intervent ion, but 95%CI
crosses null ef fect
149 per 1000 222 per 1000
(127 to 388)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NMR: nicot ine metabolite rat io; NRT: nicot ine replacement therapy; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.






























































































































aDowngraded one level owing to risk of bias: 755/ 1532 (49%) part icipants f rom Patch Trial (GPRG 1993) were genotyped,
which could contribute to select ion bias.
bDowngraded one level owing to imprecision: opt imal information size criterion is met, but 95%CIs include the null ef fect and































































































































D I S C U S S I O N
Summary of main results
Using data from 18 randomised controlled trials (RCTs), we in-
vestigated whether a total of 13 biomarkers, including nine single-
nucleotide polymorphisms (SNPs), two variable number tandem
repeats (VNTRs) (DRD4 and SLC6A4), and the nicotine metabo-
lite ratio (NMR) modify the effects of different smoking cessation
pharmacotherapies (nicotine replacement therapy (NRT), bupro-
pion, varenicline, and combination therapy) on abstinence from
smoking at six months and at end of treatment. We carried out
analyses separately in non-Hispanic whites (NHWs) and non-
Hispanic blacks (NHBs). Results showed statistical heterogene-
ity between genotypes for only NRT versus placebo in NHWs
for rs1051730 and rs16969968 at end of treatment. In addition,
rs16969968 showed evidence of heterogeneity in NHBs at six
months, as well as at end of treatment, but sample sizes for some
genotype subgroups were small, rendering these results unreli-
able. Results at rs16969968 for NRT versus placebo in NHWs
and in NHBs reflect opposite directions. For the other seven
SNPs evaluated in clinical trials, we found no evidence of SNP
× treatment interaction. Within-treatment arm analyses indicated
that six-month abstinence was less often achieved in NHW nor-
mal metabolisers and more often among NHB individuals with
rs16969968 GG and and rs2036527 GG genotype who received
NRT, and that end-of-treatment abstinence was less often achieved
among NHWs with rs1329650 TT genotype and NHBs with
rs3733829 GG or AG genotype who received bupropion + any
NRT, and among NHBs with rs16969968 AA or GA genotype
who received placebo. Trial results revealed no such differences
for other treatments or biomarkers. In conclusion, although these
findings suggest superior short-term efficacy of NRT in specific
rs1051730 and rs16969968 genotype subgroups among NHWs,
lack of significant genotype differences within treatment arms lim-
its confidence in the validity of these findings. The same holds
true for results of within-treatment analyses.
Overall completeness and applicability of
evidence
For the vast majority of biomarkers for which we had data, we
foundno evidence that theymaymodify the effects of smoking ces-
sation interventions, although evidence showed nominally signifi-
cant treatment effects in specific genotype groups. Various reasons
may explain this. First, identification of biomarker × treatment
interactions may require large sample sizes (Cardon 2000), which
were not available for the current RCTs. Traditionally, RCTs are
designed to address comparative effectiveness questions regarding
one or more active drugs. Genomic analyses are usually conducted
retrospectively after trial completion and are rarely taken into ac-
count at design stages. Although we aimed to overcome sample
size limitations of individual studies by combining data through
meta-analysis, for most comparisons we were not able to obtain
summary level data that would allow us to quantitatively synthe-
sise all available information. Second, RCTs that were included in
our analyses used genotype information for a few preselected SNPs
that were chosen on the basis of biological plausibility and prior
genome-wide significance with regards to smoking phenotypes.
However, treatment response is likely to be under polygenic influ-
ences of biomarkers with small and large effects. Therefore, addi-
tional biomarkers across the genome may confer useful predictive
information from which to identify individuals who will bene-
fit from a particular smoking cessation intervention. To achieve
this, RCTs should routinely collect and analyse DNA samples at
the genome-wide level. We refer readers to our recent reviews of
progress of and recommendations for genomic studies of clinical
trials of smoking cessation therapies (Chen 2017; Saccone 2017).
Quality of the evidence
Our analysis constitutes a synthesis of evidence from RCTs ret-
rospectively evaluated for effects of smoking cessation treatments
according to specific genotypes. Therefore, our results should
be interpreted as evidence of heterogeneity of treatment effects
(Varadhan 2013) according to specific biomarkers. Given the large
number of analyses performed and assessment of the quality of
evidence (GRADE) as moderate, one should interpret the results
of this review with caution.
Although treatment effect heterogeneity is critical for making clin-
ical and policy decisions, it provides only indirect evidence of the
clinical utility of these genetic markers (i.e. whether measuring
a particular biomarker will result in better or worse clinical out-
comes).
The chr15q25.1 SNPs rs2036527, rs16969968, and rs1051730
are highly correlated (r2 = 0.90 for rs2036527 vs the latter two
SNPs, and r2 = 1 vs the latter two SNPs) in individuals of Euro-
pean ancestry (Utah residents from North and West Europe), but
are less highly correlated in African American individuals (r2 =
0.28, 0.38, and 0.46 for rs2036527 vs rs16969968, rs2036527 vs
rs1051730, and rs16969968 vs rs1051730; Americans of African
Ancestry in SW USA). In addition, the minor allele frequency of
all three SNPs is lower among individuals of African American
ancestry (from 0.40 to 0.22 for rs2036527, from 0.38 to 0.07
for rs16969968, and from 0.38 to 0.15 for rs1051730). In par-
ticular, the minor allele frequency of rs16969968 is much lower
among those of African ancestry (means are < 0.01 in sub-Sa-
haran Africans, 0.027 in East Asians, 0.21 in Amerindians, 0.37
in Europeans, and 0.18 in South Asians; 1000 Genomes Project
Consortium 2015). Therefore, one should use caution when com-
paring results at these chr15q25.1 SNPs between NHWs and
NHBs owing to differences in linkage disequilibrium (LD) and
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power (due to differences in allele frequency). All three vari-
ants constitute susceptibility loci for lung cancer and are associ-
ated with measures of nicotine dependence (David 2012; Landi
2009; Liu 2010; McKay 2008; Thorgeirsson 2008;Thorgeirsson
2010;Tobacco and Genetics Consortium 2010; Zanetti 2016).
rs16969968 (NM 000745.3:c.1192G>A) is a missense variant
(Asp398Asn) of the nicotinic acetylcholine receptor alpha 5 sub-
unit gene (CHRNA5); African American individuals who are ho-
mozygous for the major allele have a higher probability of smok-
ing abstinence with NRT than with placebo, but individuals
of European ancestry who are heterozygous for rs16969968 (A/
G genotype) have a higher probability of smoking abstinence
with NRT than with placebo (see Results). Similarly, rs1051730
(NM 000743.4:c.645C>T) is a synonymous substitution in the
nicotinic acetylcholine receptor alpha 3 subunit gene (CHRNA3)
that confers higher probability of abstinence among individuals of
European ancestry who are heterozygous or homozygous for the
minor allele (AA genotype) (see Results). rs2036527, found proxi-
mal toCHRNA5, is associated with nicotine dependence and with
lung cancer in African Americans, but has much lower LD with
the two other chr15q25.1 SNPs in African Americans than in Eu-
ropean Americans. We did observe that NHB with GG genotype
may benefit more fromNRT than from placebo (see Results). Dif-
ferences in SNP allele frequencies and in LD between NHW and
NHB populations at chr15q25.1 (above) and differences in allele
frequencies betweenNHW andNHB at chr19q13.2 (rs3733829)
and chr10q23.32 (rs1329650), together with known differences
in LD, suggest cautionwhen results are compared betweenNHWs
and NHBs. Given the small number of trials with available data
for these and other comparisons, review findings should be inter-
preted with caution and should be revisited when results of future
trials become available.
Potential biases in the review process
We should acknowledge that owing to the numbers of biomark-
ers, interventions, endpoints, and ancestry subgroups, our system-
atic review includes a large number of analyses. However, we did
not correct for the multiplicity of comparisons because our aim
was to synthesise existing evidence rather than focus on hypothe-
sis testing. Therefore, we put greater emphasis on the estimation
of effects of smoking cessation interventions than on testing for
these effects (Higgins 2011).Moreover, in our review, we report all
performed analyses regardless of whether they achieved statistical
significance at the nominal P = 0.05 threshold; hence, we are not
selectively reporting nominally significant results. Another issue
of multiple comparisons relates to the selection of particular SNP
× treatment interactions among many in the primary RCTs. Al-
though most trials report only one or a few SNPs, we cannot ex-
clude the possibility that these associations may have been selected
among a number of analyses. Formally controlling for this type
of multiplicity (e.g. using the approach proposed by Benjamini
and Bogomolov) is difficult in the absence of detailed reporting in
primary studies (Benjamini 2014). However, most RCTs had low
risk of selective reporting and had specified a priori the SNPs of
interest used in analyses of pharmacogenomics.
Agreements and disagreements with other
studies or reviews
In European ancestry samples, minor alleles of both variants
(rs1051730 and rs16969968) have been associated with increased
abstinence (Bergen 2013; Chen 2012) and with decreased absti-
nence after NRT (Munafò 2011). Others have not been associ-
ated with abstinence (Tyndale 2015). In addition, a recent meta-
analysis revealed that neither of these SNPs was associated with
smoking cessation among individuals randomised to NRT (Leung
2015). In contrast to our meta-analysis, the studies of Leung et al
evaluated only the per-allele effect for each SNP among those ran-
domised to NRT; these investigators did not examine effect mod-
ification, as we did in our analysis. In other words, they did not
address the comparative effectiveness of NRT relative to placebo
or some other smoking cessation intervention. On the other hand,
in our meta-analysis, we performed both within- and across-treat-
ment arms comparisons of effects of biomarkers to evaluate the
efficacy of smoking cessation interventions in specific genotype
groups. Hence, the fact that we did find evidence of treatment ef-
fect heterogeneity for both rs169969968 and rs1051730 suggests
a likely gene × treatment interaction.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
These data suggest that response to nicotine replacement therapy
(NRT) may be greater for non-Hispanic black (NHB) individuals
at six months with rs16969968 GG genotype than for those with
GA or AA genotype; among individuals treated with active NRT,
nicotine metabolite ratio (NMR) slow metaboliser status predicts
higher six-month abstinence outcomes than among those with
normal metaboliser status. For NHWs andNHBs, rs1051730 GA
and AA genotypes were associated with higher NRT response at
end of treatment, and rs16969968 GG genotypes were associated
with greater NRT response for abstinence at end of therapy.
Genotype comparisons within treatment arms were notable for
higher abstinence rates on NRT among NHBs for rs2036527
GG (vs AA or AG) genotypes, and lower abstinence rates among
NHWs treated with combination bupropion with NRT for
rs1329650 TT (vs GG), and among NHBs for rs3733829 AG or
GG (vs AA).
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Although we did identify some genotype-treatment interactions
and genotype effects within treatment arms, the vast majority of
analyses indicated no such results. Significant results should be
considered preliminary and interpreted with caution because none
of the statistically significant meta-analyses included more than
two trials per genotype comparison, many confidence intervals
were wide, and the quality of evidence (GRADE) was generally
moderate. In addition, our analyses could not adjust for ancestry
informative markers; thus, these findings have the potential to be
confounded by population stratification.
Implications for research
Weobserved that smokers with slowNMRonNRTpatch demon-
strated higher abstinence rates than smokers with normal NMR
on NRT patch. Our meta-analyses did not detect heterogeneity
in NRT patch efficacy (active vs placebo patch) between NMR
groups, which could be a function of statistical power or lack of
superior efficacy for slow metabolisers. Data provided by extant
trials would increase the reliability of effect estimates and con-
fidence in determining the potential clinical utility of NMR to
guide selection of NRT versus an alternative treatment. In partic-
ular, access to individual participant data (IPD) would be desir-
able, as this may help to improve the quantity and quality of data,
while standardising outcomes across included trials and enabling
detailed data checking (Debray 2015; Tierney 2015). IPD offer
greater flexibility in investigating effect modifiers and appear to be
particularly useful for addressing genotype-treatment interactions.
Increases in data sharing by randomised controlled trials (RCTs)
reporting response to treatment GWAS summary statistics (e.g.
as exemplified by sharing of the response to treatment summary
result from the Clinical Antipsychotic Trials of Intervention Effec-
tiveness) may provide the catalyst to encourage future replications
and meta-analyses (McClay 2011).
Recent methodological advances may facilitate the design and
analysis of such predictive trials (e.g. the adaptive signature design
and the cross-validated adaptive signature design are clinical trial
designs used for development and validation of high-dimensional
biosignatures within single trials) (Freidlin 2005; Freidlin 2010).
In a setting with SNPmarkers routinely available for patients, and
with genomic architecture and genome-wide significant single-nu-
cleotide polymorphisms (SNPs) known for nicotine dependence
behavioural components, development and validation of predic-
tive genomic signatures for response to smoking cessation thera-
pies might begin (Sun 2015; Weiss 2016). Additionally, polygenic
risk scores could be helpful, as even if many individual markers
produce no detected effect on their own, combined scores could
serve as a strong predictor of outcomes (Dudbridge 2013).
Prediction of response to smoking cessation pharmacotherapies
based on genomic information is a complex issue that poses chal-
lenges for the design and analysis of clinical trials. As genotyping
costs continue to fall, it is important that existing and future phar-
macotherapy trials interrogate genome-wide variation to identify
biomarkers that predict treatment response for future assessment
of clinical utility. Availability of genome-wide data enables correc-
tion of population genetic variation in genome-wide association
studies, as exemplified in Pharmacogenomics of Nicotine Addic-
tion Treatment (PNAT)Consortium Group RCT analyses, as well
as examination of effects of genetic ancestry on treatment efficacy,
as observed in analyses of response to treatment for tobacco depen-
dence, major depression, and schizophrenia (Adkins 2013; Bress
2015; Murphy 2013). Genome-wide genotype data will permit
examination of multiple a priori SNPs in risk score format for
treatment response, along with novel searches for SNPs associated
with response to treatment at genome-wide significance, as has re-
cently been accomplished in relatively modest samples for lithium
and bipolar disorder (Hou 2016; Uhl 2014).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahluwalia 2006
Methods 2 × 2 factorial randomised clinical trial conducted to evaluate the efficacy of nicotine
gum and counseling for African American light smokers (the “Kick It at Swope II Trial”
(KIS-II))
Study period: March 2003 to June 2004
Participants N = 755
Participants were recruited using clinic, media, and community outreach efforts, in-
cluding radio, television, gas pump, billboard advertising, community health fairs, signs
posted in minority-owned businesses, and referral letters mailed from physicians in the
Kansas City, KS, USA, area
Inclusion criteria: (a) self-identified as ‘African American or black’, (b) ≥ 18 years, (c)
smoked≤ 10 cigarettes/d for≥ 6 months, (d) before enrolment, smoked on≥ 25 of the
last 30 days, (e) was interested in quitting in the next 2 weeks, (f ) spoke English, and (g)
had a permanent home address and working telephone. Only 1 smoker per household
was allowed to enrol
Exclusion criteria: (a) contraindication for nicotine gum (jaw problems, irregular heart-
beat, recent myocardial infarction, or stroke), (b) used other pharmacotherapy for smok-
ing cessation in the last 30 days, (c) used other forms of tobacco within the last 30 days,
(d) was pregnant or planning to become pregnant within the next 6 months, (e) was
breastfeeding, or (f ) was planning tomove out of the local area within the next 6 months.
Individuals demonstrating marked inappropriate affect or behavior were excluded from
the study
Interventions Health education plus NRT gum (N = 189)
Motivational interviewing plus NRT gum (N = 189)
Health education plus placebo gum (N = 189)
Motivational interviewing plus placebo gum (N = 188)
Participants were assigned randomly to 1 of 4 study arms: 2 mg nicotine gum plus health
education (HE); 2 mg nicotine gum plus motivational interviewing (MI); placebo gum
plus HE; and placebo gum plus MI
Outcomes Primary outcomes: cotinine-verified 7-day abstinence at week 26, defined as having
smoked no cigarettes - not even a puff - on the previous 7 days
A salivary cotinine cutoff of ≤ 20 ng/mL was used to verify abstinence at 26 weeks; a
cutoff of ≤ 10 ppm was used for CO
Secondary outcomes: Secondary outcome was 7-day abstinence at week 8. Process
measures included counseling attendance at randomisation and at weeks 1, 3, 6, and 8;
and 16 counseling visits and self-reported gum usage in the past 7 days at weeks 1, 3,
and 8 (end of gum treatment)
Funding source This project was supported by the National Cancer Institute at the National Institutes
of Health (R01 CA091912). GlaxoSmithKline provided study medication but played
no role in design or conduct of the study nor in interpretation and analysis of data
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Ahluwalia 2006 (Continued)
Declaration of interest “NLB serves as a consultant to several pharmaceutical companies that
market smoking cessation medications and has been a paid expert
witness in litigation against tobacco companies. SPD is a scientific
adviser to Genophen. RFT has participated in one-day advisory meetings
for Novartis and McNeil. RFT is an Associate Editor for Clinical Pharmacology
& Therapeutics but was not involved in the review or decision process for this
article. The other authors declared no conflict of interest.”
Notes The present study didnot report analyses of pharmacogenetics.However, 608/755 (80%)
were successfully genotyped. These results were published in subsequent papers (Ho
2009; Zhu 2014).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation codes were generated in
blocks and were linked to medication dis-
tribution and counseling assignment
Allocation concealment (selection bias) Low risk “The Investigative Pharmacy at the Uni-
versity of Kansas Medical Center packaged
the study medication using codes to main-
tain blinding. At the randomization visit, a
sealed envelope with pre-assigned random-
ization numbers was drawn to determine
which form of counseling the participant
would receive. The envelope and box of
gum with matching randomization num-
bers were given to participants in the order
in which they were randomized.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Study staff and participants were blinded
towhether participants received active gum
or placebo. However, assignment to MI
counseling versus HE was not blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Researchers and participants were blinded
to active or placebo medication
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were ac-
counted for in the analyses
Selective reporting (reporting bias) Low risk Primary endpoints were reported.
Other bias Low risk 80%of participantswere genotyped,which
was balanced across drug treatment groups.
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Methods Randomised controlled clinical trial of behavioural support for smoking cessation (the
“Patch in Practice Study”)
Study period: July 2002 to March 2005
Participants N = 925
Recruited from 26 general practice clinics in Buckinghamshire and Oxfordshire, UK
Inclusion criteria: current smokers, age ≥ 18, smoked ≥ 10 cigarettes/d
Exclusion criteria: contraindications to nicotine replacement therapy (NRT)
Interventions Basic support (N = 469)
Weekly support (N = 456)
Participants were randomised to behavioural support provided by practice nurse before
quitting, telephoned aroundquit day, and seen1 and4weeks after the initial appointment
(basic support) vs basic support plus weekly support - additional telephone call at 10
days and 3 weeks after the initial appointment, and an additional visit at 2 weeks to
motivate adherence to nicotine replacement and to renew quit attempts. 15 mg/16 h
nicotine patches were given to all participants
Outcomes Primary outcomes: confirmed sustained abstinence at 1, 4, 12, and 26 weeks from quit
day. Sustained abstinence was defined as self-reported total abstinence after a 14-day
grace period from quit date confirmed by expired air carbon monoxide (CO) < 10 ppm
Secondary outcomes: not indicated
Funding source “This study was funded by a programme grant from Cancer Research UK (trial regis-
tration ISRCTN 05689186). United Pharmaceuticals supplied the nicotine patches for
the study free to be given without charge to the participants.”
Declaration of interest “PA has received free nicotine replacement products from Novartis and nortriptyline
from King Pharmaceuticals for distribution to trial participants; personal income for
advice to Xenova, a biotechnology company investigating a nicotine vaccine; small gifts
and had numerous meals paid for by drug companies, including those producing medi-
cations for smoking cessation; and travel grants to attend conferences from the Society
for Research in Nicotine and Tobacco. KB, CS, and AA have received small gifts and
had meals paid for by drug companies, including those manufacturing medications for
smoking cessation. M Munafó has received fees for invited lectures from the National
Health Service, GlaxoSmithKline, Novartis, the Moffitt Cancer Research Center, and
the Karolinska Institutet; benefits in kind (hospitality, etc.) from various pharmaceutical
companies; research and travel support from the European Research Advisory Board,
GlaxoSmithKline, Pfizer Consumer Healthcare and Novartis; and he has acted as a con-
sultant to the EuropeanCommission, The American Institutes for Research, theNational
Audit Office, and G-Nostics Ltd. EJ has received consultancy income from the European
Network for Smoking Prevention. MMurphy has received consultancy income from the
European Network for Smoking Prevention and has provided scientific consultancy ser-
vices through the University of Oxford ISIS Innovation to theNational Audit Office and
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Aveyard 2007 (Continued)
G-Nostics Ltd. The Childhood Cancer Research Group and the Cancer Research UK
General Practice Research Group have received unrestricted educational grants, research
project grants, and consultancy fees from Ciba Geigy/Novartis, GlaxoSmithKline, Phar-
macia/Pfizer, Ares-Serono, Sanofi-Synthelabo, Third Wave Technologies, Astra Zeneca,
and G-Nostics.”
Notes This paper did not report analyses of pharmacogenetics. However, DNA was collected
from all trial participants and analyses of pharmacogenetics were reported in subsequent
papers (David 2008; David 2011; Munafò 2008;Munafò 2009; Munafò 2011; Munafò
2012;Spruell 2012; Uhl 2010).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number sequence generation
specified
Allocation concealment (selection bias) Low risk Random number sequence sealed in num-
bered envelopes. Nurses opened sealed en-
velopes in sequence following eligibility
and consent determination
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and nurses were
necessarily not blinded to allocation.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Research staff was blinded to allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was balanced and trans-
parently reported.
Selective reporting (reporting bias) Low risk Primary outcomes were reported.
Other bias Low risk DNA samples were collected on all partic-
ipants at the time of study entry
Bloch 2010
Methods Double-blind parallel-group placebo-controlled randomised clinical trial
Study period: dates not reported
Participants N = 61
Participants were schizophrenic patients on stable neuroleptic medication who were
recruited by hospital doctors and clinicians from community mental health centres and
ambulatory clinics
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Bloch 2010 (Continued)
Inclusion criteria: age between 18 and 70 years, met DSM-IV-TR criteria for
schizophrenia or schizoaffective disorder, clinically stable (based on psychotic and af-
fective symptoms) as judged by treatment team and psychiatrists, had a stable dose of
antipsychotic drugs for ≥ 1 month before the start date, in stable physical health, stable
cigarette smoking habits (not defined), strong desire to quit smoking or at least to reduce
significantly the number of cigarettes per day (score > 5 on motivational questionnaire)
Exclusion criteria: not reported
Interventions Sustained-release bupropion + cognitive-behavioural group therapy (n = 45)
Placebo + cognitive-behavioural group therapy (n = 16)
All participants had 2-week stabilisation period followed by 14 weeks of study medica-
tion. Initial dose was 150 mg/d for 3 days, then 300 mg/d. All participants participated
in a 14-week, 15-session group cognitive-behavioural therapy. Participants received no
additional treatment
Outcomes Outcomes: self-reports of daily cigarette consumption and the Fagerstrom Test of Nico-
tine Dependence (FTND), both measured at baseline, week 7, and week 14
Funding source This researchwas supported by a Junior InvestigatorAward from theNational Alliance for
Research on Schizophrenia andDepression (NARSAD) (AR) andwas partially supported
by Phillip Morris USA and Phillip Morris International
Declaration of interest Declaration of interest was not reported.
Notes This paper provided analysis of pharmacogenetics.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were randomly allocated ac-
cording to order of arrival
Allocation concealment (selection bias) High risk Allocation was based on order of arrival.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was double-blind; however it is
unclear who exactly was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of participants and personnel was
unclear; study outcome is objective and can
be influenced by participants
Incomplete outcome data (attrition bias)
All outcomes
High risk Incomplete outcome data were greater in
the bupropion group, potentially influenc-
ing the overall treatment effect
Selective reporting (reporting bias) Unclear risk No protocol was found.
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Other bias Low risk Analysis of pharmacogenetics was per-
formed on the total study population
Brown 2007
Methods Randomised double-blind placebo-controlled trial of sustained-release bupropion and
behavioural support for smoking cessation (the “Zyban Collaborative Trial”)
Study period: November 1997 to January 2001
Participants N = 524
Recruited from the general population and treated at 1 of 3 community-based academic
teaching hospitals in Pawtucket and Providence, RI, USA
Inclusion criteria: current smokers, age ≥ 18, smoked ≥ 10 cigarettes/d
Exclusion criteria: (a) current Axis I disorder according to the Diagnostic and Statistical
Manual of Mental Disorders (4th edition; DSM-IV; American Psychiatric Association,
1994), (b) DSM-IV diagnosis of past-year psychoactive substance abuse or dependence
(other than nicotine), (c) current use of psychotropic medication or medication that may
interact adversely with bupropion, (d) current weekly (or more frequent) psychotherapy,
or (e) use of other tobacco products. Participants also were screened by a study physician
to rule out the following: any unstable medical condition; hypertension; pregnancy,
lactation, or refusal to use contraception while on study medication; history of seizure
disorder or head injury with loss of consciousness; eating disorder; or panic disorder.
Participants agreed to use only study-supplied medication for smoking cessation for the
duration of their study participation
Interventions Standard treatment + placebo (N = 157)
Standard plus depression treatment + placebo (N = 112)
Standard treatment + bupropion sustained-release (SR) (N = 147)
Standard plus depression treatment + bupropion SR (N = 108)
Participants were randomised to 1 of 4 twelve-week treatments: (a) standard, cogni-
tive-behavioural smoking cessation treatment (ST) plus bupropion (BUP), (b) ST plus
placebo (PLAC), (c) standard cessation treatment combined with cognitive-behavioural
treatment for depression (CBTD) plus BUP, and (d) CBTD plus PLAC. Follow-up as-
sessments were conducted 2, 6, and 12 months after treatment, and self-reported ab-
stinence was verified biochemically. Bupropion was delivered according to the standard
therapeutic dose (150 mg/d for the first 3 days, followed by 300 mg/d) for a total of 12
weeks. All participants and study staff were blind to medication condition
Outcomes Primary outcomes: biochemically verified point prevalence abstinence at end of treat-
ment and at 2-, 6- and 12-month follow-up. Abstinence was confirmed by a combination
of CO ≤ 10 ppm and cotinine ≤ 15 ng/mL.
Secondary outcomes: withdrawal and depression symptoms, craving
Funding source This study was funded in part by US Public Health Service grants HL32318, DA08511,
CA84719, and DA14276, and by GlaxoSmithKline, Inc., which provided study medi-
cation
56Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Declaration of interest SPD is a scientific advisor with BaseHealth and participated in a 1-day workshop with
Pfizer. MRM has received research support from Pfizer and GlaxoSmithKline. CL has
served as a consultant and has received research funding from Astra Zeneca, Glaxo-
SmithKline, and Pfizer
Notes DNAwas collected after start of trial, resulting in genotyping for 59%of trial participants.
Participants contributing DNA were significantly more likely to be female (51% vs
40%) and older (45.4 vs 43.2 years), and had been smoking longer (27.1 vs 24.8 years)
. Analyses of pharmacogenetics were reported in subsequent papers from the original
study sample (PMID: 17654295, PMID: 18058343). An additional 60 participants
were recruited, randomised to bupropion vs placebo, and administered the same ST
behavioural treatment following completion of the original trial. Analyses of the larger
sample were reported in additional publications (David 2013a; Leventhal 2012; Uhl
2008).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to 1 of
2 treatment sites, where theywere to receive
1 of 2 manualised group treatments, ST,
or CBTD, and were randomly assigned to
receive 1 of 2medication conditions or 1 of
2 behavioural interventions, using the urn
randomisation technique
Allocation concealment (selection bias) Unclear risk Behavioural treatment allocation may not
have been blinded but did appear to re-
sult in balanced pharmacological treatment
arms
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants and study staff were blind
to medication condition
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Handling of missing data was described.
Analyses using intention-to-treat vs only
complete data were conducted and demon-
strated concordance
Selective reporting (reporting bias) Low risk Primary endpoints were reported.
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Other bias High risk 59% of original trial participants were
genotyped, which may not be representa-
tive of the original study population. Anal-
yses of pharmacogenetics were reported in
multiple subsequent papers. See ‘Notes’
above
Cinciripini 2005
Methods Double-blind parallel-group placebo-controlled randomised clinical trial
Study period: February 1996 to April 1997
Participants N = 147
Participants were smokers recruited from the Houston, Texas, metropolitan area via
newspaper, radio, and TV advertisements and public service announcements
Inclusion criteria: smoking ≥ 10 cigarettes/d at baseline, between 18 and 75 years old
Exclusion criteria: taking smoking cessation treatment; taking psychoactivemedication;
or having any uncontrolled systemic illness, contraindications for taking venlafaxine or
the nicotine patch, current substance abuse, or other psychiatric disorders
Interventions Venlafaxine (n = 71)
Placebo (n = 76)
21 weeks of active venlafaxine or placebo. After a 1-week no-medication baseline (3
weeks before the quit date), participants began antidepressant therapy 2 weeks before
quitting at an initial dose of 75 mg/d (37.5 mg/d twice daily). The dose was increased
up to 150 mg/d during the week just before participants were to quit. During each
subsequent week, the dose was raised in 37.5-mg increments up to a maximum 225 mg/
d. Two weeks before the end of treatment, the dose was decreased by 37.5 mg every 2 to
3 days. The medication cycle was completed 18 weeks after quitting.
All participants also used the nicotine patch (Prostep, 22 mg) for 6 weeks, beginning on
their quit date, and received smoking cessation counseling
Outcomes Outcomes: Abstinence was assessed on the quit date and at post quit weeks 1, 3, 6, 18
(end of treatment), 26, and 52. Abstinence was verified in person by expired air carbon
monoxide ≤ 10 ppm or by a saliva cotinine sample of < 15 ng/µL at 26 or 52 weeks
Funding source Support for this research was provided by grants from the MD Anderson Cancer Center
(PRS), the National Cancer Institute (P50CA70907), and the National Institute on
Drug Abuse (R01DA1182-01) to Paul M. Cinciripini. Study medication was provided
by Wyeth-Ayerst Laboratories
Declaration of interest Declaration of interest was not reported.
Notes Analysis of pharmacogenetics was reported in Cinciripini 2005.
Risk of bias
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Cinciripini 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisationwas performedby the phar-
macy, but details are absent
Allocation concealment (selection bias) Low risk Randomisation was centralised and was
performed by a third party (pharmacy)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, study staff, and study person-
nel with direct patient contact were blinded
to group assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was appropriate and the outcome
of the study was objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data were similar be-
tween groups.
Selective reporting (reporting bias) Unclear risk No protocol was found.
Other bias Low risk Additional analyses of pharmacogenetics in
Cinciripini 2004 were conducted in the
large majority of the original randomised
trial population, so selection bias seems un-
likely
Cox 2012
Methods Randomised double-blind placebo-controlled trial of sustained-release bupropion for
smoking cessation in African Americans (the “Kick It at Swope III Trial” (KIS-III))
(ClinicalTrials.gov Identifier: NCT00666978)
Study period: December 2007 to May 2010
Participants N = 540
Participants were recruited through clinic- and community-based efforts. Clinic-based
efforts included use of fliers, posters, physician letters, pharmacy inserts, and lobby re-
cruitment at the primary study site, Swope Health Services in Kansas City, 2 Swope affil-
iate clinics, and 2 regional hospitals (University of Kansas Medical Center and Truman
Medical Center) in Kansas City, Kansas, USA
Inclusion criteria: (a) African American, (b) ≥ 18 years, (c) interested in stopping
smoking, (d) smoked ≤ 10 cigarettes/d for ≥ 2 years, (e) smoked on ≥ 25 days in the
past month, and (f ) were willing to attend 4 clinic visits over the course of 6 months; (g)
must have smoked≥ 3 years, and (h) had a home address and (i) a functioning telephone
number
Exclusion criteria: (a) current use of bupropion; (b) use of psychoactive medications;
(c) use of NRT, (d) fluoxetine, (e) clonidine, (f ) buspirone, or (g) doxepin in the past
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Cox 2012 (Continued)
30 days; (h) history of alcohol or (i) substance abuse within the past year; (j) current
drinking of 14 or more alcoholic drinks per week and/or binge drinking (≥ 5 drinks on
1 occasion) 2 or more times in the past month; (k) history of seizures or head trauma;
(l) history of bulimia or anorexia nervosa; (m) pregnant (verified by over-the-counter
pregnancy test kit for women of childbearing age only) or (n) contemplating pregnancy;
(o) breastfeeding; (p) myocardial infarction in the past 30 days; (q) use of other forms
of tobacco in the past 30 days; (r) reported use of opiates, (s) cocaine, (t) or stimulants;
(u) diabetes treated with oral hypoglycaemics or insulin; (v) planning to move from the
Kansas City metro area in the next 12 months; and (w) having another smoker in the
household enrolled in the study
Interventions Bupropion SR (N = 270)
Placebo (N = 270)
Participants were randomly assigned to receive 300 mg bupropion SR (150 mg once
daily for 3 days, then 150 mg twice daily) (n = 270 participants) or placebo (n = 270
participants) for 7 weeks, and up to 6 sessions of health education counseling
Outcomes Primary outcomes: salivary cotinine-verified 7-day point prevalence smoking abstinence
at week 26 (a cut point of 15 ng/mL differentiated smokers from non-smokers)
Secondary outcomes: Salivary cotinine-verified smoking abstinence at end of medica-
tion treatment at week 7 was also examined
Funding source “The Kick It at Swope III (KIS-III) study is a federally funded registered clinical trial
(ClinicalTrials.gov identifier: NCT00666978) from the grant “Enhancing Tobacco Use
Treatment for African American Light Smokers”.”
Declaration of interest “JSA serves as a consultant to Pfizer Pharmaceuticals, Inc.; NLB serves as a consultant
to Pfizer Pharmaceuticals, Inc., and has been a paid expert witness in litigation against
tobacco companies; RFT holds shares in Nicogen Research, Inc., a company that is
focused on novel smoking cessation treatment approaches; no Pfizer or Nicogen funds
were used in this work.” “NLB serves as a consultant to several pharmaceutical companies
thatmarket smoking cessationmedications andhas been a paid expertwitness in litigation
against tobacco companies. SPD is a scientific adviser toGenophen. RFThas participated
in one-day advisory meetings for Novartis and McNeil. RFT is an Associate Editor for
Clinical Pharmacology & Therapeutics but was not involved in the review or decision
process for this article. The other authors declared no conflict of interest.”
Notes The present study did not report analyses of pharmacogenetics. However, 534/540 (~
90%) were successfully genotyped. These results were published in subsequent papers
(Zhu 2013; Zhu 2014).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated table of random
numbers was used to randomise
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Cox 2012 (Continued)
Allocation concealment (selection bias) Low risk Allocation was concealed before group as-
signment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study staff and participants were blinded
to treatment conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was appropriate, and the outcome
of the study was objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was ~ 30% in both
groups, but all participants were accounted
for in intention-to-treat follow-up
Selective reporting (reporting bias) Low risk Primary outcomes were reported.
Other bias Low risk 534/540 (~ 90%) from the original trial
were successfully genotyped, and distribu-
tion of participants across treatment groups
was balanced. See ‘Notes’ above
Gilbert 2009
Methods Randomised parallel-group double-blind placebo-controlled trial of NRT vs placebo
patch with non-randomised continuing smoking control arm
Study period: 1998 to 2004 (specific months not reported)
Participants N = 171
Inclusion criteria: “Smokers wanting to quit”
Exclusion criteria: (a) smoking < 7 cigarettes/d for the past 2 years, (b) habitual cigarette
nicotine deliveries < 0.6 mg, (c) use of psychoactive drugs or medications other than
alcohol and caffeine, (d) alcohol use in excess of 28 alcoholic drinks/week, (e) age < 18
or > 50 years, (f ) non-English speaking, (g) atypical sleep cycles, (h) pregnancy, and (i)
serious medical or visual problems
Interventions Smoke control (N = 38)
Nicotine patch (N = 90)
Placebo patch (N = 81)
Participants were randomly assigned in an 80:20 ratio to a quit group or a group that
continued to smoke; those in the quit group were randomised (50:50) to nicotine patch
or placebo patch. Participants received an abbreviated form of the American Lung As-
sociation smoking cessation programme. Nicotine patches and placebo patches of cor-
responding size were 21 mg for the first 17 days of abstinence, 14 mg for days 18 to 26,
and 7 mg for days 27 to 38
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Outcomes Primary outcomes: Implied primary outcomes are symptom trajectories of affect (anger,
anxiety, depression)
Secondary outcomes: Abstinence was biochemically verified but was not reported as
an outcome. Abstinence failure was defined as smoking a total of more than 4 cigarettes
after quitting
Funding source Research was supported by National Institute on Drug Abuse Grant R01 DA12289
awarded toDavidG.Gilbert and by nicotine and placebo patches fromGlaxoSmithKline
Declaration of interest None
Notes Participants were excluded for abstinence failure. DNA appears to have been collected
for all participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence described using
an urn technique
Allocation concealment (selection bias) Unclear risk Quit group allocation and pharmacological
treatment allocation were randomised, but
quit group allocation was not blinded
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind design
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk 77% in the nicotine patch group correctly
guessed treatment assignment, which may
have been shared with data collectors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Treatment dropout high in both groups
were reported as “all relapsed to smoking”
Selective reporting (reporting bias) High risk Multiple gene x treatment interactionswere
reported for multiple behavioural pheno-
types
Other bias High risk Exclusion of relapsers from analyses may
create study population imbalance for ge-
netic predisposition to successfully quit
smoking
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Gonzales 2006
Methods Double-blindparallel-groupplacebo and active treatment-controlled randomised clinical
trial
Study period: June 2003 to April 2005
Participants N = 1025
Participants generally were healthy smokers (≥ 10 cigarettes/d) with < 3 months of
smoking abstinence in the past year, 18 to 75 years old, recruited via media advertising
Inclusion criteria: generally healthy, smoking≥ 10 cigarettes/d, < 3 months of smoking
abstinence in the past year, 18 to 75 years old, motivated to stop smoking
Exclusion criteria: any serious or unstable disease within past 6 months; seizure risk; di-
abetes mellitus requiring insulin or oral hypoglycaemic medications; hepatic or renal im-
pairment; clinically significant cardiovascular disease within past 6months; uncontrolled
hypertension; severe chronic obstructive pulmonary disease; history of cancer (except
treated basal cell or squamous cell carcinoma of the skin); history of clinically significant
allergic reactions; major depressive disorder within past year requiring treatment; history
of panic disorder, psychosis, bipolar disorder, or eating disorders; alcohol or drug abuse/
dependency within the past year; use of tobacco products other than cigarettes; use of
nicotine replacement therapy, clonidine, or nortriptyline within the month before enrol-
ment; body mass index < 15 or > 38 or weight < 45.5 kg; prior exposure to bupropion;
and prior varenicline exposure
Interventions Varenicline (n = 352)
Bupropion SR (n = 329)
Placebo (n = 344)
Study medication was taken orally for 12 weeks. Active drugs were titrated as follows:
varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg
twice per day through week 12; bupropion SR 150 mg/d for days 1 to 3, then 150 mg
twice per day through week 12
All participants received brief (≤ 10-minute), standardised, individual counseling to
assist in problem solving and skills training for relapse prevention
Outcomes Primary outcome: exhaled carbon monoxide-confirmed 4-week continuous abstinence
rate for weeks 9 through 12, defined as the proportion of participants who reported no
smoking (not even a puff ) or use of any nicotine-containing products confirmed by an
exhaled carbon monoxide measurement ≤ 10 ppm
Other outcomes: continuous abstinence rates from week 9 through week 24, and from
week 9 through week 52; 7-day point prevalence abstinence rates at weeks 12, 24, and
52
Funding source This studywas supported byPfizer Inc., which provided funding, study drug andplacebo,
and monitoring. The database containing findings of the 19 individual investigator sites
was maintained by Pfizer Inc., and statistical analyses were performed at Pfizer Inc. by
Mr Billing and by Ann Pennington, MS. Independent analysis was performed to verify
the findings of Pfizer Inc
Declaration of interest DrGonzales reports having received research contracts from Pfizer, Sanofi-Aventis, Glax-
oSmithKline, and Nabi Biopharmaceuticals; and consulting fees and honoraria from
Pfizer, Sanofi-Aventis, and GlaxoSmithKline; and owning 5 shares of Pfizer stock. Dr
Rennard reports having had or currently having a number of relationships with com-
panies who provide products and/or services relevant to outpatient management of
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chronic obstructive pulmonary disease. These relationships include serving as a con-
sultant for Adams, Almirall, Altana, Array Biopharma, AstraZeneca, Aventis, Biolipox,
Centocor, Dey, Critical Therapeutics, GlaxoSmithKline, Johnson & Johnson, Merck,
Novartis,OnoPharma, Otsuka, RJ Reynolds, Roche, Sankyo, Schering-Plough, Scios,
and Wyeth; advising regarding clinical trials for Altana, AstraZeneca, Aventis, Cento-
cor, GlaxoSmithKline, Novartis, Pfizer, and Philip Morris; and speaking at continuing
medical education programs and performing funded research at both basic and clinical
levels for Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis.
Dr Nides reports having received research grants, consulting fees, and honoraria from
Pfizer, Sanofi-Aventis, and GlaxoSmithKline. Dr Oncken reports having received re-
search grants, consulting fees, and honoraria from Pfizer; receiving, at no cost, nicotine
replacement and placebo products from GlaxoSmithKline for smoking cessation stud-
ies; and receiving honoraria from Pri-Med. Drs Azoulay, Watsky, Gong, Williams, and
Reeves and Mr Billing report owning Pfizer stock or having stock options in Pfizer
Notes Analysis of pharmacogenetics was reported in King 2012.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A predefined, central, computer-generated
randomisation sequence stratified by centre
assigned participants to treatment groups
using a block size of 6
Allocation concealment (selection bias) Low risk Centralised randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were blinded
to drug treatment assignments. Partici-
pants were not encouraged to guess their
treatment assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was appropriate, and the outcome
of the study was objective
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More refusal to continue participation in
the placebo group and more dropout in the
bupropion SR group due to adverse effects.
Dropouts were assumed to be smoking
Selective reporting (reporting bias) Low risk All outcomes listed on clinicaltrials.gov
(NCT00141206) are reported
Other bias Low risk Additional analyses of pharmacogenetics in
King 2012 were conducted in a subset of
the original randomised trial population,
but baseline characteristics were compara-
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ble between treatment groups, so selection
bias seems unlikely
GPRG 1993
Methods Randomised double-blind placebo-controlled trial of smoking cessation with a 2 × 2
factorial design (the “Patch Trial”)
Study period: June 1991 to March 1992
Participants N = 1686
Recruited from 19 general practice clinics in Oxfordshire, UK
Inclusion criteria: current smokers, age ≥ 18 and ≤ 65 years, smoked ≥ 15 cigarettes/
d
Exclusion criteria: (a) known skin hypersensitivity to nicotine, (b) severe skin condi-
tion likely to make patch use impossible, (c) untreated peptic ulcer, (d) life-threatening
arrhythmia, (e) active cancer, (f ) cerebrovascular or cardiovascular event within past 6
months, (g) lactation, and (h) existing or planned pregnancy. Patients were warned that
they should not use other forms of nicotine, such as cigars, pipes, or nicotine chewing
gum, during the trial, and that medication with centrally acting alpha activity (such as
clonidine) was contraindicated
Interventions 16-Page booklet plus nicotine patch (N = 422)
46-Page booklet plus nicotine patch (N = 420)
16-Page booklet plus placebo patch (N = 422)
46-Page booklet plus placebo patch (N = 422)
Participants were randomised to 1 of 4 treatment groups: (a) nicotine patch with a
standard, 16-page Health Education Authority pamphlet on smoking cessation; (b)
nicotine patch with a 46-page booklet giving specific and more detailed information on
smoking cessation with the help of patches; (c) placebo patch with a standard, 16-page
Health Education Authority pamphlet on smoking cessation; or (d) placebo patch with
a 46-page booklet giving specific and more detailed information on smoking cessation
with the help of patches. Patches were delivered 21 mg/d × 4 weeks, followed by 14 mg/
d × 4 weeks, then 7 mg/d × 4 weeks
Outcomes Primary outcomes: biochemically verified point prevalence abstinence at 1 and 4 weeks
(CO ≤ 10 ppm), and at 12, 24, and 52 weeks by cotinine ≤ 20 ng/mL or CO ≤ 10
ppm. Non-attenders were assumed to be smoking
Abstinence at follow-up in 1999 to 2000 was confirmed by a plasma cotinine level≤ 20
ng/mL
Secondary outcomes: withdrawal symptoms
Funding source The Patch Trial was supported by Ciba-Geigy Pharmaceuticals, which also supplied the
nicotine and placebo patches. The Patch II Study was funded by the Imperial Can-
cer Research Fund and Cancer Research UK. “Personal funding to SPD provided by
DA027331; National Institute for Health Research fellowship (to PA); and the UKCen-
tre for Tobacco Control Studies (UKCTCS to P.A. and M.M.). The UKCTCS gratefully
acknowledges funding from British Heart Foundation, Cancer Research UK, Economic
and Social Research Council, Medical Research Council, and theDepartment of Health,
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under the auspices of the UK Clinical Research Collaboration.”
Declaration of interest No conflicts of interest were declared for the original Patch Trial. However, subsequent
papers on pharmacogenetics report: “Paul Aveyard has done consultancy for McNeil,
Pfizer, and Celtic Biotechnology and Sean David has done consultancy with Pfizer-both
with regard to smoking cessation” (PMID: 21330274)
Notes The “Patch II Study”: 1532 of the original 1686 Patch Trial participants were contacted
again between July 1999 and July 2000 and were invited to participate in 8-year follow-
up of smoking status and to provideDNA samples, of whom840 returned questionnaires
and 755 were successfully genotyped. These results were published in subsequent papers
(David 2007; David 2008; David 2008a; David 2011; Johnstone 2004; Johnstone 2006;
Johnstone 2007; Munafò 2007; Munafò 2011; Munafò 2012; Uhl 2010; Yudkin 2004)
.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was carried out by prior
random allocation of study numbers to
each intervention group and by sequential
allocation of a study number to patients on
entry.”
Allocation concealment (selection bias) Low risk “Prepared precoded packages containing
the patches were handed to the patients by
the
general practitioner.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The packaging and appearance of the two
types of patch were identical.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Research staff were blinded to randomisa-
tion status throughout the trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 755/1686 (45%) Patch Trial participants
were genotyped and Patch II Study par-
ticipants were more female, were slightly
older, and were more likely to be absti-
nent than non-genotyped Patch Trial par-
ticipants. However, Patch II Study partic-
ipants were balanced to treatment alloca-
tion
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Selective reporting (reporting bias) Low risk Primary outcome resultswere published for
all candidate genes in comprehensive re-
views and subsequent papers
Other bias High risk 45% of original trial participants were
genotyped, which may not be representa-
tive of the original study population. Anal-
yses of pharmacogenetics were reported in
multiple subsequent papers. See ‘Notes’
above
Hall 2008
Methods Randomised parallel-group open-label efficacy clinical trial consisting of 2 phases: phase
1 lasting 12 weeks, during which all participants receive a standard treatment of NRT,
bupropion, and 5 group counseling sessions; followed by phase 2, randomisation to 1 of
5 treatments for another 40 weeks
Outcomes are measured at multiple time points to 104 weeks.
Study period: 2002 to 2004
Participants N = 407
Recruited through multi-media advertising, public service announcements, flyers, and
direct mailing
Inclusion criteria: treatment-seeking smokers 18 years of age or older who currently
smoke 10 cigarettes/d, report a regular smoking history ≥ 5 years, and answer “yes” to
the question, “Do you smoke within 30 minutes of arising?”
Exclusion criteria: history of seizure or head injury resulting in unconsciousness; any
condition that might predispose to seizures (brain tumour or stroke); current or history
of anorexia nervosa or bulimia; any disease acutely life-threatening or so severe that the
patient is judged unable to comply with the protocol; use of a protease inhibitor or
MAO inhibitor within the past 2 weeks; current use of psychiatric drugs that would
interfere with interpretation of study results, including antidepressants; treatment for
alcohol dependence during the past year, or evidence of alcohol abuse so severe that
the patient is judged potentially unable to comply with the protocol; patients who
know they are leaving the Bay Area within the study period and non-English speakers;
suicidal or homicidal ideation; current major depression; history of bipolar disorder;
recent (within 12months)myocardial infarction; any othermedical condition thatwould
contraindicate use of NRT or bupropion; physical limitation so severe that participation
in a programme of moderate exercise is not possible; and pregnancy or lactation
Interventions All participants receive 10 weeks of NRT (patch, tapering from 21 mg to 7 mg over
8 weeks, starting at week 3) and 12 weeks of bupropion treatment and 5 mandatory
group counseling sessions. At week 11, subjects are randomly assigned to 1 of 5 treat-
ment groups: (a) no further treatment, with assessments at weeks 12, 24, 36, 52, 64,
and 104 weeks (standard assessments for all treatments); (b) extended active medication
(bupropion) treatment through week 52 with low-intensity (monthly) counseling with
medical staff; (c) extended placebo medication treatment through week 52 with low-
intensity counseling with medical staff; (d) extended active medication treatment with
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high-intensity (session 20 to 40 minutes in duration at weeks 12, 14, 16, 18, 20, 24, 28,
32, 36, 44, and 52, and telephone contact at weeks 13, 15, 18, 22, 26, 30, 34, 36, 40,
and 48) counseling; and (e) extended placebo medication treatment with high-intensity
counseling. High-intensity counseling sessions included additional information focus-
ing on motivation, social support, mood management, weight gain, and dependence/
withdrawal
Outcomes Primary outcome: biochemically verified 7-day point prevalence abstinence at weeks
12, 24, 52, 64, and 104
Funding source The clinical trial was supported by a grant from the National Institute on Drug Abuse
(R01DA015732, Maintaining Abstinence in Chronic Smokers, PI: Sharon M Hall)
Declaration of interest Declaration of interest was not reported.
Notes Analyses of pharmacogenetics were described in Bergen 2013.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised allocationwas performed by
study statistician who did not have contact
with participants
Allocation concealment (selection bias) Low risk Assignment for individual participants was
transmitted electronically to staff
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial was open-label, but other aspects
of the trial suggest rigorous management
and lower probability of high performance
bias to unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was done by self-re-
port and by 2 biochemical methods using
exhaled breath and urine (i.e. very thor-
ough outcome assessment)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were low for the companion
trial.
Selective reporting (reporting bias) Low risk Outcome assessment was very thorough,
with 3 pieces of information required to
note an individual as abstinent. In the com-
panion trial, only 17/905 urine determina-
tions had data discordant with outcomes of
self-report and CO measurement (< 2%)
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Other bias Low risk Analyses of pharmacogenetics were per-
formed on ~ 37% of total study, ~ 50% of
self-identified “Caucasian”. Minimum arm
N was 26. Data show no significant dif-
ferences by arm with respect to proportion
of the arm genotyped. Not generalisable to
other ancestries
Hall 2009
Methods Randomised parallel-group open-label efficacy clinical trial consisting of 2 phases: phase
1, lasting 12 weeks during which all participants receive a standard treatment of NRT,
bupropion, and 5 group counseling sessions; followed by phase 2, randomization to 1
of 4 treatments for another 40 weeks
Outcomes are measured at multiple time points to 104 weeks.
Study period: 2002 to 2004
Participants N = 402
N = 403 were enrolled, but 1 individual died before randomisation
Recruited through multi-media advertising, public service announcements, flyers, and
direct mailing
Inclusion criteria: treatment-seeking smokers 50 years of age or older who currently
smoke 10 cigarettes/d
Exclusion criteria: history of seizure or head injury resulting in unconsciousness; any
condition that might predispose to seizures (brain tumour or stroke); current or history
of anorexia nervosa or bulimia; any disease acutely life-threatening or so severe that the
patient is judged unable to comply with the protocol; use of a protease inhibitor or
MAO inhibitor within the past 2 weeks; current use of psychiatric drugs that would
interfere with interpretation of study results, including antidepressants; treatment for
alcohol dependence during the past year, or evidence of alcohol abuse so severe that
the patient is judged potentially unable to comply with the protocol; patients who
know they are leaving the Bay Area within the study period and non-English speakers;
suicidal or homicidal ideation; current major depression; history of bipolar disorder;
recent (within 12months)myocardial infarction; any othermedical condition thatwould
contraindicate use of NRT or bupropion; physical limitation so severe that participation
in a programme of moderate exercise is not possible; and pregnancy or lactation
Interventions All participants receive 10 weeks of NRT (gum, 2 mg for those smoking < 25 cigarettes/
d, up to 12 pieces a day, or 4 mg for heavier smokers or heavy users of 2-mg gum still
reporting withdrawal) and 12 weeks of bupropion treatment (150 mg for a week, then
300 mg the second week and thereafter, with no adverse effects) and 5 mandatory group
counseling sessions (90 minutes each). At week 8 (to permit NRT tapering for those
assigned to no further treatment), participants are randomly assigned to 1 of 4 treatment
groups: (a) no further treatment, with assessments at weeks 12, 24, 36, 52, 64, and 104
(standard assessments for all treatments); (b) extendedNRT (to week 52) with no further
counseling; (c) extended NRT with extended cognitive-behavioural therapy to prevent
relapse and encourage abstinence in case of relapse before week 12, and in case of lapses
after week 12, where extended individual (20 to 40minutes) counseling occurred at week
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10, every 2 weeks thereafter, then every 4 weeks, then at weeks 44 and 52, with telephone
contact in between clinical visits; and (d) extended NRT and extended counseling.
Extended counseling sessions included additional information focusing on motivation,
social support, mood management, weight gain, and dependence/withdrawal
Outcomes Primary outcome: biochemically verified 7-day point prevalence abstinence at weeks
12, 24, 52, 64, and 104
Funding source Clinical trial and publications (portion related to this trial) were supported by grants
from the National Institute on Drug Abuse (R01 DA02538, K05 DA016752, K23
DA018691 and P50 DA 09253, and R01 DA15732)
Declaration of interest Declarations of interest were not reported.
Notes Neither this paper nor the clinicaltrials.gov record provided analyses of pharmacogenetics.
These were provided in Bergen 2013.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised allocation performed by
study statistician who did not have contact
with participants
Allocation concealment (selection bias) Low risk Assignment for individual participants was
transmitted electronically to staff
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Trial was open-label, but other aspects
of trial suggest rigorous management and
lower probability of high performance bias
to unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was done by self-re-
port and by 2 biochemical methods using
exhaled breath and urine (i.e. very thor-
ough outcome assessment)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were low (ranging from 3.
2% at week 12 to 13.4% at week 104)
. Per-arm assessment rates averaged 93%,
and abstinence assessments were available
for 92% of participants
Selective reporting (reporting bias) Low risk Outcome assessment was very thorough,
with 3 pieces of information required to
note an individual as abstinent. Only 17/
905 urine determinations had data discor-
dant with outcomes of self-report and CO
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measurement (< 2%)
Other bias Low risk Analyses of pharmacogenetics performed
on ~ 42% of total study; ~ 55% of self-
identified “Caucasian”; minimum arm N
was 35; no significant differences by arm
with respect to proportion of arm analysed.
Not generalisable to other ancestries
Jorenby 2006
Methods Double-blindparallel-groupplacebo and active treatment-controlled randomised clinical
trial
Study period: June 2003 to March 2005
Participants N = 1027
Participants were generally healthy smokers.
Inclusion criteria: smoking ≥ 10 cigarettes/d the previous year, < 3 months of smoking
abstinence in the past year, and 18 to 75 years old
Exclusion criteria: previous use of bupropion in any form; contraindications for use
of bupropion (e.g. history of seizure, diagnosis of eating disorder, use of a monoamine
oxidase inhibitor in the prior 14 days, hepatic or renal impairment, diabetes requiring
insulin, oral hypoglycaemics); serious or unstable disease within previous 6months; clin-
ically significant cardiovascular disease in previous 6 months; uncontrolled hyperten-
sion; baseline systolic blood pressure higher than 150 mmHg or diastolic blood pressure
higher than 95 mmHg; severe chronic obstructive pulmonary disease; history of cancer;
clinically significant allergic reactions; body mass index < 15 or > 38; body weight < 45
kg; history of alcohol or other drug abuse or dependence in the previous 12 months
(nicotine excepted); treatment for major depression in the previous 12 months; history
of or current panic disorder, psychosis, or bipolar disorder; use of another investigational
drug within the past 30 days; intention to donate blood or blood products during treat-
ment phase of the study (12 weeks); previous participation in any varenicline study; use
in the previous month or intention to use medications that might interfere with study
medication evaluation (e.g. nicotine replacement, nortriptyline, clonidine); use of mari-
juana or other tobacco products during the study; clinically significant abnormalities in
screening laboratory values
Interventions Varenicline (n = 344)
Bupropion SR (n = 342)
Placebo (n = 341)
Treatment phase doses were 1 mg of varenicline twice daily and 150 mg of bupropion
SR twice daily for 12 weeks, with an initial dose titration to full strength during the first
week for both drugs
All participants received a folder on the study medication without de-blinding treatment
allocation
Outcomes Primary outcome: exhaled carbon monoxide-confirmed 4-week continuous abstinence
rate for weeks 9 through 12, defined as the proportion of participants who reported no
smoking (not even a puff ) and no use of nicotine-containing products confirmed by an
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exhaled carbon monoxide measurement ≤ 10 ppm
Other outcomes: continuous abstinence rates from week 9 through week 24, and from
week 9 through week 52; 7-day point prevalence abstinence rates at weeks 12, 24, and
52
Funding source The clinical trial was sponsored by Pfizer Inc., which provided funding, study drug and
placebo, and monitoring. Drs Azoulay, Watsky, Williams, Gong, and Reeves, and Mr
Billing, employees of Pfizer Inc., were involved in all elements of this study. In addition,
the database containing findings of the 14 investigator sites was maintained by Pfizer Inc.
, and statistical analyses were performed at Pfizer Inc. byMr Billing and Ann Pennington,
MS. Independent analysis was performed to verify the findings of Pfizer Inc
Declaration of interest Dr Jorenby reported receiving research support from Pfizer, Nabi Biopharmaceutical,
and Sanofi-Aventis, and consulting fees fromNabi Biopharmaceutical. Dr Hays reported
receiving a research grant from Pfizer. Dr Rigotti reported receiving research grant fund-
ing and consulting fees from GlaxoSmithKline, which markets smoking cessation med-
ications, and from Pfizer and Sanofi-Aventis, which are developing smoking cessation
medications. Dr Rigotti also reported receiving consulting fees from Merck, which is
developing smoking cessation medications
Notes Analysis of pharmacogenetics was reported in King 2012.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was completed centrally
with the use of a computer-generated list;
sites used an electronic system to assign par-
ticipants to treatment
Allocation concealment (selection bias) Low risk Centralised randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of personnel is not explicitly de-
scribed.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome of the study was objective.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More refusal to continue participation in
the placebo group. Dropouts were assumed
to be smoking
Selective reporting (reporting bias) Low risk All outcomes listed on clinicaltrials.gov
(NCT00143364) are reported
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Other bias Low risk Additional analyses of pharmacogenetics in
King 2012 were conducted in a subset of
the original randomised trial population,
but baseline characteristics were compara-
ble between treatment groups, so selection
bias seems unlikely
Kalman 2011
Methods Double-blind parallel-group placebo-controlled randomised clinical trial
Study period: June 2005 to April 2010
Participants N = 143
Participants were in recovery from alcohol problems and were recruited from a residential
substance abuse treatment programme and from the community
Inclusion criteria: smoked ≥ 10 cigarettes/d, history of alcohol abuse or dependence,
and between 2 and 12 months of abstinence from alcohol
Exclusion criteria: older than age 70; diagnosis of schizophrenia; current psychotic
episode; cardiac problems in the past 3 months; uncontrolled hypertension; history of
seizure; history of head injury with neurological sequelae or prolonged loss of conscious-
ness; and use of medications that lower the seizure threshold
Interventions Bupropion + nicotine patch (n = 73)
Placebo + nicotine patch (n = 70)
Participants were taking study medication for 8 weeks. They began study medication
(bupropion 150 mg SR tablets or placebo) 1 week before their quit day. Participants
were instructed to take 1 tabletd for 3 days, then one 150-mg tablet twice per day for
the remainder of the treatment phase of the study
All participants received a nicotine patch for 7 weeks, starting 1 week after starting study
medication on their quit day. They received a 21-mg patch for 4 weeks, a 14-mg patch
for 2 weeks, and a 7-mg patch for 1 week
Outcomes Outcomes: 7-day point prevalence smoking abstinence at week 7 (end of treatment)
, week 11, and week 24. At week 7, smoking abstinence was defined via self-report
(complete abstinence during the 7 days before the time of assessment) and biochemical
verification (CO reading < 8 ppm). At week 11 and week 24, smoking abstinence was
defined via self-report and biochemical verification (salivary cotinine levels≤ 15 ng/mL)
Funding source Study was sponsored through personal funding by David Kalman: NIDA R01-
DA11713-01; Peter Monti: NIAAA K05 Senior Scientist Award; and Marc Mooney:
NIDA K01-DA-019446. NIDA and NIAAA had no further role in study design; in
collection, analysis, and interpretation of data; in writing of the report; or in the decision
to submit the paper for publication
Declaration of interest No conflicts were declared. None of the review authors have any connection with the
tobacco, alcohol, pharmaceutical, or gaming industries or with any body substantially
funded by 1 of these organizations
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Notes Analysis of pharmacogenetics was reported in McGeary 2012.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Urn randomisation with 4 variables was
used to allocate participants
Allocation concealment (selection bias) Low risk Randomisation was based on 4 variables.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Active and placebo medications were iden-
tical in appearance. No further details are
presented
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome of the study was objective.
Incomplete outcome data (attrition bias)
All outcomes
High risk Excluded from analysis participants who
did not receive the study medication; no
ITT analysis was performed
Selective reporting (reporting bias) High risk Weeks of abstinence assessment are differ-
ent from those listed on clinicaltrials.gov
(NCT00304707)
Other bias Unclear risk Additional analyses of pharmacogenetics
were conducted in a subset of the original
randomised trial population in McGeary
2012, but comparability of baseline char-
acteristics between treatment groups is un-
clear
Killen 2006
Methods Open-label cessation and double-blind extended treatment phase
Setting: community cessation clinic, USA
Recruitment: community volunteers
Study period: December 2001 to March 2004
Participants N = 362
54% males; average age ~ 45; average number of cigarettes/d: ~ 20
Inclusion criteria: smokers; 18 to 65 years of age; smoking at least 10 cigarettes/d or 3.
5 packs/week
Exclusion criteria: pregnancy, current lactation, epilepsy, bipolar disorder, schizophre-
nia, receiving active treatment for or reporting current depression or substance abuse,
current use of bupropion or NRT, use of medication that could interact with bupropion
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or NRT
Interventions Open-label phase: All participants received bupropion SR 300 mg/d (Zyban) for 11
weeks and nicotine patch therapy for 10 weeks
Double-blind phase: bupropion SR (150 mg/d) (n = 181) vs placebo (n = 181) for 14
weeks; at week 12, those assigned to placebo had their bupropion SR dose tapered to
150 mg/d for 2 weeks, then were switched to placebo in week 14
Outcomes Primary outcome: point prevalence abstinence rates at 25-week and 52-week follow-up
Secondary outcomes: repeated point prevalence abstinence; continuous abstinence;
craving and withdrawal symptoms; physiological measurements; adverse events; medi-
cation compliance
Funding source Support was provided solely by National Cancer Institute Grant CA 090300 awarded to
Joel D. Killen. Nicotine patches and bupropion were kindly provided by GlaxoSmithK-
line
Declaration of interest GlaxoSmithKline did not otherwise participate in the design, conduct, analysis, or re-
porting of this study
Notes Analysis of pharmacogenetics was reported in Sarginson 2011.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted before
study entry by the method of permuted
block (block size = 2 to obtain balance be-
tween groups) and was stratified on gender
in the order of participant ID numbers
Allocation concealment (selection bias) Low risk When aparticipantwas assigned to the next
available ID number in the corresponding
gender, he or she was associated with that
treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and researchers were
blinded to treatment at extended treatment
phases
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Both participants and researchers were
blinded to treatment at extended treatment
phases
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost at 12 months’ follow-up: 8% bupro-
pion; 13% placebo
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Killen 2006 (Continued)
Selective reporting (reporting bias) Low risk Study protocol was not available, but de-
tailed reporting of outcomes does not sug-
gest selective reporting
Other bias Unclear risk Of 304 trial participants, 270 provided
samples for DNA extraction, but the selec-
tion process for those 270 is unclear
Killen 2008
Methods Open-label cessation and double-blind extended treatment phase with follow-up con-
ducted at 20 and 52 weeks
Setting: community cessation clinic, USA
Recruitment: community volunteers
Study period: February 2004 to March 2006
Participants N = 304; 3 were excluded because of wrong treatment
40% females; average age: ~ 46; average cigarettes/d: ~ 20
Inclusion criteria: smokers, 18 to 65 years of age; smoking ≥ 10 cigarettes/d or 3.5
packs/week
Exclusion criteria: pregnancy, current lactation, epilepsy, bipolar disorder, schizophre-
nia, receiving active treatment for or reporting current depression or substance abuse,
history of heart problems in the previous 6months, head trauma leading to unconscious-
ness in the past year, history of severe head injury resulting in brain surgery or specific
neurological problems, current use of bupropion or nicotine replacement therapy (NRT)
, or medication that could interact with bupropion or NRT
Interventions Open-label - pharmacotherapy: bupropion SR for 9 weeks and nicotine patch therapy
for 8 weeks. During their first week, participants continued to smoke while taking
bupropion SR (150 mg/d on days 1 to 3, then 300 mg/d on days 4 to 7). Nicotine patch
(21 mg) was added to treatment with bupropion (300 mg) on the target quit date if the
participant succeeded. After 1 month, participants were tapered to 14 mg nicotine patch
for 2 weeks, then to 7 mg for 2 weeks
Open-label - commonbehavioural therapy: 6 clinic sessions, 30minutes each, at baseline,
quit week, and weeks 1, 2, 4, and 6
Double-blind - telephone support (control): n = 147 (excluded: n = 1); 5minutes general
support calls at weeks 8, 12, 16, and 20
Double-blind - extended cognitive-behavioural therapy: n = 154 (excluded: n = 2); 4
sessions, 30 minutes each, at weeks 8, 12, 16, and 20 and weekly check-in calls to
automated system; report of relapse or craving prompted proactive calls
Outcomes Primary outcomes: expired air CO-confirmed 7-day point prevalence abstinence eval-
uated at both 20 and 52 weeks
Secondary outcomes: nicotine dependence (craving and withdrawal symptoms); major
depressive disorder;medication compliance; heart rate andbloodpressure; adverse events;
medication compliance
Funding source Support was provided solely by a grant from the National Institute on Drug Abuse
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Killen 2008 (Continued)
Declaration of interest Dr Schatzberg serves as a consultant to GlaxoSmithKline.
Notes Analysis of pharmacogenetics is reported in Sarginson 2011.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation to extended treatment con-
dition was conducted via a permuted block
method (block size = 4 to obtain balance
between groups) and was stratified by gen-
der
Allocation concealment (selection bias) Low risk Participants were assigned to the next avail-
able ID number in the corresponding gen-
der
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Research team and participants were
blinded to extended treatment assignment
until the end of the open-label phase
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Research team and participants were
blinded to extended treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 89% in standard care; 90% in
intervention group
Selective reporting (reporting bias) Low risk Study protocol was not available but de-
tailed reporting of outcomes does not sug-
gest selective reporting
Other bias Unclear risk Of 304 trial participants, 270 provided
samples for DNA extraction, but the selec-
tion process for those 270 was unclear
Killen 2010
Methods 8-Week double-blind randomized placebo-controlled clinical trial
Setting: community-based, USA
Recruitment: community recruitment through radio, newspapers, community website,
and notices distributed via local organisations
Study period: May 2006 to July 2008
Participants N = 243
Inclusion criteria: 18 to 65 years of age; smoked 10 or more cigarettes a day
Males: 70%; average age: 45; average cigarettes/d: 19
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Killen 2010 (Continued)
Interventions Selegiline patch for 8 weeks, 6 mg/24 hours, starting on TQD vs identical placebo patch
on same schedule
Both groups received 9 sessions of individual cognitive-behavioural therapy
Outcomes Primary outcome: point prevalence abstinence (PPA) at week 25 and week 52 (i.e.
report of non-smoking (not even a puff ) for 7 consecutive days before contact and an
expired air carbon monoxide level < 10 ppm)
Secondary outcomes: time to relapse; occurrence, duration, and severity of adverse
events
Funding source National Institute on Drug Abuse; medication and matching placebo were provided by
Somerset Pharmaceuticals, Inc
Declaration of interest Dr Schatzberg served as a consultant for Somerset Pharmaceuticals
Notes Analyses of pharmacogenomics are reported in Sarginson 2015 (N = 231 with DNA
samples; 77.1% Caucasian, 9.1% Hispanic, 3.9% Asian, 1.3% black, 0.4% other, and
8.2% mixed ancestry)
All analyses of pharmacogenomics were performed in both the full cohort and the Cau-
casian-only cohort
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of random number generator
Allocation concealment (selection bias) Low risk Participants were assigned sequential ID
numbers corresponding to drugs used.
Also: “The drug (active or placebo) associ-
ated with each IDwas pre-packaged and la-
belled by ID only at an off-site location by
an individual who had no association with
the participants.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Treatment assignmentwas concealed from
staff and both research staff and partici-
pants were blind to week 52.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Treatment assignmentwas concealed from
staff and both research staff and partici-
pants were blind to week 52.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up at 12 months: 87% (same in
both arms)
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Killen 2010 (Continued)
Selective reporting (reporting bias) Low risk Registered in clinicaltrials.gov
under NCT01330030; no deviation from
prespecified outcomes
Other bias Low risk 12 people did not provide DNA for analy-
ses of pharmacogenomics; use of PCA was
included in analyses of pharmacogenomics
Lerman 2002
Methods Double-blind randomised placebo-controlled clinical trial of bupropion HCL (brand
name Zyban) in adult male and female smokers
Study period: June 1999 to March 2002
Participants N = 555 allocated and received intervention (Lerman 2006). Numbers included in
published pharmacogenetic analyses include ~ 414 (Lerman, 2006), ~ 412 (Conti, 2008)
, and ~ 416 (Bergen, 2013), which refer to European ancestry individuals only, but data
made available for this review include non-Hispanic white and non-Hispanic black, total
~ 494
Participants were smokers seeking treatment and were recruited through advertisements
for a free smoking cessation programme at Georgetown University and at the State
University of New York at Buffalo
Inclusion criteria: age ≥ 18 years, reported smoking ≥ 10 cigarettes/d for the previous
12 months, who provided informed consent for both genotyping and treatment
Exclusion criteria: planning a pregnancy, pregnant, lactating; seizure disorder, history
of head trauma or prior seizure, family history of a seizure disorder; brain (or CNS)
tumour; history of or current diagnosis of bulimia or anorexia nervosa; diabetes treated
with oral hypoglycaemics or insulin; excessive use of alcohol or alcoholism; current ad-
diction to opiates, cocaine, or stimulants; use of other drugs containing bupropion (e.g.
Wellbutrin, Wellbutrin SR); allergy to bupropion; currently taking particular medica-
tions (e.g. monoamine oxidase inhibitor, antipsychotics, antidepressants, theophylline,
systemic steroids, over-the-counter stimulants and anorectics); recently taking an MAOI
(< 14 days); or recent discontinuation of a benzodiazepine
Interventions Bupropion and 7 sessions of in-person behavioural group counseling (N = 285 allocated,
229 received allocation), and
Placebo and 7 sessions of in-person behavioural group counseling (N = 70 allocated, 211
received allocation)
Participants received 10 weeks of pills (active or placebo) initiated on the first day of
counseling. Bupropion treatment was standard (150 mg/d for 3 days, then 300 mg/d).
The target quit day was day of the third counseling session
Outcomes Primaryoutcomes: continuous abstinencemeasured at endof treatment and at 6months
after cessation
Secondary outcomes: short-term quit rates using 7-day and 30-day point prevalence
83% and 86% of participants reporting abstinence at end of treatment and at 6 months
provided a CO sample for verification
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Lerman 2002 (Continued)
Funding source Study medication for the bupropion trial was provided by GlaxoSmithKline. This re-
search was supported by grants from the National Cancer Institute and the National
Institutes of Drug Abuse, P50CA/DA84718 and RO1CA 63562
Declaration of interest Dr Berrettini has consulted for GlaxoSmithKline.
Notes Lerman 2002 described an interim analysis of mediators on cessation and was the first
published description of this trial. Lerman 2006 is the definitive description of the trial
and the first published analysis of pharmacogenetics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas computer generated by
a senior data manager
Allocation concealment (selection bias) Low risk Allocation was concealed from counselors
and study assistants




Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed via a timeline fol-
low-back method through phone inter-
views with study assistants
Incomplete outcome data (attrition bias)
All outcomes
High risk As described in Lerman 2006, 17% with-
drew after allocation but before interven-
tion (not included in ITT analysis), and
23% of the remainder were lost to follow-
up or discontinued treatment but were in-
cluded in the ITT analysis. No significant
differences in losses were reported at either
stage by arm. However, as abstinence out-
comes were 27% at EOT and 22% at 6
months, attrition proportion seems high
Selective reporting (reporting bias) Low risk Conti 2008 reported on continuous absti-
nence.
Other bias Low risk Genotype completion rate was very high
overall, so selection bias by treatment group
is low
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Lerman 2004
Methods Open-label randomised clinical trial of transdermal vs spray nicotine replacement therapy
(brand names Nicoderm and Nicotrol), with behavioural group counseling provided to
all participants
Study period: February 2000 to August 2003
Participants Participants were smokers seeking treatment and were recruited through advertisements
for a free smoking cessation programme at Georgetown University and at the University
of Pennsylvania
Inclusion criteria: ≥ 18 years of age, reported smoking of ≥ 10 cigarettes/d for the
previous 12 months, and provided informed consent for both genotyping and treatment
Exclusion criteria:planning a pregnancy, pregnancy or lactation; seizure disorder, history
of head trauma or prior seizure; unstable angina, heart attack, or stroke within past 6
months; current treatment for or recent diagnosis of cancer; drug or alcohol dependence;
current diagnosis or history of a DSM-IV axis I psychiatric disorder; current use of
bupropion or nicotine-containing products other than cigarettes; and skin allergies or
chronic dermatitis
Interventions N = 600 allocated and received intervention (Lerman 2006). Numbers included in
published pharmacogenetic analyses include ~ 368 (Lerman 2006) and ~ 378 (Bergen
2013), which refer to European ancestry individuals only.
Treatment allocation could not be concealed.
Eight weeks of NRT (standard Nicoderm patch, N = 302, or Nicotrol spray, N = 298)
was provided to participants on the target quit date after 2 weeks of counseling. A total
of 7 sessions of behavioural group counselling was provided
Outcomes Primaryoutcomes: continuous abstinencemeasured at endof treatment and at 6months
after cessation
Secondary outcomes: short-term quit rates using 7-day and 30-day point prevalence
76% and 72% of participants reporting abstinence at end of treatment and at 6 months
provided a CO sample for verification
Funding source Thisworkwas supported by aTransdisciplinaryTobaccoUseResearchCenterGrant from
the National Cancer Institute and the National Institute on Drug Abuse P5084718, and
the Abramson Cancer Center and Annenberg Public PolicyCenter (CL), and PHS grants
P60DA005186 (WB), DA02277, DA12393, CA078703, and the UCSF Comprehen-
sive Cancer Center (NB), and Public Health Services Research Grant M01-RR0040
from the National Institutes of Health. Nicotine nasal spray was provided by Pharmacia,
Helsingborg, Sweden
Declaration of interest Dr Berrettini acts as a consultant to GlaxoSmithKline.
Notes Lerman 2004 described an interim analysis of pharmacogenetics of abstinence and was
the first published description of this trial. Lerman 2006 is the definitive description of
the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
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Lerman 2004 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisationwas computer generated by
a senior data manager
Allocation concealment (selection bias) High risk Allocation could not be concealed from
counselors and study assistants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were assessed via a timeline fol-
low-back method through phone inter-
views with study assistants
Incomplete outcome data (attrition bias)
All outcomes
High risk As described in Lerman 2006, 11% with-
drew after allocation but before interven-
tion (not included in ITT analysis), and
22% of the remainder were lost to fol-
low-up or discontinued treatment but were
included in the ITT analysis. No signif-
icant differences in losses at either stage
by arm. However, as abstinence outcomes
were 33% at EOT and 20% at 6 months,
attrition proportion seems high
Selective reporting (reporting bias) Unclear risk Lerman et al reported on primary and sec-
ondary outcomes; Bergen et al on sec-
ondary outcomes
Other bias Low risk Genotype completion rate was very high
overall, so selection bias by treatment group
is low
Lerman 2015
Methods Double-blindparallel-groupplacebo and active treatment-controlled randomised clinical
trial
Study period: November 2010 to September 2013
Participants N = 1246
Participants were smokers seeking treatment and were recruited through advertisements
for a free smoking cessation programme
Inclusion criteria: age between 18 and 65 years, reported smoking ≥ 10 cigarettes/d
for 6 months or longer (verified by carbon monoxide concentrations > 10 ppm)
Exclusion criteria: use of non-cigarette tobacco products, e-cigarettes, or current smok-
ing treatment; history of substance misuse treatment, current use of cocaine or metham-
phetamine, or more than 25 alcoholic drinks/week; medical contraindications; history
of DSM-IV Axis I psychiatric disorder or suicide risk score on the Mini-International
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Lerman 2015 (Continued)
Neuropsychiatric Interview (MINI) > 1, or current major depression; current use of
antipsychotics, stimulants, opiate medications, anticoagulants, rescue inhalers, antiarry-
hthmics, or medications altering CYP2A6 activity (e.g. monoamine oxidase inhibitors,
tricyclic antidepressants); and inability to provide informed consent or any condition
that could compromise safety
Interventions Placebo pill + placebo patch (n = 408)
Placebo pill + nicotine patch (n = 418)
Varenicline + placebo patch (n = 420)
Participants received 11 weeks of patches: 21 mg (6 weeks), 14 mg (2 weeks), and 7 mg
(3 weeks). Varenicline (or placebo) was delivered for 12 weeks (1 week before the target
quit date): days 1 to 3 (0·5 mg once daily); days 4 to 7 (0·5 mg twice daily); and days 8
to 84 (1·0 mg twice daily)
Outcomes Primary outcome: biochemically verified 7-day point prevalence abstinence at end of
treatment
Secondary outcomes: side effects, withdrawal symptoms, 6-month and 12-month quit
rates
Funding source This work was supported by a grant from the National Institute on Drug Abuse, the
National Cancer Institute, theNational HumanGenomeResearch Institute, and theNa-
tional Institute on General Medical Sciences (U01-DA20830) to CL and RFT; funding
from the AbramsonCancer Center at theUniversity of Pennsylvania (P30CA16520) and
a grant from the Commonwealth of Pennsylvania Department of Health was provided
to CL; a grant from the Canadian Institutes of Health Research (CIHR TMH109787),
an endowed Chair in Addiction for the Department of Psychiatry, CAMH Foundation,
the Canada Foundation for Innovation (#20289 and #16014), and the Ontario Min-
istry of Research and Innovation were given to RFT. The Pennsylvania Department of
Health disclaims responsibility for analyses, interpretations, or conclusions. Pfizer pro-
vided varenicline and placebo pills at no cost
Declaration of interest CL received study medication and placebo, and support for medication packaging, from
Pfizer; she has also consulted for Gilead, and has been a paid expert witness in litigation
against tobacco companies.
PC served on the scientific advisory board of Pfizer Pharmaceuticals, presented edu-
cational talks sponsored by Pfizer on smoking cessation from 2006 to 2008, and has
received grant support from Pfizer.
RAS received medication and placebo free of charge from Pfizer for a different project,
and has consulted for Pfizer and GlaxoSmithKline.
TPG has received both investigator-initiated and industry-sponsored grants from Pfizer
in the past 12 months, and serves on a data monitoring committee for Novartis.
NIB has served as a consultant to several pharmaceutical companies that market smoking
cessation medications and has been a paid expert witness in litigation against tobacco
companies.
RFT has acted as a consultant to pharmaceutical companies, primarily on smoking
cessation.
The remaining authors declare no competing interests.
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Lerman 2015 (Continued)
Notes This paper provided analysis of pharmacogenetics. Additional analyses are reported in
Tyndale 2015.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A biostatistician, independent of study
investigators, developed a randomisation
procedure, whichwas integrated into a cen-
tralised data management system
Allocation concealment (selection bias) Low risk Randomisation was centrally organised.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, study investigators, and per-
sonnel were masked to treatment group al-
location
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was appropriate, and the outcome
of the study was objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data are similar in all
treatment groups; different validation anal-
yses were performed to deal with missing
data
Selective reporting (reporting bias) Low risk All outcomes listed on clinicaltrials.gov
(NCT01314001) are reported. However,
12-month quit rates were not listed in
the protocol but are presented in the
manuscript
Other bias Low risk Additional analyses of pharmacogenetics
in Tyndale 2015 were conducted in Cau-
casians only, but these seem to be dis-
tributed equally among treatment groups,
so selection bias seems unlikely
Marteau 2012
Methods Open-label parallel-group randomised controlled trial of genotype-based vs dependence
score-based oral dose of NRT for smoking cessation (the “Personalised Extra Treatment
(PET) Trial”)
Study period: June 2007 to September 2009
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Marteau 2012 (Continued)
Participants N = 633
Participants were recruited from 29 primary care practices in Birmingham and Bristol,
UK
Inclusion criteria: (a) ≥ 18 years of age, (b) regular cigarette smoker of ≥ 10 cigarettes/
d, (c) wants to stop smoking, (d) able to give informed consent to participate, (e) able
to complete study questionnaires, alone or with assistance
Exclusion criteria: (a) cigar, pipe, and oral tobacco users who do not also smoke ≥ 10
cigarettes/d, (b) contraindications toNRTuse, (c) pregnant or lactatingwomen and those
who plan to become pregnant during the course of treatment, (d) previous severe adverse
reactions to NRT patch or to oral NRT, (e) currently taking medication for smoking
cessation that they are unwilling to stop, (f ) taking medication with a known influence
on smoking cessation that they should not stop (e.g. nortriptyline for depression), (g)
non-English speakers, (h) those deemed unsuitable for the study by their primary care
physicians
Interventions DNA-tailored oral NRT dose (N = 315)
Nicotine dependence-tailored NRT dose (N = 318)
Participants were randomly allocated on a 1:1 basis to 1 of 2 groups:
(a) NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype), or (b) NRT oral
dose tailored by nicotine dependence questionnaire score (phenotype). All participants
were offered behavioural support and an NRT patch, tailored for all
participants by phenotype (daily cigarettes smoked). Trial interventions comprised com-
munication that the prescribed dose of oral NRT was based on either genotype
(intervention) or phenotype (comparison). Support for behavioural change was based on
withdrawal-oriented therapy and was provided for all participants twice before quit day
and weekly thereafter until 4 weeks after quitting, then once more 8 weeks after quitting
Outcomes Primary outcomes: adherence to prescription of NRT over 28 days, motivation to make
further quit attempts
Secondary outcomes: adherence to prescription of NRT over 7 days, 6-month absti-
nence
Funding source “This study was funded as part of a grant from the Medical Research Council, UK (Risk
communication in preventive medicine: Optimising the impact of DNA risk informa-
tion; G0500274 PI: TMM). The trial protocol was peer reviewed by the Council. PA is
funded by a personal award from the National Institute of Health Research (NIHR) and
by the UK Centre for Tobacco Control Studies (UKCTCS). PA and MRM are mem-
bers of UKCTCS, a UKCRC Public Health Research Centre of Excellence. Funding
from British Heart Foundation, Cancer Research UK, Economic and Social Research
Council, Medical Research Council, and National Institute for Health Research, under
the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. The
sponsors and funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.”
Declaration of interest “PA has done consultancy and research on smoking cessation for pharmaceutical com-
panies. The remaining authors declare that they have no conflicts of interest.”
Notes DNA samples were collected at study entry.
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Marteau 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The trial statistician generated the se-
quences and received the stratifier data and
participant and family identifier required
to randomise participants, and participant
date of birth to confirm group allocation at
trial closure.”
Allocation concealment (selection bias) Low risk Before group assignment, allocation was
concealed.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Randomisation sequence was revealed se-
quentially and was concealed from the
study team, nurses, and participants. Af-
ter assignment to groups, allocation was no
longer blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was appropriate, and the outcome
of the study was objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was modest and bal-
anced, and all participants were analysed by
intention-to-treat
Selective reporting (reporting bias) Low risk Trial protocol was pre-registered and was
published before the results paper, which
reported prespecified outcomes
Other bias Low risk The trial and its outcomes were reported
openly.
McCarthy 2008
Methods Open-label behavioural intervention and placebo-controlled pharmacotherapy interven-
tion randomised clinical trial
Study period: January 2001 to October 2003
Participants N = 463
Participants were smokers seeking treatment recruited through mass media and screened
by 3 rounds (telephone, group orientation, office visit)
Inclusion criteria: aged 18 years or older who reported smoking ≥ 10 cigarettes/d and
whose expired carbon monoxide (CO) levels exceeded 9 ppm. Participants reported
being motivated to quit smoking (3 or 4 on a 4-point self-report scale) and being willing
to fulfil study requirements
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McCarthy 2008 (Continued)
Exclusion criteria: serious psychopathology (bipolar disorder or psychosis), current
depression, contraindications to use of bupropion SR (e.g. uncontrolled hypertension,
history of seizure disorder, history of eating disorders, current heavy drinking, risk of
pregnancy, current breastfeeding). Participants were excluded if their score on the Center
for Epidemiologic Studies Depression (CES-D) scale was above 16, except when an
interview with a licensed clinician suggested that symptoms were related to a cause other
than clinical depression
Interventions Active (bupropion SR) pharmacotherapy and individual targeted counseling (n = 113)
Active pharmacotherapy, general counseling (N = 116)
Placebo pharmacotherapy, individual targeted counseling (N = 121)
Placebo pharmacotherapy, general counseling (N = 113)
Participants attended 5 office visits in the 3 weeks before the quit date. Participants
received 9 weeks of study pills (active or placebo), to begin 1 week before and to end
8 weeks after the planned quit date. Participants attended another 8 office visits over
the 8 weeks following the quit date (provided breath samples at each visit and a blood
sample at baseline and at end of treatment), then completed 10 monthly follow-up calls.
All participants received education regarding medication use and adherence, quit day
information, and general encouragement, and completed electronic diaries for 2 weeks
before and 4 weeks after the quit date. Participants randomised to individual targeted
counseling received eight 10-minute individual counseling sessions (2 prequit, 1 quit
day, 5 postquit over 4 weeks)
Outcomes Primary outcomes: electronic diary and retrospective report of lapse and of relapse (7
days) with 7-day point prevalence abstinence confirmed via CO at each office visit and
cotinine testing at end of treatment; 7-day point prevalence abstinence at 6 and 12
months with CO testing
Secondary outcomes: prolonged abstinence outcomes at end of treatment, at 6 and 12
months
Funding source This work was supported by Transdisciplinary Tobacco Use Research Center grants
CA084724 from the National Cancer Institute and DA19706 from the National In-
stitute on Drug Abuse. GlaxoSmithKline provided complimentary active and placebo
medication used in this study. GlaxoSmithKline was not involved in the design, data
collection, analysis, or reporting of this study
Declaration of interest DEJ has received research support from Nabi Biopharmaceutical and Pfizer, Inc., and
consulting fees from Nabi Biopharmaceutical. SS serves as consultant to GlaxoSmithK-
line Consumer Healthcare on an exclusive basis regarding over-the-counter smoking
cessation products and is a partner in a company that is developing a new nicotine med-
ication. He is a cofounder of invivodata, Inc., which provides electronic diary services
for clinical research. In 1998 the University of Wisconsin appointed MCF to a named
Chair made possible by an unrestricted gift to the university from GlaxoWellcome
Notes This work did not report analyses of pharmacogenetics, but these were reported inBergen
2013.
Risk of bias
87Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCarthy 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation via random number list
Allocation concealment (selection bias) Unclear risk Study pills did not differ in appearance be-
tween active and placebo but were pack-
aged in containers before enrolment of par-
ticipants. Randomisation was done via a
random number list
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Research staff and participants were blind
to pharmacotherapy randomisation but
were not blind to counseling randomisa-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was done by elec-
tronic diary through end of treatment, and
by interview (self-report), performed in of-
fice or by phone calls, with biochemical ab-
stinence verified at each office visit (CO)
and at 6 and 12 months (cotinine). Discor-
dance between reports or verificationmeth-
ods analysed in multiple ways, but final
prevalences highly similar
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was substantial and did not differ
by treatment arm at quit, end of treatment,
or any other follow-up point. Attrition was
related to various covariates included in ab-
stinence models in the primary paper
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were re-
ported.
Other bias High risk DNA samples were provided for 41% of
self-identified whites for analysis of phar-
macogenetics.Most (~ 99%)DNA samples
were successfully genotyped. Analyses of
pharmacogenetics in Bergen 2013 are dis-
tributed equally among treatment groups,
so selection bias is unlikely in this sample
88Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Oncken 2006
Methods Double-blindparallel-groupplacebo and active treatment-controlled randomised clinical
trial
Study period: study dates not reported
Participants N = 647
Participants were healthy cigarette smokers. Recruitment methods not reported
Inclusion criteria: 18 to 65 years of age, smoke ≥ 10 cigarettes/d
Exclusion criteria: treatment with an investigational drug within the previous month;
major depression within the prior year; panic disorder, psychosis, or bipolar disorder;
use of nicotine replacement or bupropion within the previous 3 months; cardiovascular
disease; clinically significant medical disease; drug or alcohol abuse or dependence within
the past year; use of tobacco products other than cigarettes or marijuana within the
previous month
Interventions 0.5 mg twice-daily non-titrated varenicline (n = 129)
0.5 mg twice-daily titrated varenicline (n = 130)
1.0 mg twice-daily non-titrated varenicline (n = 129)
1.0 mg twice-daily titrated varenicline (n = 130)
Placebo (n = 129)
Participants received study medication for 12 weeks. Specifically, participants in each of
these groups received the following medication: 0.5 mg twice daily non-titrated (i.e. 0.
5 mg twice daily for 12 weeks); 0.5 mg twice daily titrated (i.e. 0.5 mg once daily for 7
days, then 0.5 mg twice daily for 11 weeks); 1.0 mg twice daily non-titrated (i.e. 1.0 mg
twice daily for 12 weeks); 1.0 mg twice daily titrated (i.e. 0.5 mg once daily for 3 days,
then 0.5 mg twice daily for 4 days, then 1.0 mg twice daily for 11 weeks); or placebo (i.
e. 2 placebo tablets twice daily for 12 weeks)
All participants received a smoking cessation booklet at the baseline visit and brief
smoking cessation counseling (up to 10 minutes) at each visit
Outcomes Primary outcomes: carbon monoxide-confirmed 4-week continuous quit rate for weeks
4 through 7 and weeks 9 through 12 during treatment and continuous abstinence rates
for weeks 9 through 52 for each dose relative to placebo. Continuous abstinence was
defined as self-report of no cigarette use during the specified time period confirmed by
an exhaled carbon monoxide measurement ≤ 10 ppm
Other outcomes: carbon monoxide-confirmed 7-day point prevalence abstinence,
changes in the Minnesota Nicotine Withdrawal Scale and the modified Cigarette Evalu-
ation Questionnaire, carbon monoxide-confirmed 7-day point prevalence abstinence at
weeks 24 and 52
Funding source Pfizer Inc. provided funding for this study. Pfizer Inc. was involved in all elements of
this study, including, but not limited to, study design and monitoring
Declaration of interest DrOncken has received research grants, consulting fees, and honoraria fromPfizer; nico-
tine replacement and placebo products from GlaxoSmithKline at no cost for smoking
cessation studies; and honoraria from Pri-Med. Dr Gonzales has received research con-
tracts, consulting fees, and honoraria from Pfizer, Sanofi-Aventis, and GlaxoSmithKline,
and owns 5 shares of Pfizer stock that he received as a gift from his parents. Dr Rennard
has had or currently has a number of relationships with companies that provide products
and/or services relevant to outpatient management of chronic obstructive pulmonary
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disease. These relationships include serving as a consultant (for Adams, Almirall, Altana,
Array Biopharma, AstraZeneca, Aventis, Biolipox, Centocor, Dey, Critical Therapeu-
tics, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Ono Pharma, Otsuka, RJ
Reynolds, Roche, Sankyo, Schering-Plough, Scios, and Wyeth), advising regarding clin-
ical trials (Altana, AstraZeneca, Aventis, Centocor, GlaxoSmithKline, Novartis, Pfizer,
and Philip Morris), speaking at continuing medical education programs and performing
funded research at both basic and clinical levels (Altana, AstraZeneca, Boehringer Ingel-
heim, GlaxoSmithKline, and Novartis). He does not own any stock in any pharmaceu-
tical companies. Dr Nides has received research grants, consulting fees, and honoraria
from Pfizer, Sanofi-Avenits, and GlaxoSmithKline. Drs Watsky and Reeves and Messrs
Billing and Anziano are employees of Pfizer and own Pfizer stock or hold Pfizer stock
options
Notes Analysis of pharmacogenetics was reported in King 2012.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details reported
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were blinded
to study drug treatment assignment. Partic-
ipants were not encouraged to guess their
treatment assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was appropriate, and the outcome
of the study was objective
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More dropout in the placebo group and
specific dropout for lack of efficacy oc-
curredmore often in the 1.0mg twice-daily
titrated varenicline group. Dropouts were
assumed to be smoking
Selective reporting (reporting bias) Unclear risk No protocol was found.
Other bias Low risk Additional analyses of pharmacogenetics
were conducted in King 2012 in a subset
of the original randomised trial population,
but baseline characteristics were compara-
ble between treatment groups, so selection
bias seems unlikely
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Piper 2007
Methods Double-blind placebo-controlled combination pharmacotherapy intervention ran-
domised clinical trial. Ten cohorts of participants were randomised in a block manner
to 3 intervention arms
Study period: January 2001 to October 2002
Participants N = 608
Participants were smokers seeking treatment who were recruited through mass media
Inclusion criteria: 18 years of age or older, who reported smoking ≥ 10 cigarettes/d
and being motivated to quit (3 or 4 on a 4-point self-report scale)
Exclusion criteria: expired carbon monoxide (CO) levels < 10 ppm; CES-D score > 16;
suicidality; contraindications to use of bupropion SR (e.g. uncontrolled hypertension,
history of seizure disorder, history of eating disorders, current heavy drinking, current
breastfeeding). Female participants were not pregnant and agreed to prevent pregnancy
during treatment
Interventions Active (bupropion SR) pharmacotherapy and active nicotine gum (4 mg as needed up
to 12 mg/d) (n = 228)
Active bupropion pharmacotherapy and placebo gum (N = 224)
Placebo pharmacotherapy and placebo gum (N = 156)
Participants attended a baseline screening (physical exam, questionnaires to assess medi-
cal/psychological exclusions, and nicotine dependence inventories), were randomised to
1 of 3 intervention arms for 9 weeks of treatment. After the baseline visit, participants
attended office visits each week for 4 weeks, then every other week for 4 weeks (through
the end of treatment). Participants received three 10-minute counseling sessions (at
baseline, quit day, and first post-quit day weeks), providing medication instruction and
Public Health Service Guideline elements. At remaining office visits, participants com-
pleted questionnaires and vital sign assessment and received medications. Participants
completed a daily diary through treatment and used a cell phone for 2 weeks to collect
real-time data. Participants were followed monthly by telephone (smoking calendar and
symptoms) to 6 months and 12 months
Outcomes Primary outcome: 7-day point prevalence abstinence at 6 months confirmed via CO
(breath) or cotinine (blood) analysis
Secondary outcomes: 7-day point prevalence abstinence at 1 week post quit, at end
of treatment, and at 12 months (12-month abstinence confirmed via CO (breath) or
cotinine (blood) analysis), continuous abstinence
Funding source This work was supported by Transdisciplinary Tobacco Use Research Center grants
CA084724 from the National Cancer Institute and DA019706 from the National In-
stitute on Drug Abuse
Declaration of interest Dr Fiore neither consults for nor accepts honoraria from the pharmaceutical industry,
effective 1 January 2006. In 1998 the University of Wisconsin appointed Dr Fiore to a
named chair,made possible by anunrestricted gift to the university fromGlaxoWellcome.
Dr Baker has received monies from pharmaceutical companies (Nabi, Glaxo, Pfizer,
Sanofi) to conduct clinical trials; he has received no personal remuneration from these
companies
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Notes This work did not report analyses of pharmacogenetics, but these were reported inBergen
2013.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description
Allocation concealment (selection bias) Unclear risk No description
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Research staff and participants were blind
to pharmacotherapy randomisation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was done by daily di-
ary and by self-report through end of treat-
ment, and by self-report through the re-
maining 12 months, with biochemical ab-
stinence verified at 6 and 12 months
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was moderate and did not differ
by treatment arm at quit, at end of treat-
ment, and at 6 and 12 months
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were re-
ported.
Other bias Unclear risk DNA samples were provided for 60%
of self-identified white trial participants
for analysis of pharmacogenetics. Most
(~ 99%) DNA samples were successfully
genotyped. Analyses of pharmacogenetics
are distributed equally among treatment
groups in Bergen 2013, so selection bias is
unlikely in this sample.
Piper 2009
Methods Double-blind placebo-controlled single and combination pharmacotherapy intervention
randomised clinical trial
Study period: September 2004 to August 2010
Participants N = 1504
Participants were smokers seeking treatment who were recruited through mass media
Inclusion criteria: 18 years of age or older who reported smoking ≥ 10 cigarettes/dfor
the past 6 months, expired CO > 9 ppm, motivated to quit (3 or 4 on a 4-point self-
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report scale), able to read and write English, and willing to complete assessments
Exclusion criteria: using any form of tobacco other than cigarettes, currently taking
bupropion, or having a current psychosis or schizophrenia diagnosis. In addition, par-
ticipants were excluded if they had medical contraindications for any of the study med-
ications, including high alcohol consumption (6 drinks/d on 6 or 7 days of the week), a
history of seizure, high blood pressure (> 160/100 mm Hg), bipolar disorder, an eating
disorder, a recent cardiac event, or allergies to any of the medications. Only 1 person
per household could participate. Finally, pregnant and breastfeeding women were not
eligible for participation; eligible female participants had to agree to take steps to prevent
pregnancy during the medication treatment phase of the study
Interventions Active (bupropion SR) pharmacotherapy for 9 weeks - 1 week prequit, 8 weeks post quit
(n = 264)
Nicotine lozenge (2 or 4 mg for 12 weeks post quit) (n = 260)
Nicotine patch (24-hour patch 21, 14, and 7 mg over 8 weeks post quit) (n = 262)
Nicotine patch (8 weeks post quit) plus nicotine lozenge (12 weeks post quit) (n = 267)
Active bupropion pharmacotherapy plus nicotine lozenge (n = 262)
Placebo pharmacotherapy (placebo bupropion, placebo lozenge, placebo patch, placebo
patch plus lozenge, and placebo bupropion plus lozenge) (n = 189)
Participants attended 5 baseline (prequit) screenings (physical exam, questionnaires to
assess medical/psychological exclusions, and nicotine dependence inventories, and car-
diovascular assessments). Participants were randomised to 1 of 6 intervention arms for
9 to 12 weeks of treatment at the fifth baseline visit. Participants attended study visits
on their quit day and 1, 2, 4, and 8 weeks post quit, and received six 10- to 20-minute
counseling sessions at the third and fifth baseline visits, on their quit day, and at weeks
1, 2, and 4
Outcomes Primary outcome: 7-day point prevalence abstinence at 1 week post quit, at end of
treatment, and at 6 months post quit, confirmed via CO (breath) analysis
Secondary outcomes: initial cessation, days to lapse, days to relapse, latency to relapse
after lapse
Funding source This research was conducted at the University ofWisconsin-Madison and was supported
by grant P50 DA019706 from the National Institute on Drug Abuse and by grant M01
RR03186 from the General Clinical Research Centers Program of the National Center
for Research Resources. Dr Piper was supported by an Institutional Clinical and Trans-
lational Science Award, University of Wisconsin-Madison (KL2 grant 1KL2RR025012-
01). Medication was provided to participants at no cost under a research agreement with
GlaxoSmithKline
Declaration of interest Study authors report the following potential conflicts of interest for the past 5 years:
Dr Smith has received research support from Elan Corporation. Dr Baker has served as
an investigator on research projects sponsored by pharmaceutical companies, including
Sanofi-Synthelabo, Pfizer Inc., and Nabi Biopharmaceuticals. Dr Jorenby has received
research support from the National Institute on Drug Abuse, the National Cancer Insti-
tute, Pfizer Inc., Sanofi-Synthelabo, and Nabi Biopharmaceuticals. He has received sup-
port for educational activities from the National Institute on Drug Abuse and the Vet-
erans Administration, and consulting fees from Nabi Biopharmaceuticals. Dr Fiore has
received honoraria from Pfizer. He has served as an investigator on research studies at the
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University of Wisconsin that were funded by Pfizer, Sanofi- Synthelabo, GlaxoSmithK-
line, and Nabi Biopharmaceuticals. In 1998, the University of Wisconsin appointed Dr
Fiore to a named chair funded by an unrestricted gift to University of Wisconsin from
Glaxo Wellcome
Notes This work did not report analyses of pharmacogenetics, but these were reported inBergen
2013.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Blocked on sex and self-reported race but
no other description
Allocation concealment (selection bias) Low risk Allocationwas concealed until themoment
of randomisation (3 different types of phar-
macotherapy)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Research staff and participants were blind
to active vs placebo pharmacotherapy ran-
domisation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was done by self-re-
port, with biochemical (CO) verification at
6 and 12 months
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was very modest and did not dif-
fer by treatment arm during treatment or
follow-up
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were re-
ported.
Other bias Low risk DNA samples were provided for 83%
of self-identified white trial participants
for analysis of pharmacogenetics. Most
(~ 99%) DNA samples were success-
fully genotyped. Pharmacogenetic analyses
are distributed equally amongst treatment
groups in Bergen 2013, so selection bias is
unlikely in these arms and subsamples
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Rose 2010
Methods Randomised double-blind parallel-arm placebo-controlled factorial trial with 2 levels of
nicotine dependence and 2 nicotine doses
Setting: academic centre, USA
Recruitment: community volunteers
Study period: not reported; August 2007 to May 2009 according to clinicaltrials.gov
Participants N = 479
43.4% males; average age: ~ 44; average cigarettes/d: 24
Inclusion criteria (as reported in clincatrials.gov): “18-65 years old, smokers of at least
10 cigarettes per day for three cumulative or continuous years of a brand that delivers at
least 0.5 mg nicotine, have an expired air carbon monoxide reading of at least 10 ppm,
and express a desire to quit smoking. Additionally, subjects must express a willingness to
switch to denicotinized cigarettes.”
Exclusion criteria (as reported in clincatrials.gov): “Participants with hypertension or
hypotension may, however, be allowed to participate in the study if the study physician
or P.A. determines that the condition is stable, controlled by medication, and in no
way jeopardizes the individual’s safety. Subjects with no previous diagnosis of hyperten-
sion may have a screening blood pressure up to 160/100. Potential subjects who report
coronary heart disease; heart attack; cardiac rhythm disorder (irregular heart rhythm);
chest pains (unless history, exam, and EKG clearly indicate a non-cardiac source); cardiac
(heart) disorder (including but not limited to valvular heart disease, heart murmur, heart
failure); history of skin allergy; active skin condition (psoriasis) within the last five years;
skin disorder except minor skin conditions (including but not limited to facial acne,
minor localized infections, and superficial minor wounds.); liver or kidney disorder (ex-
cept kidney stones, gallstones); gastrointestinal problems or disease other than gastroe-
sophageal reflux or heartburn; ulcers; lung disorder (including but not limited to COPD,
emphysema, and asthma); brain abnormality (including but not limited to, stroke, brain
tumour, seizure disorder); history of fainting; problems giving blood samples; difficulty
passing urine; diabetes treated with insulin, non-insulin treated diabetes (unless glucose
is less than 180mg/dcl and HbA1c is less than 7%); current cancer or treatment for
cancer in the past 6 months (except basal or squamous cell skin cancer); other major
medical condition; current psychiatric disease (with the exception of depression, anxiety
disorders, OCD and ADHD) will be excluded from the study. Potential subjects who do
not have a self reported diagnosis of the above listed conditions may be excluded if the
study physician or P.A. determines that the history, physical findings, EKG, or laboratory
studies reveal information that may jeopardize the subject’s safe study participation.”
Interventions Nicotine patch 21 mg/24 h vs 42 mg/24 h in low vs high nicotine dependence groups
Treatment groups: (a) less dependent/21 mg nicotine patch, (b) less dependent/42 mg
nicotine patch, (c) more dependent/21 mg nicotine patch, and (d) more dependent/42
mg nicotine patch
Outcomes Primary outcome: continuous abstinence from target quit date through endof treatment
(10 weeks)
Secondary outcomes: 4-week continuous abstinence during weeks 7 to 10 after target
quit date; 7-day point abstinence at 6 months
Funding source National Institutes of Health (NIH), Intramural Research Program, National Institute
on Drug Abuse, Department of Health and Social Services; grant to Duke University
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from Philip Morris USA, Richmond, VA, USA
Declaration of interest G.R. Uhl and J.E. Rose are listed as inventors for a patent application filed by Duke
University based on genomic markers that distinguishes successful quitters from unsuc-
cessful quitters in data from other clinical trials
Rose is the Principal Investigator for a grant from Philip Morris USA, Richmond, VA,
USA, to Duke University; the company had no role in planning or execution of the
study, data analysis, or publication of results
Notes This study provides analysis of pharmacogenetics.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information
Allocation concealment (selection bias) Unclear risk Double-blind design but no further details
provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind design but no further details
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind design but no further details
provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Protocol available at clinicaltrials.
gov (NCT00734617); no deviations from
prespecified endpoints
Schnoll 2010
Methods Parallel randomised double-blind placebo-controlled trial
Setting: academic centre, USA
Recruitment: community volunteers
Study period: October 2004 to March 2008
Participants N = 575
44.7% females; average age: 44.8; average cigarettes/d: 21.2
Inclusion criteria: age 18 to 65 years, smoked≥ 10 cigarettes/d for at least the past year
Exclusion criteria: pregnancy or lactation, uncontrolled hypertension, unstable angina,
heart attack or stroke within previous 6 months, recent diagnosis of cancer or kidney or
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liver failure, history of organ transplantation, current diabetes, drug or alcohol depen-
dence, history of Axis I psychiatric disorder, current use of a concomitant medication,
or current treatment of nicotine addiction
Interventions Transdermal nicotine (21 mg) for 8 weeks and placebo for 16 weeks (standard therapy)
(n = 287) vs transdermal nicotine (21 mg) for 24 weeks (extended therapy) (n = 288)
Behavioural counseling was provided to both groups at weeks -2, 0, 1, 4, 8, 12, 16, and
20
Outcomes Primary outcome: self-reported and biochemically confirmed 7-day point prevalence
abstinence at weeks 24 and 52
Secondary outcomes: self-reported continuous abstinence; prolonged abstinence; time
to relapse; incremental cost per additional quitter by treatment group at week 24
Also evaluated: side effects; adherence
Funding source TransdisciplinaryTobaccoUseResearchCenterGrant from theNationalCancer Institute
and the National Institute on Drug Abuse at the National Institutes of Health
Declaration of interest Dr Lerman has served as a consultant to GlaxoSmithKline - one company that manufac-
tures the nicotine patch. She has also served as a consultant for or has received research
funding from AstraZeneca, Pfizer, and Novartis. Financial support for this study was
not provided by an industry sponsor. Dr Lerman had full access to the data and had full
responsibility for the decision to submit for publication
Notes Analyses of pharmacogenetics are reported in Gold 2012 and Lerman 2010.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation; non-
stratified randomisation schemewas gener-
ated by sampling without replacement and
by using small blocks of 20 participants
Allocation concealment (selection bias) Low risk A computer programme linked randomi-
sation to the patch supply, and only the
database manager could link identification
to treatment allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and all study personnel, except
for the database manager, were blinded to
randomisation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and all study personnel, except
for the database manager, were blinded to
randomisation
97Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schnoll 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Completion rates at 52 weeks: 83% for ex-
tended therapy; 79% for standard therapy
Selective reporting (reporting bias) Low risk Protocol available at ClinicalTrials.gov
(registration number: NCT00364156); no
deviations from prespecified outcomes
identified
Other bias Low risk Analyses of pharmacogenetics were con-
ducted only in Caucasians. Distribution
seems balanced between treatment groups
because of randomisation
Sun 2012
Methods Double-blind randomised clinical trial
Setting: community hospital, China
Recruitment: community volunteers
Study period: March to December 2004
Participants N = 249
93.5% males; average age: 41; average cigarettes/d: 23
Inclusion criteria: (a) Han Chinese 20 to 70 years of age who lived in the Haidian
District of Beijing; (b) had to be motivated to stop smoking; (c) smoked C10 cigarettes/
d and smoked for C3 years; (d) presented with carbon monoxide (CO) level C10 ppm
in exhaled air; (e) provided written informed consent and able to take part in assessment
Exclusion criteria: psychiatric disorder, alcohol abuse, and other drug abuse (per DSM-
IV); pathological changes in the floor of the mouth; cardiovascular disease; taking psy-
chotropic medications; using other forms of tobacco or any other NRT products during
the past 6 months; pregnant or breastfeeding
Interventions Nicotine sublingual tablet (NST) vs placebo
“Smokers were recommended to use one or two tablets (4 mg of nicotine) per hour, up
to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose
for 4 weeks (minimum of 15 tablets and maximum of 20 tablets per day). After this
time-point, treatment could be tapered off up to the 8-week visit. During the next 4-
week follow-up phase, no further medication was dispensed.”
“In addition, all participants received six sessions of standardized behavioral group coun-
seling focusing on self- monitoring and behavioral modification approaches.”
Outcomes Continuous, self-reported complete abstinence for ≥ 7 days, verified by exhaled CO
level < 10 ppm
Funding source National Natural Science Foundation of China; Training Program Foundation for Ex-
cellent Talents by the Beijing Municipal Government, China; Stanley Medical Research
Institute; Department of Veterans Affairs, Mental Illness Research, Education and Clin-
ical Center (MIRECC); US National Institutes of Health
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Declaration of interest Not reported
Notes This study provides analysis of pharmacogenetics.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of a computer-generated randomisa-
tion scheme operated by a senior data man-
ager
Allocation concealment (selection bias) Low risk “Allocation was concealed from the investi-
gator who delivered the interventions and
assessed the outcomes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Interviewers were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers and reasons for missing partici-
pants are not given.
Selective reporting (reporting bias) Unclear risk No relevant details on protocol availability
Swan 2003
Methods Open-label randomised trial
Setting: HMO, USA
Recruitment: volunteers from Group Health Cooperative (GHC) membership
Study duration: April 1998 to May 1999
Participants N = 1524
57% females; average age: 45; average cigarettes/d: ~ 23
Inclusion criteria: at least 18 years of age, smoked≥ 10 cigarettes/d, were motivated to
stop smoking, were otherwise in good general health, had sufficient verbal and written
command of English to provide informed consent and study responses, andwere enrolled
and planned to stay enrolled in GHC for the next 12 months
Exclusion criteria: (1) any predisposition to seizure, as defined by a personal or family
history of a seizure disorder, such as epilepsy, or a personal history of febrile seizures; (2)
history of stroke or transient ischaemic attack; (3) history of head injury resulting in loss
of consciousness for longer than 1 hour; (4) current use ofmedications contraindicated to
bupropionSRor known to lower the seizure threshold (complete list available on request);
(5) history of or current diagnosis of anorexia nervosa or bulimia; (6) being of poor general
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health, as defined by the presence of severe and chronic cardiovascular disease (including
myocardial infarction within the previous 3 months), severe and chronic pulmonary
disease, renal or hepatic dysfunction, neurological disease, uncontrolled hypertension, or
uncontrolled diabetes mellitus; (7) participation in GHC’s Free & Clear (FC) smoking
cessation programme in the previous 12 months (1 of the treatments included in the
present study); (8) current depression; (9) current drinking of 14 or more alcoholic
drinks/week and/or binge drinking 2 or more times in the past month; and (10) current
pregnancy or plans to become pregnant or current nursing of a child
Interventions Factorial design crossing 2 drug doses with 2 intensities of behavioural counseling: 150
mg bupropion SR with less intensive counseling (n = 382) or with more intensive
counseling (n = 4381); or 300 mg bupropion SR with less intensive counseling (n =
4383) or with more intensive counseling (n = 4378)
Free & Clear proactive telephone counseling (4 brief calls), access to quit-line and S-H
materials vs Zyban Advantage Program (ZAP) tailored S-H materials, single telephone
call after TQD, access to Zyban support line
Prescription was mailed. No face-to-face contact during enrolment or Rx
Outcomes Primary outcomes: self-reported point prevalence 7-day non-smoking status at 3 and
12 months following target quit date
Secondary outcomes: adverse and abstinence effects reported since beginning of treat-
ment with bupropion SR
Funding source US National Cancer Institute
Declaration of interest Study authors have no relevant financial interests and have received no financial support
or medication from GlaxoSmithKline
Notes Analyses of pharmacogenetics are reported in Swan 2005 and Swan 2007.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Open-label randomized trial. The com-
puter code for the procedure calculated
probabilities of group assignment that were
dynamically modified based on the num-
ber of members in each group so that fi-
nal group sizes were equal. No restrictions
such as stratification or blocking were used
as part of the randomization process.”
Allocation concealment (selection bias) Low risk Procedure using a random number gener-
ator was built into study database
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study was not blinded.
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study was not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up at 12 months: 83% interven-
tion; 88% control
Selective reporting (reporting bias) Unclear risk No relevant information reported
Other bias High risk Participants who responded at 12-month
follow-up (n = 1299)were invited to partic-
ipate in the ‘genetic factors’ supplemental
study; 496 (50%) actually provided sam-
ples
Swan 2010
Methods Open-label randomised behavioural intervention clinical trial
Study period: October 2005 to June 2008
Participants N = 1202
Participants were smokers seeking treatment who were recruited through health plan
advertisements, physician referrals, and a commercial smoking cessation plan’s advertise-
ments
Inclusion criteria: age≥ 18years, reported smoking≥ 10 cigarettes/d for 12months and
≥ 5 cigarettes/d for the past week, with dependable telephone and Internet access; were
financially eligible for smoking cessation services under their health plan and medically
eligible for varenicline treatment
Exclusion criteria: current pregnancy, plans to become pregnant during the medication
treatment period, or breastfeeding; self-report of poor health; severe or chronic heart
disease; severe COPD; on dialysis with recent creatinine values > 3; current self-reported
diagnosis of or treatment for psychotic disorder; concurrent use of bupropion or nicotine
replacement therapy; current use of recreational or street drugs; current drinking of ≥
14 alcoholic drinks/week or binge drinking ≥ 2 times in the past month; current use of
cimetidine,metformin, phenformin, pindolol, or procainamide; and recent participation
in 2 specific smoking cessation programmes
Interventions Varenicline and Proactive Telephone Counseling (PTC, n = 402)
Varenicline and Web (N = 401)
Varenicline, PTC and Web (N = 399)
All randomised participants received a prescription for 12 weeks of varenicline, a 5- to
10-minute orientation call, printed Quit Guides including recommended guidelines for
varenicline, and access to a toll-free telephone call in line for ad hoc calls
PTC arm participants received up to 5 phone calls. Web arm participants had online
access to an interactive online programme modified from PTC content. PTC and Web
arm participants received calls that encouraged them to use Web programme tools
101Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Swan 2010 (Continued)
Outcomes Primary outcome: self-reported 7-day and 30-day point prevalence abstinence at 3
months and at 6 months after the targeted quit day
Secondary outcomes: probable side effects (6) and probable abstinence effects (9) at 3
months after the targeted quit day
Funding source This work was supported by Grant R01CA071358 from the National Cancer Institute.
Pfizer provided varenicline and nominal support for recruiting participants
Declaration of interest SMZ owns stock in Free & Clear, Inc.; GES received financial support from Pf zer
to attend a 1-day advisory meeting in 2008, and a small grant from Pf zer to support
recruitment and study intake
Notes This paper did not provide analyses of pharmacogenetics, but these were reported in
Bergen 2013.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Automated algorithm
Allocation concealment (selection bias) Unclear risk No data on which to make a judgement
(method of concealment not described)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and staff were not blinded to
treatment assignment.Differences between
treatments were obvious to both partici-
pants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was done by self-re-
port, whichwas performed through follow-
up calls. Those who could not be contacted
were assumed to be smoking
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Although missing outcome data were sub-
stantial (~ 25% for 3-month and 6-month
follow-up), missing outcome data were
balanced in numbers across intervention
groups. In this trial, self-report was not bio-
chemically confirmed
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were re-
ported.
Other bias Unclear risk Biospecimen collection was done post hoc;
47% of the trial population provided a
biospecimen after a multiple-step consent
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Swan 2010 (Continued)
and exclusion process. Data show a highly
significant difference in abstinence preva-
lence in the sample available for pharmaco-
genetic analysis vs the overall trial popula-
tion (55% vs 44%, P = 1E-5 at 3 months;
43% vs 33% at 6 months, P = 1E-4). Most
(~ 94%) samples collected were genotyped.
Pharmacogenetic analyses were conducted
in self-identified whites only in Bergen
2013, distributed equally among treatment
groups.
Verde 2014
Methods Randomised open-label trial of bupropion SR or nicotine patch in adult male and female
smokers
Setting: community hospital, Spain
Recruitment period: 2007 to 2010 (months not indicated)
Participants N = 76
“Heavy smokers”
100% were genotyped
Inclusion criteria: (a) to be enrolled in a ‘standard’ (12-week duration) smoking cessation
programme with nicotine substitutive treatment (NST) or bupropion following medical
criteria, (b) smoking history > 10 cigarettes/d and > 10 packs/y, and (c) > 3 scores in the
Fagerstrom test for nicotine dependence (FTND)
Exclusion criteria: not defined
Interventions Bupropion (N = 34)
NRT (N = 36)
Doses of bupropion SR provided were 150 mg once per day for days 1 to 6, followed by
150 mg twice per day for days 7 to 84), for 12 weeks
For NRT, doses were as follows: (1) for smokers ≥ 20 cigarettes/d, Nicotinell TTS
30 (4 weeks), Nicotinell TTS 20 (4 weeks), and Nicotinell TTS 10 (4 weeks); (2) for
smokers < 20 cigarettes/d, Nicotinell TTS 20 (4 weeks), Nicotinell TTS 20 (4 weeks),
and Nicotinell TTS 10 (4 weeks)
Outcomes 12-Month post-treatment prolonged abstinence; abstinence rate was measured at 3, 6,
9, and 12 months during follow-up visits. Biochemical verification was not mentioned
Funding source Research was supported by the UEM 03-2006 Internal Project of European University
of Madrid and by the 035-2006 Project of the Spanish Lung Foundation (SEPAR)
Declaration of interest No competing interests
Notes 6 candidate polymorphisms in CYP2A6, 5-HTT, and HTR2A genes were genotyped.
Risk of bias
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Verde 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Random sequence generation was not
mentioned in the paper.
Allocation concealment (selection bias) High risk Open-label design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label design
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No frequencies of abstinence outcomes re-
ported; thus no way to confirm reporting
of outcomes for all participants
Selective reporting (reporting bias) Unclear risk Outcomes were not described transpar-
ently; thus one cannot confirm whether se-
lective outcome reporting occurred
Other bias Unclear risk Only 3 CYP2A6 alleles were genotyped.
Therefore, *1 allele calls are likely overrep-
resented. SLC6A4 5-HTTLPR “L” and “S”
are not defined
Wagena 2005
Methods Placebo-controlled double-dummy randomised trial of bupropion SR vs nortriptyline
or placebo for smoking cessation in patients at risk for chronic obstructive pulmonary
disease (COPD) or with COPD
Study period: March 2002 to August 2003
Participants N = 255
Inclusion criteria: (a) current daily smokers at risk for COPD or with COPD, (b) 30
to 70 years of age, (c) smoking history≥ 5 years, (d) smoked on average≥ 10 cigarettes/
d during the past year, and (e) were motivated to stop smoking
Exclusion criteria: (a) having used or were still using bupropion SR or nortriptyline; (b)
were using NRT or (c) psychoactive medication at the time of assessment; and (d) had
any serious or unstable medical disorders that might affect lung function or for which
bupropion SR or nortriptyline was contraindicated
Interventions Bupropion SR (N = 86)
Nortriptyline (N = 80)
Placebo (N = 89)
Eligible individuals were randomly assigned in a 1:1 ratio to receive the following: (1)
104Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wagena 2005 (Continued)
bupropion SR, 150 mg once daily, for days 1 through 6, followed by 150 mg twice daily
for days 7 through 84; (2) nortriptyline, 25 mg once daily, for days 1 through 3, followed
by 50 mg once daily for days 3 through 7, then 75 mg once daily for days 8 through 84;
or (3) placebo. At the baseline visit, the target quit date (TQD) was set for the second
week, usually day 11 from the start of medication
Outcomes Primary outcomes: prolonged abstinence from smoking from week 4 to week 26 after
the target quit date. Prolonged abstinence was defined as a participant’s report of 0
cigarettes/d (not even a puff ) during weeks 4 through 26, confirmed by urinary cotinine
values≤ 60 ng/mL at weeks 4, 12, and 26 after TQD. Participants were allowed to miss
1 in-person visit but not the last follow-up visit
Secondary outcomes: prolonged abstinence during weeks 4 through 12 and 7-day point
prevalence abstinence (defined as having smoked 0 cigarettes, not even a puff, for the
previous 7 days) at weeks 4, 12, and 26, confirmed by urinary cotinine levels ≤ 60 ng/
mL
Funding source This work has been supported by a grant from the Netherlands Organization for Health
Research and Development (ZonMW, The Hague; Project no. 50-50101-96-404). The
original trial was funded by grants of theDutch Asthma Foundation (NAF grant no. 3.2.
00.21) and theHealth Research andDevelopment Council (ZorgOnderzoekNederland,
grant no. 2200.0111), the Netherlands. Lundbeck B.V. provided active nortriptyline
free of charge. Lundbeck B.V. as well as GlaxoSmithKline B.V. did not play a role in the
design and conduct of the study, nor in interpretation and analysis of the data and the
decision to submit for publication
Declaration of interest “CPVS has received financing (grants, consultancy and/or travel/accommodation costs)
from AstraZeneca, Boehringer Ingelheim, and Pfizer, unrelated to this study. DSP has
receivedfinancing (grants, consultancy, and/or travel/accommodation costs) fromChiesi,
GlaxoSmithKline, AstraZeneca, Nycomed, and Boehringer Ingelheim, unrelated to this
study. MQ, EJW, FJVS declare no conflict of interest.”
Notes The original study did not report pharmacogenetic outcomes. 214/255 (84%) partici-
pants in the original clinical trial were genotyped. Results were published in a subsequent
pharmacogenetic paper (Quaak 2012).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated.
Allocation concealment (selection bias) Low risk Randomisation list by a pharmacist, strati-
fied by COPD severity
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and research staff were blinded
to treatment assignment
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Wagena 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “No patient, research nurse, counselor, in-
vestigator, or any other staff member was
aware of the treatment assignments
for the duration of the study.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in analyses.
Selective reporting (reporting bias) Low risk Primary outcomes were reported.
Other bias Low risk 214/255 (84%) participants in the original
clinical trial were genotyped, with results
subsequently published. See ‘Notes’ above
Wilcox 2011
Methods Double-blind placebo-controlled trial
Pilot study
Setting: (not specified), USA
Recruitment: community volunteers
Study period: not reported
Participants N = 78
Inclusion criteria:male and female white smokers of European descent, at least 18 years
of age, who were smoking ≥ 10 cigarettes/d for ≥ 5 years and were in generally good
physical and mental health
Exclusion criteria: not reported
Interventions Rimonabant 20 mg/d (n = 48) vs placebo (n = 28) for 10 weeks
Outcomes Smoking status; exhaled CO level
Funding source This study reports analysis of pharmacogenetics.
Declaration of interest Pharmacology Research Institute and laboratory of one of the study authors at the
University of California Los Angeles (UCLA)
Notes Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No relevant information reported
Allocation concealment (selection bias) Unclear risk No relevant information reported
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Wilcox 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind design but no other informa-
tion reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind design but no other informa-
tion reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk No information on protocol availability re-
ported
Other bias Unclear risk Distribution of ethnicities between treat-
ment groups unclear
Winst 2006
Methods Double-blind parallel-group placebo-controlled randomised clinical trial
Study period: June 2006 to February 2008
Participants N = 420
Participants included hospitalised smokers who needed to stop smoking at admission.
Participants were approached by information presented in the general hospital admission
leaflet and/or on the intranet and by active recruitment by smoking consults in specific
departments of the hospital
Inclusion criteria: over 18 years of age; daily consumption of≥ 15 cigarettes in the past 3
years and average daily consumption of 10 cigarettes the week before study inclusion; life
expectancy of ≥ 1 year; conscious and approachable; able to read and sign an informed
consent form; Dutch- or French-speaking; expected duration of hospitalisation ≥ 72
hours; treating physician and anaesthetist agree on the patient’s study inclusion
Exclusion criteria: already usingNSwithin 14days before study inclusion; use of tobacco
products other than cigarettes; alcohol abuse of > 5U/d; simultaneous use of psychoactive
drugs or hallucinogens; referred from other hospitals; existing contraindications for NS
use; predicted postoperative ICU stay longer than 48 hours; pregnant or lactating
Interventions 15 minutes counseling + placebo patch (n = 210)
15 minutes counseling + nicotine transdermal patch (n = 210)
Participants received a nicotine transdermal patch at a 15 mg/16 hours dose, daily, for
maximum 7 days after hospital admission (study inclusion), or a placebo patch for the
same study duration
Outcomes Primary outcome: total addiction score, calculated from the Minnesota questionnaires,
taken up at randomisation, after≥ 72 hours of hospital admission and after a maximum
of 7 treatment days
Additional outcomes: point prevalence of quit rate at short (7 days) and long term (6
months)
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Winst 2006 (Continued)
Funding source Study was conducted through a grant from the Foundation of Scientific Research (FWO
number G.0604.06), Vlaamse Liga tegen Kanker, and an independent research grant
from McNeil AB, Helsingborg, Sweden
Declaration of interest Apart from the funding source, study authors report no other relevant affiliations or
financial involvement with any organisation or entity with a financial interest in or
financial conflict with the subject matter or materials discussed in the manuscript, apart
from those disclosed
Notes All information from this study is extracted from the study protocol; thus information
regarding sample size should be interpreted as the initial target rather than the actual
number of recruited participants
Analysis of pharmacogenetics is reported in De Ruyck 2010.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed via an on-
line-available registration and randomisa-
tion website
Allocation concealment (selection bias) Unclear risk Randomisation occurred online, but it is
unclear whether allocation was properly
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Active and placebo medications were iden-
tical in appearance, and the study is labeled
as double-blind. No additional details are
presented
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome is subjective and can be influ-
enced by study participants
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Final study report not available
Selective reporting (reporting bias) Unclear risk Final study report not available
Other bias Unclear risk Final study report not available
BUP: bupropion; CBTD: cognitive-behavioural treatment for depression; CES-D: Center for Epidemiologic Studies Depression Scale;
CO: carbon monoxide; DSM-IV: Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition; DSM-IV-TR, Diagnostic
and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision; EOT: end of therapy; FTND: FagerstromTest of Nicotine
Dependence; GHC: GroupHealth Cooperative; HE: health education; ITT: intention-to-treat analysis; MAO:monoamine oxidase;
MAOI:monoamine oxidase inhibitor;MI:myocardial infarction;MINI:Mini-InternationalNeuropsychiatric Interview;NARSAD:
National Alliance for Research on Schizophrenia and Depression; NIAAA: National Institute on Alcohol Abuse and Alcoholism;
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NIDA: National Institute on Drug Abuse; NIHR: National Institute on Health Research; NRT: nicotine replacement therapy;
NST: nicotine sublingual tablet; PCA: Principal Component Analysis; PLAC: placebo; PPA: point prevalence abstinence; ppm: parts
per million; SR: sustained-release; ST: standard treatment; TQD: target quit date; UKCRC: UK Clinical Research Collaboration;
UKCTCS: UK Centre for Tobacco Control Studies.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baker 2009 Primary paper was not a randomised controlled trial (RCT).
Becker 2008 Pharmacogenetic analyses presented results frompooled (not individual) allelotyping (Drgon 2009). This investigation
analysed results from Becker 2008 (no data available).
Uhl 2007 Pharmacogenetic analyses presented results from pooled (not individual) allelotyping (Uhl 2008). This investigation
analysed results from Lerman 2002, Lerman 2004, David 2007, and Uhl 2007 (no data available).
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D A T A A N D A N A L Y S E S
Comparison 1. Active NRT vs placebo - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 3 1597 Risk Ratio (M-H, Random, 95% CI) 1.42 [1.16, 1.75]
1.1 Homozygous Major 3 659 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.93, 1.72]
1.2 Heterozygous 3 731 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.08, 2.01]
1.3 Homozygous Minor 3 207 Risk Ratio (M-H, Random, 95% CI) 2.07 [1.06, 4.01]
2 End of Treatment 2 1391 Risk Ratio (M-H, Random, 95% CI) 1.63 [1.14, 2.32]
2.1 Homozygous Major 2 582 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.85, 1.41]
2.2 Heterozygous 2 631 Risk Ratio (M-H, Random, 95% CI) 2.13 [1.52, 2.97]
2.3 Homozygous Minor 2 178 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.04, 4.58]
Comparison 2. Active NRT vs placebo - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 1127 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.97, 1.98]
1.1 Homozygous Major 2 449 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.77, 1.33]
1.2 Heterozygous 2 550 Risk Ratio (M-H, Random, 95% CI) 1.85 [1.33, 2.59]
1.3 Homozygous Minor 2 128 Risk Ratio (M-H, Random, 95% CI) 1.80 [0.45, 7.23]
Comparison 3. Active NRT vs placebo - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 709 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.55, 2.26]
1.1 Homozygous Major 2 637 Risk Ratio (M-H, Random, 95% CI) 1.47 [1.07, 2.03]
1.2 Heterozygous or
Homozygous Minor
2 72 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.15, 1.26]
2 End of Treatment 2 709 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.36, 2.94]
2.1 Homozygous Major 2 637 Risk Ratio (M-H, Random, 95% CI) 1.57 [1.15, 2.15]
2.2 Heterozygous or
Homozygous Minor
2 72 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.10, 0.86]
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Comparison 4. Active NRT vs placebo - rs 588765 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 923 Risk Ratio (M-H, Random, 95% CI) 1.33 [1.04, 1.71]
1.1 Homozygous Major 2 296 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.89, 2.16]
1.2 Heterozygous 2 469 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.89, 1.79]
1.3 Homozygous Minor 2 158 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.74, 3.06]
Comparison 5. Active NRT vs placebo - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 708 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.75, 1.87]
1.1 Homozygous Major 2 425 Risk Ratio (M-H, Random, 95% CI) 1.95 [0.46, 8.26]
1.2 Heterozygous or
Homozygous Minor
2 283 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.40, 2.03]
2 End of Treatment 2 708 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.77, 1.93]
2.1 Homozygous Major 2 425 Risk Ratio (M-H, Random, 95% CI) 2.39 [0.43, 13.35]
2.2 Heterozygous or
Homozygous Minor
2 283 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.55, 1.46]
Comparison 6. Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 900 Risk Ratio (M-H, Random, 95% CI) 1.44 [1.08, 1.92]
1.1 Homozygous Major 2 566 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.93, 1.93]
1.2 Heterozygous 2 290 Risk Ratio (M-H, Random, 95% CI) 1.76 [1.00, 3.10]
1.3 Homozygous Minor 2 44 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.40, 4.11]
2 End of Treatment 2 900 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.88, 1.63]
2.1 Homozygous Major 2 566 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.59, 2.51]
2.2 Heterozygous 2 290 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.57, 3.39]
2.3 Homozygous Minor 2 44 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.65, 1.58]
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Comparison 7. Active NRT vs placebo - NMR - non-Hispanic black and white




participants Statistical method Effect size
1 Six-Month Abstinence 2 1417 Risk Ratio (M-H, Random, 95% CI) 1.51 [1.08, 2.10]
1.1 Slow NMR 2 628 Risk Ratio (M-H, Random, 95% CI) 1.82 [1.12, 2.94]
1.2 Normal NMR 2 789 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.78, 1.87]
2 End of Treatment 2 1417 Risk Ratio (M-H, Random, 95% CI) 1.51 [1.19, 1.90]
2.1 Slow NMR 2 847 Risk Ratio (M-H, Random, 95% CI) 1.61 [1.18, 2.20]
2.2 Normal NMR 2 570 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.85, 2.60]
Comparison 8. Bupropion vs placebo - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 4 1329 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.11, 1.61]
1.1 Homozygous Major 4 495 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.94, 1.65]
1.2 Heterozygous 4 633 Risk Ratio (M-H, Random, 95% CI) 1.44 [1.09, 1.91]
1.3 Homozygous Minor 4 201 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.57, 2.99]
2 End of Treatment 6 1379 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.19, 1.64]
2.1 Homozygous Major 6 496 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.05, 1.67]
2.2 Heterozygous 6 655 Risk Ratio (M-H, Random, 95% CI) 1.36 [1.03, 1.79]
2.3 Homozygous Minor 6 228 Risk Ratio (M-H, Random, 95% CI) 1.83 [1.20, 2.79]
Comparison 9. Bupropion vs placebo - rs1051730 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 124 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.75, 3.00]
1.1 Homozygous Major 2 92 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.71, 3.64]
1.2 Heterozygous 2 32 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.32, 5.34]
2 End of Treatment 3 157 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.70, 2.06]
2.1 Homozygous Major 3 117 Risk Ratio (M-H, Random, 95% CI) 1.76 [0.96, 3.23]
2.2 Heterozygous 3 40 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.32, 1.44]
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Comparison 10. Bupropion vs placebo - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 557 Risk Ratio (M-H, Random, 95% CI) 1.42 [1.13, 1.77]
1.1 Homozygous Major 3 198 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.92, 1.99]
1.2 Heterozygous 3 276 Risk Ratio (M-H, Random, 95% CI) 1.46 [1.04, 2.04]
1.3 Homozygous Minor 3 83 Risk Ratio (M-H, Random, 95% CI) 2.55 [0.95, 6.85]
Comparison 11. Bupropion vs placebo - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 578 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.84, 2.00]
1.1 Homozygous Major 2 512 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.75, 1.87]
1.2 Heterozygous or
Homozygous Minor
2 66 Risk Ratio (M-H, Random, 95% CI) 2.82 [0.76, 10.45]
2 End of Treatment 3 611 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.23, 3.08]
2.1 Homozygous Major 3 541 Risk Ratio (M-H, Random, 95% CI) 2.12 [1.44, 3.10]
2.2 Heterozygous or
Homozygous Minor
3 70 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.33, 8.36]
Comparison 12. Bupropion vs placebo - rs588765 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 4 1107 Risk Ratio (M-H, Random, 95% CI) 1.37 [1.12, 1.67]
1.1 Homozygous Major 4 384 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.85, 2.08]
1.2 Heterozygous 4 526 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.95, 1.65]
1.3 Homozygous Minor 4 197 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.18, 3.22]
2 End of Treatment 4 1107 Risk Ratio (M-H, Random, 95% CI) 1.36 [1.13, 1.65]
2.1 Homozygous Major 4 385 Risk Ratio (M-H, Random, 95% CI) 1.37 [1.05, 1.79]
2.2 Heterozygous 4 525 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.86, 2.01]
2.3 Homozygous Minor 4 197 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.99, 2.06]
113Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 13. Bupropion vs placebo - rs2036527 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 738 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.05, 1.86]
1.1 Homozygous Major 2 260 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.73, 1.80]
1.2 Heterozygous 2 370 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.99, 2.06]
1.3 Homozygous Minor 2 108 Risk Ratio (M-H, Random, 95% CI) 2.73 [1.02, 7.36]
2 End of Treatment 4 975 Risk Ratio (M-H, Random, 95% CI) 1.43 [1.19, 1.73]
2.1 Homozygous Major 4 339 Risk Ratio (M-H, Random, 95% CI) 1.37 [1.04, 1.80]
2.2 Heterozygous 4 482 Risk Ratio (M-H, Random, 95% CI) 1.36 [1.04, 1.79]
2.3 Homozygous Minor 4 154 Risk Ratio (M-H, Random, 95% CI) 2.64 [1.33, 5.25]
Comparison 14. Bupropion vs placebo - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 3 660 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.88, 1.92]
1.1 Homozygous Major 3 377 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.70, 1.98]
1.2 Heterozygous or
Homozygous Minor
3 283 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.71, 2.91]
2 End of Treatment 4 693 Risk Ratio (M-H, Random, 95% CI) 1.87 [1.36, 2.56]
2.1 Homozygous Major 4 395 Risk Ratio (M-H, Random, 95% CI) 2.11 [1.39, 3.22]
2.2 Heterozygous or
Homozygous Minor
4 298 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.93, 2.62]
Comparison 15. Bupropion vs placebo - rs3733829 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 571 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.07, 1.87]
1.1 Homozygous Major 2 268 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.81, 1.82]
1.2 Heterozygous 2 218 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.22, 3.13]
1.3 Homozygous Minor 2 85 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.58, 2.17]
2 End of Treatment 4 807 Risk Ratio (M-H, Random, 95% CI) 1.55 [1.29, 1.87]
2.1 Homozygous Major 4 367 Risk Ratio (M-H, Random, 95% CI) 1.44 [1.11, 1.86]
2.2 Heterozygous 4 333 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.24, 2.30]
2.3 Homozygous Minor 4 107 Risk Ratio (M-H, Random, 95% CI) 1.69 [0.96, 2.95]
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Comparison 16. Bupropion vs placebo - rs3733829 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 61 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.75, 3.04]
1.1 Homozygous Major 2 61 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.75, 3.04]
Comparison 17. Bupropion vs placebo - rs7937 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 557 Risk Ratio (M-H, Random, 95% CI) 1.42 [1.13, 1.78]
1.1 Homozygous Major 3 159 Risk Ratio (M-H, Random, 95% CI) 1.76 [1.13, 2.75]
1.2 Heterozygous 3 285 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.95, 1.76]
1.3 Homozygous Minor 3 113 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.82, 2.31]
Comparison 18. Bupropion vs placebo - rs7937 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 76 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.77, 3.18]
1.1 Homozygous Major 2 38 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.57, 5.10]
1.2 Heterozygous or
Homozygous Minor
2 38 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.42, 5.84]
Comparison 19. Bupropion vs placebo - rs1329650 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 559 Risk Ratio (M-H, Random, 95% CI) 1.37 [1.07, 1.74]
1.1 Homozygous Major 3 280 Risk Ratio (M-H, Random, 95% CI) 1.54 [1.07, 2.22]
1.2 Heterozygous 3 244 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.88, 1.96]
1.3 Homozygous Minor 3 35 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.33, 4.74]
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Comparison 20. Bupropion vs placebo - rs1329650 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 76 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.70, 2.99]
1.1 Homozygous Major 2 63 Risk Ratio (M-H, Random, 95% CI) 1.62 [0.67, 3.96]
1.2 Heterozygous or
Homozygous Minor
2 13 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.15, 5.70]
Comparison 21. Bupropion vs placebo - rs1028936 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 559 Risk Ratio (M-H, Random, 95% CI) 1.39 [1.11, 1.74]
1.1 Homozygous Major 3 370 Risk Ratio (M-H, Random, 95% CI) 1.54 [1.15, 2.06]
1.2 Heterozygous 3 175 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.75, 2.35]
1.3 Homozygous Minor 3 14 Risk Ratio (M-H, Random, 95% CI) 1.60 [0.30, 8.49]
Comparison 22. Bupropion vs placebo - rs1028936 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 76 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.68, 3.21]
1.1 Homozygous Major 2 65 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.74, 4.20]
1.2 Heterozygous or
Homozygous Minor
2 11 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.09, 4.77]
Comparison 23. Bupropion vs placebo - rs215605 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 558 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.18, 1.87]
1.1 Homozygous Major 3 219 Risk Ratio (M-H, Random, 95% CI) 1.77 [1.23, 2.55]
1.2 Heterozygous 3 259 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.98, 1.87]
1.3 Homozygous Minor 3 80 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.49, 2.55]
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Comparison 24. Bupropion vs placebo - rs215605 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 76 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.54, 3.69]
1.1 Homozygous Major 2 49 Risk Ratio (M-H, Random, 95% CI) 1.93 [0.15, 24.95]
1.2 Heterozygous or
Homozygous Minor
2 27 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.46, 6.13]
Comparison 25. Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 444 Risk Ratio (M-H, Random, 95% CI) 1.80 [1.07, 3.03]
1.1 Homozygous Major 2 183 Risk Ratio (M-H, Random, 95% CI) 2.11 [0.31, 14.60]
1.2 Heterozygous 2 216 Risk Ratio (M-H, Random, 95% CI) 1.82 [1.23, 2.69]
1.3 Homozygous Minor 2 45 Risk Ratio (M-H, Random, 95% CI) 2.84 [0.90, 8.89]
Comparison 26. Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 69 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.27, 3.07]
1.1 Homozygous Major 2 58 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.56, 4.83]
1.2 Heterozygous or
Homozygous Minor
2 11 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.03, 1.43]
Comparison 27. Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 441 Risk Ratio (M-H, Random, 95% CI) 1.79 [1.07, 2.99]
1.1 Homozygous Major 2 183 Risk Ratio (M-H, Random, 95% CI) 2.11 [0.31, 14.60]
1.2 Heterozygous 2 215 Risk Ratio (M-H, Random, 95% CI) 1.80 [1.22, 2.66]
1.3 Homozygous Minor 2 43 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.89, 8.88]
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Comparison 28. Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 69 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.46, 2.38]
1.1 Homozygous Major 2 63 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.51, 2.85]
1.2 Heterozygous or
Homozygous Minor
2 6 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 4.19]
Comparison 29. Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 443 Risk Ratio (M-H, Random, 95% CI) 1.74 [1.09, 2.77]
1.1 Homozygous Major 2 181 Risk Ratio (M-H, Random, 95% CI) 2.20 [0.33, 14.75]
1.2 Heterozygous 2 220 Risk Ratio (M-H, Random, 95% CI) 1.83 [1.23, 2.72]
1.3 Homozygous Minor 2 42 Risk Ratio (M-H, Random, 95% CI) 2.12 [0.79, 5.65]
Comparison 30. Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 69 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.52, 1.92]
1.1 Homozygous Major 2 38 Risk Ratio (M-H, Random, 95% CI) 2.03 [0.39, 10.56]
1.2 Heterozygous 2 23 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.38, 2.77]
1.3 Homozygous Minor 2 8 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.26, 2.05]
Comparison 31. Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 442 Risk Ratio (M-H, Random, 95% CI) 1.55 [1.20, 2.01]
1.1 Homozygous Major 2 187 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.83, 2.65]
1.2 Heterozygous 2 201 Risk Ratio (M-H, Random, 95% CI) 1.87 [1.04, 3.36]
1.3 Homozygous Minor 2 54 Risk Ratio (M-H, Random, 95% CI) 1.85 [0.91, 3.74]
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Comparison 32. Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 48 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.14, 1.24]
1.1 Homozygous Major 2 48 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.14, 1.24]
Comparison 33. Bupropion + any NRT vs placebo - rs7937 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 442 Risk Ratio (M-H, Random, 95% CI) 1.51 [1.16, 1.97]
1.1 Homozygous Major 2 131 Risk Ratio (M-H, Random, 95% CI) 2.00 [0.84, 4.75]
1.2 Heterozygous 2 229 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.99, 1.94]
1.3 Homozygous Minor 2 82 Risk Ratio (M-H, Random, 95% CI) 2.34 [0.49, 11.08]
Comparison 34. Bupropion + any NRT vs placebo - rs7937 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 69 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.47, 2.38]
1.1 Homozygous Major 2 31 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.40, 2.73]
1.2 Heterozygous or
Homozygous Minor
2 38 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.23, 4.99]
Comparison 35. Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 442 Risk Ratio (M-H, Random, 95% CI) 1.62 [1.10, 2.39]
1.1 Homozygous Major 2 240 Risk Ratio (M-H, Random, 95% CI) 1.98 [1.31, 3.00]
1.2 Heterozygous 2 172 Risk Ratio (M-H, Random, 95% CI) 1.60 [0.70, 3.67]
1.3 Homozygous Minor 2 30 Risk Ratio (M-H, Random, 95% CI) 2.04 [0.17, 25.25]
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Comparison 36. Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 69 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.48, 2.41]
1.1 Homozygous Major 2 55 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.40, 2.55]
1.2 Heterozygous or
Homozygous Minor
2 14 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.26, 6.80]
Comparison 37. Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 444 Risk Ratio (M-H, Random, 95% CI) 1.64 [1.08, 2.49]
1.1 Homozygous Major 2 305 Risk Ratio (M-H, Random, 95% CI) 1.89 [1.34, 2.67]
1.2 Heterozygous 2 125 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.48, 4.20]
1.3 Homozygous Minor 2 14 Risk Ratio (M-H, Random, 95% CI) 1.93 [0.47, 8.02]
Comparison 38. Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 69 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.48, 2.41]
1.1 Homozygous Major 2 57 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.43, 2.84]
1.2 Heterozygous or
Homozygous Minor
2 12 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.17, 5.39]
Comparison 39. Bupropion + any NRT vs placebo - rs215605 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 442 Risk Ratio (M-H, Random, 95% CI) 1.72 [1.16, 2.53]
1.1 Homozygous Major 2 171 Risk Ratio (M-H, Random, 95% CI) 2.00 [1.32, 3.03]
1.2 Heterozygous 2 200 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.60, 3.63]
1.3 Homozygous Minor 2 71 Risk Ratio (M-H, Random, 95% CI) 2.29 [0.72, 7.27]
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Comparison 40. Bupropion + any NRT vs placebo - rs215605 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 68 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.41, 1.77]
1.1 Homozygous Major 2 36 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.29, 1.76]
1.2 Heterozygous or
Homozygous Minor
2 32 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.34, 4.13]
Comparison 41. Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 533 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.90, 1.55]
1.1 Homozygous Major 2 206 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.54, 2.42]
1.2 Heterozygous 2 262 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.93, 1.61]
1.3 Homozygous Minor 2 65 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.68, 2.44]
Comparison 42. Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 87 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.37, 1.31]
1.1 Homozygous Major 2 66 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.40, 1.49]
1.2 Heterozygous or
Homozygous Minor
2 21 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.05, 2.19]
Comparison 43. Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 531 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.90, 1.55]
1.1 Homozygous Major 2 206 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.54, 2.42]
1.2 Heterozygous 2 262 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.93, 1.61]
1.3 Homozygous Minor 2 63 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.66, 2.44]
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Comparison 44. Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 87 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.37, 1.27]
1.1 Homozygous Major 2 74 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.38, 1.40]
1.2 Heterozygous or
Homozygous Minor
2 13 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.06, 2.76]
Comparison 45. Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 532 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.91, 1.52]
1.1 Homozygous Major 2 204 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.54, 2.52]
1.2 Heterozygous 2 264 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.92, 1.60]
1.3 Homozygous Minor 2 64 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.68, 2.25]
Comparison 46. Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 87 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.35, 1.23]
1.1 Homozygous Major 2 50 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.23, 1.35]
1.2 Heterozygous or
Homozygous Minor
2 37 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.32, 1.90]
Comparison 47. Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 531 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.96, 1.39]
1.1 Homozygous Major 2 236 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.77, 1.84]
1.2 Heterozygous 2 229 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.82, 1.51]
1.3 Homozygous Minor 2 66 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.80, 2.25]
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Comparison 48. Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 94 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.25, 0.99]
1.1 Homozygous Major 2 65 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.18, 1.01]
1.2 Heterozygous or
Homozygous Minor
2 29 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.13, 4.20]
Comparison 49. Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 533 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.95, 1.42]
1.1 Homozygous Major 2 145 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.65, 1.59]
1.2 Heterozygous 2 272 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.81, 2.00]
1.3 Homozygous Minor 2 116 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.90, 1.84]
Comparison 50. Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 87 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.39, 1.43]
1.1 Homozygous Major 2 33 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.13, 2.86]
1.2 Heterozygous or
Homozygous Minor
2 54 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.27, 1.93]
Comparison 51. Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 531 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.97, 1.49]
1.1 Homozygous Major 2 279 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.66, 2.25]
1.2 Heterozygous 2 214 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.92, 1.62]
1.3 Homozygous Minor 2 38 Risk Ratio (M-H, Random, 95% CI) 1.68 [0.89, 3.17]
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Comparison 52. Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 87 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.33, 1.20]
1.1 Homozygous Major 2 76 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.30, 1.15]
1.2 Heterozygous or
Homozygous Minor
2 11 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.17, 8.24]
Comparison 53. Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 533 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.92, 1.50]
1.1 Homozygous Major 2 359 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.86, 1.37]
1.2 Heterozygous 2 159 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.62, 2.75]
1.3 Homozygous Minor 2 15 Risk Ratio (M-H, Random, 95% CI) 2.17 [0.51, 9.18]
Comparison 54. Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 87 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.33, 1.20]
1.1 Homozygous Major 2 76 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.30, 1.15]
1.2 Heterozygous or
Homozygous Minor
2 11 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.17, 8.24]
Comparison 55. Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 532 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.93, 1.47]
1.1 Homozygous Major 2 211 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.91, 1.80]
1.2 Heterozygous 2 241 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.69, 1.45]
1.3 Homozygous Minor 2 80 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.64, 4.08]
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Comparison 56. Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 87 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.37, 1.35]
1.1 Homozygous Major 2 49 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.09, 2.94]
1.2 Heterozygous or
Homozygous Minor
2 38 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.26, 1.93]
Comparison 57. Active NRT - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
7 1559 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.71, 1.19]
1.2 Heterozygous vs
Homozygous Minor
7 1650 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.11]
2 End of Treatment 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
5 1200 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.73, 1.06]
2.2 Heterozygous vs
Homozygous Minor
5 1291 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.10]
Comparison 58. Active NRT - rs1051730 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 187 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.26, 4.57]
1.2 Heterozygous vs
Homozygous Minor
2 56 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.25, 4.99]
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Comparison 59. Active NRT - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 392 Risk Ratio (M-H, Random, 95% CI) 2.24 [0.92, 5.45]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 392 Risk Ratio (M-H, Random, 95% CI) 2.75 [1.08, 7.02]
Comparison 60. Active NRT - rs588765 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 433 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.80, 1.37]
1.2 Heterozygous vs
Homozygous Minor
3 546 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.76, 1.29]
2 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
3 429 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.76, 1.18]
2.2 Heterozygous vs
Homozygous Minor
3 542 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.77, 1.17]
Comparison 61. Active NRT - rs2036527 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 501 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.60, 1.03]
1.2 Heterozygous vs
Homozygous Minor
2 579 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.63, 1.10]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
2 501 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.59, 1.35]
2.2 Heterozygous vs
Homozygous Minor
2 579 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.61, 1.64]
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Comparison 62. Active NRT - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 391 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.87, 1.81]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 391 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.20, 2.49]
Comparison 63. Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 866 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.51, 1.76]
1.2 Heterozygous vs
Homozygous Minor
3 321 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.42, 1.60]
2 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
3 866 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.71, 1.23]
2.2 Heterozygous vs
Homozygous Minor
3 321 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.58, 1.26]
Comparison 64. Active NRT - SLC6A4 (Promoter) - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 461 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.50, 1.67]
1.2 Heterozygous vs
Homozygous Minor
2 649 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.66, 1.90]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
2 461 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.23]
2.2 Heterozygous vs
Homozygous Minor
2 649 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.74, 1.18]
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Comparison 65. Active NRT-NMR - non-Hispanic white or black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Normal NMR vs Slow
NMR
2 718 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.37, 0.78]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Normal NMR vs Slow
NMR
2 718 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.58, 1.03]
Comparison 66. Bupropion - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
4 316 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.67, 2.43]
1.2 Heterozygous vs
Homozygous Minor
4 390 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.65, 2.03]
2 End of Treatment 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
6 386 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.88, 1.50]
2.2 Heterozygous vs
Homozygous Minor
6 480 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.81, 1.33]
Comparison 67. Bupropion - rs1051730 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 63 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.36, 1.95]
2 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
3 84 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.51, 1.72]
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Comparison 68. Bupropion - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 160 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.96, 2.25]
1.2 Heterozygous vs
Homozygous Minor
3 216 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.79, 1.84]
Comparison 69. Bupropion - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 294 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.31, 1.21]
2 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
3 315 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.48, 1.32]
Comparison 70. Bupropion - rs588765 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
4 304 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.52, 1.34]
1.2 Heterozygous vs
Homozygous Minor
4 401 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.66, 1.21]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
4 304 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.69, 1.14]
2.2 Heterozygous vs
Homozygous Minor
4 400 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.76, 1.22]
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Comparison 71. Bupropion - rs2036527 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 208 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.33, 1.81]
1.2 Heterozygous vs
Homozygous Minor
2 269 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.51, 1.37]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
4 277 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.79, 1.70]
2.2 Heterozygous vs
Homozygous Minor
4 361 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.61, 1.51]
Comparison 72. Bupropion - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
3 331 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.55, 1.46]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
4 352 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.87, 1.76]
Comparison 73. Bupropion - rs3733829 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 191 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.56, 1.46]
1.2 Heterozygous vs
Homozygous Minor
2 161 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.65, 1.71]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
4 259 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.73, 1.40]
2.2 Heterozygous vs
Homozygous Minor
4 237 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.70, 1.36]
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Comparison 74. Bupropion - rs3733829 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 46 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.37, 2.99]
Comparison 75. Bupropion - rs7937 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 159 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.71, 1.40]
1.2 Heterozygous vs
Homozygous Minor
3 238 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.65, 1.23]
Comparison 76. Bupropion - rs7937 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 23 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.32, 4.26]
1.2 Heterozygous vs
Homozygous Minor
2 27 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.18, 2.93]
Comparison 77. Bupropion - rs1329650 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 186 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.54, 1.35]
1.2 Heterozygous vs
Homozygous Minor
3 163 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.56, 1.42]
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Comparison 78. Bupropion - rs1329650 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 47 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.35, 6.01]
Comparison 79. Bupropion - rs1028936 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 221 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.42, 1.55]
1.2 Heterozygous vs
Homozygous Minor
3 112 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.40, 1.64]
Comparison 80. Bupropion - rs1028936 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 47 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.35, 6.01]
Comparison 81. Bupropion - rs215605 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 170 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.87, 3.00]
1.2 Heterozygous vs
Homozygous Minor
3 199 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.79, 3.06]
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Comparison 82. Bupropion - rs215605 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 47 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.54, 2.44]
Comparison 83. Varenicline - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 358 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.71, 1.25]
1.2 Heterozygous vs
Homozygous Minor
2 438 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.75, 1.30]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
2 358 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.78, 1.24]
2.2 Heterozygous vs
Homozygous Minor
2 438 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.22]
Comparison 84. Varenicline - rs588765 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 354 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.91, 1.60]
1.2 Heterozygous vs
Homozygous Minor
2 465 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.90, 1.54]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
2 354 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.91, 1.43]
2.2 Heterozygous vs
Homozygous Minor
2 465 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.89, 1.37]
133Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 85. Bupropion + any NRT - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 138 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.67, 1.78]
1.2 Heterozygous vs
Homozygous Minor
2 155 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.69, 1.80]
Comparison 86. Bupropion + any NRT - rs1051730 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 40 Risk Ratio (M-H, Random, 95% CI) 2.26 [0.36, 14.38]
Comparison 87. Bupropion + any NRT - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 136 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.67, 1.85]
1.2 Heterozygous vs
Homozygous Minor
2 153 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.68, 1.86]
Comparison 88. Bupropion + any NRT - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 40 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.27, 10.32]
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Comparison 89. Bupropion + any NRT - rs2036527 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 135 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.70, 1.79]
1.2 Heterozygous vs
Homozygous Minor
2 156 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.65, 1.66]
Comparison 90. Bupropion + any NRT - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 28 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.06, 4.51]
1.2 Heterozygous vs
Homozygous Minor
2 17 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.03, 15.98]
Comparison 91. Bupropion + any NRT - rs3733829 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 144 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.66, 1.34]
1.2 Heterozygous vs
Homozygous Minor
2 153 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.55, 1.14]
Comparison 92. Bupropion + any NRT - rs3733829 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 40 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.13, 0.99]
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Comparison 93. Bupropion + any NRT - rs7937 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 128 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
1.2 Heterozygous vs
Homozygous Minor
2 194 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.51, 1.28]
Comparison 94. Bupropion + any NRT - rs7937 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 40 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.12, 13.56]
Comparison 95. Bupropion + any NRT - rs1329650 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 170 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.43, 0.94]
1.2 Heterozygous vs
Homozygous Minor
2 117 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.50, 1.03]
Comparison 96. Bupropion + any NRT - rs1329650 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 40 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.15, 1.94]
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Comparison 97. Bupropion + any NRT - rs1028936 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 193 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.37, 1.07]
1.2 Heterozygous vs
Homozygous Minor
2 85 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.42, 1.32]
Comparison 98. Bupropion + any NRT - rs1028936 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 40 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.15, 1.94]
Comparison 99. Bupropion + any NRT - rs215605 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 148 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.84, 1.66]
1.2 Heterozygous vs
Homozygous Minor
2 162 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.61, 1.26]
Comparison 100. Bupropion + any NRT - rs215605 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 40 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.04, 13.56]
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Comparison 101. Placebo - rs1051730 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
6 533 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.86, 1.92]
1.2 Heterozygous vs
Homozygous Minor
6 597 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.72, 1.62]
2 End of Treatment 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
7 542 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.91, 2.13]
2.2 Heterozygous vs
Homozygous Minor
7 605 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.81, 1.89]
Comparison 102. Placebo - rs1051730 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 63 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.08, 6.73]
2 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
3 83 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.24, 2.45]
Comparison 103. Placebo - rs16969968 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 162 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.51, 2.14]
1.2 Heterozygous vs
Homozygous Minor
2 211 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.32, 1.96]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
4 218 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.68, 3.53]
2.2 Heterozygous vs
Homozygous Minor
4 276 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.51, 3.53]
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Comparison 104. Placebo - rs16969968 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
3 584 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.42, 1.33]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
4 596 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.35, 0.86]
Comparison 105. Placebo - rs588765 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
5 383 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.69, 1.57]
1.2 Heterozygous vs
Homozygous Minor
5 470 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.72, 1.58]
2 End of Treatment 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
5 362 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.63, 1.21]
2.2 Heterozygous vs
Homozygous Minor
5 404 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.80, 1.46]
Comparison 106. Placebo - rs588765 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 566 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.80, 1.79]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 566 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.71, 1.77]
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Comparison 107. Placebo - rs2036527 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 160 Risk Ratio (M-H, Random, 95% CI) 1.85 [0.77, 4.44]
1.2 Heterozygous vs
Homozygous Minor
2 209 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.66, 3.77]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
4 216 Risk Ratio (M-H, Random, 95% CI) 1.98 [0.91, 4.35]
2.2 Heterozygous vs
Homozygous Minor
4 275 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.94, 3.69]
Comparison 108. Placebo - rs2036527 - non-Hispanic black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
4 629 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.71, 1.77]
2 End of Treatment 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
5 641 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.71, 1.64]
Comparison 109. Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 387 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.37, 3.16]
1.2 Heterozygous vs
Homozygous Minor
3 212 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.22, 1.63]
2 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
3 387 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.51, 2.29]
2.2 Heterozygous vs
Homozygous Minor
3 212 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.61, 1.29]
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Comparison 110. Placebo - rs3733829 - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
2 162 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.46, 1.51]
1.2 Heterozygous vs
Homozygous Minor
2 142 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.35, 1.26]
2 End of Treatment 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major vs
Homozygous Minor
4 215 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.74, 2.05]
2.2 Heterozygous vs
Homozygous Minor
4 203 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.57, 1.65]
Comparison 111. Placebo - rs7937 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 113 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.45, 1.45]
1.2 Heterozygous vs
Homozygous Minor
3 160 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.57, 1.60]
Comparison 112. Placebo - rs7937 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 29 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.27, 5.04]
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Comparison 113. Placebo - rs1329650 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 129 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.18, 3.62]
1.2 Heterozygous vs
Homozygous Minor
3 116 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.39, 1.63]
Comparison 114. Placebo - rs1329650 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 29 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.19, 2.78]
Comparison 115. Placebo - rs1028936 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 163 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.29, 3.14]
1.2 Heterozygous vs
Homozygous Minor
3 77 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.36, 4.03]
Comparison 116. Placebo - rs1028936 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 29 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.18, 1.32]
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Comparison 117. Placebo - rs215605 - non-Hispanic white




participants Statistical method Effect size
1 End of Treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Homozygous Minor
3 129 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.52, 1.82]
1.2 Heterozygous vs
Homozygous Minor
3 140 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.63, 2.12]
Comparison 118. Placebo - rs215605 - non-Hispanic black or African American




participants Statistical method Effect size
1 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major vs
Heterozygous or Homozygous
Minor
2 29 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.03, 38.58]
Comparison 119. Placebo - SLC6A4 (Promoter) - non-Hispanic white




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Homozygous Major or
Heterozygous vs Homozygous
Minor
2 151 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.32, 1.79]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Homozygous Major or
Heterozygous vs Homozygous
Minor
2 151 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.83, 1.38]
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Comparison 120. Placebo - NMR - non-Hispanic white or black or African American




participants Statistical method Effect size
1 Six-Month Abstinence 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Normal NMR vs Slow
NMR
2 699 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.70, 1.48]
2 End of Treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Normal NMR vs Slow
NMR
2 718 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.35, 1.14]
Analysis 1.1. Comparison 1 Active NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 1 Active NRT vs placebo - rs1051730 - non-Hispanic white
Outcome: 1 Six-Month Abstinence









GPRG 1993 32/151 21/145 17.1 % 1.46 [ 0.89, 2.42 ]
Winst 2006 10/41 11/36 8.0 % 0.80 [ 0.38, 1.66 ]
Piper 2009 89/233 15/53 20.4 % 1.35 [ 0.85, 2.13 ]
Subtotal (95% CI) 425 234 45.5 % 1.27 [ 0.93, 1.72 ]
Total events: 131 (Active NRT), 47 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Heterozygous
GPRG 1993 28/152 15/143 12.6 % 1.76 [ 0.98, 3.15 ]
Winst 2006 17/53 13/47 11.7 % 1.16 [ 0.63, 2.13 ]
Piper 2009 98/269 16/67 20.6 % 1.53 [ 0.97, 2.41 ]
Subtotal (95% CI) 474 257 44.8 % 1.48 [ 1.08, 2.01 ]
Total events: 143 (Active NRT), 44 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
3 Homozygous Minor
GPRG 1993 8/42 7/59 4.9 % 1.61 [ 0.63, 4.09 ]
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(Continued . . . )
144Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)








Winst 2006 7/17 2/12 2.2 % 2.47 [ 0.62, 9.89 ]
Piper 2009 31/65 2/12 2.6 % 2.86 [ 0.79, 10.40 ]
Subtotal (95% CI) 124 83 9.7 % 2.07 [ 1.06, 4.01 ]
Total events: 46 (Active NRT), 11 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
Total (95% CI) 1023 574 100.0 % 1.42 [ 1.16, 1.75 ]
Total events: 320 (Active NRT), 102 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.34, df = 8 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00082)
Test for subgroup differences: Chi2 = 1.81, df = 2 (P = 0.40), I2 =0.0%
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Analysis 1.2. Comparison 1 Active NRT vs placebo - rs1051730 - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 1 Active NRT vs placebo - rs1051730 - non-Hispanic white
Outcome: 2 End of Treatment









GPRG 1993 36/151 27/145 20.1 % 1.28 [ 0.82, 2.00 ]
Piper 2009 111/233 25/53 23.8 % 1.01 [ 0.74, 1.38 ]
Subtotal (95% CI) 384 198 43.8 % 1.09 [ 0.85, 1.41 ]
Total events: 147 (Active NRT), 52 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Heterozygous
GPRG 1993 37/152 16/143 17.4 % 2.18 [ 1.27, 3.73 ]
Piper 2009 143/269 17/67 20.6 % 2.10 [ 1.37, 3.21 ]
Subtotal (95% CI) 421 210 38.0 % 2.13 [ 1.52, 2.97 ]
Total events: 180 (Active NRT), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 4.42 (P < 0.00001)
3 Homozygous Minor
GPRG 1993 11/42 9/59 12.0 % 1.72 [ 0.78, 3.77 ]
Piper 2009 41/65 2/12 6.1 % 3.78 [ 1.05, 13.59 ]
Subtotal (95% CI) 107 71 18.1 % 2.18 [ 1.04, 4.58 ]
Total events: 52 (Active NRT), 11 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 2.07 (P = 0.039)
Total (95% CI) 912 479 100.0 % 1.63 [ 1.14, 2.32 ]
Total events: 379 (Active NRT), 96 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 13.56, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Chi2 = 10.83, df = 2 (P = 0.00), I2 =82%
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Analysis 2.1. Comparison 2 Active NRT vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 2 Active NRT vs placebo - rs16969968 - non-Hispanic white
Outcome: 1 End of Treatment









Piper 2009 110/232 25/53 25.4 % 1.01 [ 0.73, 1.38 ]
Lerman 2015 21/85 19/79 18.3 % 1.03 [ 0.60, 1.76 ]
Subtotal (95% CI) 317 132 43.7 % 1.01 [ 0.77, 1.33 ]
Total events: 131 (Active NRT), 44 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
2 Heterozygous
Piper 2009 142/265 17/66 21.8 % 2.08 [ 1.36, 3.18 ]
Lerman 2015 25/104 18/115 18.2 % 1.54 [ 0.89, 2.65 ]
Subtotal (95% CI) 369 181 40.0 % 1.85 [ 1.33, 2.59 ]
Total events: 167 (Active NRT), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00030)
3 Homozygous Minor
Piper 2009 41/65 2/12 6.2 % 3.78 [ 1.05, 13.59 ]
Lerman 2015 9/33 5/18 10.0 % 0.98 [ 0.39, 2.49 ]
Subtotal (95% CI) 98 30 16.3 % 1.80 [ 0.45, 7.23 ]
Total events: 50 (Active NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.69; Chi2 = 3.11, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 784 343 100.0 % 1.38 [ 0.97, 1.98 ]
Total events: 348 (Active NRT), 86 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 12.08, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Chi2 = 7.82, df = 2 (P = 0.02), I2 =74%
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Analysis 3.1. Comparison 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence









Ahluwalia 2006 69/276 46/268 50.6 % 1.46 [ 1.04, 2.03 ]
Piper 2009 24/77 3/16 24.7 % 1.66 [ 0.57, 4.86 ]
Subtotal (95% CI) 353 284 75.3 % 1.47 [ 1.07, 2.03 ]
Total events: 93 (Active NRT), 49 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Heterozygous or Homozygous Minor
Ahluwalia 2006 4/33 9/32 24.7 % 0.43 [ 0.15, 1.26 ]
Piper 2009 0/6 0/1 Not estimable
Subtotal (95% CI) 39 33 24.7 % 0.43 [ 0.15, 1.26 ]
Total events: 4 (Active NRT), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 392 317 100.0 % 1.11 [ 0.55, 2.26 ]
Total events: 97 (Active NRT), 58 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 4.70, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 4.64, df = 1 (P = 0.03), I2 =78%
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Analysis 3.2. Comparison 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 3 Active NRT vs placebo - rs16969968 - non-Hispanic black or African American
Outcome: 2 End of Treatment









Ahluwalia 2006 75/276 48/268 38.4 % 1.52 [ 1.10, 2.09 ]
Piper 2009 28/77 2/16 24.4 % 2.91 [ 0.77, 11.00 ]
Subtotal (95% CI) 353 284 62.8 % 1.57 [ 1.15, 2.15 ]
Total events: 103 (Active NRT), 50 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
2 Heterozygous or Homozygous Minor
Ahluwalia 2006 3/33 12/32 26.7 % 0.24 [ 0.08, 0.78 ]
Piper 2009 1/6 0/1 10.5 % 0.86 [ 0.05, 13.93 ]
Subtotal (95% CI) 39 33 37.2 % 0.29 [ 0.10, 0.86 ]
Total events: 4 (Active NRT), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
Total (95% CI) 392 317 100.0 % 1.03 [ 0.36, 2.94 ]
Total events: 107 (Active NRT), 62 (Placebo)
Heterogeneity: Tau2 = 0.72; Chi2 = 10.21, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 8.63, df = 1 (P = 0.00), I2 =88%
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Analysis 4.1. Comparison 4 Active NRT vs placebo - rs 588765 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 4 Active NRT vs placebo - rs 588765 - non-Hispanic white
Outcome: 1 End of Treatment









Piper 2009 36/116 9/42 15.2 % 1.45 [ 0.76, 2.75 ]
Lerman 2015 20/74 13/64 16.5 % 1.33 [ 0.72, 2.46 ]
Subtotal (95% CI) 190 106 31.7 % 1.39 [ 0.89, 2.16 ]
Total events: 56 (Active NRT), 22 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
2 Heterozygous
Piper 2009 64/186 17/62 30.5 % 1.25 [ 0.80, 1.97 ]
Lerman 2015 25/115 18/106 20.8 % 1.28 [ 0.74, 2.21 ]
Subtotal (95% CI) 301 168 51.3 % 1.27 [ 0.89, 1.79 ]
Total events: 89 (Active NRT), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
3 Homozygous Minor
Piper 2009 23/63 3/20 5.2 % 2.43 [ 0.82, 7.26 ]
Lerman 2015 10/33 11/42 11.8 % 1.16 [ 0.56, 2.39 ]
Subtotal (95% CI) 96 62 17.0 % 1.50 [ 0.74, 3.06 ]
Total events: 33 (Active NRT), 14 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 587 336 100.0 % 1.33 [ 1.04, 1.71 ]
Total events: 178 (Active NRT), 71 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.48, df = 5 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Chi2 = 0.22, df = 2 (P = 0.89), I2 =0.0%
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Analysis 5.1. Comparison 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence









Ahluwalia 2006 46/189 33/183 45.9 % 1.35 [ 0.91, 2.01 ]
Piper 2009 15/43 0/10 2.7 % 7.75 [ 0.50, 119.73 ]
Subtotal (95% CI) 232 193 48.6 % 1.95 [ 0.46, 8.26 ]
Total events: 61 (Active NRT), 33 (Placebo)
Heterogeneity: Tau2 = 0.65; Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Heterozygous or Homozygous Minor
Ahluwalia 2006 25/119 20/117 36.1 % 1.23 [ 0.72, 2.09 ]
Piper 2009 9/40 3/7 15.3 % 0.53 [ 0.19, 1.47 ]
Subtotal (95% CI) 159 124 51.4 % 0.90 [ 0.40, 2.03 ]
Total events: 34 (Active NRT), 23 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 391 317 100.0 % 1.18 [ 0.75, 1.87 ]
Total events: 95 (Active NRT), 56 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.78, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.82, df = 1 (P = 0.36), I2 =0.0%
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Analysis 5.2. Comparison 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 5 Active NRT vs placebo - rs2036527 - non-Hispanic black or African American
Outcome: 2 End of Treatment









Ahluwalia 2006 57/189 38/183 50.0 % 1.45 [ 1.02, 2.07 ]
Piper 2009 19/43 0/10 2.7 % 9.75 [ 0.64, 149.24 ]
Subtotal (95% CI) 232 193 52.7 % 2.39 [ 0.43, 13.35 ]
Total events: 76 (Active NRT), 38 (Placebo)
Heterogeneity: Tau2 = 1.01; Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.99 (P = 0.32)
2 Heterozygous or Homozygous Minor
Ahluwalia 2006 21/119 23/117 36.4 % 0.90 [ 0.53, 1.53 ]
Piper 2009 10/40 2/7 10.8 % 0.88 [ 0.24, 3.17 ]
Subtotal (95% CI) 159 124 47.3 % 0.89 [ 0.55, 1.46 ]
Total events: 31 (Active NRT), 25 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 391 317 100.0 % 1.22 [ 0.77, 1.93 ]
Total events: 107 (Active NRT), 63 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.77, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 1.16, df = 1 (P = 0.28), I2 =14%
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Analysis 6.1. Comparison 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white, Outcome 1
Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white
Outcome: 1 Six-Month Abstinence









Gilbert 2009 14/57 10/40 16.8 % 0.98 [ 0.49, 1.99 ]
GPRG 1993 48/231 33/238 50.9 % 1.50 [ 1.00, 2.25 ]
Subtotal (95% CI) 288 278 67.7 % 1.34 [ 0.93, 1.93 ]
Total events: 62 (Active NRT), 43 (Placebo NRT)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Heterozygous
Gilbert 2009 5/21 5/33 6.7 % 1.57 [ 0.52, 4.78 ]
GPRG 1993 22/118 12/118 19.4 % 1.83 [ 0.95, 3.53 ]
Subtotal (95% CI) 139 151 26.1 % 1.76 [ 1.00, 3.10 ]
Total events: 27 (Active NRT), 17 (Placebo NRT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
3 Homozygous Minor
Gilbert 2009 1/4 0/3 1.0 % 2.40 [ 0.13, 44.41 ]
GPRG 1993 5/22 3/15 5.1 % 1.14 [ 0.32, 4.05 ]
Subtotal (95% CI) 26 18 6.1 % 1.28 [ 0.40, 4.11 ]
Total events: 6 (Active NRT), 3 (Placebo NRT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 453 447 100.0 % 1.44 [ 1.08, 1.92 ]
Total events: 95 (Active NRT), 63 (Placebo NRT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.97, df = 5 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Chi2 = 0.67, df = 2 (P = 0.72), I2 =0.0%
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Analysis 6.2. Comparison 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white, Outcome 2
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 6 Active NRT vs placebo - DRD4 (exon 3 48 bp) - non-Hispanic white
Outcome: 2 End of Treatment









GPRG 1993 64/231 41/238 19.7 % 1.61 [ 1.14, 2.28 ]
Gilbert 2009 47/57 35/40 24.4 % 0.94 [ 0.80, 1.11 ]
Subtotal (95% CI) 288 278 44.1 % 1.22 [ 0.59, 2.51 ]
Total events: 111 (Active NRT), 76 (Placebo NRT)
Heterogeneity: Tau2 = 0.25; Chi2 = 14.08, df = 1 (P = 0.00018); I2 =93%
Test for overall effect: Z = 0.53 (P = 0.60)
2 Heterozygous
GPRG 1993 24/118 12/118 12.2 % 2.00 [ 1.05, 3.81 ]
Gilbert 2009 18/21 27/33 22.7 % 1.05 [ 0.83, 1.33 ]
Subtotal (95% CI) 139 151 34.9 % 1.40 [ 0.57, 3.39 ]
Total events: 42 (Active NRT), 39 (Placebo NRT)
Heterogeneity: Tau2 = 0.35; Chi2 = 6.77, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Homozygous Minor
GPRG 1993 5/22 3/15 4.8 % 1.14 [ 0.32, 4.05 ]
Gilbert 2009 4/4 3/3 16.2 % 1.00 [ 0.62, 1.60 ]
Subtotal (95% CI) 26 18 21.0 % 1.02 [ 0.65, 1.58 ]
Total events: 9 (Active NRT), 6 (Placebo NRT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
Total (95% CI) 453 447 100.0 % 1.20 [ 0.88, 1.63 ]
Total events: 162 (Active NRT), 121 (Placebo NRT)
Heterogeneity: Tau2 = 0.09; Chi2 = 21.13, df = 5 (P = 0.00076); I2 =76%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.47, df = 2 (P = 0.79), I2 =0.0%
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Analysis 7.1. Comparison 7 Active NRT vs placebo - NMR - non-Hispanic black and white, Outcome 1 Six-
Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 7 Active NRT vs placebo - NMR - non-Hispanic black and white
Outcome: 1 Six-Month Abstinence









GPRG 1993 16/91 6/95 12.4 % 2.78 [ 1.14, 6.80 ]
Lerman 2015 50/227 30/215 42.2 % 1.58 [ 1.05, 2.38 ]
Subtotal (95% CI) 318 310 54.6 % 1.82 [ 1.12, 2.94 ]
Total events: 66 (active NRT), 36 (placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 2.43 (P = 0.015)
2 Normal NMR
GPRG 1993 16/209 9/196 15.3 % 1.67 [ 0.75, 3.68 ]
Lerman 2015 25/191 24/193 30.2 % 1.05 [ 0.62, 1.78 ]
Subtotal (95% CI) 400 389 45.4 % 1.21 [ 0.78, 1.87 ]
Total events: 41 (active NRT), 33 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 718 699 100.0 % 1.51 [ 1.08, 2.10 ]
Total events: 107 (active NRT), 69 (placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.74, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 1.50, df = 1 (P = 0.22), I2 =33%
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of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 7 Active NRT vs placebo - NMR - non-Hispanic black and white
Outcome: 2 End of Treatment









GPRG 1993 27/209 15/196 15.2 % 1.69 [ 0.93, 3.08 ]
Lerman 2015 62/227 37/215 41.9 % 1.59 [ 1.11, 2.28 ]
Subtotal (95% CI) 436 411 57.1 % 1.61 [ 1.18, 2.20 ]
Total events: 89 (Active NRT), 52 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
2 Normal NMR
GPRG 1993 17/91 8/95 8.8 % 2.22 [ 1.01, 4.89 ]
Lerman 2015 42/191 35/193 34.1 % 1.21 [ 0.81, 1.81 ]
Subtotal (95% CI) 282 288 42.9 % 1.49 [ 0.85, 2.60 ]
Total events: 59 (Active NRT), 43 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.80, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 718 699 100.0 % 1.51 [ 1.19, 1.90 ]
Total events: 148 (Active NRT), 95 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.27, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.42 (P = 0.00062)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 8.1. Comparison 8 Bupropion vs placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 8 Bupropion vs placebo - rs1051730 - non-Hispanic white
Outcome: 1 Six-Month Abstinence









Lerman 2002 18/80 15/67 9.7 % 1.01 [ 0.55, 1.84 ]
Brown 2007 17/47 13/54 9.6 % 1.50 [ 0.82, 2.76 ]
Hall 2008 15/28 9/22 9.5 % 1.31 [ 0.71, 2.41 ]
Piper 2009 50/144 15/53 15.1 % 1.23 [ 0.76, 1.99 ]
Subtotal (95% CI) 299 196 44.0 % 1.24 [ 0.94, 1.65 ]
Total events: 100 (Bupropion), 52 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Heterozygous
Lerman 2002 25/104 15/90 10.7 % 1.44 [ 0.81, 2.56 ]
Brown 2007 22/65 13/71 9.9 % 1.85 [ 1.02, 3.36 ]
Hall 2008 11/25 10/23 8.6 % 1.01 [ 0.53, 1.92 ]
Piper 2009 67/188 16/67 16.1 % 1.49 [ 0.93, 2.38 ]
Subtotal (95% CI) 382 251 45.3 % 1.44 [ 1.09, 1.91 ]
Total events: 125 (Bupropion), 54 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.87, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.010)
3 Homozygous Minor
Lerman 2002 13/35 4/35 3.4 % 3.25 [ 1.17, 8.99 ]
Brown 2007 3/24 4/29 1.8 % 0.91 [ 0.22, 3.66 ]
Hall 2008 4/12 5/9 3.6 % 0.60 [ 0.22, 1.62 ]
Piper 2009 12/45 2/12 1.9 % 1.60 [ 0.41, 6.20 ]
Subtotal (95% CI) 116 85 10.8 % 1.31 [ 0.57, 2.99 ]
Total events: 32 (Bupropion), 15 (Placebo)
Heterogeneity: Tau2 = 0.35; Chi2 = 6.01, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 797 532 100.0 % 1.34 [ 1.11, 1.61 ]
Total events: 257 (Bupropion), 121 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.13, df = 11 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0024)
Test for subgroup differences: Chi2 = 0.53, df = 2 (P = 0.77), I2 =0.0%
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Analysis 8.2. Comparison 8 Bupropion vs placebo - rs1051730 - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 8 Bupropion vs placebo - rs1051730 - non-Hispanic white
Outcome: 2 End of Treatment









Lerman 2002 26/80 16/67 6.9 % 1.36 [ 0.80, 2.32 ]
Piper 2007 11/28 2/17 1.3 % 3.34 [ 0.84, 13.28 ]
Brown 2007 22/47 13/54 6.3 % 1.94 [ 1.11, 3.41 ]
McCarthy 2008 9/15 8/20 4.7 % 1.50 [ 0.76, 2.95 ]
Hall 2008 20/28 15/22 11.6 % 1.05 [ 0.72, 1.52 ]
Piper 2009 36/65 25/53 12.0 % 1.17 [ 0.82, 1.68 ]
Subtotal (95% CI) 263 233 42.8 % 1.32 [ 1.05, 1.67 ]
Total events: 124 (Bupropion), 79 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.08, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 2.36 (P = 0.019)
2 Heterozygous
Lerman 2002 30/104 21/90 8.1 % 1.24 [ 0.76, 2.00 ]
Brown 2007 35/65 19/71 9.0 % 2.01 [ 1.29, 3.14 ]
Piper 2007 10/32 6/19 3.2 % 0.99 [ 0.43, 2.29 ]
Hall 2008 15/24 16/23 10.1 % 0.90 [ 0.60, 1.36 ]
McCarthy 2008 17/32 10/28 5.8 % 1.49 [ 0.82, 2.69 ]
Piper 2009 43/100 17/67 8.4 % 1.69 [ 1.06, 2.71 ]
Subtotal (95% CI) 357 298 44.6 % 1.36 [ 1.03, 1.79 ]
Total events: 150 (Bupropion), 89 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 8.79, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 2.16 (P = 0.031)
3 Homozygous Minor
Lerman 2002 14/35 4/35 2.3 % 3.50 [ 1.28, 9.59 ]
Brown 2007 12/24 10/29 5.1 % 1.45 [ 0.76, 2.75 ]
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Piper 2007 6/15 1/8 0.7 % 3.20 [ 0.46, 22.16 ]
McCarthy 2008 4/12 1/11 0.6 % 3.67 [ 0.48, 28.00 ]
Hall 2008 6/12 4/10 2.6 % 1.25 [ 0.48, 3.22 ]
Piper 2009 8/25 2/12 1.3 % 1.92 [ 0.48, 7.69 ]
Subtotal (95% CI) 123 105 12.5 % 1.83 [ 1.20, 2.79 ]
Total events: 50 (Bupropion), 22 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.75, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
Total (95% CI) 743 636 100.0 % 1.40 [ 1.19, 1.64 ]
Total events: 324 (Bupropion), 190 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 21.03, df = 17 (P = 0.23); I2 =19%
Test for overall effect: Z = 4.15 (P = 0.000034)
Test for subgroup differences: Chi2 = 1.80, df = 2 (P = 0.41), I2 =0.0%
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Analysis 9.1. Comparison 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence









Lerman 2002 7/25 6/34 51.8 % 1.59 [ 0.61, 4.15 ]
Piper 2009 4/18 2/15 19.8 % 1.67 [ 0.35, 7.88 ]
Subtotal (95% CI) 43 49 71.6 % 1.61 [ 0.71, 3.64 ]
Total events: 11 (Bupropion), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Heterozygous
Lerman 2002 3/11 1/11 10.8 % 3.00 [ 0.37, 24.58 ]
Piper 2009 3/8 1/2 17.6 % 0.75 [ 0.14, 3.90 ]
Subtotal (95% CI) 19 13 28.4 % 1.30 [ 0.32, 5.34 ]
Total events: 6 (Bupropion), 2 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 62 62 100.0 % 1.50 [ 0.75, 3.00 ]
Total events: 17 (Bupropion), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 9.2. Comparison 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 9 Bupropion vs placebo - rs1051730 - non-Hispanic black or African American
Outcome: 2 End of Treatment









Lerman 2002 9/25 8/34 30.5 % 1.53 [ 0.69, 3.41 ]
Piper 2007 8/15 3/10 20.3 % 1.78 [ 0.62, 5.12 ]
Piper 2009 5/18 1/15 6.5 % 4.17 [ 0.54, 31.88 ]
Subtotal (95% CI) 58 59 57.3 % 1.76 [ 0.96, 3.23 ]
Total events: 22 (Bupropion), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 Heterozygous
Lerman 2002 3/11 3/11 13.4 % 1.00 [ 0.26, 3.91 ]
Piper 2007 2/6 2/2 18.7 % 0.43 [ 0.14, 1.31 ]
Piper 2009 4/8 1/2 10.7 % 1.00 [ 0.21, 4.71 ]
Subtotal (95% CI) 25 15 42.7 % 0.68 [ 0.32, 1.44 ]
Total events: 9 (Bupropion), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI) 83 74 100.0 % 1.20 [ 0.70, 2.06 ]
Total events: 31 (Bupropion), 18 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.09, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 3.71, df = 1 (P = 0.05), I2 =73%
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Analysis 10.1. Comparison 10 Bupropion vs placebo - rs16969968 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 10 Bupropion vs placebo - rs16969968 - non-Hispanic white
Outcome: 1 End of Treatment









Piper 2007 11/28 2/17 2.6 % 3.34 [ 0.84, 13.28 ]
McCarthy 2008 9/15 8/20 10.7 % 1.50 [ 0.76, 2.95 ]
Piper 2009 36/65 25/53 38.1 % 1.17 [ 0.82, 1.68 ]
Subtotal (95% CI) 108 90 51.4 % 1.35 [ 0.92, 1.99 ]
Total events: 56 (Bupropion), 35 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.41, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.54 (P = 0.12)
2 Heterozygous
Piper 2007 10/32 6/19 7.0 % 0.99 [ 0.43, 2.29 ]
McCarthy 2008 17/32 10/27 14.1 % 1.43 [ 0.80, 2.59 ]
Piper 2009 43/100 17/66 22.4 % 1.67 [ 1.05, 2.66 ]
Subtotal (95% CI) 164 112 43.6 % 1.46 [ 1.04, 2.04 ]
Total events: 70 (Bupropion), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.15, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
3 Homozygous Minor
Piper 2007 6/15 1/8 1.3 % 3.20 [ 0.46, 22.16 ]
McCarthy 2008 4/12 1/11 1.2 % 3.67 [ 0.48, 28.00 ]
Piper 2009 8/25 2/12 2.5 % 1.92 [ 0.48, 7.69 ]
Subtotal (95% CI) 52 31 5.0 % 2.55 [ 0.95, 6.85 ]
Total events: 18 (Bupropion), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Total (95% CI) 324 233 100.0 % 1.42 [ 1.13, 1.77 ]
Total events: 144 (Bupropion), 72 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.71, df = 8 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 3.08 (P = 0.0021)
Test for subgroup differences: Chi2 = 1.38, df = 2 (P = 0.50), I2 =0.0%
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Analysis 11.1. Comparison 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence









Piper 2009 5/20 3/16 11.5 % 1.33 [ 0.37, 4.75 ]
Cox 2012 31/241 26/235 77.7 % 1.16 [ 0.71, 1.90 ]
Subtotal (95% CI) 261 251 89.2 % 1.18 [ 0.75, 1.87 ]
Total events: 36 (Bupropion), 29 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Heterozygous or Homozygous Minor
Piper 2009 2/6 0/1 2.8 % 1.43 [ 0.11, 19.20 ]
Cox 2012 6/27 2/32 8.1 % 3.56 [ 0.78, 16.19 ]
Subtotal (95% CI) 33 33 10.8 % 2.82 [ 0.76, 10.45 ]
Total events: 8 (Bupropion), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 294 284 100.0 % 1.30 [ 0.84, 2.00 ]
Total events: 44 (Bupropion), 31 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Chi2 = 1.51, df = 1 (P = 0.22), I2 =34%
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Analysis 11.2. Comparison 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 11 Bupropion vs placebo - rs16969968 - non-Hispanic black or African American
Outcome: 2 End of Treatment









Piper 2007 9/18 4/11 20.0 % 1.38 [ 0.55, 3.41 ]
Piper 2009 6/20 2/16 8.9 % 2.40 [ 0.56, 10.32 ]
Cox 2012 57/241 24/235 50.5 % 2.32 [ 1.49, 3.60 ]
Subtotal (95% CI) 279 262 79.4 % 2.12 [ 1.44, 3.10 ]
Total events: 72 (Bupropion), 30 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.07, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 Heterozygous or Homozygous Minor
Piper 2007 1/3 1/1 8.5 % 0.50 [ 0.11, 2.23 ]
Piper 2009 3/6 0/1 3.2 % 2.00 [ 0.16, 24.66 ]
Cox 2012 8/27 2/32 8.9 % 4.74 [ 1.10, 20.46 ]
Subtotal (95% CI) 36 34 20.6 % 1.65 [ 0.33, 8.36 ]
Total events: 12 (Bupropion), 3 (Placebo)
Heterogeneity: Tau2 = 1.23; Chi2 = 5.12, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 315 296 100.0 % 1.95 [ 1.23, 3.08 ]
Total events: 84 (Bupropion), 33 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 5.94, df = 5 (P = 0.31); I2 =16%
Test for overall effect: Z = 2.86 (P = 0.0043)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 12.1. Comparison 12 Bupropion vs placebo - rs588765 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 12 Bupropion vs placebo - rs588765 - non-Hispanic white
Outcome: 1 Six-Month Abstinence









Lerman 2002 24/67 11/66 10.1 % 2.15 [ 1.15, 4.03 ]
Brown 2007 11/50 9/59 6.2 % 1.44 [ 0.65, 3.20 ]
Hall 2008 9/23 11/22 9.1 % 0.78 [ 0.40, 1.51 ]
Piper 2009 15/55 9/42 7.6 % 1.27 [ 0.62, 2.62 ]
Subtotal (95% CI) 195 189 33.0 % 1.33 [ 0.85, 2.08 ]
Total events: 59 (Bupropion), 40 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.88, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Heterozygous
Lerman 2002 22/106 17/89 12.3 % 1.09 [ 0.62, 1.92 ]
Brown 2007 23/66 14/64 12.2 % 1.59 [ 0.90, 2.81 ]
Hall 2008 12/27 9/19 9.8 % 0.94 [ 0.50, 1.77 ]
Piper 2009 35/93 17/62 17.0 % 1.37 [ 0.85, 2.22 ]
Subtotal (95% CI) 292 234 51.4 % 1.25 [ 0.95, 1.65 ]
Total events: 92 (Bupropion), 57 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.87, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
3 Homozygous Minor
Lerman 2002 10/45 4/27 3.5 % 1.50 [ 0.52, 4.32 ]
Brown 2007 7/19 5/29 4.0 % 2.14 [ 0.79, 5.76 ]
Hall 2008 9/14 4/12 5.0 % 1.93 [ 0.79, 4.70 ]
Piper 2009 11/31 3/20 3.0 % 2.37 [ 0.75, 7.44 ]
Subtotal (95% CI) 109 88 15.6 % 1.95 [ 1.18, 3.22 ]
Total events: 37 (Bupropion), 16 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0096)
Total (95% CI) 596 511 100.0 % 1.37 [ 1.12, 1.67 ]
Total events: 188 (Bupropion), 113 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.41, df = 11 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.10 (P = 0.0020)
Test for subgroup differences: Chi2 = 2.29, df = 2 (P = 0.32), I2 =13%
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Analysis 12.2. Comparison 12 Bupropion vs placebo - rs588765 - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 12 Bupropion vs placebo - rs588765 - non-Hispanic white
Outcome: 2 End of Treatment









Lerman 2002 26/67 14/66 8.1 % 1.83 [ 1.05, 3.18 ]
Brown 2007 20/50 16/59 8.4 % 1.48 [ 0.86, 2.53 ]
Hall 2008 14/23 12/23 9.0 % 1.17 [ 0.70, 1.94 ]
Piper 2009 21/55 14/42 8.3 % 1.15 [ 0.66, 1.97 ]
Subtotal (95% CI) 195 190 33.8 % 1.37 [ 1.05, 1.79 ]
Total events: 81 (Bupropion), 56 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.96, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
2 Heterozygous
Lerman 2002 27/106 22/89 9.5 % 1.03 [ 0.63, 1.68 ]
Brown 2007 39/66 18/64 10.8 % 2.10 [ 1.35, 3.26 ]
Hall 2008 16/26 14/19 11.8 % 0.84 [ 0.56, 1.25 ]
Piper 2009 49/93 20/62 11.7 % 1.63 [ 1.09, 2.46 ]
Subtotal (95% CI) 291 234 43.8 % 1.31 [ 0.86, 2.01 ]
Total events: 131 (Bupropion), 74 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 11.61, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 1.25 (P = 0.21)
3 Homozygous Minor
Lerman 2002 16/45 4/27 3.3 % 2.40 [ 0.90, 6.44 ]
Brown 2007 9/19 7/29 4.7 % 1.96 [ 0.88, 4.37 ]
Hall 2008 10/14 8/12 8.8 % 1.07 [ 0.64, 1.80 ]
Piper 2009 15/31 7/20 5.8 % 1.38 [ 0.69, 2.78 ]
Subtotal (95% CI) 109 88 22.5 % 1.43 [ 0.99, 2.06 ]
Total events: 50 (Bupropion), 26 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.29, df = 3 (P = 0.35); I2 =9%
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Test for overall effect: Z = 1.91 (P = 0.056)
Total (95% CI) 595 512 100.0 % 1.36 [ 1.13, 1.65 ]
Total events: 262 (Bupropion), 156 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 16.78, df = 11 (P = 0.11); I2 =34%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Chi2 = 0.09, df = 2 (P = 0.96), I2 =0.0%
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Analysis 13.1. Comparison 13 Bupropion vs placebo - rs2036527 - non-Hispanic white, Outcome 1 Six-
Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 13 Bupropion vs placebo - rs2036527 - non-Hispanic white
Outcome: 1 Six-Month Abstinence









Lerman 2002 15/78 14/64 17.0 % 0.88 [ 0.46, 1.68 ]
Piper 2009 24/65 14/53 22.6 % 1.40 [ 0.81, 2.42 ]
Subtotal (95% CI) 143 117 39.6 % 1.15 [ 0.73, 1.80 ]
Total events: 39 (Bupropion), 28 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.14, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.59 (P = 0.55)
2 Heterozygous
Lerman 2002 27/105 17/97 23.3 % 1.47 [ 0.85, 2.52 ]
Piper 2009 34/99 17/69 27.0 % 1.39 [ 0.85, 2.29 ]
Subtotal (95% CI) 204 166 50.3 % 1.43 [ 0.99, 2.06 ]
Total events: 61 (Bupropion), 34 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
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Test for overall effect: Z = 1.91 (P = 0.056)
3 Homozygous Minor
Lerman 2002 15/39 3/33 5.9 % 4.23 [ 1.34, 13.36 ]
Piper 2009 8/26 2/10 4.2 % 1.54 [ 0.39, 6.04 ]
Subtotal (95% CI) 65 43 10.1 % 2.73 [ 1.02, 7.36 ]
Total events: 23 (Bupropion), 5 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 1.99 (P = 0.046)
Total (95% CI) 412 326 100.0 % 1.40 [ 1.05, 1.86 ]
Total events: 123 (Bupropion), 67 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.63, df = 5 (P = 0.34); I2 =11%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 2.52, df = 2 (P = 0.28), I2 =21%
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Analysis 13.2. Comparison 13 Bupropion vs placebo - rs2036527 - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 13 Bupropion vs placebo - rs2036527 - non-Hispanic white
Outcome: 2 End of Treatment









Lerman 2002 27/78 15/64 12.0 % 1.48 [ 0.86, 2.53 ]
Piper 2007 11/28 2/17 1.8 % 3.34 [ 0.84, 13.28 ]
McCarthy 2008 8/14 8/20 7.0 % 1.43 [ 0.71, 2.88 ]
Piper 2009 36/65 24/53 25.6 % 1.22 [ 0.85, 1.77 ]
Subtotal (95% CI) 185 154 46.3 % 1.37 [ 1.04, 1.80 ]
Total events: 82 (Bupropion), 49 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
2 Heterozygous
Lerman 2002 28/105 24/97 15.6 % 1.08 [ 0.67, 1.72 ]
Piper 2007 10/33 5/19 4.1 % 1.15 [ 0.46, 2.87 ]
McCarthy 2008 18/32 10/28 10.2 % 1.58 [ 0.88, 2.82 ]
Piper 2009 42/99 18/69 16.4 % 1.63 [ 1.03, 2.57 ]
Subtotal (95% CI) 269 213 46.4 % 1.36 [ 1.04, 1.79 ]
Total events: 98 (Bupropion), 57 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
3 Homozygous Minor
Lerman 2002 16/39 3/33 2.6 % 4.51 [ 1.44, 14.15 ]
Piper 2007 6/14 2/8 1.9 % 1.71 [ 0.45, 6.57 ]
McCarthy 2008 4/13 1/11 0.8 % 3.38 [ 0.44, 26.00 ]
Piper 2009 9/26 2/10 1.9 % 1.73 [ 0.45, 6.66 ]
Subtotal (95% CI) 92 62 7.3 % 2.64 [ 1.33, 5.25 ]
Total events: 35 (Bupropion), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.72, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
Total (95% CI) 546 429 100.0 % 1.43 [ 1.19, 1.73 ]
Total events: 215 (Bupropion), 114 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.14, df = 11 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.79 (P = 0.00015)
Test for subgroup differences: Chi2 = 3.26, df = 2 (P = 0.20), I2 =39%
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Analysis 14.1. Comparison 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence









Lerman 2002 4/18 4/24 9.8 % 1.33 [ 0.38, 4.63 ]
Piper 2009 4/14 0/10 1.9 % 6.60 [ 0.39, 110.31 ]
Cox 2012 20/155 19/156 44.0 % 1.06 [ 0.59, 1.91 ]
Subtotal (95% CI) 187 190 55.8 % 1.17 [ 0.70, 1.98 ]
Total events: 28 (Bupropion), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Heterozygous or Homozygous Minor
Lerman 2002 6/19 3/22 9.8 % 2.32 [ 0.67, 8.02 ]
Piper 2009 3/12 3/7 9.0 % 0.58 [ 0.16, 2.14 ]
Cox 2012 16/113 9/110 25.4 % 1.73 [ 0.80, 3.75 ]
Subtotal (95% CI) 144 139 44.2 % 1.44 [ 0.71, 2.91 ]
Total events: 25 (Bupropion), 15 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.65, df = 2 (P = 0.27); I2 =25%
Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI) 331 329 100.0 % 1.30 [ 0.88, 1.92 ]
Total events: 53 (Bupropion), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.62, df = 5 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 14.2. Comparison 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 14 Bupropion vs placebo - rs2036527 - non-Hispanic black or African American
Outcome: 2 End of Treatment









Lerman 2002 6/18 6/24 11.0 % 1.33 [ 0.51, 3.46 ]
Piper 2007 6/13 1/5 2.9 % 2.31 [ 0.36, 14.66 ]
Piper 2009 5/14 0/10 1.3 % 8.07 [ 0.50, 131.14 ]
Cox 2012 43/155 19/156 41.2 % 2.28 [ 1.39, 3.73 ]
Subtotal (95% CI) 200 195 56.4 % 2.11 [ 1.39, 3.22 ]
Total events: 60 (Bupropion), 26 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.94, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.49 (P = 0.00049)
2 Heterozygous or Homozygous Minor
Lerman 2002 7/19 5/22 10.6 % 1.62 [ 0.61, 4.27 ]
Piper 2007 4/8 4/7 11.2 % 0.88 [ 0.34, 2.25 ]
Piper 2009 4/12 2/7 5.0 % 1.17 [ 0.28, 4.82 ]
Cox 2012 21/113 8/110 16.8 % 2.56 [ 1.18, 5.52 ]
Subtotal (95% CI) 152 146 43.6 % 1.57 [ 0.93, 2.62 ]
Total events: 36 (Bupropion), 19 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.41, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 1.70 (P = 0.088)
Total (95% CI) 352 341 100.0 % 1.87 [ 1.36, 2.56 ]
Total events: 96 (Bupropion), 45 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.12, df = 7 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
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Analysis 15.1. Comparison 15 Bupropion vs placebo - rs3733829 - non-Hispanic white, Outcome 1 Six-
Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 15 Bupropion vs placebo - rs3733829 - non-Hispanic white
Outcome: 1 Six-Month Abstinence









Brown 2007 14/55 11/66 15.6 % 1.53 [ 0.76, 3.09 ]
Piper 2009 30/91 17/56 31.8 % 1.09 [ 0.66, 1.78 ]
Subtotal (95% CI) 146 122 47.4 % 1.21 [ 0.81, 1.82 ]
Total events: 44 (Bupropion), 28 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.34)
2 Heterozygous
Brown 2007 18/47 9/45 16.3 % 1.91 [ 0.96, 3.81 ]
Piper 2009 24/69 10/57 18.4 % 1.98 [ 1.04, 3.79 ]
Subtotal (95% CI) 116 102 34.7 % 1.95 [ 1.22, 3.13 ]
Total events: 42 (Bupropion), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0055)
3 Homozygous Minor
Brown 2007 4/16 5/22 5.9 % 1.10 [ 0.35, 3.46 ]
Piper 2009 11/29 6/18 12.0 % 1.14 [ 0.51, 2.54 ]
Subtotal (95% CI) 45 40 17.9 % 1.13 [ 0.58, 2.17 ]
Total events: 15 (Bupropion), 11 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 307 264 100.0 % 1.41 [ 1.07, 1.87 ]
Total events: 101 (Bupropion), 58 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.42, df = 5 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Chi2 = 2.79, df = 2 (P = 0.25), I2 =28%
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Analysis 15.2. Comparison 15 Bupropion vs placebo - rs3733829 - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 15 Bupropion vs placebo - rs3733829 - non-Hispanic white
Outcome: 2 End of Treatment









Piper 2007 13/31 5/17 4.9 % 1.43 [ 0.61, 3.32 ]
Brown 2007 26/55 17/66 14.2 % 1.84 [ 1.12, 3.01 ]
McCarthy 2008 16/26 10/25 10.8 % 1.54 [ 0.87, 2.72 ]
Piper 2009 43/91 22/56 22.8 % 1.20 [ 0.81, 1.78 ]
Subtotal (95% CI) 203 164 52.8 % 1.44 [ 1.11, 1.86 ]
Total events: 98 (Bupropion), 54 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.79, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
2 Heterozygous
Brown 2007 24/47 14/45 13.1 % 1.64 [ 0.98, 2.75 ]
Piper 2007 12/37 3/21 2.7 % 2.27 [ 0.72, 7.14 ]
McCarthy 2008 13/28 7/29 6.1 % 1.92 [ 0.90, 4.10 ]
Piper 2009 30/69 16/57 14.3 % 1.55 [ 0.94, 2.54 ]
Subtotal (95% CI) 181 152 36.1 % 1.69 [ 1.24, 2.30 ]
Total events: 79 (Bupropion), 40 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 3.29 (P = 0.00098)
3 Homozygous Minor
Brown 2007 2/7 1/6 0.8 % 1.71 [ 0.20, 14.55 ]
Piper 2007 9/16 4/22 3.6 % 3.09 [ 1.15, 8.29 ]
McCarthy 2008 1/4 2/5 0.9 % 0.63 [ 0.08, 4.66 ]
Piper 2009 13/29 6/18 5.9 % 1.34 [ 0.62, 2.90 ]
Subtotal (95% CI) 56 51 11.2 % 1.69 [ 0.96, 2.95 ]
Total events: 25 (Bupropion), 13 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.73, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
Total (95% CI) 440 367 100.0 % 1.55 [ 1.29, 1.87 ]
Total events: 202 (Bupropion), 107 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.72, df = 11 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.68, df = 2 (P = 0.71), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Placebo Favours Bupropion
173Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 16.1. Comparison 16 Bupropion vs placebo - rs3733829 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 16 Bupropion vs placebo - rs3733829 - non-Hispanic black or African American
Outcome: 1 End of Treatment









Piper 2007 9/16 5/12 76.7 % 1.35 [ 0.61, 2.99 ]
Piper 2009 6/19 2/14 23.3 % 2.21 [ 0.52, 9.36 ]
Total (95% CI) 35 26 100.0 % 1.51 [ 0.75, 3.04 ]
Total events: 15 (Bupropion), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 Bupropion vs placebo - rs7937 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 17 Bupropion vs placebo - rs7937 - non-Hispanic white
Outcome: 1 End of Treatment









Piper 2007 7/19 2/15 2.6 % 2.76 [ 0.67, 11.41 ]
McCarthy 2008 7/15 5/16 6.3 % 1.49 [ 0.60, 3.70 ]
Piper 2009 26/52 12/42 17.1 % 1.75 [ 1.01, 3.03 ]
Subtotal (95% CI) 86 73 25.9 % 1.76 [ 1.13, 2.75 ]
Total events: 40 (Bupropion), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
2 Heterozygous
Piper 2007 11/38 6/20 7.4 % 0.96 [ 0.42, 2.22 ]
McCarthy 2008 17/33 9/31 12.5 % 1.77 [ 0.93, 3.37 ]
Piper 2009 42/94 25/69 34.8 % 1.23 [ 0.84, 1.81 ]
Subtotal (95% CI) 165 120 54.7 % 1.30 [ 0.95, 1.76 ]
Total events: 70 (Bupropion), 40 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.098)
3 Homozygous Minor
Piper 2007 9/18 1/8 1.4 % 4.00 [ 0.60, 26.50 ]
McCarthy 2008 6/11 5/12 7.0 % 1.31 [ 0.55, 3.09 ]
Piper 2009 19/44 7/20 11.0 % 1.23 [ 0.62, 2.45 ]
Subtotal (95% CI) 73 40 19.4 % 1.38 [ 0.82, 2.31 ]
Total events: 34 (Bupropion), 13 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 324 233 100.0 % 1.42 [ 1.13, 1.78 ]
Total events: 144 (Bupropion), 72 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.62, df = 8 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.54), I2 =0.0%
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Analysis 18.1. Comparison 18 Bupropion vs placebo - rs7937 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 18 Bupropion vs placebo - rs7937 - non-Hispanic black or African American
Outcome: 1 End of Treatment









Piper 2007 5/9 4/9 57.7 % 1.25 [ 0.49, 3.19 ]
Piper 2009 5/11 1/9 13.2 % 4.09 [ 0.58, 28.98 ]
Subtotal (95% CI) 20 18 70.8 % 1.70 [ 0.57, 5.10 ]
Total events: 10 (Bupropion), 5 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Heterozygous or Homozygous Minor
Piper 2007 5/12 1/3 16.8 % 1.25 [ 0.22, 7.08 ]
Piper 2009 4/15 1/8 12.4 % 2.13 [ 0.28, 16.02 ]
Subtotal (95% CI) 27 11 29.2 % 1.57 [ 0.42, 5.84 ]
Total events: 9 (Bupropion), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 47 29 100.0 % 1.56 [ 0.77, 3.18 ]
Total events: 19 (Bupropion), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 19.1. Comparison 19 Bupropion vs placebo - rs1329650 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 19 Bupropion vs placebo - rs1329650 - non-Hispanic white
Outcome: 1 End of Treatment









Piper 2007 8/29 5/22 6.0 % 1.21 [ 0.46, 3.20 ]
McCarthy 2008 16/31 12/28 17.6 % 1.20 [ 0.70, 2.08 ]
Piper 2009 47/101 16/69 22.4 % 2.01 [ 1.24, 3.24 ]
Subtotal (95% CI) 161 119 46.1 % 1.54 [ 1.07, 2.22 ]
Total events: 71 (Bupropion), 33 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.23, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 2.34 (P = 0.019)
2 Heterozygous
Piper 2007 15/37 4/18 6.3 % 1.82 [ 0.71, 4.71 ]
McCarthy 2008 9/20 7/30 8.5 % 1.93 [ 0.86, 4.33 ]
Piper 2009 37/81 25/58 32.9 % 1.06 [ 0.73, 1.55 ]
Subtotal (95% CI) 138 106 47.8 % 1.31 [ 0.88, 1.96 ]
Total events: 61 (Bupropion), 36 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.48, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 1.32 (P = 0.19)
3 Homozygous Minor
Piper 2007 4/9 0/4 0.8 % 4.50 [ 0.30, 68.13 ]
McCarthy 2008 5/8 0/1 1.0 % 2.44 [ 0.21, 28.51 ]
Piper 2009 3/8 3/5 4.4 % 0.63 [ 0.20, 1.97 ]
Subtotal (95% CI) 25 10 6.1 % 1.25 [ 0.33, 4.74 ]
Total events: 12 (Bupropion), 3 (Placebo)
Heterogeneity: Tau2 = 0.46; Chi2 = 2.83, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 324 235 100.0 % 1.37 [ 1.07, 1.74 ]
Total events: 144 (Bupropion), 72 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.53, df = 8 (P = 0.38); I2 =6%
Test for overall effect: Z = 2.53 (P = 0.011)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.83), I2 =0.0%
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Analysis 20.1. Comparison 20 Bupropion vs placebo - rs1329650 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 20 Bupropion vs placebo - rs1329650 - non-Hispanic black or African American
Outcome: 1 End of Treatment









Piper 2007 10/19 4/10 70.0 % 1.32 [ 0.55, 3.14 ]
Piper 2009 8/23 1/11 13.9 % 3.83 [ 0.54, 26.91 ]
Subtotal (95% CI) 42 21 83.9 % 1.62 [ 0.67, 3.96 ]
Total events: 18 (Bupropion), 5 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 1.07 (P = 0.29)
2 Heterozygous or Homozygous Minor
Piper 2007 0/2 1/2 6.9 % 0.33 [ 0.02, 5.33 ]
Piper 2009 1/3 1/6 9.2 % 2.00 [ 0.18, 22.06 ]
Subtotal (95% CI) 5 8 16.1 % 0.93 [ 0.15, 5.70 ]
Total events: 1 (Bupropion), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 47 29 100.0 % 1.44 [ 0.70, 2.99 ]
Total events: 19 (Bupropion), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.21, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 21.1. Comparison 21 Bupropion vs placebo - rs1028936 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 21 Bupropion vs placebo - rs1028936 - non-Hispanic white
Outcome: 1 End of Treatment









Piper 2007 16/41 6/31 7.6 % 2.02 [ 0.89, 4.55 ]
McCarthy 2008 18/36 15/36 19.7 % 1.20 [ 0.72, 1.99 ]
Piper 2009 60/135 24/91 32.9 % 1.69 [ 1.14, 2.49 ]
Subtotal (95% CI) 212 158 60.1 % 1.54 [ 1.15, 2.06 ]
Total events: 94 (Bupropion), 45 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0033)
2 Heterozygous
Piper 2007 11/32 3/12 4.2 % 1.38 [ 0.46, 4.09 ]
McCarthy 2008 9/19 4/22 5.0 % 2.61 [ 0.95, 7.12 ]
Piper 2009 26/52 19/38 28.8 % 1.00 [ 0.66, 1.52 ]
Subtotal (95% CI) 103 72 38.0 % 1.33 [ 0.75, 2.35 ]
Total events: 46 (Bupropion), 26 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 3.18, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 0.98 (P = 0.33)
3 Homozygous Minor
Piper 2007 0/2 0/1 Not estimable
McCarthy 2008 3/4 0/1 0.8 % 2.80 [ 0.24, 33.04 ]
Piper 2009 1/3 1/3 1.0 % 1.00 [ 0.10, 9.61 ]
Subtotal (95% CI) 9 5 1.8 % 1.60 [ 0.30, 8.49 ]
Total events: 4 (Bupropion), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 324 235 100.0 % 1.39 [ 1.11, 1.74 ]
Total events: 144 (Bupropion), 72 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.54, df = 7 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Chi2 = 0.21, df = 2 (P = 0.90), I2 =0.0%
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Analysis 22.1. Comparison 22 Bupropion vs placebo - rs1028936 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 22 Bupropion vs placebo - rs1028936 - non-Hispanic black or African American
Outcome: 1 End of Treatment









Piper 2007 10/19 4/11 65.9 % 1.45 [ 0.59, 3.53 ]
Piper 2009 8/23 1/12 15.2 % 4.17 [ 0.59, 29.58 ]
Subtotal (95% CI) 42 23 81.1 % 1.77 [ 0.74, 4.20 ]
Total events: 18 (Bupropion), 5 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.06, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Heterozygous or Homozygous Minor
Piper 2007 0/2 1/1 8.4 % 0.22 [ 0.02, 3.16 ]
Piper 2009 1/3 1/5 10.5 % 1.67 [ 0.16, 17.89 ]
Subtotal (95% CI) 5 6 18.9 % 0.67 [ 0.09, 4.77 ]
Total events: 1 (Bupropion), 2 (Placebo)
Heterogeneity: Tau2 = 0.39; Chi2 = 1.23, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 47 29 100.0 % 1.47 [ 0.68, 3.21 ]
Total events: 19 (Bupropion), 7 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.11, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 0.79, df = 1 (P = 0.37), I2 =0.0%
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Analysis 23.1. Comparison 23 Bupropion vs placebo - rs215605 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 23 Bupropion vs placebo - rs215605 - non-Hispanic white
Outcome: 1 End of Treatment









Piper 2007 10/27 4/14 5.7 % 1.30 [ 0.49, 3.40 ]
McCarthy 2008 12/19 8/28 11.4 % 2.21 [ 1.12, 4.36 ]
Piper 2009 39/79 15/52 22.7 % 1.71 [ 1.06, 2.77 ]
Subtotal (95% CI) 125 94 39.9 % 1.77 [ 1.23, 2.55 ]
Total events: 61 (Bupropion), 27 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.08 (P = 0.0021)
2 Heterozygous
Piper 2007 15/37 4/20 5.7 % 2.03 [ 0.78, 5.29 ]
McCarthy 2008 17/32 8/24 12.4 % 1.59 [ 0.83, 3.06 ]
Piper 2009 38/85 23/61 33.0 % 1.19 [ 0.79, 1.77 ]
Subtotal (95% CI) 154 105 51.1 % 1.35 [ 0.98, 1.87 ]
Total events: 70 (Bupropion), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
3 Homozygous Minor
Piper 2007 2/11 1/10 1.0 % 1.82 [ 0.19, 17.12 ]
McCarthy 2008 1/8 3/7 1.3 % 0.29 [ 0.04, 2.21 ]
Piper 2009 10/26 5/18 6.7 % 1.38 [ 0.57, 3.37 ]
Subtotal (95% CI) 45 35 9.0 % 1.12 [ 0.49, 2.55 ]
Total events: 13 (Bupropion), 9 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.11, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 324 234 100.0 % 1.48 [ 1.18, 1.87 ]
Total events: 144 (Bupropion), 71 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.94, df = 8 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00077)
Test for subgroup differences: Chi2 = 1.67, df = 2 (P = 0.43), I2 =0.0%
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Analysis 24.1. Comparison 24 Bupropion vs placebo - rs215605 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 24 Bupropion vs placebo - rs215605 - non-Hispanic black or African American
Outcome: 1 End of Treatment









Piper 2007 7/13 5/8 52.2 % 0.86 [ 0.41, 1.80 ]
Piper 2009 6/18 0/10 10.3 % 7.53 [ 0.47, 121.19 ]
Subtotal (95% CI) 31 18 62.5 % 1.93 [ 0.15, 24.95 ]
Total events: 13 (Bupropion), 5 (Placebo)
Heterogeneity: Tau2 = 2.57; Chi2 = 3.39, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 0.50 (P = 0.61)
2 Heterozygous or Homozygous Minor
Piper 2007 3/8 0/4 10.4 % 3.89 [ 0.25, 61.09 ]
Piper 2009 3/8 2/7 27.1 % 1.31 [ 0.30, 5.73 ]
Subtotal (95% CI) 16 11 37.5 % 1.67 [ 0.46, 6.13 ]
Total events: 6 (Bupropion), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 47 29 100.0 % 1.41 [ 0.54, 3.69 ]
Total events: 19 (Bupropion), 7 (Placebo)
Heterogeneity: Tau2 = 0.32; Chi2 = 4.40, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 25.1. Comparison 25 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic white, Outcome
1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 25 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 23/34 2/17 10.5 % 5.75 [ 1.53, 21.58 ]
Piper 2009 35/79 25/53 28.1 % 0.94 [ 0.64, 1.37 ]
Subtotal (95% CI) 113 70 38.6 % 2.11 [ 0.31, 14.60 ]
Total events: 58 (Bupropion + any NRT), 27 (Placebo)
Heterogeneity: Tau2 = 1.72; Chi2 = 8.00, df = 1 (P = 0.005); I2 =88%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Heterozygous
Piper 2007 21/42 6/19 20.0 % 1.58 [ 0.76, 3.28 ]
Piper 2009 43/88 17/67 26.1 % 1.93 [ 1.21, 3.06 ]
Subtotal (95% CI) 130 86 46.2 % 1.82 [ 1.23, 2.69 ]
Total events: 64 (Bupropion + any NRT), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.01 (P = 0.0027)
3 Homozygous Minor
Piper 2007 2/5 1/8 5.1 % 3.20 [ 0.38, 26.78 ]
Piper 2009 9/20 2/12 10.2 % 2.70 [ 0.70, 10.46 ]
Subtotal (95% CI) 25 20 15.2 % 2.84 [ 0.90, 8.89 ]
Total events: 11 (Bupropion + any NRT), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.074)
Total (95% CI) 268 176 100.0 % 1.80 [ 1.07, 3.03 ]
Total events: 133 (Bupropion + any NRT), 53 (Placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 13.05, df = 5 (P = 0.02); I2 =62%
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Chi2 = 0.53, df = 2 (P = 0.77), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Placebo Favours Bupropion + any NRT
183Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 26.1. Comparison 26 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 26 Bupropion + any NRT vs placebo - rs1051730 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 3/10 43.5 % 1.19 [ 0.37, 3.87 ]
Piper 2009 5/19 1/15 24.0 % 3.95 [ 0.51, 30.28 ]
Subtotal (95% CI) 33 25 67.5 % 1.64 [ 0.56, 4.83 ]
Total events: 10 (Bupropion + any NRT), 4 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 2/2 18.4 % 0.30 [ 0.03, 3.49 ]
Piper 2009 0/6 1/2 14.2 % 0.14 [ 0.01, 2.60 ]
Subtotal (95% CI) 7 4 32.5 % 0.22 [ 0.03, 1.43 ]
Total events: 0 (Bupropion + any NRT), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Total (95% CI) 40 29 100.0 % 0.91 [ 0.27, 3.07 ]
Total events: 10 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.52; Chi2 = 4.50, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 3.32, df = 1 (P = 0.07), I2 =70%
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Analysis 27.1. Comparison 27 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 27 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 23/34 2/17 10.4 % 5.75 [ 1.53, 21.58 ]
Piper 2009 35/79 25/53 28.3 % 0.94 [ 0.64, 1.37 ]
Subtotal (95% CI) 113 70 38.7 % 2.11 [ 0.31, 14.60 ]
Total events: 58 (Bupropion + any NRT), 27 (Placebo)
Heterogeneity: Tau2 = 1.72; Chi2 = 8.00, df = 1 (P = 0.005); I2 =88%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Heterozygous
Piper 2007 21/42 6/19 20.0 % 1.58 [ 0.76, 3.28 ]
Piper 2009 43/88 17/66 26.3 % 1.90 [ 1.20, 3.01 ]
Subtotal (95% CI) 130 85 46.3 % 1.80 [ 1.22, 2.66 ]
Total events: 64 (Bupropion + any NRT), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
3 Homozygous Minor
Piper 2007 2/5 1/8 5.0 % 3.20 [ 0.38, 26.78 ]
Piper 2009 8/18 2/12 10.0 % 2.67 [ 0.68, 10.46 ]
Subtotal (95% CI) 23 20 14.9 % 2.81 [ 0.89, 8.88 ]
Total events: 10 (Bupropion + any NRT), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
Total (95% CI) 266 175 100.0 % 1.79 [ 1.07, 2.99 ]
Total events: 132 (Bupropion + any NRT), 53 (Placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 12.82, df = 5 (P = 0.03); I2 =61%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 0.53, df = 2 (P = 0.77), I2 =0.0%
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Analysis 28.1. Comparison 28 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 28 Bupropion + any NRT vs placebo - rs16969968 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 4/11 60.3 % 0.98 [ 0.34, 2.81 ]
Piper 2009 5/22 2/16 29.3 % 1.82 [ 0.40, 8.21 ]
Subtotal (95% CI) 36 27 89.6 % 1.20 [ 0.51, 2.85 ]
Total events: 10 (Bupropion + any NRT), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 1/1 10.4 % 0.33 [ 0.03, 4.19 ]
Piper 2009 0/3 0/1 Not estimable
Subtotal (95% CI) 4 2 10.4 % 0.33 [ 0.03, 4.19 ]
Total events: 0 (Bupropion + any NRT), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI) 40 29 100.0 % 1.05 [ 0.46, 2.38 ]
Total events: 10 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 0.88, df = 1 (P = 0.35), I2 =0.0%
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Analysis 29.1. Comparison 29 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic white, Outcome
1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 29 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 23/33 2/17 9.3 % 5.92 [ 1.58, 22.20 ]
Piper 2009 35/78 24/53 29.3 % 0.99 [ 0.67, 1.46 ]
Subtotal (95% CI) 111 70 38.5 % 2.20 [ 0.33, 14.75 ]
Total events: 58 (Bupropion + any NRT), 26 (Placebo)
Heterogeneity: Tau2 = 1.66; Chi2 = 7.75, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Heterozygous
Piper 2007 19/41 5/19 17.1 % 1.76 [ 0.77, 4.00 ]
Piper 2009 44/91 18/69 27.3 % 1.85 [ 1.18, 2.91 ]
Subtotal (95% CI) 132 88 44.3 % 1.83 [ 1.23, 2.72 ]
Total events: 63 (Bupropion + any NRT), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
3 Homozygous Minor
Piper 2007 3/6 2/8 8.1 % 2.00 [ 0.47, 8.46 ]
Piper 2009 8/18 2/10 9.0 % 2.22 [ 0.58, 8.51 ]
Subtotal (95% CI) 24 18 17.1 % 2.12 [ 0.79, 5.65 ]
Total events: 11 (Bupropion + any NRT), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.13)
Total (95% CI) 267 176 100.0 % 1.74 [ 1.09, 2.77 ]
Total events: 132 (Bupropion + any NRT), 53 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 10.81, df = 5 (P = 0.06); I2 =54%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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Analysis 30.1. Comparison 30 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 30 Bupropion + any NRT vs placebo - rs2036527 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 3/10 1/5 10.8 % 1.50 [ 0.20, 11.00 ]
Piper 2009 2/13 0/10 5.0 % 3.93 [ 0.21, 73.71 ]
Subtotal (95% CI) 23 15 15.7 % 2.03 [ 0.39, 10.56 ]
Total events: 5 (Bupropion + any NRT), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Heterozygous
Piper 2007 2/3 3/5 37.1 % 1.11 [ 0.38, 3.25 ]
Piper 2009 1/9 1/6 6.5 % 0.67 [ 0.05, 8.73 ]
Subtotal (95% CI) 12 11 43.6 % 1.03 [ 0.38, 2.77 ]
Total events: 3 (Bupropion + any NRT), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
3 Homozygous Minor
Piper 2007 0/2 1/2 5.6 % 0.33 [ 0.02, 5.33 ]
Piper 2009 2/3 1/1 35.1 % 0.83 [ 0.28, 2.51 ]
Subtotal (95% CI) 5 3 40.7 % 0.74 [ 0.26, 2.05 ]
Total events: 2 (Bupropion + any NRT), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Total (95% CI) 40 29 100.0 % 1.00 [ 0.52, 1.92 ]
Total events: 10 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Chi2 = 1.06, df = 2 (P = 0.59), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Placebo Favours Bupropion + any NRT
188Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 31.1. Comparison 31 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic white, Outcome
1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 31 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 24/37 5/17 11.2 % 2.21 [ 1.02, 4.78 ]
Piper 2009 36/77 22/56 40.6 % 1.19 [ 0.79, 1.78 ]
Subtotal (95% CI) 114 73 51.8 % 1.48 [ 0.83, 2.65 ]
Total events: 60 (Bupropion + any NRT), 27 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 1.96, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Heterozygous
Piper 2007 15/33 3/21 5.4 % 3.18 [ 1.05, 9.68 ]
Piper 2009 40/90 16/57 29.4 % 1.58 [ 0.98, 2.55 ]
Subtotal (95% CI) 123 78 34.8 % 1.87 [ 1.04, 3.36 ]
Total events: 55 (Bupropion + any NRT), 19 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 2.08 (P = 0.037)
3 Homozygous Minor
Piper 2007 6/10 1/6 1.9 % 3.60 [ 0.56, 23.11 ]
Piper 2009 11/20 6/18 11.5 % 1.65 [ 0.77, 3.54 ]
Subtotal (95% CI) 30 24 13.4 % 1.85 [ 0.91, 3.74 ]
Total events: 17 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
Total (95% CI) 267 175 100.0 % 1.55 [ 1.20, 2.01 ]
Total events: 132 (Bupropion + any NRT), 53 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.03, df = 5 (P = 0.41); I2 =1%
Test for overall effect: Z = 3.32 (P = 0.00090)
Test for subgroup differences: Chi2 = 0.37, df = 2 (P = 0.83), I2 =0.0%
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Analysis 32.1. Comparison 32 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 32 Bupropion + any NRT vs placebo - rs3733829 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 3/11 5/12 59.9 % 0.65 [ 0.20, 2.12 ]
Piper 2009 2/19 3/6 40.1 % 0.21 [ 0.05, 0.98 ]
Total (95% CI) 30 18 100.0 % 0.42 [ 0.14, 1.24 ]
Total events: 5 (Bupropion + any NRT), 8 (Placebo)
Heterogeneity: Tau2 = 0.16; Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 33.1. Comparison 33 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic white, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 33 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 11/21 2/15 3.8 % 3.93 [ 1.02, 15.20 ]
Piper 2009 23/53 12/42 20.9 % 1.52 [ 0.86, 2.68 ]
Subtotal (95% CI) 74 57 24.6 % 2.00 [ 0.84, 4.75 ]
Total events: 34 (Bupropion + any NRT), 14 (Placebo)
Heterogeneity: Tau2 = 0.19; Chi2 = 1.68, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Heterozygous
Piper 2007 21/42 6/20 12.6 % 1.67 [ 0.80, 3.47 ]
Piper 2009 47/98 25/69 46.4 % 1.32 [ 0.91, 1.93 ]
Subtotal (95% CI) 140 89 59.0 % 1.39 [ 0.99, 1.94 ]
Total events: 68 (Bupropion + any NRT), 31 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
3 Homozygous Minor
Piper 2007 14/18 1/8 2.0 % 6.22 [ 0.98, 39.57 ]
Piper 2009 17/36 7/20 14.3 % 1.35 [ 0.68, 2.69 ]
Subtotal (95% CI) 54 28 16.3 % 2.34 [ 0.49, 11.08 ]
Total events: 31 (Bupropion + any NRT), 8 (Placebo)
Heterogeneity: Tau2 = 0.86; Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI) 268 174 100.0 % 1.51 [ 1.16, 1.97 ]
Total events: 133 (Bupropion + any NRT), 53 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.09, df = 5 (P = 0.40); I2 =2%
Test for overall effect: Z = 3.08 (P = 0.0021)
Test for subgroup differences: Chi2 = 0.95, df = 2 (P = 0.62), I2 =0.0%
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Analysis 34.1. Comparison 34 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 34 Bupropion + any NRT vs placebo - rs7937 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 4/8 4/9 64.9 % 1.13 [ 0.41, 3.08 ]
Piper 2009 0/5 1/9 7.1 % 0.56 [ 0.03, 11.57 ]
Subtotal (95% CI) 13 18 72.0 % 1.05 [ 0.40, 2.73 ]
Total events: 4 (Bupropion + any NRT), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Heterozygous or Homozygous Minor
Piper 2007 1/7 1/3 11.2 % 0.43 [ 0.04, 4.82 ]
Piper 2009 5/20 1/8 16.7 % 2.00 [ 0.27, 14.55 ]
Subtotal (95% CI) 27 11 28.0 % 1.08 [ 0.23, 4.99 ]
Total events: 6 (Bupropion + any NRT), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 40 29 100.0 % 1.06 [ 0.47, 2.38 ]
Total events: 10 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 35.1. Comparison 35 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic white, Outcome
1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 35 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 16/32 5/22 14.2 % 2.20 [ 0.95, 5.12 ]
Piper 2009 52/117 16/69 26.6 % 1.92 [ 1.19, 3.08 ]
Subtotal (95% CI) 149 91 40.8 % 1.98 [ 1.31, 3.00 ]
Total events: 68 (Bupropion + any NRT), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
2 Heterozygous
Piper 2007 25/42 4/18 13.1 % 2.68 [ 1.09, 6.59 ]
Piper 2009 27/54 25/58 30.2 % 1.16 [ 0.78, 1.73 ]
Subtotal (95% CI) 96 76 43.2 % 1.60 [ 0.70, 3.67 ]
Total events: 52 (Bupropion + any NRT), 29 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 2.98, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 1.12 (P = 0.26)
3 Homozygous Minor
Piper 2007 5/6 0/4 2.0 % 7.86 [ 0.55, 112.09 ]
Piper 2009 8/15 3/5 13.9 % 0.89 [ 0.38, 2.10 ]
Subtotal (95% CI) 21 9 16.0 % 2.04 [ 0.17, 25.25 ]
Total events: 13 (Bupropion + any NRT), 3 (Placebo)
Heterogeneity: Tau2 = 2.47; Chi2 = 3.43, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 266 176 100.0 % 1.62 [ 1.10, 2.39 ]
Total events: 133 (Bupropion + any NRT), 53 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 8.56, df = 5 (P = 0.13); I2 =42%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.20, df = 2 (P = 0.90), I2 =0.0%
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Analysis 36.1. Comparison 36 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 36 Bupropion + any NRT vs placebo - rs1329650 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 4/10 61.3 % 0.89 [ 0.32, 2.51 ]
Piper 2009 3/20 1/11 14.3 % 1.65 [ 0.19, 14.03 ]
Subtotal (95% CI) 34 21 75.6 % 1.00 [ 0.40, 2.55 ]
Total events: 8 (Bupropion + any NRT), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 1.0)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 1/2 9.3 % 0.50 [ 0.04, 7.10 ]
Piper 2009 2/5 1/6 15.1 % 2.40 [ 0.30, 19.34 ]
Subtotal (95% CI) 6 8 24.4 % 1.32 [ 0.26, 6.80 ]
Total events: 2 (Bupropion + any NRT), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 40 29 100.0 % 1.07 [ 0.48, 2.41 ]
Total events: 10 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 37.1. Comparison 37 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic white, Outcome
1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 37 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 22/45 6/31 17.7 % 2.53 [ 1.16, 5.50 ]
Piper 2009 64/138 24/91 32.7 % 1.76 [ 1.19, 2.59 ]
Subtotal (95% CI) 183 122 50.4 % 1.89 [ 1.34, 2.67 ]
Total events: 86 (Bupropion + any NRT), 30 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00032)
2 Heterozygous
Piper 2007 22/33 3/12 12.5 % 2.67 [ 0.97, 7.32 ]
Piper 2009 19/42 19/38 29.3 % 0.90 [ 0.57, 1.43 ]
Subtotal (95% CI) 75 50 41.8 % 1.42 [ 0.48, 4.20 ]
Total events: 41 (Bupropion + any NRT), 22 (Placebo)
Heterogeneity: Tau2 = 0.47; Chi2 = 3.94, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.63 (P = 0.53)
3 Homozygous Minor
Piper 2007 2/3 0/1 2.6 % 2.50 [ 0.20, 31.00 ]
Piper 2009 4/7 1/3 5.2 % 1.71 [ 0.31, 9.61 ]
Subtotal (95% CI) 10 4 7.8 % 1.93 [ 0.47, 8.02 ]
Total events: 6 (Bupropion + any NRT), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 268 176 100.0 % 1.64 [ 1.08, 2.49 ]
Total events: 133 (Bupropion + any NRT), 53 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 8.75, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 0.25, df = 2 (P = 0.88), I2 =0.0%
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Analysis 38.1. Comparison 38 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 38 Bupropion + any NRT vs placebo - rs1028936 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 4/11 59.7 % 0.98 [ 0.34, 2.81 ]
Piper 2009 3/20 1/12 14.3 % 1.80 [ 0.21, 15.41 ]
Subtotal (95% CI) 34 23 74.1 % 1.10 [ 0.43, 2.84 ]
Total events: 8 (Bupropion + any NRT), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 1/1 10.3 % 0.33 [ 0.03, 4.19 ]
Piper 2009 2/5 1/5 15.6 % 2.00 [ 0.26, 15.62 ]
Subtotal (95% CI) 6 6 25.9 % 0.96 [ 0.17, 5.39 ]
Total events: 2 (Bupropion + any NRT), 2 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 40 29 100.0 % 1.07 [ 0.48, 2.41 ]
Total events: 10 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 39.1. Comparison 39 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic white, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 39 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 21/34 4/14 13.7 % 2.16 [ 0.91, 5.16 ]
Piper 2009 40/71 15/52 26.7 % 1.95 [ 1.22, 3.14 ]
Subtotal (95% CI) 105 66 40.4 % 2.00 [ 1.32, 3.03 ]
Total events: 61 (Bupropion + any NRT), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
2 Heterozygous
Piper 2007 17/33 4/20 12.3 % 2.58 [ 1.01, 6.57 ]
Piper 2009 33/86 23/61 29.2 % 1.02 [ 0.67, 1.55 ]
Subtotal (95% CI) 119 81 41.6 % 1.47 [ 0.60, 3.63 ]
Total events: 50 (Bupropion + any NRT), 27 (Placebo)
Heterogeneity: Tau2 = 0.31; Chi2 = 3.24, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.84 (P = 0.40)
3 Homozygous Minor
Piper 2007 8/14 1/10 3.8 % 5.71 [ 0.84, 38.74 ]
Piper 2009 13/29 5/18 14.2 % 1.61 [ 0.69, 3.77 ]
Subtotal (95% CI) 43 28 18.0 % 2.29 [ 0.72, 7.27 ]
Total events: 21 (Bupropion + any NRT), 6 (Placebo)
Heterogeneity: Tau2 = 0.29; Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 267 175 100.0 % 1.72 [ 1.16, 2.53 ]
Total events: 132 (Bupropion + any NRT), 52 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 8.47, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 2.73 (P = 0.0063)
Test for subgroup differences: Chi2 = 0.46, df = 2 (P = 0.79), I2 =0.0%
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Analysis 40.1. Comparison 40 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 40 Bupropion + any NRT vs placebo - rs215605 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 4/9 5/8 65.5 % 0.71 [ 0.29, 1.76 ]
Piper 2009 0/9 0/10 Not estimable
Subtotal (95% CI) 18 18 65.5 % 0.71 [ 0.29, 1.76 ]
Total events: 4 (Bupropion + any NRT), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
2 Heterozygous or Homozygous Minor
Piper 2007 1/6 0/3 6.2 % 1.71 [ 0.09, 32.93 ]
Piper 2009 5/16 2/7 28.3 % 1.09 [ 0.28, 4.34 ]
Subtotal (95% CI) 22 10 34.5 % 1.19 [ 0.34, 4.13 ]
Total events: 6 (Bupropion + any NRT), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 40 28 100.0 % 0.85 [ 0.41, 1.77 ]
Total events: 10 (Bupropion + any NRT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
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Analysis 41.1. Comparison 41 Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 41 Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 23/34 11/28 17.0 % 1.72 [ 1.03, 2.88 ]
Piper 2009 35/79 36/65 26.7 % 0.80 [ 0.58, 1.11 ]
Subtotal (95% CI) 113 93 43.6 % 1.14 [ 0.54, 2.42 ]
Total events: 58 (Bupropion + any NRT), 47 (Bupropion)
Heterogeneity: Tau2 = 0.25; Chi2 = 6.04, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Heterozygous
Piper 2007 21/42 10/32 14.1 % 1.60 [ 0.88, 2.90 ]
Piper 2009 43/88 43/100 27.9 % 1.14 [ 0.83, 1.55 ]
Subtotal (95% CI) 130 132 42.0 % 1.22 [ 0.93, 1.61 ]
Total events: 64 (Bupropion + any NRT), 53 (Bupropion)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 1.43 (P = 0.15)
3 Homozygous Minor
Piper 2007 2/5 6/15 4.3 % 1.00 [ 0.29, 3.45 ]
Piper 2009 9/20 8/25 10.1 % 1.41 [ 0.66, 2.97 ]
Subtotal (95% CI) 25 40 14.4 % 1.28 [ 0.68, 2.44 ]
Total events: 11 (Bupropion + any NRT), 14 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 268 265 100.0 % 1.18 [ 0.90, 1.55 ]
Total events: 133 (Bupropion + any NRT), 114 (Bupropion)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.48, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Chi2 = 0.05, df = 2 (P = 0.97), I2 =0.0%
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Analysis 42.1. Comparison 42 Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic black or
African American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 42 Bupropion + any NRT vs bupropion - rs1051730 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 8/15 54.3 % 0.67 [ 0.29, 1.56 ]
Piper 2009 5/19 5/18 34.8 % 0.95 [ 0.33, 2.73 ]
Subtotal (95% CI) 33 33 89.1 % 0.77 [ 0.40, 1.49 ]
Total events: 10 (Bupropion + any NRT), 13 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 2/6 5.8 % 0.70 [ 0.05, 9.41 ]
Piper 2009 0/6 4/8 5.2 % 0.14 [ 0.01, 2.23 ]
Subtotal (95% CI) 7 14 10.9 % 0.33 [ 0.05, 2.19 ]
Total events: 0 (Bupropion + any NRT), 6 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 40 47 100.0 % 0.70 [ 0.37, 1.31 ]
Total events: 10 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.70, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 43.1. Comparison 43 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 43 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 23/34 11/28 17.0 % 1.72 [ 1.03, 2.88 ]
Piper 2009 35/79 36/65 26.8 % 0.80 [ 0.58, 1.11 ]
Subtotal (95% CI) 113 93 43.9 % 1.14 [ 0.54, 2.42 ]
Total events: 58 (Bupropion + any NRT), 47 (Bupropion)
Heterogeneity: Tau2 = 0.25; Chi2 = 6.04, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Heterozygous
Piper 2007 21/42 10/32 14.1 % 1.60 [ 0.88, 2.90 ]
Piper 2009 43/88 43/100 28.1 % 1.14 [ 0.83, 1.55 ]
Subtotal (95% CI) 130 132 42.2 % 1.22 [ 0.93, 1.61 ]
Total events: 64 (Bupropion + any NRT), 53 (Bupropion)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 1.43 (P = 0.15)
3 Homozygous Minor
Piper 2007 2/5 6/15 4.3 % 1.00 [ 0.29, 3.45 ]
Piper 2009 8/18 8/25 9.7 % 1.39 [ 0.64, 3.00 ]
Subtotal (95% CI) 23 40 14.0 % 1.27 [ 0.66, 2.44 ]
Total events: 10 (Bupropion + any NRT), 14 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 266 265 100.0 % 1.18 [ 0.90, 1.55 ]
Total events: 132 (Bupropion + any NRT), 114 (Bupropion)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.42, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.04, df = 2 (P = 0.98), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Bupropion Favours Bupropion + any NRT
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Analysis 44.1. Comparison 44 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic black or
African American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 44 Bupropion + any NRT vs bupropion - rs16969968 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 9/18 53.4 % 0.71 [ 0.31, 1.66 ]
Piper 2009 5/22 6/20 36.3 % 0.76 [ 0.27, 2.10 ]
Subtotal (95% CI) 36 38 89.7 % 0.73 [ 0.38, 1.40 ]
Total events: 10 (Bupropion + any NRT), 15 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 1/3 5.1 % 0.67 [ 0.04, 10.05 ]
Piper 2009 0/3 3/6 5.2 % 0.25 [ 0.02, 3.71 ]
Subtotal (95% CI) 4 9 10.3 % 0.41 [ 0.06, 2.76 ]
Total events: 0 (Bupropion + any NRT), 4 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI) 40 47 100.0 % 0.69 [ 0.37, 1.27 ]
Total events: 10 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
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Analysis 45.1. Comparison 45 Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 45 Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 23/33 11/28 16.6 % 1.77 [ 1.06, 2.96 ]
Piper 2009 35/78 36/65 26.9 % 0.81 [ 0.58, 1.13 ]
Subtotal (95% CI) 111 93 43.5 % 1.17 [ 0.54, 2.52 ]
Total events: 58 (Bupropion + any NRT), 47 (Bupropion)
Heterogeneity: Tau2 = 0.26; Chi2 = 6.38, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.40 (P = 0.69)
2 Heterozygous
Piper 2007 19/41 10/33 12.9 % 1.53 [ 0.83, 2.82 ]
Piper 2009 44/91 42/99 28.0 % 1.14 [ 0.83, 1.56 ]
Subtotal (95% CI) 132 132 41.0 % 1.21 [ 0.92, 1.60 ]
Total events: 63 (Bupropion + any NRT), 52 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
3 Homozygous Minor
Piper 2007 3/6 6/14 5.8 % 1.17 [ 0.43, 3.18 ]
Piper 2009 8/18 9/26 9.7 % 1.28 [ 0.61, 2.69 ]
Subtotal (95% CI) 24 40 15.6 % 1.24 [ 0.68, 2.25 ]
Total events: 11 (Bupropion + any NRT), 15 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 267 265 100.0 % 1.18 [ 0.91, 1.52 ]
Total events: 132 (Bupropion + any NRT), 114 (Bupropion)
Heterogeneity: Tau2 = 0.04; Chi2 = 7.99, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi2 = 0.01, df = 2 (P = 0.99), I2 =0.0%
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Analysis 46.1. Comparison 46 Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic black or
African American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 46 Bupropion + any NRT vs bupropion - rs2036527 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 3/10 6/13 32.0 % 0.65 [ 0.21, 1.98 ]
Piper 2009 2/13 5/14 18.8 % 0.43 [ 0.10, 1.85 ]
Subtotal (95% CI) 23 27 50.8 % 0.56 [ 0.23, 1.35 ]
Total events: 5 (Bupropion + any NRT), 11 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Heterozygous or Homozygous Minor
Piper 2007 2/5 4/8 24.4 % 0.80 [ 0.22, 2.87 ]
Piper 2009 3/12 4/12 24.8 % 0.75 [ 0.21, 2.66 ]
Subtotal (95% CI) 17 20 49.2 % 0.77 [ 0.32, 1.90 ]
Total events: 5 (Bupropion + any NRT), 8 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 40 47 100.0 % 0.66 [ 0.35, 1.23 ]
Total events: 10 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 47.1. Comparison 47 Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 47 Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 24/37 13/31 15.4 % 1.55 [ 0.96, 2.49 ]
Piper 2009 36/77 43/91 33.7 % 0.99 [ 0.72, 1.37 ]
Subtotal (95% CI) 114 122 49.1 % 1.19 [ 0.77, 1.84 ]
Total events: 60 (Bupropion + any NRT), 56 (Bupropion)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.31, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.80 (P = 0.42)
2 Heterozygous
Piper 2007 15/33 12/37 9.9 % 1.40 [ 0.77, 2.55 ]
Piper 2009 40/90 30/69 27.9 % 1.02 [ 0.72, 1.46 ]
Subtotal (95% CI) 123 106 37.7 % 1.11 [ 0.82, 1.51 ]
Total events: 55 (Bupropion + any NRT), 42 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
3 Homozygous Minor
Piper 2007 6/10 2/7 2.2 % 2.10 [ 0.59, 7.52 ]
Piper 2009 11/20 13/29 11.0 % 1.23 [ 0.70, 2.16 ]
Subtotal (95% CI) 30 36 13.1 % 1.34 [ 0.80, 2.25 ]
Total events: 17 (Bupropion + any NRT), 15 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 267 264 100.0 % 1.15 [ 0.96, 1.39 ]
Total events: 132 (Bupropion + any NRT), 113 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.07, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Chi2 = 0.39, df = 2 (P = 0.82), I2 =0.0%
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Analysis 48.1. Comparison 48 Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic black or
African American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 48 Bupropion + any NRT vs bupropion - rs3733829 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 3/11 9/16 43.9 % 0.48 [ 0.17, 1.40 ]
Piper 2009 2/19 6/19 22.7 % 0.33 [ 0.08, 1.45 ]
Subtotal (95% CI) 30 35 66.6 % 0.43 [ 0.18, 1.01 ]
Total events: 5 (Bupropion + any NRT), 15 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
2 Heterozygous or Homozygous Minor
Piper 2007 2/4 1/4 12.8 % 2.00 [ 0.28, 14.20 ]
Piper 2009 2/14 3/7 20.6 % 0.33 [ 0.07, 1.56 ]
Subtotal (95% CI) 18 11 33.4 % 0.73 [ 0.13, 4.20 ]
Total events: 4 (Bupropion + any NRT), 4 (Bupropion)
Heterogeneity: Tau2 = 0.80; Chi2 = 1.98, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 48 46 100.0 % 0.49 [ 0.25, 0.99 ]
Total events: 9 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.48, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.58), I2 =0.0%
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Analysis 49.1. Comparison 49 Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic white, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 49 Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 11/21 7/19 7.3 % 1.42 [ 0.69, 2.91 ]
Piper 2009 23/53 26/52 20.3 % 0.87 [ 0.58, 1.31 ]
Subtotal (95% CI) 74 71 27.6 % 1.01 [ 0.65, 1.59 ]
Total events: 34 (Bupropion + any NRT), 33 (Bupropion)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.38, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.06 (P = 0.95)
2 Heterozygous
Piper 2007 21/42 11/38 10.7 % 1.73 [ 0.96, 3.09 ]
Piper 2009 47/98 42/94 33.5 % 1.07 [ 0.79, 1.46 ]
Subtotal (95% CI) 140 132 44.2 % 1.27 [ 0.81, 2.00 ]
Total events: 68 (Bupropion + any NRT), 53 (Bupropion)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.05 (P = 0.29)
3 Homozygous Minor
Piper 2007 14/18 9/18 13.1 % 1.56 [ 0.92, 2.63 ]
Piper 2009 17/36 19/44 15.1 % 1.09 [ 0.67, 1.77 ]
Subtotal (95% CI) 54 62 28.2 % 1.29 [ 0.90, 1.84 ]
Total events: 31 (Bupropion + any NRT), 28 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
Total (95% CI) 268 265 100.0 % 1.16 [ 0.95, 1.42 ]
Total events: 133 (Bupropion + any NRT), 114 (Bupropion)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.53, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 0.75, df = 2 (P = 0.69), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Bupropion Favours Bupropion + any NRT
207Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 50.1. Comparison 50 Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 50 Bupropion + any NRT vs bupropion - rs7937 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 4/8 5/9 50.7 % 0.90 [ 0.36, 2.23 ]
Piper 2009 0/5 5/11 5.6 % 0.18 [ 0.01, 2.77 ]
Subtotal (95% CI) 13 20 56.3 % 0.61 [ 0.13, 2.86 ]
Total events: 4 (Bupropion + any NRT), 10 (Bupropion)
Heterogeneity: Tau2 = 0.61; Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Heterozygous or Homozygous Minor
Piper 2007 1/7 5/12 11.1 % 0.34 [ 0.05, 2.37 ]
Piper 2009 5/20 4/15 32.5 % 0.94 [ 0.30, 2.91 ]
Subtotal (95% CI) 27 27 43.7 % 0.73 [ 0.27, 1.93 ]
Total events: 6 (Bupropion + any NRT), 9 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 40 47 100.0 % 0.75 [ 0.39, 1.43 ]
Total events: 10 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.26, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 51.1. Comparison 51 Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 51 Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 16/32 8/29 9.0 % 1.81 [ 0.91, 3.59 ]
Piper 2009 52/117 47/101 35.6 % 0.96 [ 0.71, 1.28 ]
Subtotal (95% CI) 149 130 44.6 % 1.22 [ 0.66, 2.25 ]
Total events: 68 (Bupropion + any NRT), 55 (Bupropion)
Heterogeneity: Tau2 = 0.14; Chi2 = 2.88, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Heterozygous
Piper 2007 25/42 15/37 17.8 % 1.47 [ 0.92, 2.33 ]
Piper 2009 27/54 37/81 26.8 % 1.09 [ 0.77, 1.56 ]
Subtotal (95% CI) 96 118 44.5 % 1.22 [ 0.92, 1.62 ]
Total events: 52 (Bupropion + any NRT), 52 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
3 Homozygous Minor
Piper 2007 5/6 4/9 6.5 % 1.88 [ 0.83, 4.23 ]
Piper 2009 8/15 3/8 4.3 % 1.42 [ 0.52, 3.91 ]
Subtotal (95% CI) 21 17 10.8 % 1.68 [ 0.89, 3.17 ]
Total events: 13 (Bupropion + any NRT), 7 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Total (95% CI) 266 265 100.0 % 1.20 [ 0.97, 1.49 ]
Total events: 133 (Bupropion + any NRT), 114 (Bupropion)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.93, df = 5 (P = 0.31); I2 =16%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Chi2 = 0.84, df = 2 (P = 0.66), I2 =0.0%
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Analysis 52.1. Comparison 52 Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic black or
African American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 52 Bupropion + any NRT vs bupropion - rs1329650 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 10/19 60.1 % 0.68 [ 0.30, 1.54 ]
Piper 2009 3/20 8/23 29.0 % 0.43 [ 0.13, 1.41 ]
Subtotal (95% CI) 34 42 89.1 % 0.59 [ 0.30, 1.15 ]
Total events: 8 (Bupropion + any NRT), 18 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 0/2 Not estimable
Piper 2009 2/5 1/3 10.9 % 1.20 [ 0.17, 8.24 ]
Subtotal (95% CI) 6 5 10.9 % 1.20 [ 0.17, 8.24 ]
Total events: 2 (Bupropion + any NRT), 1 (Bupropion)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 40 47 100.0 % 0.63 [ 0.33, 1.20 ]
Total events: 10 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
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Analysis 53.1. Comparison 53 Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 53 Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 22/45 16/41 18.7 % 1.25 [ 0.77, 2.04 ]
Piper 2009 64/138 60/135 40.0 % 1.04 [ 0.80, 1.35 ]
Subtotal (95% CI) 183 176 58.8 % 1.09 [ 0.86, 1.37 ]
Total events: 86 (Bupropion + any NRT), 76 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Heterozygous
Piper 2007 22/33 11/32 16.1 % 1.94 [ 1.13, 3.31 ]
Piper 2009 19/42 26/52 22.4 % 0.90 [ 0.59, 1.39 ]
Subtotal (95% CI) 75 84 38.5 % 1.30 [ 0.62, 2.75 ]
Total events: 41 (Bupropion + any NRT), 37 (Bupropion)
Heterogeneity: Tau2 = 0.23; Chi2 = 4.74, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.69 (P = 0.49)
3 Homozygous Minor
Piper 2007 2/3 0/2 0.8 % 3.75 [ 0.27, 52.64 ]
Piper 2009 4/7 1/3 1.9 % 1.71 [ 0.31, 9.61 ]
Subtotal (95% CI) 10 5 2.8 % 2.17 [ 0.51, 9.18 ]
Total events: 6 (Bupropion + any NRT), 1 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 268 265 100.0 % 1.18 [ 0.92, 1.50 ]
Total events: 133 (Bupropion + any NRT), 114 (Bupropion)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.49, df = 5 (P = 0.26); I2 =23%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Chi2 = 1.02, df = 2 (P = 0.60), I2 =0.0%
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Analysis 54.1. Comparison 54 Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic black or
African American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 54 Bupropion + any NRT vs bupropion - rs1028936 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 5/14 10/19 60.1 % 0.68 [ 0.30, 1.54 ]
Piper 2009 3/20 8/23 29.0 % 0.43 [ 0.13, 1.41 ]
Subtotal (95% CI) 34 42 89.1 % 0.59 [ 0.30, 1.15 ]
Total events: 8 (Bupropion + any NRT), 18 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Heterozygous or Homozygous Minor
Piper 2007 0/1 0/2 Not estimable
Piper 2009 2/5 1/3 10.9 % 1.20 [ 0.17, 8.24 ]
Subtotal (95% CI) 6 5 10.9 % 1.20 [ 0.17, 8.24 ]
Total events: 2 (Bupropion + any NRT), 1 (Bupropion)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 40 47 100.0 % 0.63 [ 0.33, 1.20 ]
Total events: 10 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
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Analysis 55.1. Comparison 55 Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic white,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 55 Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic white
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 21/34 10/27 13.5 % 1.67 [ 0.95, 2.91 ]
Piper 2009 40/71 39/79 31.3 % 1.14 [ 0.84, 1.55 ]
Subtotal (95% CI) 105 106 44.8 % 1.28 [ 0.91, 1.80 ]
Total events: 61 (Bupropion + any NRT), 49 (Bupropion)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 1.41 (P = 0.16)
2 Heterozygous
Piper 2007 17/33 15/37 15.5 % 1.27 [ 0.76, 2.12 ]
Piper 2009 33/86 38/85 25.8 % 0.86 [ 0.60, 1.23 ]
Subtotal (95% CI) 119 122 41.3 % 1.00 [ 0.69, 1.45 ]
Total events: 50 (Bupropion + any NRT), 53 (Bupropion)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.01 (P = 1.0)
3 Homozygous Minor
Piper 2007 8/14 2/11 2.8 % 3.14 [ 0.83, 11.92 ]
Piper 2009 13/29 10/26 11.0 % 1.17 [ 0.62, 2.19 ]
Subtotal (95% CI) 43 37 13.9 % 1.61 [ 0.64, 4.08 ]
Total events: 21 (Bupropion + any NRT), 12 (Bupropion)
Heterogeneity: Tau2 = 0.23; Chi2 = 1.81, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 267 265 100.0 % 1.17 [ 0.93, 1.47 ]
Total events: 132 (Bupropion + any NRT), 114 (Bupropion)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.62, df = 5 (P = 0.25); I2 =24%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 1.40, df = 2 (P = 0.50), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Bupropion Favours Bupropion + any NRT
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Analysis 56.1. Comparison 56 Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic black or
African American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 56 Bupropion + any NRT vs bupropion - rs215605 - non-Hispanic black or African American
Outcome: 1 End of Treatment
Study or subgroup
Bupropion









Piper 2007 4/9 7/13 52.9 % 0.83 [ 0.34, 2.00 ]
Piper 2009 0/9 6/18 5.4 % 0.15 [ 0.01, 2.34 ]
Subtotal (95% CI) 18 31 58.3 % 0.51 [ 0.09, 2.94 ]
Total events: 4 (Bupropion + any NRT), 13 (Bupropion)
Heterogeneity: Tau2 = 0.89; Chi2 = 1.80, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Heterozygous or Homozygous Minor
Piper 2007 1/6 3/8 10.4 % 0.44 [ 0.06, 3.29 ]
Piper 2009 5/16 3/8 31.3 % 0.83 [ 0.26, 2.64 ]
Subtotal (95% CI) 22 16 41.7 % 0.71 [ 0.26, 1.93 ]
Total events: 6 (Bupropion + any NRT), 6 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.51)
Total (95% CI) 40 47 100.0 % 0.71 [ 0.37, 1.35 ]
Total events: 10 (Bupropion + any NRT), 19 (Bupropion)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.96, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Bupropion Favours Bupropion + any NRT
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Analysis 57.1. Comparison 57 Active NRT - rs1051730 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 57 Active NRT - rs1051730 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
GPRG 1993 32/151 8/42 11.0 % 1.11 [ 0.56, 2.23 ]
Lerman 2004 23/149 14/62 14.0 % 0.68 [ 0.38, 1.24 ]
Winst 2006 10/41 7/17 9.0 % 0.59 [ 0.27, 1.30 ]
Aveyard 2007 30/348 5/101 6.8 % 1.74 [ 0.69, 4.37 ]
Hall 2009 24/36 9/13 21.8 % 0.96 [ 0.63, 1.48 ]
Piper 2009 89/233 31/65 31.5 % 0.80 [ 0.59, 1.08 ]
Marteau 2012 29/232 4/69 5.8 % 2.16 [ 0.79, 5.92 ]
Subtotal (95% CI) 1190 369 100.0 % 0.92 [ 0.71, 1.19 ]
Total events: 237 (major), 78 (minor)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.16, df = 6 (P = 0.23); I2 =27%
Test for overall effect: Z = 0.65 (P = 0.52)
2 Heterozygous vs Homozygous Minor
GPRG 1993 28/152 8/42 7.8 % 0.97 [ 0.48, 1.96 ]
Lerman 2004 37/168 14/62 13.1 % 0.98 [ 0.57, 1.68 ]
Winst 2006 17/53 7/17 8.1 % 0.78 [ 0.39, 1.55 ]
Aveyard 2007 34/370 5/101 4.7 % 1.86 [ 0.75, 4.62 ]
Hall 2009 33/49 9/13 22.2 % 0.97 [ 0.64, 1.47 ]
Piper 2009 98/269 31/65 40.4 % 0.76 [ 0.57, 1.03 ]
Marteau 2012 23/220 4/69 3.7 % 1.80 [ 0.65, 5.04 ]
Subtotal (95% CI) 1281 369 100.0 % 0.91 [ 0.75, 1.11 ]
Total events: 270 (major), 78 (minor)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.16, df = 6 (P = 0.41); I2 =3%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 57.2. Comparison 57 Active NRT - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 57 Active NRT - rs1051730 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
GPRG 1993 36/151 11/42 9.8 % 0.91 [ 0.51, 1.63 ]
Lerman 2004 46/149 18/62 15.5 % 1.06 [ 0.67, 1.68 ]
Aveyard 2007 38/348 8/101 6.4 % 1.38 [ 0.66, 2.86 ]
Hall 2009 24/36 9/13 17.4 % 0.96 [ 0.63, 1.48 ]
Piper 2009 111/233 41/65 50.8 % 0.76 [ 0.60, 0.95 ]
Subtotal (95% CI) 917 283 100.0 % 0.88 [ 0.73, 1.06 ]
Total events: 255 (major), 87 (minor)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.34, df = 4 (P = 0.36); I2 =8%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Heterozygous vs Homozygous Minor
GPRG 1993 37/152 11/42 8.0 % 0.93 [ 0.52, 1.66 ]
Lerman 2004 59/168 18/62 13.9 % 1.21 [ 0.78, 1.88 ]
Aveyard 2007 34/370 8/101 4.9 % 1.16 [ 0.55, 2.43 ]
Hall 2009 34/49 9/13 16.2 % 1.00 [ 0.67, 1.51 ]
Piper 2009 143/269 41/65 57.0 % 0.84 [ 0.68, 1.05 ]
Subtotal (95% CI) 1008 283 100.0 % 0.93 [ 0.79, 1.10 ]
Total events: 307 (major), 87 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 58.1. Comparison 58 Active NRT - rs1051730 - non-Hispanic black or African American, Outcome
1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 58 Active NRT - rs1051730 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2004 22/111 1/5 64.7 % 0.99 [ 0.17, 5.95 ]
Piper 2009 22/70 0/1 35.3 % 1.27 [ 0.11, 14.32 ]
Subtotal (95% CI) 181 6 100.0 % 1.08 [ 0.26, 4.57 ]
Total events: 44 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
2 Heterozygous vs Homozygous Minor
Lerman 2004 10/38 1/5 67.6 % 1.32 [ 0.21, 8.22 ]
Piper 2009 2/12 0/1 32.4 % 0.77 [ 0.05, 10.85 ]
Subtotal (95% CI) 50 6 100.0 % 1.11 [ 0.25, 4.99 ]
Total events: 12 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 59.1. Comparison 59 Active NRT - rs16969968 - non-Hispanic black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 59 Active NRT - rs16969968 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 69/276 4/33 89.1 % 2.06 [ 0.80, 5.29 ]
Piper 2009 24/77 0/6 10.9 % 4.40 [ 0.30, 64.85 ]
Subtotal (95% CI) 353 39 100.0 % 2.24 [ 0.92, 5.45 ]
Total events: 93 (Major), 4 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Minor Favours Homozygous Major
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Analysis 59.2. Comparison 59 Active NRT - rs16969968 - non-Hispanic black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 59 Active NRT - rs16969968 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 75/276 3/33 73.2 % 2.99 [ 1.00, 8.94 ]
Piper 2009 28/77 1/6 26.8 % 2.18 [ 0.36, 13.38 ]
Subtotal (95% CI) 353 39 100.0 % 2.75 [ 1.08, 7.02 ]
Total events: 103 (Major), 4 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Minor Favours Homozygous Major
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Analysis 60.1. Comparison 60 Active NRT - rs588765 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 60 Active NRT - rs588765 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2004 31/131 12/68 20.2 % 1.34 [ 0.74, 2.44 ]
Hall 2009 28/39 10/16 39.6 % 1.15 [ 0.75, 1.76 ]
Piper 2009 36/116 23/63 40.3 % 0.85 [ 0.56, 1.30 ]
Subtotal (95% CI) 286 147 100.0 % 1.05 [ 0.80, 1.37 ]
Total events: 95 (Major), 45 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.77, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
2 Heterozygous vs Homozygous Minor
Lerman 2004 31/175 12/68 18.6 % 1.00 [ 0.55, 1.84 ]
Piper 2009 25/38 10/16 34.6 % 1.05 [ 0.68, 1.64 ]
Hall 2009 64/186 23/63 46.8 % 0.94 [ 0.64, 1.38 ]
Subtotal (95% CI) 399 147 100.0 % 0.99 [ 0.76, 1.29 ]
Total events: 120 (Major), 45 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 60.2. Comparison 60 Active NRT - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 60 Active NRT - rs588765 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Lerman 2004 49/131 20/64 26.4 % 1.20 [ 0.78, 1.83 ]
Hall 2009 26/39 12/16 37.0 % 0.89 [ 0.62, 1.27 ]
Piper 2009 44/116 28/63 36.6 % 0.85 [ 0.59, 1.22 ]
Subtotal (95% CI) 286 143 100.0 % 0.95 [ 0.76, 1.18 ]
Total events: 119 (Major), 60 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
2 Heterozygous vs Homozygous Minor
Lerman 2004 53/175 20/64 24.0 % 0.97 [ 0.63, 1.49 ]
Piper 2009 83/186 28/63 43.0 % 1.00 [ 0.73, 1.38 ]
Hall 2009 25/38 12/16 33.0 % 0.88 [ 0.61, 1.26 ]
Subtotal (95% CI) 399 143 100.0 % 0.95 [ 0.77, 1.17 ]
Total events: 161 (Major), 60 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 61.1. Comparison 61 Active NRT - rs2036527 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 61 Active NRT - rs2036527 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2004 23/141 13/63 19.1 % 0.79 [ 0.43, 1.46 ]
Piper 2009 86/228 33/69 80.9 % 0.79 [ 0.59, 1.06 ]
Subtotal (95% CI) 369 132 100.0 % 0.79 [ 0.60, 1.03 ]
Total events: 109 (major), 46 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
2 Heterozygous vs Homozygous Minor
Lerman 2004 39/177 13/63 24.3 % 1.07 [ 0.61, 1.87 ]
Piper 2009 99/270 33/69 75.7 % 0.77 [ 0.57, 1.03 ]
Subtotal (95% CI) 447 132 100.0 % 0.83 [ 0.63, 1.10 ]
Total events: 138 (major), 46 (minor)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 61.2. Comparison 61 Active NRT - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 61 Active NRT - rs2036527 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Lerman 2004 44/141 17/63 37.9 % 1.16 [ 0.72, 1.86 ]
Piper 2009 111/228 44/69 62.1 % 0.76 [ 0.61, 0.95 ]
Subtotal (95% CI) 369 132 100.0 % 0.89 [ 0.59, 1.35 ]
Total events: 155 (major), 61 (minor)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.53 (P = 0.59)
2 Heterozygous vs Homozygous Minor
Lerman 2004 63/177 17/63 42.1 % 1.32 [ 0.84, 2.07 ]
Piper 2009 140/270 44/69 57.9 % 0.81 [ 0.66, 1.00 ]
Subtotal (95% CI) 447 132 100.0 % 1.00 [ 0.61, 1.64 ]
Total events: 203 (major), 61 (minor)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.05, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 62.1. Comparison 62 Active NRT - rs2036527 - non-Hispanic black or African American, Outcome
1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 62 Active NRT - rs2036527 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 46/189 25/119 72.9 % 1.16 [ 0.75, 1.78 ]
Piper 2009 15/43 9/40 27.1 % 1.55 [ 0.77, 3.14 ]
Subtotal (95% CI) 232 159 100.0 % 1.25 [ 0.87, 1.81 ]
Total events: 61 (Major), 34 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Minor Favours Homozygous Major
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Analysis 62.2. Comparison 62 Active NRT - rs2036527 - non-Hispanic black or African American, Outcome
2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 62 Active NRT - rs2036527 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 57/189 21/119 67.0 % 1.71 [ 1.10, 2.67 ]
Piper 2009 19/43 10/40 33.0 % 1.77 [ 0.94, 3.33 ]
Subtotal (95% CI) 232 159 100.0 % 1.73 [ 1.20, 2.49 ]
Total events: 76 (Major), 31 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Minor Favours Homozygous Major
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Analysis 63.1. Comparison 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-
Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
GPRG 1993 48/231 5/22 58.0 % 0.91 [ 0.41, 2.06 ]
Aveyard 2007 37/510 3/42 29.7 % 1.02 [ 0.33, 3.16 ]
Gilbert 2009 14/57 1/4 12.3 % 0.98 [ 0.17, 5.70 ]
Subtotal (95% CI) 798 68 100.0 % 0.95 [ 0.51, 1.76 ]
Total events: 99 (major), 9 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.88)
2 Heterozygous vs Homozygous Minor
GPRG 1993 22/118 5/22 61.7 % 0.82 [ 0.35, 1.93 ]
Aveyard 2007 6/114 3/42 25.3 % 0.74 [ 0.19, 2.81 ]
Gilbert 2009 5/21 1/4 13.1 % 0.95 [ 0.15, 6.13 ]
Subtotal (95% CI) 253 68 100.0 % 0.81 [ 0.42, 1.60 ]
Total events: 33 (major), 9 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 63.2. Comparison 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 63 Active NRT - DRD-4 (exon 3 48 bp) - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
GPRG 1993 64/231 5/22 12.2 % 1.22 [ 0.55, 2.71 ]
Aveyard 2007 50/510 5/42 10.4 % 0.82 [ 0.35, 1.95 ]
Gilbert 2009 47/57 4/4 77.5 % 0.91 [ 0.66, 1.25 ]
Subtotal (95% CI) 798 68 100.0 % 0.93 [ 0.71, 1.23 ]
Total events: 161 (major), 14 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
2 Heterozygous vs Homozygous Minor
GPRG 1993 24/118 5/22 18.4 % 0.89 [ 0.38, 2.09 ]
Aveyard 2007 6/114 5/42 10.9 % 0.44 [ 0.14, 1.37 ]
Gilbert 2009 18/21 4/4 70.7 % 0.93 [ 0.66, 1.32 ]
Subtotal (95% CI) 253 68 100.0 % 0.85 [ 0.58, 1.26 ]
Total events: 48 (major), 14 (minor)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.34, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 64.1. Comparison 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white, Outcome 1 Six-
Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Aveyard 2007 18/250 12/169 72.9 % 1.01 [ 0.50, 2.05 ]
Gilbert 2009 5/27 4/15 27.1 % 0.69 [ 0.22, 2.20 ]
Subtotal (95% CI) 277 184 100.0 % 0.92 [ 0.50, 1.67 ]
Total events: 23 (major), 16 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Heterozygous vs Homozygous Minor
Aveyard 2007 35/425 12/169 70.6 % 1.16 [ 0.62, 2.18 ]
Gilbert 2009 11/40 4/15 29.4 % 1.03 [ 0.39, 2.74 ]
Subtotal (95% CI) 465 184 100.0 % 1.12 [ 0.66, 1.90 ]
Total events: 46 (major), 16 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 64.2. Comparison 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 64 Active NRT - SLC6A4 (Promoter) - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Aveyard 2007 20/250 15/169 13.5 % 0.90 [ 0.48, 1.71 ]
Gilbert 2009 23/27 13/15 86.5 % 0.98 [ 0.76, 1.27 ]
Subtotal (95% CI) 277 184 100.0 % 0.97 [ 0.77, 1.23 ]
Total events: 43 (major), 28 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Heterozygous vs Homozygous Minor
Aveyard 2007 38/425 15/169 16.3 % 1.01 [ 0.57, 1.78 ]
Gilbert 2009 32/40 13/15 83.7 % 0.92 [ 0.72, 1.19 ]
Subtotal (95% CI) 465 184 100.0 % 0.94 [ 0.74, 1.18 ]
Total events: 70 (major), 28 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 65.1. Comparison 65 Active NRT-NMR - non-Hispanic white or black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 65 Active NRT-NMR - non-Hispanic white or black or African American
Outcome: 1 Six-Month Abstinence








1 Normal NMR vs Slow NMR
GPRG 1993 16/209 16/91 31.6 % 0.44 [ 0.23, 0.83 ]
Lerman 2015 25/191 50/227 68.4 % 0.59 [ 0.38, 0.92 ]
Subtotal (95% CI) 400 318 100.0 % 0.54 [ 0.37, 0.78 ]
Total events: 41 (Normal), 66 (Slow)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00086)
Test for subgroup differences: Not applicable
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Analysis 65.2. Comparison 65 Active NRT-NMR - non-Hispanic white or black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 65 Active NRT-NMR - non-Hispanic white or black or African American
Outcome: 2 End of Treatment








1 Normal NMR vs Slow NMR
GPRG 1993 27/209 17/91 27.4 % 0.69 [ 0.40, 1.20 ]
Lerman 2015 42/191 62/227 72.6 % 0.81 [ 0.57, 1.13 ]
Subtotal (95% CI) 400 318 100.0 % 0.77 [ 0.58, 1.03 ]
Total events: 69 (Normal), 79 (Slow)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.081)
Test for subgroup differences: Not applicable
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Analysis 66.1. Comparison 66 Bupropion - rs1051730 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 66 Bupropion - rs1051730 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2002 18/80 13/35 30.5 % 0.61 [ 0.33, 1.10 ]
Brown 2007 17/47 3/24 18.3 % 2.89 [ 0.94, 8.91 ]
Hall 2008 15/28 4/12 23.5 % 1.61 [ 0.67, 3.84 ]
Piper 2009 25/65 7/25 27.7 % 1.37 [ 0.68, 2.77 ]
Subtotal (95% CI) 220 96 100.0 % 1.27 [ 0.67, 2.43 ]
Total events: 75 (major), 27 (minor)
Heterogeneity: Tau2 = 0.27; Chi2 = 8.04, df = 3 (P = 0.05); I2 =63%
Test for overall effect: Z = 0.73 (P = 0.47)
2 Heterozygous vs Homozygous Minor
Lerman 2002 25/104 13/35 33.2 % 0.65 [ 0.37, 1.12 ]
Brown 2007 22/65 3/24 17.0 % 2.71 [ 0.89, 8.23 ]
Hall 2008 11/25 4/12 21.5 % 1.32 [ 0.53, 3.29 ]
Piper 2009 34/100 7/25 28.4 % 1.21 [ 0.61, 2.41 ]
Subtotal (95% CI) 294 96 100.0 % 1.15 [ 0.65, 2.03 ]
Total events: 92 (major), 27 (minor)
Heterogeneity: Tau2 = 0.17; Chi2 = 6.41, df = 3 (P = 0.09); I2 =53%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 66.2. Comparison 66 Bupropion - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 66 Bupropion - rs1051730 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Lerman 2002 26/80 14/35 22.8 % 0.81 [ 0.49, 1.36 ]
Brown 2007 22/47 12/24 23.6 % 0.94 [ 0.57, 1.55 ]
Piper 2007 11/28 6/15 11.2 % 0.98 [ 0.45, 2.13 ]
McCarthy 2008 9/15 4/12 8.4 % 1.80 [ 0.73, 4.43 ]
Hall 2008 20/28 6/12 16.9 % 1.43 [ 0.77, 2.64 ]
Piper 2009 36/65 8/25 17.0 % 1.73 [ 0.94, 3.19 ]
Subtotal (95% CI) 263 123 100.0 % 1.15 [ 0.88, 1.50 ]
Total events: 124 (major), 50 (minor)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.72, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 1.00 (P = 0.32)
2 Heterozygous vs Homozygous Minor
Lerman 2002 30/104 14/35 23.6 % 0.72 [ 0.43, 1.20 ]
Piper 2007 10/32 6/15 9.3 % 0.78 [ 0.35, 1.75 ]
Brown 2007 35/65 12/24 28.6 % 1.08 [ 0.68, 1.70 ]
Hall 2008 15/24 6/12 14.5 % 1.25 [ 0.66, 2.38 ]
McCarthy 2008 17/32 4/12 8.1 % 1.59 [ 0.67, 3.78 ]
Piper 2009 43/100 8/25 16.0 % 1.34 [ 0.73, 2.48 ]
Subtotal (95% CI) 357 123 100.0 % 1.04 [ 0.81, 1.33 ]
Total events: 150 (major), 50 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.44, df = 5 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 67.1. Comparison 67 Bupropion - rs1051730 - non-Hispanic black or African American, Outcome 1
Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 67 Bupropion - rs1051730 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 7/25 3/12 53.3 % 1.12 [ 0.35, 3.59 ]
Piper 2009 4/18 3/8 46.7 % 0.59 [ 0.17, 2.06 ]
Subtotal (95% CI) 43 20 100.0 % 0.83 [ 0.36, 1.95 ]
Total events: 11 (major), 6 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 67.2. Comparison 67 Bupropion - rs1051730 - non-Hispanic black or African American, Outcome 2
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 67 Bupropion - rs1051730 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 9/25 4/12 40.2 % 1.08 [ 0.42, 2.81 ]
Piper 2007 8/15 2/6 24.4 % 1.60 [ 0.47, 5.46 ]
Piper 2009 5/18 4/8 35.4 % 0.56 [ 0.20, 1.54 ]
Subtotal (95% CI) 58 26 100.0 % 0.94 [ 0.51, 1.72 ]
Total events: 22 (major), 10 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.85, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 68.1. Comparison 68 Bupropion - rs16969968 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 68 Bupropion - rs16969968 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 11/28 6/15 30.0 % 0.98 [ 0.45, 2.13 ]
McCarthy 2008 9/15 4/12 22.1 % 1.80 [ 0.73, 4.43 ]
Piper 2009 36/65 8/25 47.9 % 1.73 [ 0.94, 3.19 ]
Subtotal (95% CI) 108 52 100.0 % 1.47 [ 0.96, 2.25 ]
Total events: 56 (major), 18 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.52, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
2 Heterozygous vs Homozygous Minor
Piper 2007 10/32 6/15 27.9 % 0.78 [ 0.35, 1.75 ]
McCarthy 2008 17/32 4/12 24.2 % 1.59 [ 0.67, 3.78 ]
Piper 2009 43/100 8/25 47.9 % 1.34 [ 0.73, 2.48 ]
Subtotal (95% CI) 164 52 100.0 % 1.20 [ 0.79, 1.84 ]
Total events: 70 (major), 18 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 69.1. Comparison 69 Bupropion - rs16969968 - non-Hispanic black or African American, Outcome
1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 69 Bupropion - rs16969968 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2009 5/20 2/6 24.6 % 0.75 [ 0.19, 2.93 ]
Cox 2012 31/241 6/27 75.4 % 0.58 [ 0.27, 1.26 ]
Subtotal (95% CI) 261 33 100.0 % 0.62 [ 0.31, 1.21 ]
Total events: 36 (Major), 8 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 69.2. Comparison 69 Bupropion - rs16969968 - non-Hispanic black or African American, Outcome
2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 69 Bupropion - rs16969968 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 9/18 1/3 9.4 % 1.50 [ 0.28, 7.93 ]
Piper 2009 6/20 3/6 23.9 % 0.60 [ 0.21, 1.70 ]
Cox 2012 57/241 8/27 66.8 % 0.80 [ 0.43, 1.49 ]
Subtotal (95% CI) 279 36 100.0 % 0.79 [ 0.48, 1.32 ]
Total events: 72 (Major), 12 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 70.1. Comparison 70 Bupropion - rs588765 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 70 Bupropion - rs588765 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2002 24/67 10/45 26.5 % 1.61 [ 0.86, 3.04 ]
Brown 2007 11/50 7/19 21.1 % 0.60 [ 0.27, 1.31 ]
Hall 2008 9/23 9/14 26.2 % 0.61 [ 0.32, 1.16 ]
Piper 2009 15/55 11/31 26.2 % 0.77 [ 0.40, 1.46 ]
Subtotal (95% CI) 195 109 100.0 % 0.83 [ 0.52, 1.34 ]
Total events: 59 (major), 37 (minor)
Heterogeneity: Tau2 = 0.12; Chi2 = 5.99, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Heterozygous vs Homozygous Minor
Lerman 2002 22/106 10/45 21.0 % 0.93 [ 0.48, 1.81 ]
Brown 2007 23/66 7/19 20.1 % 0.95 [ 0.48, 1.86 ]
Hall 2008 12/27 9/14 27.7 % 0.69 [ 0.39, 1.23 ]
Piper 2009 35/93 11/31 31.2 % 1.06 [ 0.62, 1.82 ]
Subtotal (95% CI) 292 109 100.0 % 0.90 [ 0.66, 1.21 ]
Total events: 92 (major), 37 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 70.2. Comparison 70 Bupropion - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 70 Bupropion - rs588765 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Lerman 2002 26/67 16/45 26.0 % 1.09 [ 0.67, 1.79 ]
Brown 2007 20/50 9/19 18.7 % 0.84 [ 0.47, 1.51 ]
Hall 2008 14/23 10/14 29.3 % 0.85 [ 0.53, 1.36 ]
Piper 2009 21/55 15/31 26.0 % 0.79 [ 0.48, 1.29 ]
Subtotal (95% CI) 195 109 100.0 % 0.89 [ 0.69, 1.14 ]
Total events: 81 (major), 50 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
2 Heterozygous vs Homozygous Minor
Lerman 2002 27/106 16/45 20.8 % 0.72 [ 0.43, 1.19 ]
Brown 2007 39/66 9/19 20.4 % 1.25 [ 0.75, 2.09 ]
Hall 2008 16/26 10/14 26.8 % 0.86 [ 0.55, 1.35 ]
Piper 2009 49/93 15/31 32.0 % 1.09 [ 0.72, 1.64 ]
Subtotal (95% CI) 291 109 100.0 % 0.96 [ 0.76, 1.22 ]
Total events: 131 (major), 50 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.84, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 71.1. Comparison 71 Bupropion - rs2036527 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 71 Bupropion - rs2036527 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2002 15/78 15/39 51.2 % 0.50 [ 0.27, 0.91 ]
Piper 2009 24/65 8/26 48.8 % 1.20 [ 0.62, 2.32 ]
Subtotal (95% CI) 143 65 100.0 % 0.77 [ 0.33, 1.81 ]
Total events: 39 (major), 23 (minor)
Heterogeneity: Tau2 = 0.28; Chi2 = 3.69, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Heterozygous vs Homozygous Minor
Lerman 2002 27/105 15/39 57.1 % 0.67 [ 0.40, 1.12 ]
Piper 2009 34/99 8/26 42.9 % 1.12 [ 0.59, 2.11 ]
Subtotal (95% CI) 204 65 100.0 % 0.83 [ 0.51, 1.37 ]
Total events: 61 (major), 23 (minor)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 71.2. Comparison 71 Bupropion - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 71 Bupropion - rs2036527 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Lerman 2002 27/78 16/39 36.4 % 0.84 [ 0.52, 1.37 ]
Piper 2007 11/28 6/14 19.7 % 0.92 [ 0.43, 1.96 ]
McCarthy 2008 8/14 4/13 14.2 % 1.86 [ 0.73, 4.72 ]
Piper 2009 36/65 9/26 29.7 % 1.60 [ 0.90, 2.83 ]
Subtotal (95% CI) 185 92 100.0 % 1.16 [ 0.79, 1.70 ]
Total events: 82 (major), 35 (minor)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.22, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Heterozygous vs Homozygous Minor
Lerman 2002 28/105 16/39 32.9 % 0.65 [ 0.40, 1.06 ]
Piper 2007 10/33 6/14 20.3 % 0.71 [ 0.32, 1.57 ]
McCarthy 2008 18/32 4/13 18.1 % 1.83 [ 0.77, 4.37 ]
Piper 2009 42/99 9/26 28.8 % 1.23 [ 0.69, 2.18 ]
Subtotal (95% CI) 269 92 100.0 % 0.96 [ 0.61, 1.51 ]
Total events: 98 (major), 35 (minor)
Heterogeneity: Tau2 = 0.10; Chi2 = 5.73, df = 3 (P = 0.13); I2 =48%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
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Analysis 72.1. Comparison 72 Bupropion - rs2036527 - non-Hispanic black or African American, Outcome 1
Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 72 Bupropion - rs2036527 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 4/18 6/19 20.4 % 0.70 [ 0.24, 2.09 ]
Piper 2009 4/14 3/12 14.7 % 1.14 [ 0.32, 4.12 ]
Cox 2012 20/155 16/113 64.9 % 0.91 [ 0.49, 1.68 ]
Subtotal (95% CI) 187 144 100.0 % 0.89 [ 0.55, 1.46 ]
Total events: 28 (Major), 25 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 72.2. Comparison 72 Bupropion - rs2036527 - non-Hispanic black or African American, Outcome 2
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 72 Bupropion - rs2036527 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 6/18 7/19 16.0 % 0.90 [ 0.38, 2.18 ]
Piper 2007 6/13 4/8 15.0 % 0.92 [ 0.37, 2.29 ]
Piper 2009 5/14 4/12 10.9 % 1.07 [ 0.37, 3.11 ]
Cox 2012 43/155 21/113 58.0 % 1.49 [ 0.94, 2.37 ]
Subtotal (95% CI) 200 152 100.0 % 1.24 [ 0.87, 1.76 ]
Total events: 60 (Major), 36 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.63, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 73.1. Comparison 73 Bupropion - rs3733829 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 73 Bupropion - rs3733829 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Brown 2007 14/55 4/16 24.7 % 1.02 [ 0.39, 2.66 ]
Piper 2009 30/91 11/29 75.3 % 0.87 [ 0.50, 1.51 ]
Subtotal (95% CI) 146 45 100.0 % 0.90 [ 0.56, 1.46 ]
Total events: 44 (major), 15 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
2 Heterozygous vs Homozygous Minor
Brown 2007 18/47 4/16 27.4 % 1.53 [ 0.61, 3.86 ]
Piper 2009 24/69 11/29 72.6 % 0.92 [ 0.52, 1.62 ]
Subtotal (95% CI) 116 45 100.0 % 1.06 [ 0.65, 1.71 ]
Total events: 42 (major), 15 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
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Analysis 73.2. Comparison 73 Bupropion - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 73 Bupropion - rs3733829 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Brown 2007 26/55 9/16 39.7 % 0.84 [ 0.50, 1.41 ]
Piper 2007 13/31 2/7 6.8 % 1.47 [ 0.42, 5.08 ]
McCarthy 2008 16/26 1/4 3.5 % 2.46 [ 0.44, 13.81 ]
Piper 2009 43/91 13/29 50.0 % 1.05 [ 0.67, 1.67 ]
Subtotal (95% CI) 203 56 100.0 % 1.02 [ 0.73, 1.40 ]
Total events: 98 (major), 25 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Heterozygous vs Homozygous Minor
Piper 2007 12/37 2/7 7.0 % 1.14 [ 0.32, 4.00 ]
Brown 2007 24/47 9/16 42.0 % 0.91 [ 0.54, 1.52 ]
McCarthy 2008 13/28 1/4 3.7 % 1.86 [ 0.32, 10.62 ]
Piper 2009 30/69 13/29 47.3 % 0.97 [ 0.60, 1.58 ]
Subtotal (95% CI) 181 56 100.0 % 0.98 [ 0.70, 1.36 ]
Total events: 79 (major), 25 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 74.1. Comparison 74 Bupropion - rs3733829 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 74 Bupropion - rs3733829 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 9/16 1/4 31.4 % 2.25 [ 0.39, 12.97 ]
Piper 2009 6/19 3/7 68.6 % 0.74 [ 0.25, 2.17 ]
Subtotal (95% CI) 35 11 100.0 % 1.05 [ 0.37, 2.99 ]
Total events: 15 (major), 4 (minor)
Heterogeneity: Tau2 = 0.11; Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 75.1. Comparison 75 Bupropion - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 75 Bupropion - rs7937 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 7/19 9/18 20.3 % 0.74 [ 0.35, 1.56 ]
McCarthy 2008 7/15 6/11 19.5 % 0.86 [ 0.40, 1.84 ]
Piper 2009 26/52 19/44 60.2 % 1.16 [ 0.75, 1.79 ]
Subtotal (95% CI) 86 73 100.0 % 1.00 [ 0.71, 1.40 ]
Total events: 40 (major), 34 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Heterozygous vs Homozygous Minor
Piper 2007 11/38 9/18 20.9 % 0.58 [ 0.29, 1.14 ]
McCarthy 2008 17/33 6/11 24.0 % 0.94 [ 0.50, 1.78 ]
Piper 2009 42/94 19/44 55.2 % 1.03 [ 0.69, 1.55 ]
Subtotal (95% CI) 165 73 100.0 % 0.90 [ 0.65, 1.23 ]
Total events: 70 (major), 34 (minor)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.09, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.66), I2 =0.0%
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Analysis 76.1. Comparison 76 Bupropion - rs7937 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 76 Bupropion - rs7937 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 5/9 0/1 27.8 % 2.20 [ 0.19, 25.88 ]
Piper 2009 5/11 1/2 72.2 % 0.91 [ 0.20, 4.20 ]
Subtotal (95% CI) 20 3 100.0 % 1.16 [ 0.32, 4.26 ]
Total events: 10 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Heterozygous vs Homozygous Minor
Piper 2007 5/11 0/1 32.1 % 1.83 [ 0.15, 21.85 ]
Piper 2009 3/13 1/2 67.9 % 0.46 [ 0.08, 2.54 ]
Subtotal (95% CI) 24 3 100.0 % 0.72 [ 0.18, 2.93 ]
Total events: 8 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
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Analysis 77.1. Comparison 77 Bupropion - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 77 Bupropion - rs1329650 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 8/29 4/9 23.7 % 0.62 [ 0.24, 1.59 ]
McCarthy 2008 16/31 5/8 51.6 % 0.83 [ 0.44, 1.56 ]
Piper 2009 47/101 3/8 24.7 % 1.24 [ 0.50, 3.11 ]
Subtotal (95% CI) 161 25 100.0 % 0.85 [ 0.54, 1.35 ]
Total events: 71 (major), 12 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.11, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Heterozygous vs Homozygous Minor
Piper 2007 15/37 4/9 32.1 % 0.91 [ 0.40, 2.09 ]
McCarthy 2008 9/20 5/8 42.1 % 0.72 [ 0.35, 1.48 ]
Piper 2009 37/81 3/8 25.7 % 1.22 [ 0.48, 3.07 ]
Subtotal (95% CI) 138 25 100.0 % 0.89 [ 0.56, 1.42 ]
Total events: 61 (major), 12 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 78.1. Comparison 78 Bupropion - rs1329650 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 78 Bupropion - rs1329650 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 10/19 0/2 30.4 % 3.15 [ 0.24, 40.93 ]
Piper 2009 8/23 1/3 69.6 % 1.04 [ 0.19, 5.69 ]
Subtotal (95% CI) 42 5 100.0 % 1.46 [ 0.35, 6.01 ]
Total events: 18 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 79.1. Comparison 79 Bupropion - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 79 Bupropion - rs1028936 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 16/41 0/2 6.4 % 2.36 [ 0.18, 30.43 ]
McCarthy 2008 18/36 3/4 77.8 % 0.67 [ 0.35, 1.28 ]
Piper 2009 60/135 1/3 15.8 % 1.33 [ 0.27, 6.68 ]
Subtotal (95% CI) 212 9 100.0 % 0.81 [ 0.42, 1.55 ]
Total events: 94 (major), 4 (minor)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.11, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Heterozygous vs Homozygous Minor
Piper 2007 11/32 0/2 7.4 % 2.09 [ 0.16, 27.40 ]
McCarthy 2008 9/19 3/4 74.4 % 0.63 [ 0.30, 1.32 ]
Piper 2009 26/52 1/3 18.2 % 1.50 [ 0.30, 7.60 ]
Subtotal (95% CI) 103 9 100.0 % 0.81 [ 0.40, 1.64 ]
Total events: 46 (major), 4 (minor)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.11, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 80.1. Comparison 80 Bupropion - rs1028936 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 80 Bupropion - rs1028936 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 10/19 0/2 30.4 % 3.15 [ 0.24, 40.93 ]
Piper 2009 8/23 1/3 69.6 % 1.04 [ 0.19, 5.69 ]
Subtotal (95% CI) 42 5 100.0 % 1.46 [ 0.35, 6.01 ]
Total events: 18 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 81.1. Comparison 81 Bupropion - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 81 Bupropion - rs215605 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 10/27 2/11 18.6 % 2.04 [ 0.53, 7.83 ]
McCarthy 2008 12/19 1/8 10.3 % 5.05 [ 0.78, 32.63 ]
Piper 2009 39/79 10/26 71.1 % 1.28 [ 0.75, 2.19 ]
Subtotal (95% CI) 125 45 100.0 % 1.61 [ 0.87, 3.00 ]
Total events: 61 (major), 13 (minor)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.37, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Heterozygous vs Homozygous Minor
Piper 2007 15/37 2/11 21.5 % 2.23 [ 0.60, 8.29 ]
McCarthy 2008 17/32 1/8 11.8 % 4.25 [ 0.66, 27.36 ]
Piper 2009 38/85 10/26 66.7 % 1.16 [ 0.68, 2.00 ]
Subtotal (95% CI) 154 45 100.0 % 1.56 [ 0.79, 3.06 ]
Total events: 70 (major), 13 (minor)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.57, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 82.1. Comparison 82 Bupropion - rs215605 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 82 Bupropion - rs215605 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 7/13 3/8 53.8 % 1.44 [ 0.51, 4.01 ]
Piper 2009 6/18 3/8 46.2 % 0.89 [ 0.29, 2.69 ]
Subtotal (95% CI) 31 16 100.0 % 1.15 [ 0.54, 2.44 ]
Total events: 13 (major), 6 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.72)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
255Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 83.1. Comparison 83 Varenicline - rs16969968 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 83 Varenicline - rs16969968 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Swan 2010 79/183 24/56 67.0 % 1.01 [ 0.71, 1.42 ]
Lerman 2015 30/86 14/33 33.0 % 0.82 [ 0.50, 1.34 ]
Subtotal (95% CI) 269 89 100.0 % 0.94 [ 0.71, 1.25 ]
Total events: 109 (Major), 38 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
2 Heterozygous vs Homozygous Minor
Swan 2010 107/248 24/56 65.6 % 1.01 [ 0.72, 1.41 ]
Lerman 2015 41/101 14/33 34.4 % 0.96 [ 0.60, 1.52 ]
Subtotal (95% CI) 349 89 100.0 % 0.99 [ 0.75, 1.30 ]
Total events: 148 (Major), 38 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 83.2. Comparison 83 Varenicline - rs16969968 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 83 Varenicline - rs16969968 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Swan 2010 105/183 31/56 77.3 % 1.04 [ 0.79, 1.35 ]
Lerman 2015 30/86 14/33 22.7 % 0.82 [ 0.50, 1.34 ]
Subtotal (95% CI) 269 89 100.0 % 0.98 [ 0.78, 1.24 ]
Total events: 135 (Major), 45 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Heterozygous vs Homozygous Minor
Swan 2010 134/248 31/56 75.7 % 0.98 [ 0.75, 1.27 ]
Lerman 2015 41/101 14/33 24.3 % 0.96 [ 0.60, 1.52 ]
Subtotal (95% CI) 349 89 100.0 % 0.97 [ 0.77, 1.22 ]
Total events: 175 (Major), 45 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 84.1. Comparison 84 Varenicline - rs588765 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 84 Varenicline - rs588765 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Swan 2010 66/153 31/85 70.9 % 1.18 [ 0.85, 1.65 ]
Lerman 2015 35/81 12/35 29.1 % 1.26 [ 0.75, 2.12 ]
Subtotal (95% CI) 234 120 100.0 % 1.20 [ 0.91, 1.60 ]
Total events: 101 (Major), 43 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
2 Heterozygous vs Homozygous Minor
Swan 2010 108/241 31/85 73.8 % 1.23 [ 0.90, 1.68 ]
Lerman 2015 37/104 12/35 26.2 % 1.04 [ 0.61, 1.76 ]
Subtotal (95% CI) 345 120 100.0 % 1.18 [ 0.90, 1.54 ]
Total events: 145 (Major), 43 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 84.2. Comparison 84 Varenicline - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 84 Varenicline - rs588765 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Swan 2010 86/153 43/85 81.1 % 1.11 [ 0.86, 1.43 ]
Lerman 2015 35/81 12/35 18.9 % 1.26 [ 0.75, 2.12 ]
Subtotal (95% CI) 234 120 100.0 % 1.14 [ 0.91, 1.43 ]
Total events: 121 (Major), 55 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
2 Heterozygous vs Homozygous Minor
Swan 2010 136/241 43/85 83.1 % 1.12 [ 0.88, 1.41 ]
Lerman 2015 37/104 12/35 16.9 % 1.04 [ 0.61, 1.76 ]
Subtotal (95% CI) 345 120 100.0 % 1.10 [ 0.89, 1.37 ]
Total events: 173 (Major), 55 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 85.1. Comparison 85 Bupropion + any NRT - rs1051730 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 85 Bupropion + any NRT - rs1051730 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 23/34 2/5 19.7 % 1.69 [ 0.56, 5.07 ]
Piper 2009 35/79 9/20 80.3 % 0.98 [ 0.57, 1.70 ]
Subtotal (95% CI) 113 25 100.0 % 1.10 [ 0.67, 1.78 ]
Total events: 58 (major), 11 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
2 Heterozygous vs Homozygous Minor
Piper 2007 21/42 2/5 18.4 % 1.25 [ 0.41, 3.81 ]
Piper 2009 43/88 9/20 81.6 % 1.09 [ 0.64, 1.84 ]
Subtotal (95% CI) 130 25 100.0 % 1.11 [ 0.69, 1.80 ]
Total events: 64 (major), 11 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 86.1. Comparison 86 Bupropion + any NRT - rs1051730 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 86 Bupropion + any NRT - rs1051730 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 5/14 0/1 55.2 % 1.47 [ 0.12, 17.71 ]
Piper 2009 5/19 0/6 44.8 % 3.85 [ 0.24, 61.08 ]
Subtotal (95% CI) 33 7 100.0 % 2.26 [ 0.36, 14.38 ]
Total events: 10 (major), 0 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 87.1. Comparison 87 Bupropion + any NRT - rs16969968 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 87 Bupropion + any NRT - rs16969968 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 23/34 2/5 21.4 % 1.69 [ 0.56, 5.07 ]
Piper 2009 35/79 8/18 78.6 % 1.00 [ 0.56, 1.77 ]
Subtotal (95% CI) 113 23 100.0 % 1.12 [ 0.67, 1.85 ]
Total events: 58 (major), 10 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
2 Heterozygous vs Homozygous Minor
Piper 2007 21/42 2/5 20.1 % 1.25 [ 0.41, 3.81 ]
Piper 2009 43/88 8/18 79.9 % 1.10 [ 0.63, 1.92 ]
Subtotal (95% CI) 130 23 100.0 % 1.13 [ 0.68, 1.86 ]
Total events: 64 (major), 10 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 88.1. Comparison 88 Bupropion + any NRT - rs16969968 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 88 Bupropion + any NRT - rs16969968 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 5/14 0/1 53.9 % 1.47 [ 0.12, 17.71 ]
Piper 2009 5/22 0/3 46.1 % 1.91 [ 0.13, 28.28 ]
Subtotal (95% CI) 36 4 100.0 % 1.66 [ 0.27, 10.32 ]
Total events: 10 (major), 0 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 89.1. Comparison 89 Bupropion + any NRT - rs2036527 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 89 Bupropion + any NRT - rs2036527 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 23/33 3/6 32.1 % 1.39 [ 0.61, 3.20 ]
Piper 2009 35/78 8/18 67.9 % 1.01 [ 0.57, 1.79 ]
Subtotal (95% CI) 111 24 100.0 % 1.12 [ 0.70, 1.79 ]
Total events: 58 (major), 11 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Heterozygous vs Homozygous Minor
Piper 2007 19/41 3/6 29.4 % 0.93 [ 0.39, 2.20 ]
Piper 2009 44/91 8/18 70.6 % 1.09 [ 0.62, 1.90 ]
Subtotal (95% CI) 132 24 100.0 % 1.04 [ 0.65, 1.66 ]
Total events: 63 (major), 11 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 90.1. Comparison 90 Bupropion + any NRT - rs2036527 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 90 Bupropion + any NRT - rs2036527 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 3/10 0/2 37.8 % 1.91 [ 0.13, 27.68 ]
Piper 2009 2/13 2/3 62.2 % 0.23 [ 0.05, 1.04 ]
Subtotal (95% CI) 23 5 100.0 % 0.51 [ 0.06, 4.51 ]
Total events: 5 (major), 2 (minor)
Heterogeneity: Tau2 = 1.39; Chi2 = 2.13, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Heterozygous vs Homozygous Minor
Piper 2007 2/3 0/2 46.3 % 3.75 [ 0.27, 52.64 ]
Piper 2009 1/9 2/3 53.7 % 0.17 [ 0.02, 1.25 ]
Subtotal (95% CI) 12 5 100.0 % 0.70 [ 0.03, 15.98 ]
Total events: 3 (major), 2 (minor)
Heterogeneity: Tau2 = 3.67; Chi2 = 3.55, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 91.1. Comparison 91 Bupropion + any NRT - rs3733829 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 91 Bupropion + any NRT - rs3733829 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 24/37 6/10 40.7 % 1.08 [ 0.62, 1.89 ]
Piper 2009 36/77 11/20 59.3 % 0.85 [ 0.54, 1.35 ]
Subtotal (95% CI) 114 30 100.0 % 0.94 [ 0.66, 1.34 ]
Total events: 60 (major), 17 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Heterozygous vs Homozygous Minor
Piper 2007 15/33 6/10 34.7 % 0.76 [ 0.40, 1.42 ]
Piper 2009 40/90 11/20 65.3 % 0.81 [ 0.51, 1.28 ]
Subtotal (95% CI) 123 30 100.0 % 0.79 [ 0.55, 1.14 ]
Total events: 55 (major), 17 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
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Analysis 92.1. Comparison 92 Bupropion + any NRT - rs3733829 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 92 Bupropion + any NRT - rs3733829 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 3/11 2/4 55.5 % 0.55 [ 0.14, 2.16 ]
Piper 2009 2/19 3/6 44.5 % 0.21 [ 0.05, 0.98 ]
Subtotal (95% CI) 30 10 100.0 % 0.36 [ 0.13, 0.99 ]
Total events: 5 (major), 5 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
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Analysis 93.1. Comparison 93 Bupropion + any NRT - rs7937 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 93 Bupropion + any NRT - rs7937 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 11/21 14/18 48.5 % 0.67 [ 0.42, 1.08 ]
Piper 2009 23/53 17/36 51.5 % 0.92 [ 0.58, 1.46 ]
Subtotal (95% CI) 74 54 100.0 % 0.79 [ 0.57, 1.10 ]
Total events: 34 (major), 31 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Heterozygous vs Homozygous Minor
Piper 2007 21/42 14/18 50.5 % 0.64 [ 0.44, 0.95 ]
Piper 2009 47/98 17/36 49.5 % 1.02 [ 0.68, 1.52 ]
Subtotal (95% CI) 140 54 100.0 % 0.81 [ 0.51, 1.28 ]
Total events: 68 (major), 31 (minor)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.73, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 94.1. Comparison 94 Bupropion + any NRT - rs7937 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 94 Bupropion + any NRT - rs7937 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 4/8 1/7 58.3 % 3.50 [ 0.50, 24.41 ]
Piper 2009 0/5 5/20 41.7 % 0.32 [ 0.02, 4.97 ]
Subtotal (95% CI) 13 27 100.0 % 1.29 [ 0.12, 13.56 ]
Total events: 4 (major), 6 (minor)
Heterogeneity: Tau2 = 1.49; Chi2 = 2.01, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 95.1. Comparison 95 Bupropion + any NRT - rs1329650 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 95 Bupropion + any NRT - rs1329650 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 16/32 5/6 59.3 % 0.60 [ 0.36, 0.99 ]
Piper 2009 38/117 7/15 40.7 % 0.70 [ 0.38, 1.27 ]
Subtotal (95% CI) 149 21 100.0 % 0.64 [ 0.43, 0.94 ]
Total events: 54 (major), 12 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.021)
2 Heterozygous vs Homozygous Minor
Piper 2007 25/42 5/6 69.6 % 0.71 [ 0.46, 1.10 ]
Piper 2009 18/54 7/15 30.4 % 0.71 [ 0.37, 1.38 ]
Subtotal (95% CI) 96 21 100.0 % 0.71 [ 0.50, 1.03 ]
Total events: 43 (major), 12 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 96.1. Comparison 96 Bupropion + any NRT - rs1329650 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 96 Bupropion + any NRT - rs1329650 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 5/14 0/1 26.5 % 1.47 [ 0.12, 17.71 ]
Piper 2009 3/20 2/5 73.5 % 0.38 [ 0.08, 1.68 ]
Subtotal (95% CI) 34 6 100.0 % 0.54 [ 0.15, 1.94 ]
Total events: 8 (major), 2 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 97.1. Comparison 97 Bupropion + any NRT - rs1028936 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 97 Bupropion + any NRT - rs1028936 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 22/45 2/3 39.1 % 0.73 [ 0.31, 1.72 ]
Piper 2009 45/138 4/7 60.9 % 0.57 [ 0.29, 1.13 ]
Subtotal (95% CI) 183 10 100.0 % 0.63 [ 0.37, 1.07 ]
Total events: 67 (major), 6 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
2 Heterozygous vs Homozygous Minor
Piper 2007 22/33 2/3 46.0 % 1.00 [ 0.43, 2.31 ]
Piper 2009 14/42 4/7 54.0 % 0.58 [ 0.27, 1.26 ]
Subtotal (95% CI) 75 10 100.0 % 0.75 [ 0.42, 1.32 ]
Total events: 36 (major), 6 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.67), I2 =0.0%
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Analysis 98.1. Comparison 98 Bupropion + any NRT - rs1028936 - non-Hispanic black or African American,
Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 98 Bupropion + any NRT - rs1028936 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 5/14 0/1 26.5 % 1.47 [ 0.12, 17.71 ]
Piper 2009 3/20 2/5 73.5 % 0.38 [ 0.08, 1.68 ]
Subtotal (95% CI) 34 6 100.0 % 0.54 [ 0.15, 1.94 ]
Total events: 8 (major), 2 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 99.1. Comparison 99 Bupropion + any NRT - rs215605 - non-Hispanic white, Outcome 1 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 99 Bupropion + any NRT - rs215605 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 21/34 8/14 42.6 % 1.08 [ 0.64, 1.83 ]
Piper 2009 40/71 13/29 57.4 % 1.26 [ 0.80, 1.98 ]
Subtotal (95% CI) 105 43 100.0 % 1.18 [ 0.84, 1.66 ]
Total events: 61 (major), 21 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Heterozygous vs Homozygous Minor
Piper 2007 17/33 8/14 42.7 % 0.90 [ 0.51, 1.58 ]
Piper 2009 33/86 13/29 57.3 % 0.86 [ 0.53, 1.39 ]
Subtotal (95% CI) 119 43 100.0 % 0.88 [ 0.61, 1.26 ]
Total events: 50 (major), 21 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 1.35, df = 1 (P = 0.25), I2 =26%
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Analysis 100.1. Comparison 100 Bupropion + any NRT - rs215605 - non-Hispanic black or African
American, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 100 Bupropion + any NRT - rs215605 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 4/9 1/6 56.0 % 2.67 [ 0.39, 18.42 ]
Piper 2009 0/9 5/16 44.0 % 0.15 [ 0.01, 2.51 ]
Subtotal (95% CI) 18 22 100.0 % 0.76 [ 0.04, 13.56 ]
Total events: 4 (major), 6 (minor)
Heterogeneity: Tau2 = 2.88; Chi2 = 2.92, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 101.1. Comparison 101 Placebo - rs1051730 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 101 Placebo - rs1051730 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
GPRG 1993 21/145 7/59 25.0 % 1.22 [ 0.55, 2.72 ]
Lerman 2002 15/67 4/35 15.2 % 1.96 [ 0.70, 5.46 ]
Winst 2006 11/36 2/12 8.7 % 1.83 [ 0.47, 7.13 ]
Brown 2007 13/54 4/29 15.2 % 1.75 [ 0.63, 4.87 ]
Hall 2008 9/22 5/9 26.9 % 0.74 [ 0.34, 1.59 ]
Piper 2009 15/53 2/12 9.0 % 1.70 [ 0.45, 6.46 ]
Subtotal (95% CI) 377 156 100.0 % 1.29 [ 0.86, 1.92 ]
Total events: 84 (major), 24 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.65, df = 5 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Heterozygous vs Homozygous Minor
GPRG 1993 15/143 7/59 22.7 % 0.88 [ 0.38, 2.06 ]
Lerman 2002 15/90 4/35 15.2 % 1.46 [ 0.52, 4.09 ]
Winst 2006 13/47 2/12 8.9 % 1.66 [ 0.43, 6.38 ]
Brown 2007 13/71 4/29 15.1 % 1.33 [ 0.47, 3.73 ]
Hall 2008 10/23 5/9 29.0 % 0.78 [ 0.37, 1.65 ]
Piper 2009 16/67 2/12 9.1 % 1.43 [ 0.38, 5.45 ]
Subtotal (95% CI) 441 156 100.0 % 1.08 [ 0.72, 1.62 ]
Total events: 82 (major), 24 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.06, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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Analysis 101.2. Comparison 101 Placebo - rs1051730 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 101 Placebo - rs1051730 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
GPRG 1993 27/145 9/59 24.5 % 1.22 [ 0.61, 2.44 ]
Lerman 2002 16/67 4/35 14.0 % 2.09 [ 0.76, 5.77 ]
Piper 2007 2/17 1/8 3.4 % 0.94 [ 0.10, 8.92 ]
Brown 2007 13/54 10/29 24.6 % 0.70 [ 0.35, 1.39 ]
Hall 2008 15/22 4/10 19.7 % 1.70 [ 0.76, 3.84 ]
McCarthy 2008 8/20 1/11 4.5 % 4.40 [ 0.63, 30.75 ]
Piper 2009 25/53 2/12 9.3 % 2.83 [ 0.77, 10.35 ]
Subtotal (95% CI) 378 164 100.0 % 1.39 [ 0.91, 2.13 ]
Total events: 106 (major), 31 (minor)
Heterogeneity: Tau2 = 0.07; Chi2 = 7.59, df = 6 (P = 0.27); I2 =21%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Heterozygous vs Homozygous Minor
GPRG 1993 16/143 9/59 21.4 % 0.73 [ 0.34, 1.57 ]
Lerman 2002 21/90 4/35 14.3 % 2.04 [ 0.75, 5.52 ]
Piper 2007 6/19 1/8 4.4 % 2.53 [ 0.36, 17.74 ]
Brown 2007 19/71 10/29 27.0 % 0.78 [ 0.41, 1.46 ]
Hall 2008 16/23 4/10 19.6 % 1.74 [ 0.78, 3.89 ]
McCarthy 2008 10/28 1/11 4.5 % 3.93 [ 0.57, 27.17 ]
Piper 2009 17/67 2/12 8.8 % 1.52 [ 0.40, 5.76 ]
Subtotal (95% CI) 441 164 100.0 % 1.24 [ 0.81, 1.89 ]
Total events: 105 (major), 31 (minor)
Heterogeneity: Tau2 = 0.07; Chi2 = 7.63, df = 6 (P = 0.27); I2 =21%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 102.1. Comparison 102 Placebo - rs1051730 - non-Hispanic black or African American, Outcome 1
Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 102 Placebo - rs1051730 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 6/34 1/12 48.8 % 2.12 [ 0.28, 15.84 ]
Piper 2009 2/15 1/2 51.2 % 0.27 [ 0.04, 1.77 ]
Subtotal (95% CI) 49 14 100.0 % 0.73 [ 0.08, 6.73 ]
Total events: 8 (major), 2 (minor)
Heterogeneity: Tau2 = 1.57; Chi2 = 2.58, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 102.2. Comparison 102 Placebo - rs1051730 - non-Hispanic black or African American, Outcome 2
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 102 Placebo - rs1051730 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 8/34 3/12 40.8 % 0.94 [ 0.30, 2.98 ]
Piper 2007 3/10 2/2 45.2 % 0.38 [ 0.14, 1.04 ]
Piper 2009 5/19 0/6 14.1 % 3.85 [ 0.24, 61.08 ]
Subtotal (95% CI) 63 20 100.0 % 0.76 [ 0.24, 2.45 ]
Total events: 16 (major), 5 (minor)
Heterogeneity: Tau2 = 0.52; Chi2 = 4.08, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 103.1. Comparison 103 Placebo - rs16969968 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 103 Placebo - rs16969968 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Piper 2009 15/53 2/12 28.4 % 1.70 [ 0.45, 6.46 ]
Lerman 2015 19/79 5/18 71.6 % 0.87 [ 0.37, 2.01 ]
Subtotal (95% CI) 132 30 100.0 % 1.05 [ 0.51, 2.14 ]
Total events: 34 (Major), 7 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Heterozygous vs Homozygous Minor
Piper 2009 16/66 2/12 35.5 % 1.45 [ 0.38, 5.53 ]
Lerman 2015 18/115 5/18 64.5 % 0.56 [ 0.24, 1.33 ]
Subtotal (95% CI) 181 30 100.0 % 0.79 [ 0.32, 1.96 ]
Total events: 34 (Major), 7 (Minor)
Heterogeneity: Tau2 = 0.14; Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 103.2. Comparison 103 Placebo - rs16969968 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 103 Placebo - rs16969968 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 2/17 1/8 11.7 % 0.94 [ 0.10, 8.92 ]
McCarthy 2008 8/20 1/11 14.9 % 4.40 [ 0.63, 30.75 ]
Piper 2009 25/53 2/12 27.7 % 2.83 [ 0.77, 10.35 ]
Lerman 2015 19/79 5/18 45.8 % 0.87 [ 0.37, 2.01 ]
Subtotal (95% CI) 169 49 100.0 % 1.55 [ 0.68, 3.53 ]
Total events: 54 (Major), 9 (Minor)
Heterogeneity: Tau2 = 0.20; Chi2 = 4.14, df = 3 (P = 0.25); I2 =28%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Heterozygous vs Homozygous Minor
Piper 2007 6/19 1/8 17.0 % 2.53 [ 0.36, 17.74 ]
McCarthy 2008 10/27 1/11 17.2 % 4.07 [ 0.59, 28.14 ]
Piper 2009 17/66 2/12 27.1 % 1.55 [ 0.41, 5.84 ]
Lerman 2015 18/115 5/18 38.7 % 0.56 [ 0.24, 1.33 ]
Subtotal (95% CI) 227 49 100.0 % 1.34 [ 0.51, 3.53 ]
Total events: 51 (Major), 9 (Minor)
Heterogeneity: Tau2 = 0.44; Chi2 = 5.54, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 104.1. Comparison 104 Placebo - rs16969968 - non-Hispanic black or African American, Outcome
1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 104 Placebo - rs16969968 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 46/268 9/32 77.9 % 0.61 [ 0.33, 1.13 ]
Piper 2009 3/16 0/1 5.1 % 0.82 [ 0.06, 10.82 ]
Cox 2012 26/235 2/32 17.0 % 1.77 [ 0.44, 7.11 ]
Subtotal (95% CI) 519 65 100.0 % 0.74 [ 0.42, 1.33 ]
Total events: 75 (Major), 11 (Minor)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 104.2. Comparison 104 Placebo - rs16969968 - non-Hispanic black or African American, Outcome
2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 104 Placebo - rs16969968 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 48/268 12/32 70.2 % 0.48 [ 0.29, 0.80 ]
Piper 2007 4/11 1/1 16.8 % 0.50 [ 0.17, 1.48 ]
Piper 2009 2/16 0/1 2.8 % 0.59 [ 0.04, 8.41 ]
Cox 2012 24/235 2/32 10.2 % 1.63 [ 0.41, 6.59 ]
Subtotal (95% CI) 530 66 100.0 % 0.55 [ 0.35, 0.86 ]
Total events: 78 (Major), 15 (Minor)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 2.63 (P = 0.0086)
Test for subgroup differences: Not applicable
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Analysis 105.1. Comparison 105 Placebo - rs588765 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 105 Placebo - rs588765 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2002 11/66 4/27 15.4 % 1.13 [ 0.39, 3.22 ]
Brown 2007 9/59 5/29 17.1 % 0.88 [ 0.33, 2.40 ]
Hall 2008 11/22 4/12 20.9 % 1.50 [ 0.61, 3.70 ]
Piper 2009 9/42 3/20 12.0 % 1.43 [ 0.43, 4.71 ]
Lerman 2015 13/64 11/42 34.6 % 0.78 [ 0.38, 1.57 ]
Subtotal (95% CI) 253 130 100.0 % 1.04 [ 0.69, 1.57 ]
Total events: 53 (major), 27 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.70, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
2 Heterozygous vs Homozygous Minor
Lerman 2002 17/89 4/27 15.5 % 1.29 [ 0.47, 3.51 ]
Brown 2007 14/64 5/29 18.3 % 1.27 [ 0.50, 3.19 ]
Hall 2008 9/19 4/12 18.0 % 1.42 [ 0.56, 3.60 ]
Piper 2009 17/62 3/20 12.4 % 1.83 [ 0.60, 5.60 ]
Lerman 2015 18/106 11/42 35.8 % 0.65 [ 0.34, 1.25 ]
Subtotal (95% CI) 340 130 100.0 % 1.07 [ 0.72, 1.58 ]
Total events: 75 (major), 27 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.74, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 105.2. Comparison 105 Placebo - rs588765 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 105 Placebo - rs588765 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Lerman 2002 14/66 4/27 10.3 % 1.43 [ 0.52, 3.96 ]
Brown 2007 16/59 7/29 18.0 % 1.12 [ 0.52, 2.42 ]
Hall 2008 12/23 8/12 34.0 % 0.78 [ 0.45, 1.37 ]
Piper 2009 14/42 7/20 19.7 % 0.95 [ 0.46, 1.99 ]
Lerman 2015 13/64 7/20 18.0 % 0.58 [ 0.27, 1.25 ]
Subtotal (95% CI) 254 108 100.0 % 0.88 [ 0.63, 1.21 ]
Total events: 69 (major), 33 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.70, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
2 Heterozygous vs Homozygous Minor
Lerman 2002 22/89 4/27 9.4 % 1.67 [ 0.63, 4.42 ]
Brown 2007 18/64 7/29 15.6 % 1.17 [ 0.55, 2.48 ]
Hall 2008 14/19 8/12 38.4 % 1.11 [ 0.68, 1.79 ]
Piper 2009 20/62 7/20 18.3 % 0.92 [ 0.46, 1.85 ]
Lerman 2015 20/62 7/20 18.3 % 0.92 [ 0.46, 1.85 ]
Subtotal (95% CI) 296 108 100.0 % 1.08 [ 0.80, 1.46 ]
Total events: 94 (major), 33 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi2 = 0.89, df = 1 (P = 0.34), I2 =0.0%
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Analysis 106.1. Comparison 106 Placebo - rs588765 - non-Hispanic black or African American, Outcome 1
Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 106 Placebo - rs588765 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 31/153 23/146 67.3 % 1.29 [ 0.79, 2.10 ]
Cox 2012 13/122 15/145 32.7 % 1.03 [ 0.51, 2.08 ]
Subtotal (95% CI) 275 291 100.0 % 1.20 [ 0.80, 1.79 ]
Total events: 44 (Major), 38 (Minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 106.2. Comparison 106 Placebo - rs588765 - non-Hispanic black or African American, Outcome 2
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 106 Placebo - rs588765 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Ahluwalia 2006 31/153 31/146 68.2 % 0.95 [ 0.61, 1.49 ]
Cox 2012 15/124 11/143 31.8 % 1.57 [ 0.75, 3.30 ]
Subtotal (95% CI) 277 289 100.0 % 1.12 [ 0.71, 1.77 ]
Total events: 46 (Major), 42 (Minor)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 107.1. Comparison 107 Placebo - rs2036527 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 107 Placebo - rs2036527 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Lerman 2002 14/64 3/33 55.8 % 2.41 [ 0.74, 7.78 ]
Piper 2009 14/53 2/10 44.2 % 1.32 [ 0.35, 4.94 ]
Subtotal (95% CI) 117 43 100.0 % 1.85 [ 0.77, 4.44 ]
Total events: 28 (major), 5 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Heterozygous vs Homozygous Minor
Lerman 2002 17/97 3/33 55.8 % 1.93 [ 0.60, 6.16 ]
Piper 2009 17/69 2/10 44.2 % 1.23 [ 0.33, 4.55 ]
Subtotal (95% CI) 166 43 100.0 % 1.58 [ 0.66, 3.77 ]
Total events: 34 (major), 5 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 107.2. Comparison 107 Placebo - rs2036527 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 107 Placebo - rs2036527 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Lerman 2002 15/64 3/33 36.1 % 2.58 [ 0.80, 8.28 ]
Piper 2007 2/17 2/8 17.7 % 0.47 [ 0.08, 2.76 ]
McCarthy 2008 8/20 1/11 14.9 % 4.40 [ 0.63, 30.75 ]
Piper 2009 24/53 2/10 31.3 % 2.26 [ 0.63, 8.10 ]
Subtotal (95% CI) 154 62 100.0 % 1.98 [ 0.91, 4.35 ]
Total events: 49 (major), 8 (minor)
Heterogeneity: Tau2 = 0.09; Chi2 = 3.47, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 1.71 (P = 0.087)
2 Heterozygous vs Homozygous Minor
Lerman 2002 24/97 3/33 36.5 % 2.72 [ 0.88, 8.45 ]
Piper 2007 5/19 2/8 23.3 % 1.05 [ 0.26, 4.34 ]
McCarthy 2008 10/28 1/11 12.5 % 3.93 [ 0.57, 27.17 ]
Piper 2009 18/69 2/10 27.7 % 1.30 [ 0.35, 4.79 ]
Subtotal (95% CI) 213 62 100.0 % 1.86 [ 0.94, 3.69 ]
Total events: 57 (major), 8 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.90), I2 =0.0%
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Analysis 108.1. Comparison 108 Placebo - rs2036527 - non-Hispanic black or African American, Outcome 1
Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 108 Placebo - rs2036527 - non-Hispanic black or African American
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 4/24 3/22 10.3 % 1.22 [ 0.31, 4.86 ]
Ahluwalia 2006 33/183 20/117 56.7 % 1.05 [ 0.64, 1.75 ]
Piper 2009 0/10 3/7 2.6 % 0.10 [ 0.01, 1.74 ]
Cox 2012 19/156 9/110 30.5 % 1.49 [ 0.70, 3.17 ]
Subtotal (95% CI) 373 256 100.0 % 1.12 [ 0.71, 1.77 ]
Total events: 56 (Major), 35 (Minor)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.37, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 108.2. Comparison 108 Placebo - rs2036527 - non-Hispanic black or African American, Outcome 2
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 108 Placebo - rs2036527 - non-Hispanic black or African American
Outcome: 2 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Lerman 2002 6/24 5/22 14.7 % 1.10 [ 0.39, 3.10 ]
Ahluwalia 2006 38/183 23/117 54.6 % 1.06 [ 0.66, 1.68 ]
Piper 2007 1/5 4/7 4.8 % 0.35 [ 0.05, 2.26 ]
Piper 2009 0/10 2/7 2.0 % 0.15 [ 0.01, 2.63 ]
Cox 2012 19/156 8/110 23.8 % 1.67 [ 0.76, 3.69 ]
Subtotal (95% CI) 378 263 100.0 % 1.08 [ 0.71, 1.64 ]
Total events: 64 (Major), 42 (Minor)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.44, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 109.1. Comparison 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 1 Six-
Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
GPRG 1993 33/238 3/15 69.9 % 0.69 [ 0.24, 2.00 ]
Brown 2007 20/83 0/8 14.7 % 4.39 [ 0.29, 66.68 ]
Gilbert 2009 10/40 0/3 15.4 % 2.05 [ 0.15, 28.85 ]
Subtotal (95% CI) 361 26 100.0 % 1.07 [ 0.37, 3.16 ]
Total events: 63 (major), 3 (minor)
Heterogeneity: Tau2 = 0.14; Chi2 = 2.25, df = 2 (P = 0.33); I2 =11%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Heterozygous vs Homozygous Minor
GPRG 1993 12/118 3/15 76.1 % 0.51 [ 0.16, 1.60 ]
Brown 2007 1/35 0/8 10.3 % 0.75 [ 0.03, 16.92 ]
Gilbert 2009 5/33 0/3 13.7 % 1.29 [ 0.09, 19.32 ]
Subtotal (95% CI) 186 26 100.0 % 0.60 [ 0.22, 1.63 ]
Total events: 18 (major), 3 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
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Analysis 109.2. Comparison 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 109 Placebo - DRD-4 (exon 3 48 bp) - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
GPRG 1993 41/238 3/15 30.6 % 0.86 [ 0.30, 2.46 ]
Brown 2007 27/83 0/8 7.0 % 5.89 [ 0.39, 88.66 ]
Gilbert 2009 35/40 3/3 62.4 % 0.99 [ 0.67, 1.46 ]
Subtotal (95% CI) 361 26 100.0 % 1.08 [ 0.51, 2.29 ]
Total events: 103 (major), 6 (minor)
Heterogeneity: Tau2 = 0.20; Chi2 = 3.40, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Heterozygous vs Homozygous Minor
GPRG 1993 12/118 3/15 10.9 % 0.51 [ 0.16, 1.60 ]
Brown 2007 5/35 0/8 1.8 % 2.75 [ 0.17, 45.29 ]
Gilbert 2009 27/33 3/3 87.3 % 0.92 [ 0.62, 1.39 ]
Subtotal (95% CI) 186 26 100.0 % 0.88 [ 0.61, 1.29 ]
Total events: 44 (major), 6 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 110.1. Comparison 110 Placebo - rs3733829 - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 110 Placebo - rs3733829 - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major vs Homozygous Minor
Brown 2007 11/66 5/22 39.8 % 0.73 [ 0.29, 1.88 ]
Piper 2009 17/56 6/18 60.2 % 0.91 [ 0.42, 1.96 ]
Subtotal (95% CI) 122 40 100.0 % 0.84 [ 0.46, 1.51 ]
Total events: 28 (major), 11 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
2 Heterozygous vs Homozygous Minor
Brown 2007 9/45 5/22 44.3 % 0.88 [ 0.33, 2.31 ]
Piper 2009 10/57 6/18 55.7 % 0.53 [ 0.22, 1.25 ]
Subtotal (95% CI) 102 40 100.0 % 0.66 [ 0.35, 1.26 ]
Total events: 19 (major), 11 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
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Analysis 110.2. Comparison 110 Placebo - rs3733829 - non-Hispanic white, Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 110 Placebo - rs3733829 - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major vs Homozygous Minor
Brown 2007 17/66 4/22 26.8 % 1.42 [ 0.53, 3.76 ]
Piper 2007 5/17 1/6 6.8 % 1.76 [ 0.25, 12.22 ]
McCarthy 2008 10/25 2/5 18.5 % 1.00 [ 0.31, 3.24 ]
Piper 2009 22/56 6/18 47.9 % 1.18 [ 0.57, 2.45 ]
Subtotal (95% CI) 164 51 100.0 % 1.23 [ 0.74, 2.05 ]
Total events: 54 (major), 13 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Heterozygous vs Homozygous Minor
Brown 2007 14/45 4/22 28.8 % 1.71 [ 0.64, 4.59 ]
Piper 2007 3/21 1/6 6.5 % 0.86 [ 0.11, 6.82 ]
McCarthy 2008 7/29 2/5 17.9 % 0.60 [ 0.17, 2.11 ]
Piper 2009 16/57 6/18 46.8 % 0.84 [ 0.39, 1.83 ]
Subtotal (95% CI) 152 51 100.0 % 0.97 [ 0.57, 1.65 ]
Total events: 40 (major), 13 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
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Analysis 111.1. Comparison 111 Placebo - rs7937 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 111 Placebo - rs7937 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 2/15 1/8 6.8 % 1.07 [ 0.11, 10.04 ]
McCarthy 2008 5/16 5/12 34.9 % 0.75 [ 0.28, 2.01 ]
Piper 2009 12/42 7/20 58.3 % 0.82 [ 0.38, 1.75 ]
Subtotal (95% CI) 73 40 100.0 % 0.81 [ 0.45, 1.45 ]
Total events: 19 (major), 13 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Heterozygous vs Homozygous Minor
Piper 2007 6/20 1/8 6.9 % 2.40 [ 0.34, 16.90 ]
McCarthy 2008 9/31 5/12 35.1 % 0.70 [ 0.29, 1.66 ]
Piper 2009 25/69 7/20 58.0 % 1.04 [ 0.53, 2.03 ]
Subtotal (95% CI) 120 40 100.0 % 0.95 [ 0.57, 1.60 ]
Total events: 40 (major), 13 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 112.1. Comparison 112 Placebo - rs7937 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 112 Placebo - rs7937 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 4/9 1/3 68.6 % 1.33 [ 0.23, 7.74 ]
Piper 2009 1/9 1/8 31.4 % 0.89 [ 0.07, 12.00 ]
Subtotal (95% CI) 18 11 100.0 % 1.17 [ 0.27, 5.04 ]
Total events: 5 (major), 2 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 113.1. Comparison 113 Placebo - rs1329650 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 113 Placebo - rs1329650 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 5/22 0/4 20.8 % 2.39 [ 0.16, 36.62 ]
McCarthy 2008 12/28 0/1 24.1 % 1.72 [ 0.15, 19.71 ]
Piper 2009 16/69 3/5 55.1 % 0.39 [ 0.17, 0.89 ]
Subtotal (95% CI) 119 10 100.0 % 0.81 [ 0.18, 3.62 ]
Total events: 33 (major), 3 (minor)
Heterogeneity: Tau2 = 0.88; Chi2 = 3.78, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Heterozygous vs Homozygous Minor
Piper 2007 4/18 0/4 6.7 % 2.37 [ 0.15, 37.07 ]
McCarthy 2008 7/30 0/1 8.3 % 0.97 [ 0.08, 11.56 ]
Piper 2009 25/58 3/5 85.0 % 0.72 [ 0.33, 1.56 ]
Subtotal (95% CI) 106 10 100.0 % 0.80 [ 0.39, 1.63 ]
Total events: 36 (major), 3 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 114.1. Comparison 114 Placebo - rs1329650 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 114 Placebo - rs1329650 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 4/10 1/2 72.8 % 0.80 [ 0.16, 3.88 ]
Piper 2009 1/11 1/6 27.2 % 0.55 [ 0.04, 7.25 ]
Subtotal (95% CI) 21 8 100.0 % 0.72 [ 0.19, 2.78 ]
Total events: 5 (major), 2 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 115.1. Comparison 115 Placebo - rs1028936 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 115 Placebo - rs1028936 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 6/31 0/1 22.8 % 0.81 [ 0.07, 9.86 ]
McCarthy 2008 15/36 0/1 24.1 % 1.68 [ 0.15, 19.04 ]
Piper 2009 24/91 1/3 53.1 % 0.79 [ 0.15, 4.07 ]
Subtotal (95% CI) 158 5 100.0 % 0.95 [ 0.29, 3.14 ]
Total events: 45 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
2 Heterozygous vs Homozygous Minor
Piper 2007 3/12 0/1 22.3 % 1.08 [ 0.08, 13.96 ]
McCarthy 2008 4/22 0/1 22.7 % 0.78 [ 0.06, 9.92 ]
Piper 2009 19/38 1/3 55.0 % 1.50 [ 0.29, 7.67 ]
Subtotal (95% CI) 72 5 100.0 % 1.20 [ 0.36, 4.03 ]
Total events: 26 (major), 1 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 116.1. Comparison 116 Placebo - rs1028936 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 116 Placebo - rs1028936 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 4/11 1/1 84.9 % 0.50 [ 0.17, 1.48 ]
Piper 2009 1/12 1/5 15.1 % 0.42 [ 0.03, 5.43 ]
Subtotal (95% CI) 23 6 100.0 % 0.49 [ 0.18, 1.32 ]
Total events: 5 (major), 2 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 117.1. Comparison 117 Placebo - rs215605 - non-Hispanic white, Outcome 1 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 117 Placebo - rs215605 - non-Hispanic white
Outcome: 1 End of Treatment








1 Homozygous Major vs Homozygous Minor
Piper 2007 4/14 1/10 9.5 % 2.86 [ 0.37, 21.87 ]
McCarthy 2008 8/28 3/7 36.8 % 0.67 [ 0.24, 1.88 ]
Piper 2009 15/52 5/18 53.7 % 1.04 [ 0.44, 2.45 ]
Subtotal (95% CI) 94 35 100.0 % 0.97 [ 0.52, 1.82 ]
Total events: 27 (major), 9 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.69, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Heterozygous vs Homozygous Minor
Piper 2007 4/20 1/10 8.7 % 2.00 [ 0.26, 15.62 ]
McCarthy 2008 8/24 3/7 35.1 % 0.78 [ 0.28, 2.17 ]
Piper 2009 23/61 5/18 56.1 % 1.36 [ 0.60, 3.06 ]
Subtotal (95% CI) 105 35 100.0 % 1.15 [ 0.63, 2.12 ]
Total events: 35 (major), 9 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 118.1. Comparison 118 Placebo - rs215605 - non-Hispanic black or African American, Outcome 1
End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 118 Placebo - rs215605 - non-Hispanic black or African American
Outcome: 1 End of Treatment








1 Homozygous Major vs Heterozygous or Homozygous Minor
Piper 2007 5/8 0/4 51.1 % 6.11 [ 0.42, 89.20 ]
Piper 2009 0/10 2/7 48.9 % 0.15 [ 0.01, 2.63 ]
Subtotal (95% CI) 18 11 100.0 % 0.98 [ 0.03, 38.58 ]
Total events: 5 (major), 2 (minor)
Heterogeneity: Tau2 = 4.99; Chi2 = 3.46, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 119.1. Comparison 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white, Outcome 1 Six-Month
Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white
Outcome: 1 Six-Month Abstinence








1 Homozygous Major or Heterozygous vs Homozygous Minor
Wagena 2005 10/64 3/11 59.7 % 0.57 [ 0.19, 1.76 ]
Gilbert 2009 12/64 2/12 40.3 % 1.13 [ 0.29, 4.40 ]
Subtotal (95% CI) 128 23 100.0 % 0.75 [ 0.32, 1.79 ]
Total events: 22 (major), 5 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 119.2. Comparison 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white, Outcome 2 End of
Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 119 Placebo - SLC6A4 (Promoter) - non-Hispanic white
Outcome: 2 End of Treatment








1 Homozygous Major or Heterozygous vs Homozygous Minor
Wagena 2005 14/64 3/11 5.8 % 0.80 [ 0.28, 2.34 ]
Gilbert 2009 58/64 10/12 94.2 % 1.09 [ 0.83, 1.42 ]
Subtotal (95% CI) 128 23 100.0 % 1.07 [ 0.83, 1.38 ]
Total events: 72 (major), 13 (minor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Homozygous Minor Favours Major alleles
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Analysis 120.1. Comparison 120 Placebo - NMR - non-Hispanic white or black or African American,
Outcome 1 Six-Month Abstinence.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 120 Placebo - NMR - non-Hispanic white or black or African American
Outcome: 1 Six-Month Abstinence








1 Normal NMR vs Slow NMR
GPRG 1993 15/196 8/95 20.6 % 0.91 [ 0.40, 2.07 ]
Lerman 2015 35/193 37/215 79.4 % 1.05 [ 0.69, 1.60 ]
Subtotal (95% CI) 389 310 100.0 % 1.02 [ 0.70, 1.48 ]
Total events: 50 (Normal), 45 (Slow)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Slow Favours Normal
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Analysis 120.2. Comparison 120 Placebo - NMR - non-Hispanic white or black or African American,
Outcome 2 End of Treatment.
Review: Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
Comparison: 120 Placebo - NMR - non-Hispanic white or black or African American
Outcome: 2 End of Treatment








1 Normal NMR vs Slow NMR
GPRG 1993 16/209 16/91 39.6 % 0.44 [ 0.23, 0.83 ]
Lerman 2015 42/191 62/227 60.4 % 0.81 [ 0.57, 1.13 ]
Subtotal (95% CI) 400 318 100.0 % 0.63 [ 0.35, 1.14 ]
Total events: 58 (Normal), 78 (Slow)
Heterogeneity: Tau2 = 0.12; Chi2 = 2.71, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Slow Favours Normal
A D D I T I O N A L T A B L E S
Table 1. Glossary of genetic terms
Genetic term Explanation
Single-nucleotide polymorphism (SNP) A single base pair change in the DNA sequence at a particular point compared with the
“common” or “wild-type” sequence (Attia 2009)
Most common formof genetic variation in the genome, inwhich a single-base substitution
has created 2 forms of a DNA sequence that differ by a single nucleotide (Pearson 2008)
Alleles Alternate forms of a gene or chromosomal locus that differ in DNA sequence (Pearson
2008)
Genome-wide association study (GWAS) Any study of genetic variation across the entire human genome designed to identify
genetic association with observable traits or the presence or absence of a disease, usually
referring to studies with genetic marker density of 100,000 or more to represent a large
proportion of variation in the human genome (Pearson 2008)
Genotype The genetic constitution of an individual, either overall or at a specific gene (Attia 2009)
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Table 1. Glossary of genetic terms (Continued)
Hardy-Weinberg equilibrium (HWE) Population distribution of 2 alleles (with frequencies p and q) such that the distribution
is stable from generation to generation and genotypes occur at frequencies of p2, 2pq,
and q2 for the major allele homozygote, heterozygote, and minor allele homozygote,
respectively (Pearson 2008)
Linkage disequilibrium Measure of association between 2 alleles located near each other on a chromosome,
such that they are inherited together more frequently than would be expected by chance
(Pearson 2008)
Loci The site(s) on a chromosome at which the gene for a particular trait is located on a gene
at which a particular SNP is located (Attia 2009)
Minor allele The allele of a biallelic polymorphism that is less frequent in the study population (Pearson
2008)
Major allele The allele of a biallelic polymorphism that is more frequent in the study population
(Pearson 2008)
Pharmacogenetics The field of studying the genetic basis of drug response and applying this knowledge to
clinical practice by guiding drug prescribing
Pharmacogenomics Similar to pharmacogenetics but uses information across the whole genome
Population stratification A form of confounding in genetic association studies caused by genetic differences be-
tween cases and controls unrelated to disease but due to sampling from populations of
different ancestries (Pearson 2008)
Wild-type allele The allele at a particular single-nucleotide polymorphism (SNP) that is most frequent in
a population, also called “common” allele (Attia 2009)
DNA = deoxyribonucleic acid; SNP = Single-nucleotide polymorphism; GWAS = Genome-wide association study; HWE = Hardy-
Weinberg equilibrium
Table 2. Polymorphisms of interest, together with their major/minor alleles, stratified by race
Polymorphism Race group
Gene/Region SNP or VNTRa Whiteb Black or African
Americanc
East Asiand Mexicane
CHRNA3 rs1051730 G/A G/A G/A G/A
CHRNA5 rs16969968 G/A G/A G/A G/A
CHRNA5 rs588765 C/T C/T C/T C/T
CHRNA5 rs2036527 G/A G/A G/A G/A
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Table 2. Polymorphisms of interest, together with their major/minor alleles, stratified by race (Continued)
CHRNB3 rs13280604 A/G G/A A/G A/G
CYP2A6 rs4105144 T/C T/C T/C T/C
CYP2B6 rs6474412 T/C C/T T/C T/C
DBH rs3025343 G/A G/A G/A G/A
DRD4 (exon 3 48
bp)
SI000224I 4 (0.65), 7 (0.18), 3,
2
4 (0.75), 7 (0.14), 6,
5
4 (0.79), 2 (0.17), 5 7 (0.52), 4 (0.41), 2
EGLN2 rs3733829 A/G A/G A/G G/A
EGLN2 rs7937 T/C C/T T/C T/C
LOC100188947 rs1329650 G/T G/T T/G G/T
LOC100188947 rs1028936 A/C A/C C/A A/C
PDE1C rs215605 T/G G/T G/T T/G
SLC6A3 (3’ 40 bp) SI000156M 10 (0.69), 9 (0.31) 10 (0.73), 9 (0.21),
3, 8
10 (0.91), 9 10 (0.74), 9 (0.24)
SLC6A4
(Promoter)
SI664268Gf L (0.62), S (0.38) L (0.78), S (0.07), 19
(0.15)
L (0.27), S (0.71) L (0.42), S (0.58)
aSNP rsID and frequencies from the 1000 Genomes Project database (http://analysistools.nci.nih.gov/LDlink/), VNTR UID and
frequencies from ALFRED (http://alfred.med.yale.edu/alfred/index.asp).
bGBR or European (PopID = 20, SampID = 20C).
cASW or per VNTR (DRD4, Biaka (PopID = 5, SampID = 5F); SLC6A3, African American (PopID = 98R, SampID = 101C);
SLC6A4, Biaka
dCHB + JPT, or mean of Han and Japanese, for SLC6A3 and SLC6A4, Han (SampID = 9J) and Japanese (SampID = 10B)
eMXL or per VNTR (DRD4, see Table 2, Aguirre-Samudio 2014; SLC6A3, Hispanic American from ALFRED; SLC6A4, see Table
2, Peralta-Leal 2012).
f For Euro, African American and East Asian, extracted from Promoter VNTR + rs25531 Table in ALFRED. L = 16 repeats, S = 14
repeats
SNP = Single-nucleotide polymorphism; VNTR = variable number tandem repeat; G = nucleobase guanine; A = nucleobase adenine;
C = nucleobase cytosine; T = nucleobase thymine; rsID=reference SNP cluster ID; UID=Unique Identifier, from ALFRED; GBR=
British in England and Scotland population description code from 1000 Genomes Project; PopID=Population ID from ALFRED;
SampID=Sample ID from ALFRED; ASW=Americans of African Ancestry in SW USA population description code, from 1000
Genomes Project; CHB=Han Chinese in Bejing, China population description code, from 1000 Genomes Project; JPT=Japanese in
Tokyo, Japan population description code, from 1000 Genomes Project; Han=Han Chinese living in the San Francisco, California,
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from ALFRED; MXL=Mexican Ancestry from Los Angeles USA population description code, from 1000 Genomes Project; L=
Long (16 repeats); S=Short (14 repeats)

















Letter indicates which treatment is
favoured:
a = active NRT
b = bupropion








O HoMa Het HoMi
rs1051730 NHW 3 (1023/
574)



















7.1 a a 0.22
Bupropion
vs placebo
O HoMa Het HoMi
rs1051730 NHW 4 (797/
532)
8.1 b b 0.77





rs588765 NHW 4 (596/
511)
12.1 b b 0.32
310Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Data availability per treatment comparison for the outcome 6-month abstinence (Continued)
rs2036527 NHW 2 (412/
326)




rs3733829 NHW 2 (307/
264)
15.1 b b 0.25
Het: heterozygous; HoMa: homozygous major; HoMi: homozygous minor; N: normal NMR; NHB: non-Hispanic black or African
American; NHW: non-Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; O = overall; SNP:
single-nucleotide polymorphism; VNTR: variable number tandem repeat.
aHomozygous major vs heterozygous + homozygous minor.

















Letter indicates which treatment is
favoured:
a = active NRT
b = bupropion








O HoMa Het HoMi
rs1051730 NHW 2 (912/
479)







3.2 a pb 0.003a
rs588765 NHW 2 (587/
336)
4.1 a 0.89
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7.2 a a 0.80
Bupropion
vs placebo
O HoMa Het HoMi
rs1051730 NHW 6 (743/
636)
8.2 b b b b 0.41




10.1 b b 0.50
NHB 3 (315/
296)
11.2 b bb 0.77a
rs588765 NHW 4 (595/
512)
12.2 b b 0.96
rs2036527 NHW 4 (546/
429)
13.2 b b b b 0.20
NHB 4 (352/
341)
14.2 b b 0.38
rs3733829 NHW 4 (440/
367)
15.2 b b b 0.71
NHB 2 (46/29) 16.1 0.56a
rs7937 NHW 3 (324/
233)
17.1 b b 0.54
NHB 2 (47/29) 18.1 0.92a
rs1329650 NHW 3 (324/
235)
19.1 b b 0.83
NHB 2 (47/29) 20.1 0.59a
rs1028936 NHW 3 (324/
235)
21.1 b b 0.90
NHB 2 (47/29) 22.1 0.37a
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Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment (Continued)
rs215605 NHW 3 (324/
234)
23.1 b b 0.43




O HoMa Het HoMi
rs1051730 NHW 2 (268/
176)
25.1 ba ba 0.77




27.1 ba ba 0.77
NHB 2 (40/29) 28.1 0.35a
rs2036527 NHW 2 (267/
176)
29.1 ba ba 0.95
NHB 2 (40/29) 30.1 0.59
rs3733829 NHW 2 (266/
175)




rs7937 NHW 2 (268/
174)
33.1 ba 0.62
NHB 2 (40/29) 34.1 0.98a
rs1329650 NHW 2 (266/
176)
35.1 ba ba 0.90
NHB 2 (40/29) 36.1 0.78a
rs1028936 NHW 2 (268/
176)
37.1 ba ba 0.88
NHB 2 (40/29) 38.1 0.89a
rs215605 NHW 2 (267/
175)
39.1 ba ba 0.79
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Table 4. Data availability per treatment comparison for the outcome abstinence at end of treatment (Continued)





O HoMa Het HoMi
rs1051730 NHW 2 (268/
265)
41.1 0.97





NHB 2 (40/47) 44.1 0.57a
rs2036527 NHW 2 (267/
265)
45.1 0.99
NHB 2 (40/47) 46.1 0.61a
rs3733829 NHW 2 (267/
264)
47.1 0.82
NHB 2 (48/46) 48.1 b 0.58a
rs7937 NHW 2 (268/
265)
49.1 0.69
NHB 2 (40/47) 50.1 0.85a
rs1329650 NHW 2 (266/
265)
51.1 0.66
NHB 2 (40/47) 52.1 0.49a
rs1028936 NHW 2 (268/
265)
53.1 0.60
NHB 2 (40/47) 54.1 0.49a
rs215605 NHW 2 (267/
265)
55.1 0.50
NHB 2 (40/47) 56.1 0.75a
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Het: heterozygous; HoMa: homozygous major; HoMi: homozygous minor; N: normal NMR; NHB: non-Hispanic black or African
American; NHW: non-Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; O: overall; SNP:
single-nucleotide polymorphism; VNTR: variable number tandem repeat.
aHomozygous major vs heterozygous + homozygous minor.
bHeterozygous + homozygous minor.




















ma = genotype group
with 1 or more major
alleles
mi = homozygous mi-
nor
s = slow NMR
n = normal NMR
P value heterogene-
ity in genotype com-
parisons
Active NRT MaMi HetMi
rs1051730 NHW 7 (1352/
1025/310)
57.1 0.93
NHB 2 (181/50/6) 58.1 0.98
rs16969968 NHB 2 (353/39a ) 59.1 N/A
rs588765 NHW 3 (286/399/
147)
60.1 0.76
rs2036527 NHW 2 (369/447/
132)
61.1 0.79














2 (400/318) 65.1 s N/A
Bupropion
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Table 5. Data availability per treatment group for the outcome 6-month abstinence (Continued)
rs1051730 NHW 4 (220/294/
96)
66.1 0.82
NHB 2 (43/20a ) 67.1 N/A
rs16969968 NHB 2 (261/33a ) 69.1 N/A
rs588765 NHW 4 (195/292/
109)
70.1 0.80
rs2036527 NHW 2 (143/204/
65)
71.1 0.87
NHB 3 (187/144a ) 72.1 N/A




rs16969968 NHW 2 (269/349/
89)
83.1 0.81




rs1051730 NHW 6 (377/441/
156)
101.1 0.54
NHB 2 (49/14a ) 102.1 N/A
rs16969968 NHW 2 (132/181/
30)
103.1 0.63
NHB 3 (519/65a ) 104.1 N/A
rs588765 NHW 5 (253/340/
130)
105.1 0.92
NHB 2 (275/291a ) 106.1 N/A
rs2036527 NHW 2 (117/166/
43)
107.1 0.81
NHB 4 (373/256a ) 108.1 N/A
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2 (389/310) 120.1 N/A
HetMi: heterozygous vs homozygous minor; MaMi: homozygous major vs homozygous minor; NHB: non-Hispanic black or African
American; NHW: non-Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; NS: normal NMR vs
slow NMR; SNP: single-nucleotide polymorphism; VNTR: variable number tandem repeat.
aHeterozygous and homozygous minor combined.




















ma = genotype group
with 1 or more major
alleles
mi = homozygous mi-
nor
s = slow NMR
n = normal NMR
P value heterogene-
ity in genotype com-
parisons
Active NRT MaMi HetMi
rs1051730 NHW 5 (917/1008/
283)
57.2 0.64
rs16969968 NHB 2 (353/39a ) 59.2 mab N/A
rs588765 NHW 3 (286/399/
147)
60.2 0.97
rs2036527 NHW 2 (369/447/
132)
61.2 0.74
NHB 2 (232/159a ) 62.2 mab N/A
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2 (400/318) 65.2 N/A
Bupropion
rs1051730 NHW 6 (263/357/
123)
66.2 0.59
NHB 3 (58/26a ) 67.2 N/A
rs16969968 NHW 3 (108/164/
52)
68.1 0.51
NHB 3 (279/36a ) 69.2 N/A
rs588765 NHW 4 (195/292/
109)
70.2 0.65
rs2036527 NHW 4 (185/269/
92)
71.2 0.53
NHB 4 (200/152a ) 72.2 N/A
rs3733829 NHW 4 (203/181/
56)
73.2 0.87
NHB 2 (35/11a ) 74.1 N/A
rs7937 NHW 3 (86/165/73) 75.1 0.66
NHB 2 (20/24/3) 76.1 0.62
rs1329650 NHW 3 (161/138/
25)
77.1 0.90
NHB 2 (42/5a ) 78.1 N/A
rs1028936 NHW 3 (212/103/9) 79.1 1.00
NHB 2 (42/5a ) 80.1 N/A
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Table 6. Data availability per treatment group for the outcome abstinence at end of treatment (Continued)
rs215605 NHW 3 (125/154/
45)
81.1 0.94
NHB 2 (31/16a ) 82.1 N/A
Varenicline
rs16969968 NHW 2 (269/349/
89)
83.2 0.94





rs1051730 NHW 2 (113/130/
25)
85.1 0.96
NHB 2 (33/7a ) 86.1 N/A
rs16969968 NHW 2 (113/130/
23)
87.1 0.98
NHB 2 (36/4a ) 88.1 N/A
rs2036527 NHW 2 (111/132/
24)
89.1 0.82
NHB 2 (23/12/5) 90.1 0.87
rs3733829 NHW 2 (114/123/
30)
91.1 0.52
NHB 2 (30/10a ) 92.1 mib N/A
rs7937 NHW 2 (74/140/54) 93.1 0.95
NHB 2 (13/27a ) 94.1 N/A
rs1329650 NHW 2 (149/96/21) 95.1 mi 0.67
NHB 2 (34/6a ) 96.1 N/A
rs1028936 NHW 2 (183/75/10) 97.1 0.67
NHB 2 (34/6a ) 98.1 N/A
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Table 6. Data availability per treatment group for the outcome abstinence at end of treatment (Continued)
rs215605 NHW 2 (105/119/
43)
99.1 0.25
NHB 2 (18/22a ) 100.1
Placebo
rs1051730 NHW 7 (378/441/
164)
101.2 0.71
NHB 3 (63/20a ) 102.2 N/A
rs16969968 NHW 4 (169/227/
49)
103.2 0.83
NHB 4 (530/66a ) 104.2 mib N/A
rs588765 NHW 5 (254/296/
108)
105.2 0.34
NHB 2 (277/289a ) 106.2 N/A
rs2036527 NHW 4 (154/213/
62)
107.2 0.90






rs3733829 NHW 4 (164/152/
51)
110.2 0.53
rs7937 NHW 3 (73/120/40) 111.1 0.67
NHB 2 (18/11a ) 112.1 N/A
rs1329650 NHW 3 (119/106/
10)
113.1 0.99
NHB 2 (21/8a ) 114.1 N/A
rs1028936 NHW 3 (158/72/5) 115.1 0.79
NHB 2 (23/6a ) 116.1 N/A
rs215605 NHW 3 (94/105/35) 117.1 0.70
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Table 6. Data availability per treatment group for the outcome abstinence at end of treatment (Continued)
NHB 2 (18/11a ) 118.1 N/A
SLC6A4 (Pro-
moter)




2 (400/318) 120.2 N/A
HetMi: heterozygous vs homozygous minor; MaMi: homozygous major vs homozygous minor; NHB: non-Hispanic black or African
American; NHW: non-Hispanic white; NS: normal NMR vs slow NMR; SNP: single-nucleotide polymorphism; VNTR: variable
number tandem repeat; NMR = nicotine metabolite ratio.
aHeterozygous and homozygous minor combined.
bHomozygous major vs heterozygous and homozygous minor.
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includes too few studies and too few participants within genotype groups for these analyses to yield reliable results.
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